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ABSTRACT 
Adult mesenchymal stromal cells (MSCs) have enormous potential in tissue engineering and 
regenerative medicine applications. MSC have also been reported to be immune-privileged.   
The aim of this study was to develop methods to test two related hypotheses. Firstly, that 
MSCs will not directly stimulate allogeneic lymphocytes in classical lymphocyte proliferation 
assays carried out over 5-7 days due to lack of expression of immune-regulatory molecules 
(CD40, CD80, CD86 and MHC Class-II) but may be capable of the stimulation of allogeneic 
lymphocytes when cultured over extended time periods that allow the indirect pathway of 
antigen presentation. Secondly, that following differentiation of MSCs into mature 
differentiated adipose cells, the cells would become immunogenic or increase their 
immunogenicity, as determined by the stimulation of allogeneic peripheral blood mononuclear 
cells in lymphocyte transformation assays.  
MSCs from 4 human bone marrow donors were isolated, expanded and characterised and 
shown to conform to the ISCT definition of MSC through FACs analysis of key antigen 
expression and trilineage differentiation.  
MSCs (from donors 1-3) were differentiated into adipocytes, and current methodology for 
assaying adipogenesis was evaluated. A new fluorescent microplate assay was developed using 
DAPI to normalise for cell number and Nile red to stain for intracellular lipids, to generate a 
ratio of adipogenesis. 
Peripheral blood mononuclear cells (PBMCs) from 6 volunteers were isolated, in-vitro assay 
conditions for performing lymphocyte transformation assays (LTAs) were optimised, and the 
duration of the assays extended to 16-21 days.  
It was shown that undifferentiated MSCs stimulated PBMCs in all except 2 out of 24 cases, with 
the highest stimulation typically post-day 7 with stimulation indices as high as 36 observed. It 
was shown that MSCs differentiated into adipocytes also stimulated PBMCs with higher 
stimulation indices observed in differentiated MSCs compared to the undifferentiated 
counterparts. 
It was concluded that MSC, whether undifferentiated or differentiated into adipose cells, are 
indeed capable of stimulating a proliferative response in allogeneic lymphocytes. Therefore, 
the use of allogeneic MSCs in the traditional engineering setting may be limited, and a cautious 
approach should be taken before allogeneic MSCs are used in the regeneration or creation of 
tissue replacements for clinical use. 
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Chapter 1:  INTRODUCTION 
1.1 REGENERATIVE MEDICINE  
Regenerative medicine is an emergent multi-disciplinary field of research that aims to repair, 
replace, or restore normal function to diseased organs or tissues. The approaches taken 
include research in cell therapy, scaffolds, use of growth factors or any combination of these.  
Tissue engineering is one branch of regenerative medicine that aims to combine cells with 
scaffolds to generate living tissues which have the potential to be used to replace or repair 
diseased or damaged tissues. The base scaffold is the primary component and can be 
composed of a variety of materials, ranging from artificial scaffolds made from synthetic 
materials to fulfil specific criteria in order to replicate that natural tissue micro-environment, 
to decellularised natural biological scaffolds that may be generated from native tissues from a 
range of species. 
The second component is the cells. Scaffolds can be seeded with pluripotent cells (such as 
embryonic stem cells), multi-potent cells (such as multipotential mesenchymal stromal cells), 
or alternatively with precursor cells (such as seeding potential bone scaffolds with osteogenic 
cells) or even with fully differentiated  cells (such as seeding decellularised blood vessels with 
endothelial cells and smooth muscle cells). Pluri- and multi-potent cells have received a great 
deal of attention in tissue engineering applications.   
1.2 STEM CELLS 
The term “stem cell” was originally used to name the progenitor cell which exhibited the 
capacity to self renew and  provide a population of undifferentiated stem cells that have the 
potential to differentiate into one or more committed descendents, including mature cells of a 
fully functional tissue (Choumerianou et al., 2007). There are 4 main classes of stem cells; 
totipotent, pluripotent, multipotent and unipotent.  
Totipotent cells in humans are only present at the onset of the developmental process, just 
after fertilisation when the zygote is formed. This cell has the ability to differentiate into any 
mature cell type present within the body, including the extra-embryonic tissues (such as the 
placental support tissue and protective membranes). These totipotent cells do not exist for 
long before their ability to differentiate into extra-embryonic tissues is lost during cell division 
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and differentiation (Mitalipov and Wolf, 2009). Totipotent cells are the initial zygote and the 
early embryonic blastomeres up to about the 4-cell stage, with totipotency gradually lost as 
the embryo reaches the 8-cell stage and beyond. Following this, cells of the early embryo 
specialise into two lineages that go on to form the inner cell mass which form the 
trophectoderm and the fetus and the extra-embryonic cells.  
Pluripotent cells are cells that have the potential to form many cell types. The term 
pluripotency is now generally viewed as describing a stem cell that demonstrates the potential 
to differentiate into any of the 3 germ layers; the endoderm, ectoderm and the mesoderm. 
These cells are commonly called embryonic stem cells (ESCs). The endoderm is the innermost 
layer of the developing embryo and differentiates into cells that form the gastro-intestinal 
tract, the respiratory tract, endocrine glands and organs and the auditory and urinal system. 
The ectoderm is the exterior layer, and cells that form this layer are able to differentiate into 
the nervous system and the epidermis. The final germ layer mentioned is the mesoderm. This 
is the middle layer, and cells from this are able to differentiate into the mesenchyme 
(connective tissues), skeletal and cardiac muscle, tissues within the kidneys, red blood cells 
and also bone and cartilage within the developing embryo. Pluripotent cells are able to 
differentiate into any cell of a mature animal, but differ from totipotent cells in that they are 
unable to develop into a fetus or adult organism as they lack the potential to organise into an 
embryo and they lack the ability to differentiate into extra-embryonic tissue (Mitalipov and 
Wolf, 2009).  
Multipotent cells have the ability to differentiate into cells of a reduced subset of lineages. In 
humans, examples of multipotent cells are multipotent mesenchymal stromal cells (MSCs) that 
are able to differentiate into bone, fat and cartilage, and haematopoietic stem cells, that are 
able to give rise to various cell types within the blood.  
Unipotent stem cells differ from the general view of stem cells in that they are only able to 
differentiate into a single cell type, and are often called precursor cells. What defines them as 
a stem cell is their ability to self-renew (maintain a population of these cells in the 
undifferentiated state). Examples of cells of this type are hepatocytes of the liver, and 
keratinocytes in skin. These cells are more restricted in their potential as they are more 
differentiated, and because of this, issues such as ease of isolation and expansion affect the 
use of these cells in the chosen tissue regeneration/engineering strategy.  
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1.2.1 EMBRYONIC STEM CELLS 
Far from being a ‘new science’, stem cells have been studied for many years. Research has 
been conducted on murine embryonic stem cells for over 25 years with the first mouse ESC 
line created in 1981 (Martin, 1981). The first report of deriving embryonic stem cells from a 
human embryo however occurred much later (Thomson et al., 1998). Embryonic stem cells are 
derived from the inner cell mass of the 3-5 day old blastocyst, and when grown in-vitro have 
the capacity to proliferate indefinitely, while also retaining their potential to form any tissues 
of a developing organism (Daley et al., 2003). The inner cell mass is able to generate the initial 
primitive ectoderm that further develops into the 3 primary germ layers discussed previously; 
the ectoderm, mesoderm, and endoderm. Further evidence of the ability of embryonic stem 
cells to differentiate into cells of all three of the primary germ layers was produced when ESCs 
were injected into severe combined immunodeficient mice, and resulted in teratomas 
containing differentiated cell types from the 3 primary germ layers (a teratoma is a tumour or 
encapsulated cell growth containing cell types derived from the 3 primary germ layers) 
(Choumerianou et al., 2007).  
The blastocysts that human ESCs are isolated from are typically obtained from unused 
embryos generated for use in fertility treatments after in-vitro fertilisation (Brignier and 
Gewirtz, 2010). The stem cells that are obtained from embryonic tissues have a unique feature 
that sets them apart from other stem cells; they are able to maintain their pluripotent nature 
in long-term culture. Traditionally the isolated human stem cells were grown on mitotically 
inactivated murine fibroblast feeder cell layers in serum containing medium in culture 
conditions replicating those used to isolate and grow mouse embryonic stem cells (Thomson et 
al., 1998), but it has now come to light that the specific factors needed to maintain murine 
embryonic stem cells do not support human embryonic stem cells, and there are specific 
growth factors provided by the feeder cell layer that are required for extended growth of the 
stem cells without spontaneous differentiation (Yu and Thomson, 2008). This mode of culture 
introduced risks of unknown components and xeno-protein transmission, which restricted the 
potential uses of these cells in regenerative medicine. In order to combat this, an alternative to 
using the fibroblast feeder layer was sought, and some progress has been made into solving 
this issue. These solutions involve either the use of human feeder cell layers, or feeder free 
systems which involve growth medium supplemented with specific growth factors (Cho et al., 
2011). There have now been several reports on the refinement of methods to allow the 
culture and maintenance of human embryonic stem cells in xeno-free conditions, but there is 
little follow-up work on the long term safety of these systems. Chromosomal abnormalities 
arising from culturing human embryonic stem cells in the absence of the murine embryonic 
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fibroblast feeder cells have been described and this issue needs to be overcome before clinical 
grade embryonic stem cells can be obtained (Draper et al., 2004). The use of feeder cell layers 
that are human in origin eliminates the need for xeno-derived feeder cell layers and 
derivatives, while maintaining the use of feeder cells to prevent the occurrence of 
chromosomal abnormalities.  Feeder cell layers obtained from adult marrow cells, foreskin 
fibroblasts, foetal skin fibroblasts, fallopian tube endothelial cells, and uterine endometrium 
have been used, and these have been shown to allow unlimited proliferation of human 
embryonic stem cells without spontaneous differentiation (Cho et al., 2011). The preparation 
of these feeder cells however requires invasive procedures and alternative cell types that are 
easier to isolate, or do not require an invasive method are needed. Cell types such as umbilical 
cord stem cells have been suggested as a suitable feeder cell layer, and good initial results 
have been obtained in one study in which these cells were used (Cho et al., 2011).  
There are still many barriers to be overcome before embryonic stem cells can routinely be 
used in the clinic, from their maintenance and in-vitro expansion, to controlling their 
differentiation when re-implanted in-vivo. Until more is understood about how these cells can 
be maintained in culture and the risk of teratoma formation is reduced, the risks of using these 
cells clinically outweigh the rewards. However, there are currently a small number of clinical 
trials involving implanting ESCs in patients. The first of these is being performed by the US 
company Geron who are conducting a phase I trial on the efficacy of injecting oligodendrocyte 
progenitor cells (derived from ESCs) directly into the patients’ spinal cord 7-14 days after 
injury. A second study is underway is patients with Stargardt’s macular dystrophy (a condition 
in which retinal pigment epithelial cells in the macula of the eye stop working) by another USA 
based company called Advanced Cell Technology. In this trial the lab grown retinal pigment 
epithelial cells derived from human ECSs will be implanted into the eyes of patients with 
advanced Stargardts macular dystrophy. The retinal pigment epithelial cells normally function 
to provide nutrients and protection for the light sensitive cells in the retina that allow vision. 
This company has another clinical trial using the same differentiated ESCs to attempt to 
improve loss of vision due to age-related macular degeneration (information obtained from 
the eurostemcell.org clinical trials news). All of these studies have only commenced relatively 
recently, and as of now, no long term outcomes have been documented. 
1.2.2 SCNT AND IPS CELLS 
An alternative to embryonic stem cells, while still offering pluripotency, are induced 
pluripotent stem cells (iPS). These are somatic cells that are subject to nuclear reprogramming 
to reset their fate to a primordial, embryonic stem-cell-like state. The concept evolved from a 
5 
 
significant breakthrough that made headline news in many countries; the cloning of Dolly the 
sheep in 1997. When researchers did this they demonstrated that trans-acting material in 
mammalian oocytes was sufficient to reprogram a differentiated nucleus to a pluripotent state 
(Yu and Thomson, 2008). The technique of somatic cell nuclear transfer (SCNT) was suggested 
as a method to create patient specific stem cells. This procedure involves the isolation of a 
donor cell and the removal of its nucleus. The nucleus of a host oocyte is then removed, and 
the donor nucleus is inserted. The new hybrid of oocyte and donor nucleus creat a 
reprogrammed pluripotential cell that is patient matched and able to form a blastocyst 
containing embryonic stem cells with almost identical DNA to the donor nucleus. SCNT has 
only recently been demonstrated in non-human primates, and showed that reprogramming of 
donor cells could be mediated by then unknown transacting factors (Yu and Thomson, 2008). 
There are various issues, both ethical and scientific regarding the use of  SCNT to generate 
human ESCs, and therefore SCNT has not yet been demonstrated in a human system (Noisa 
and Parnpai, 2011). The generation of human ESCs using SCNT requires the use of human 
oocytes, which are difficult (rare) to obtain, and the process itself has very low efficiency. 
Using SCNT with human material also raises ethical issues about human cloning, in that the 
blastula created could be used to enable reproductive cloning. 
Due to the very low efficiencies associated with SCNT, the generation of pluripotent cells by 
inducible factors has become a much more desirable method. It was later shown that 
enforcing the expression of just four transcription factors (Oct4, Sox2, Klf4 and c-Myc) 
reprogrammed human somatic cells to a pluripotent state (Takahashi and Yamanaka, 2006; 
Takahashi et al., 2007). Even four years on from this initial discovery, the most commonly used 
factors for the generation of human iPS cells remain those four transcription factors (Hussein 
et al., 2011). There are a variety of methods currently used to drive the expression of these 
transcription factors, with one of the most common the delivery of transgenes via lenti- or 
retro-viral constructs (Nelson et al., 2010). Dangers exist with viral transgene delivery such as 
random genomic integrations and incomplete silencing or unwanted activation of viral 
transgenes, but retroviral vectors do have inherent sequences that become inactive when the 
cells enter the pluripotent state which is desired to prevent tumorgenicity (Nelson et al., 
2010). The expression of the 4 transgenes initiates a sequence of events that allows a small 
fraction of the total cell population treated to acquire an imposed pluripotent state that is 
characterised by a stable epigenetic profile. A more desirable method to generate iPS cells 
would utilise an excisable system that would allow transient integration or expression of the 
transgenes within cells until the stable epigenetic profile has been achieved, and then the 
transgenes could be removed. Methods have been attempted using cell-permeable 
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recombinant proteins to generate iPS cells, but had a very low efficiency of production (Kim et 
al., 2009). Potentially the most promising method of generating iPS cells to date is through the 
use of mRNA transfection of the transgenes into the cells. This technique uses synthetic mRNA 
that contains modified ribonucleotides attenuating the traditional intrinsic antiviral responses 
that are typically associated with the introduction of mRNA into human cells (Warren et al., 
2010). This technique has been reported to generate iPS cells with a high degree of efficiency. 
An overview of human embryonic stem cell isolation, SCNT and iPS cell generation is shown in 
Figure 1.1.  
Possibly one of the most important hurdles to overcome in order to bring both embryonic 
stem cells and induced pluripotent stem cells to the clinic is the risk of tumorgenicity. Human 
ESCs have a great deal in common with  cancer cell lines; rapid proliferation rate, lack of 
contact inhibition, propensity for genomic instability and high expression of oncogenes such as 
c-Myc and klf4. The risk of tumorgenicity has also been shown to apply to ESCs even with a 
normal karyotype in mouse models (Ben-David and Benvenisty, 2010). The transgenes 
expressed in order to form iPS cells are highly expressed in various forms of human cancers, 
and IPS cells have been shown to more readily acquire chromatic aberrations than ESCs (due 
to reprogramming stress and due to their somatic cell origin). The self-renewal genes are key 
factors in the tumorgenesis of ESCs and iPS cells, but are also key factors in their pluripotency. 
In order to generate effective clinical therapies utilising ESCs and iPS cells the tumorgencity of 
these cells must be overcome. Progress is being made in this area through the use of terminal 
differentiation of these cells, complete elimination of any residual pluripotent cells, or 
interfering with the expression of tumorgenic genes, however much still needs to be done 
before routine use of these cells can be performed in safe therapies (Ben-David and 
Benvenisty, 2010). 
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Figure 1.1: An overview of the methods used to obtain and culture pluripotent stem cells. A: 
Following isolation from the inner cell mass embryonic cells (ESCs) are expanded in culture classically 
grown on feeder cell layers (used to expand the cells while maintaining their undifferentiated state). 
When removed from the feeder cell layer and transferred to suspension cultures the ESCs form 
aggregates of differentiated and undifferentiated cells termed embryoid bodies. Plated embryoid 
bodies spontaneously display a variety of cellular types from the 3 primary germ layers at various 
differentiation stages. More specific differentiation can occur with the addition of growth factors or 
selection for more differentiated cell types. It is difficult to differentiate ESCs into a specific lineage 
without highly definite culture techniques. B: Somatic cell nuclear transfer involves injecting the 
nucleus from a somatic cell into an enucleated oocyte, followed by activation stimuli to generate an 
embryo to derive ESCs from. C: iPS cells are generated through the overexpression of key 
transcription factors, shown to be Oct4, Sox2, Klf4 and c-Myc. This can be achieved through viral 
vectors, treatment of cells with modified transgene mRNA, and plasmid vectors. This image is taken 
from Brignier and Gewirtz (2010). 
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1.2.3 ADULT STEM CELLS 
The formation of organs and tissues occurs naturally in the developing human embryo, from 
the embryonic stem cells discussed previously. The final product is a human, composed of 
several hundred distinct cell types, each with a specific function. The differences between  the 
various cell types within the body is astounding, from the brain and nervous tissue capable of 
transmitting and receiving electrical stimulus, to cells able to recognise and engulf invading 
pathogens. As established, the formation of these cells occurs in the developing embryo. In the 
mature human however the majority of these tissues and organs grow and repair if damaged; 
they need to be maintained throughout the life of the person. The maintenance of these 
tissues in-vivo is believed to be due to the presence of cell populations called ‘adult stem cells’, 
or a pool of cells within an individual that exhibit the characteristics of stem cells (self-renewal, 
and potency to differentiate into more than 2 different cell types). The presence of these cells 
in the majority of tissues within the body has been documented, from specific unipotent 
precursor cells such as the basal epithelial cells of the gastrointestinal mucosa, to bipotent 
adipofibroblasts of adipose tissue and also multipotent stem cells such as the hematopoietic 
cells in the bone marrow (Young and Black, 2004). It is currently the multipotent stem cells 
that hold the greatest promise in regenerative medicine, allowing the derivation of multiple 
cell lineages from one cell type. There are many types of multipotent adult stem cells that have 
been discovered including hematopoietic stem cells, neural stem cells, adipose derived stem 
cells, dental pulp stem cells, and multipotential mesenchymal stromal cells. 
1.2.4 HEMATOPOIETIC STEM CELLS 
Hematopoietic stem cells (HSCs) are perhaps the best characterised of all stem cells due to 
their ease of isolation, developmental potential and therapeutic applications. The existence of 
these cells was first postulated by a military doctor called Alexander Maximow in 1909, who 
suggested that there existed hematopoietic stem cells with the morphological appearance of 
lymphocytes that were able to migrate through the blood system to specific microecological 
niches where they were able to proliferate and differentiate along lineage specific pathways 
(Denham et al., 2005). HSCs are located within adult bone marrow and give rise to all of the 
lymphoid (NK cells, B-cells and T-cells) myeloid types (platelets, granulocytes, macrophages, 
dendritic cells and erythroid blood cell types). HSCs are divided into two subtypes based on the 
longevity of the cell; long term HSCs and short term HSCs. The long term HSCs undergo 
extensive self-renewal, and in dividing form their progeny, the short term HCSs. The short term 
HSCs undergo more limited self renewal, prior to further differentiating into multipotent 
myeloid or lymphoid progenitors (Denham et al., 2005). HSCs form between 0.05 and 0.5% of 
the total cell population of the bone marrow, with the remainder mainly composed of 
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quiescent cells. Even with this small percentage of HSCs, the average bone marrow still 
releases 200 billion erythrocytes and 70 billion neutrophillic leukocytes into the blood stream 
every day (Gunsilius et al., 2001). HSCs can be identified within bone marrow extracts due to 
their small size, low side staining with vital dyes Hoechst 33342 or rhodamine 1223 and a panel 
of cell surface marker expression; Sca-1+, c-kit+, CD34+,CD43+, CD45+ and lineage specific 
marker negative (Gunsilius et al., 2001; Denham et al., 2005). Examples of the lineage specific 
markers used for negative selection are CD13 and CD33 for myeloid cells, CD71 for erythroid 
cells, or CD4/8 for T-cells. Hematopoietic stem cells have been used for clinical therapies for 
over three decades, with the main use being HSC transplantation in patients with severe 
aplastic anemias, fatal leukemias, haematological malignancies, thalassemias and severe 
combined autoimmune disease (Gunsilius et al., 2001). The use of HSC transplantation is 
increasing in frequency  with over 20,000 transplants performed worldwide in 2004 (Denham 
et al., 2005), increasing to over 50,000 by 2006 (Gratwohl et al., 2010). 
1.2.5 NEURAL STEM CELLS 
Neural stem cells (NSCs) are a more recent addition to the adult stem cell field and although 
they make up the majority of early foetal brain cells, it was not until the early 1990’s that the 
presence of these stem cells in the hippocampus and lateral ventricle of adults was discovered 
(Galli et al., 2003; Massirer et al., 2010). These stem cells have been shown to have the 
capacity to self-renew and to differentiate into neurons and glia (astrocytes and 
oligodendrites). NSCs are believed to differentiate before migration to more specific areas of 
the brain as neural precursor cells where the newly formed neurons integrate into the local 
network (Massirer et al., 2010). The general dogma of neural tissue, that it was irreplaceable 
and could not be regenerated is slowly unravelling, and it is now believed that cell 
replacement occurs within specific regions of the brain throughout adulthood (Galli et al., 
2003). Isolation of these cells for study in-vitro was a major milestone that opened up the 
potential for the study of neurogenesis and the effects of pharmaceutical drug testing (Rietze 
and Reynolds, 2006). The isolation and culture of these cells involved harvesting cells from the 
periventricular region of the brain and culturing these cells in serum-free conditions in the 
presence of epidermal growth factor. This selected for a small percentage of these cells that 
were epidermal growth factor responsive (0.1%) and able to proliferate in-vitro (Rietze and 
Reynolds, 2006). These cells formed a ball of undifferentiated neural progenitor cells called a 
neurosphere, which in turn could be dissociated and re-plated to form additional 
neurospheres, or differentiated to form the 3 major cell types of the central nervous system.  
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The therapeutic potential of these cells to treat neurological diseases is yet to be realised. 
NSCs have been isolated from foetal brain tissue, but the use of this tissue as a routine source 
of these cells is beset with problems such as lack of availability and major ethical hurdles. The 
availability of a renewable source of NSCs generated from the establishment of NSC lines 
allows potential therapeutic avenues to be tested, but much more research is needed before 
these cells can be used clinically.   
1.2.6 MULTIPOTENT MESENCHYMAL STROMAL CELLS 
Mesenchymal stem cells were first characterised by Friedenstein and Petrakova, who 
identified a population of cells in adult bone marrow that were adherent, fibroblast-like, and 
able to repair bone in-vivo (Friedenstein et al., 1966; Friedenstein et al., 1968; Owen and 
Friedenstein, 1988). The cells were first purified using plastic adhesion due to their ability to 
rapidly and relatively strongly adhere to plastic surfaces. In the 1980s and 1990s further 
studies were performed that demonstrated the multipotency of these cells and in culture they 
could give rise to osteoblasts, chondrocytes, and adipocytes. Since then mesenchymal stem 
cells have also been demonstrated to differentiate into tenocytes and myoblasts (Prockop, 
1997; Pittenger et al., 1999; Barry and Murphy, 2004; Alexanian et al., 2008; McGonagle and 
Jones, 2008). It has been demonstrated more recently that MSCs are not only restricted to 
differentiating into cells from the mesoderm, but when stimulated with specific growth factors 
and cultured under specific conditions other cell types can be produced such as a neuronal cell 
phenotype (Alexanian et al., 2008; Bae et al., 2011). However, functional electro-transduction 
by these putative neuronal cells was not demonstrated. 
Due to the inconsistent terminology used to identify the isolated cells, the International 
Society For Cellular Therapy (ISCT) proposed the term “multipotent mesenchymal stromal 
cells” or MSCs (Le Blanc et al., 2005) and also defined a minimal criteria for labelling cells as 
MSCs (Dominici et al., 2006): 
1. Plastic adherent under standard culture conditions. 
2. Be positive for the expression of CD73, CD90, and CD105, and negative for the 
expression of CD34, CD45, CD14 or CD11b, CD79a or CD19, and HLA-DR. 
3. Be able to differentiate into adipocytes, osteocytes and chondrocytes under specific 
stimulus in vitro.   
Although the first putative methods to isolate MSCs relied on plastic adherence, presently a 
panel of antibody markers is used, with MSCs having been shown to be CD105, LNGFR, HLA-
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DR, CD10, CD13, CD90, STRO-1 and bone morphogenetic protein receptor type IA (BMPRIA) 
positive and CD14, CD34, CD117 and CD133 negative (Jones et al., 2002; Jones et al., 2006). 
The ISCT simplified the panel of cell surface markers so that in order for cells to be called 
MSCs, they must express CD73, CD90 and CD105, but be negative for the expression of CD34, 
CD45, CD14 or CD11b, CD79a or CD19 and HLA-DR. A table of the cell surface markers and 
their functions is shown in Table 1.1. 
Mesenchymal stromal cells have been reported to be present in almost all postnatal organs, 
but there are tissues which contain a higher ratio of MSCs than others. Typically these cells 
have been isolated from bone marrow taken from the iliac crest or the hip, but MSCs 
represent only a very small fraction of nucleated cells in the bone marrow, between 0.001-
0.01%. However, they can be isolated and expanded with high efficiency (Pittenger et al., 
1999). More recently it has been shown that placenta and umbilical cord blood/cord contain 
higher levels of MSCs than bone marrow, and these tissues are typically considered as 
biological waste and discarded after childbirth (Spitkovsky and Hescheler, 2008). Adipose 
tissue has also been shown to contain a much higher frequency of MSCs than bone marrow; 
with a study carried out finding 2% of nucleated cells in lipoaspirate after a low invasive 
subcutaneous lipoaspiration procedure were MSCs (Strem et al., 2005). It has been shown that 
MSCs from alternative areas other than the bone marrow may be more predisposed to 
differentiate into certain lineages, for example, MSCs isolated from the cartilaginous areas of 
the knee demonstrated increased levels of chondrogenesis when compared to bone marrow 
MSCs, but reduced levels of adipogenesis (English et al., 2007).  
The nomenclature associated with MSCs isolated from different tissues is currently 
inconsistent. Dental derived stem cells and adipose derived stem cells can be isolated from 
dental and adipose tissue respectively, and exhibit many of the same properties and cell 
surface markers as bone marrow derived MSCs. Here, these two classes of adult stem cells 
have therefore been grouped under the category of MSCs. 
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Table 1.1: A summary of the panel of cell surface markers used to characterise MSCs – continued below. 
Marker +/- Other names Functions Reference 
CD105 + Endoglin A proliferation associated and hypoxia inducible protein that acts as a receptor for 
transforming growth factor-β (TGF-β) I and III. TGF-β signalling is involved in cell 
proliferation, differentiation, and apoptosis 
(Janeway et 
al., 2005) 
LNGFR (low 
affinity nerve 
growth factor 
receptor) 
+ CD271 and p75 
neurotrophon 
receptor 
(p75TNR) 
This cell surface molecule acts as one of two receptors for the neurotrophin cell signalling 
molecules, with the other receptor being Trk receptor tyrpsine kinase. The neurotrophins 
are a family of 5 proteins; nerve growth factor, brain-derived neurotrophic factor, novel 
neurotrophin-1, neurotrophon 3, and neurotrophin-4. 
(Deponti et 
al., 2009) 
HLA-DR -  HLA-DR is encoded by the human leukocyte antigen genes in humans. These genes are also 
known as the major histocompatibility complex receptors, but the nomenclature in humans 
is HLA. HLA-DR is an MHC class-II receptor that presents peptide to CD4+ T-cells. 
(Janeway et 
al., 2005) 
CD10 + Neprilysin, or 
neutral 
endopeptidase 
(NEP) 
A zinc metalloendopeptidase that is involved in the metabolism of a number of peptides of 
the nervous, cardiovascular, immune, and inflammatory systems, reducing the effect that 
signalling molecules (such as enkephalins, natriuretic, and chemotactic peptides) from these 
systems have 
(Turner et 
al., 2001) 
CD13 + Aminopeptidase 
N 
A membrane bound zinc dependent ectopeptidase with broad substrate specificity that is 
involved in protein modification, activation, and degradation, in addition to the metabolism 
of bioactive peptides that are involved in leukaemia and tumour metastasis. 
(Zhang et al., 
2011) 
CD90 + Thy-1 Originally studied in mice, and is a highly glycosylated GPI-anchored surface protein, and a 
member of the immunoglobin family. Its functions are not fully known, but it has been 
shown to be involved in mediating the binding of neutrophils and monocytes to activated 
microvascular endothelial cells. It is usually highly expressed at sights of inflammation or in 
tumors, and has also been shown to be expressed on fibroblasts, neurons, and a 
subpopulation of haematopoietic stem cells in humans. It is thought that CD90 is able to 
provide mechanical support for cell adhesion, and is also able to initiate neutrophil effector 
functions (the secretion of matrix metalloprotineases such as MMP-9 and chemotactic 
factors such as CXCL8. 
(Schubert et 
al., 2011) 
13 
 
Table 1.1 continued: A summary of the panel of cell surface markers used to characterise MSCs – continued below. 
Marker +/- Other names Functions Reference 
STRO-1 +  Originally discovered in 1991, and was utlilised as a novel marker for the identification of 
stromal precursor cells within the bone marrow. The antibody developed for this purpose 
bound a trypsin-insensitive epitope that was present on these stromal cells, which later 
became known as STRO-1. 
(Simmons 
and Torok-
Storb, 1991) 
BMPR-IA +  A receptor for the bone morphogenenetic proteins (BMPs) that are secreted multifunctional 
proteins that belong to the transforming growth factor-β superfamily. These proteins are 
involved in a variety of roles within the development, regeneration, and maintenance of 
tissues in humans. Binding of BMPs to BMPR-IA results in the oligomerisation of the 
receptor, before phosphorylation occurs in the intracellular domain resulting in the 
downstream activation of the SMAD signalling cascade affecting the transcription of 
responsive genes within the nucleus. 
(Harth et al., 
2010) 
CD14 -  A member of the pattern recognition receptors that are able to recognise pathogen-
associated molecular pathogens. This receptor exists in a membrane bound form attached 
to the membrane by a glycosyl-phosphatidyl-inositol anchor, and also in a soluble form after 
cleavage from the membrane. CD14 binds to the endotoxin lipopolysaccharide (LPS), a 
polysaccharide found in the outer layer of gram negative bacteria. Binding of LPS to CD14 is 
catalysed by an acute-phase serum reactant lipopolysaccharide binding protein (LBP). 
(Stelter, 
2000) 
CD34 -  A cell surface marker widely used in the isolation and identification of hematopoietic stem 
and progenitor cells, and has more recently been used to aid in the identification of other 
tissue specific stem cells including epidermal precursor cells, and muscle satellite stem cells. 
The function of CD34 has not been fully determined, but has been demonstrated to have a 
role in promoting the proliferation and block the differentiation of progenitor cells. 
(Nielsen and 
McNagny, 
2008) 
CD117 - Receptor 
tyrosine kinase 
(RTK) c-Kit 
A transmembrane glycoprotein whose ligand is a mast cell growth factor. This receptor is 
expressed on hematopoietic cells, and also some non-hematopoietic tissues and tumours. In 
the bone marrow CD117 is specifically expressed in the progenitor department but its 
expression is downregulated except in mast cells. Binding of ligand to CD117 results in the 
activation of a transcription cascade terminating in the production of genes involved in 
proliferation and survival. 
(Edling and 
Hallberg, 
2007) 
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Marker +/- Other names Functions Reference 
CD133 - AC133 Little is currently known about the biological significance, except that CD133 is generally 
expressed on undifferentiated cells such as hematopoietic stem cells. The function remains 
unclear, except it is used as an important marker to identify various stem cell populations. 
(Shmelkov et 
al., 2005) 
CD73 + 5’Nucleotidase Involved in the salvage of extracellular nucleotides. It is thought that this enzyme plays a 
major role in tissue homeostasis catalysing the final step in the hydrolysis of extracellular 
messenger ATP. The expression of this cell surface protein in increased during certain stages 
of cell maturation and has been hypothesized to be involved in cellular interactions such as 
cell recognition and cell adhesion. 
(Zimmermann, 
1992) 
CD45 - Leukocyte 
common 
antigen (LCA) 
CD45 is expressed on all hematopoietic cells. It acts as a phosphatase that regulates 
signalling via the B-cell receptor and MHC class II molecules. 
(Janeway et 
al., 2005) 
CD19 -  CD19 forms a complex with CD21 and CD81 together they form the B-cell co-receptor 
complex. In innate immunity the complement fragment C3d binds to antigens, and the C3d-
antigen complex binds to the B-cell receptor and the cell surface protein CD21. Following 
binding, cross linking and clustering of the co-receptor with the antigen receptor results in 
the phosphorylation of tyrosine residues in the cytoplasmic domain of CD19, by receptor 
associated kinases. The phosphorylated CD19 is able to bind to the src-family of tyrosine 
kinases and further kinases resulting in the activation of signalling pathways that activate 
the B-cell. 
 
(Janeway et 
al., 2005) 
Table 1.1 continued: A summary of the panel of cell surface markers used to characterise MSCs. 
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1.2.7 DENTAL DERIVED STEM CELLS 
There are currently 5 types of dental stem cells that have been identified in humans. These are 
dental pulp stem cells (DPSCs), stem cells from exfoliated deciduous teeth (SHED), stem cells 
from the apical papilla (SCAP), periodontal ligament stem cells (PDLSCs) and dental follicle 
progenitor cells (DFPCs). These cells have been shown to be multipotent, capable of expression 
of bone, cartilage, fat and even neural cell markers (Liu et al., 2006; Petrovic and Stefanovic, 
2009; Sloan and Waddington, 2009).  
Dental pulp stem cells were first proposed in 1990, but their actual isolation and 
characterisation did not occur until 2000 in humans (Gronthos et al., 2000). DPSCs occur in low 
numbers in dental pulp and represent less than 1% of the total cell population. It has been 
shown that there are two stem cell populations within the dental pulp, with different 
characteristics. One of the stem cells has been proposed to originate from the neural crest 
(derived from the ectomesenchyme) and the other from the mesenchyme (Sloan and 
Waddington, 2009).  
Stem cells from the pulp of exfoliated deciduous teeth have been isolated and shown to have 
an increased proliferation rate and an increased number of cell population doublings when 
compared to bone marrow derived MSCs. These cells have been reported to be unable to form 
a complete dentin pulp-like complex, although they are able to differentiate into putative 
odontoblasts (Sloan and Waddington, 2009). These cells have also been shown to differentiate 
into adipocytes, chondrocytes, neuronal-like cells and glial cells and have also demonstrated 
the ability to stimulate the osteogenic differentiation of murine cells in immunocompromised 
murine models of calvarial defects (Petrovic and Stefanovic, 2009). 
The dental papilla is a collection of ectomesenchymal cells found in the developing tooth and 
as tooth developments nears completion the papilla eventually converts to pulp tissue.  It has 
been shown that stem cells isolated from the apical papilla have a twofold to threefold higher 
proliferation rate than those from the dental pulp and are more committed to osteogenic and 
dentinogenic lineages. These cells also express several neural markers and are very weakly 
adipogenic (Petrovic and Stefanovic, 2009). 
The peridontal ligament is a connective tissue that attaches the tooth to the alveolar bone that 
helps the tooth to remain attached in the mouth through the rigours of chewing food. It has 
been demonstrated that these cells are able to form a dentin-pulp complex, and periodontal 
ligament-cementum when transplanted into immunocompromised mice (Liu et al., 2006). 
These cells have also been demonstrated to be able to differentiate into odontoblasts, 
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adipocytes, neurons, oligodendrocyte and astrocyte-like cells (Seo et al., 2004; 
Techawattanawisal et al., 2007).  
The final types of stem cells currently found in the tooth are dental follicle progenitor cells and 
these are found in the dental follicle, a protective tissue that surrounds the developing tooth 
germ that can be isolated during wisdom tooth extraction. These cells have been shown to 
differentiate into periodontal ligament fibroblasts, cementoblasts, adipocytes, and neuron-like 
cells (Petrovic and Stefanovic, 2009).  
1.2.8 ADIPOSE DERIVED STEM CELLS 
Adipose derived stem cells (ADSCs) are another type of adult stem cell that has received 
attention, as a stem cell type that can be obtained from an autologous and self-replenishing 
source and differentiated into a variety of cell types. The stromal vascular fraction of adipose 
tissue has received the most attention for containing the ADSCs. The stromal vascular fraction 
of adipose tissue is composed of a heterogenous mixture of cells including fibroblasts, 
pericytes, endothelial cells, the aforementioned ADSCs (which form up to 2%) and circulating 
blood cells. Adipose tissue is a promising source of ADSCs because it is available in relatively 
large volumes through processes such as liposuction (100 ml-1 litre) with minimal morbidity 
(Yarak and Okamoto, 2010). ADSCs have been differentiated into bone, fat, cartilage, skeletal 
and cardiac myocytes and endothelial and neuronal lineages (Wilson et al., 2011). ADSCs 
appear to be very similar to bone marrow mesenchymal stromal cells and umbilical cord stem 
cells, with no differences in morphology or phenotype. ADSCs however occur at a higher 
frequency in adipose tissue than bone marrow mesenchymal stromal cells in the medullary 
stroma and also have an increased proliferative capacity (Yarak and Okamoto, 2010). These 
stem cells have been used therapeutically in a range of applications, for orthopaedic surgery, 
neurosurgery, otolaryngology (vocal cord grafting) and in general and vascular surgeries to fill 
defects and enhance wound healing (Wilson et al., 2011). ADSCs are able to express multiple 
growth factors and when differentiated into endothelial cells have been shown to express 
vascular endothelial growth factor (VEGF) and hepatocyte growth factor, which demonstrates 
the potential of these stem cells to be involved in neoangiogenesis (Fraser et al., 2006).  
1.2.9 CLINICAL POTENTIAL OF MSCS 
Aside from the fact that MSCs represent a rapidly expandable, easy to access source of 
multipotent cells that could be used to treat a wide variety of conditions, there is another 
feature that makes them very desirable for use in therapy; the reported ability of MSCs to 
reduce inflammation and exhibit immunosuppressive effects. It has been reported that human 
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MSCs are able to suppress lymphocyte alloreactivity in-vitro in mixed lymphocyte reactions 
(MLRs) through HLA independent mechanisms (Bartholomew et al., 2002; Le Blanc et al., 
2003a; Tse et al., 2003).  Animal models intravenously administered with MSCs have shown 
improved outcomes of lung, renal and neural injury, through both paracrine effects and a 
switch from pro-inflammatory to anti-inflammatory cytokines at the site of injury (Ortiz et al., 
2003; Togel et al., 2005; Zappia et al., 2005; Le Blanc and Ringden, 2007). 
Bone marrow MSCs have many therapeutic uses that can be split into two main areas, as a cell 
therapy using systematic infusion or localised injection, or as the stromal cell used in tissue 
engineered constructs (Figure 1.2). 
The use of MSCs in tissue engineering has generated a large amount of interest, due to the 
relative ease and isolation of these cells and their multipotentiality. MSCs have been 
investigated extensively for attempt the regeneration of bone, cartilage and adipose tissue. 
1.2.10 BONE TISSUE ENGINEERING 
Bone defects arising from trauma, infection and tumors represent a medical and 
socioeconomic challenge, with the majority of these defects treated using surgical techniques 
including autologous, allogeneic or artificial bone grafting. Artificial bone grafts have 
Figure 1.2: An overview of the therapeutic potential of MSCs as systemic cell therapies, or 
localised tissue engineered replacements. Image taken from (Kagami et al., 2011). 
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limitations including their mechanical properties and biodegradation (artificial bone should 
exibit the same mechanical properties as natural bone). Autologous bone grafting may result 
donor site morbidity (Hosseinkhani et al., 2006) and allogeneic bone may suffer with problems 
relating to the immunogenicity of the grafted bone. Under physiological conditions, one of the 
roles of MSCs is the supply of osteoblasts for bone synthesis. In order to induce osteogenic 
differentiation of MSCs in-vitro, various supplements are added to the culture medium. The 
most common of these are β-glycerophosphate, ascorbic acid, and dexamethasone (Jaiswal et 
al., 1997; Pittenger et al., 1999; Jones et al., 2002). Various 3D supporting matrices have been 
investigated as scaffolds to aid in the differentiation of bone formation by MSCs. There are 
numerous reports of utilising MSCs in various scaffolds with and without growth factors and 
with or without physical stimulation to generate tissue engineered bone in-vitro. Bone marrow 
MSCs have been used to treat bone defects in a small number of clinical trials/studies, with 
various results obtained. Autologous culture expanded bone marrow MSCs have been 
implanted along with hydroxyapatite particles to treat intra-oral osseous defects. This resulted 
in the formation of bone in a proportion of patients, but failed to perform as well in others 
(Meijer et al., 2008). This study highlighted some of the issues in bone tissue engineering. 
When the same experiment was performed in proof of concept studies in mice all the test 
subjects demonstrated bone formation, whereas in the clinic a large degree of variability was 
observed. Clinical products for the regeneration of bone using MSCs in man are starting to 
make their way onto the market. Mesoblast offers an allogeneic based MSC product that 
promises to aid in the union of long bone fracture after trauma or stress. A pilot clinical trial 
demonstrated increased union and healing in what would have otherwise been permanent 
non-healing of the fractures without this cell therapy. Interestingly, it has recently been 
demonstrated in an immunocompromised murine model that implantation of ceramic 
scaffolds seeded with murine MSCs stimulated the formation of host bone, rather than the 
MSCs themselves differentiating into osteoblasts (Tortelli et al., 2010). 
1.2.11 CARTILAGE TISSUE ENGINEERING 
Repair of defects in cartilage tissue, arising from trauma, osteoarthritis or osteochondritis, is 
another promising avenue for tissue engineered constructs incorporating MSCs. Articular 
cartilage has very limited regenerative capabilities, and defects rarely heal unless the defect 
extends to the subchondral bone (Khan et al., 2010). Intervention using autologous 
osteochondral plugs can result in donor site morbidity and poor integration due to 
chondrocyte death. The repair of defects using autologous chondrocyte implantion is 
problematic due to difficulty of cell isolation and expansion in culture. Micro-fracture to 
release bone marrow cells to heal the defect is also not ideal, as it can often result in the 
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formation of fibrous rather than hyaline tissue. MSCs are routinely differentiated into cartilage 
(chondrocytes) as part of their characterisation in the trilineage assay and this is usually 
performed in 3D cultures.  These cultures are usually pellet cultures, in which MSCs are 
centrifuged to form a pellet of cells that are grown in chondrogenic medium (Pittenger et al., 
1999), or in micromasses, whereby a very high density of cells is cultured in a small area in 
chondrogenic medium (De Bari et al., 2001). The medium (both low and high glucose has been 
used) is usually  supplemented with dexamethasone, ascorbic-2-phosphate, sodium pyruvate, 
insulin-transferrin-selenium, and transforming growth factor-β 3 (TGF-β 3) (Pittenger et al., 
1999; Jones et al., 2002; English et al., 2007; Richardson et al., 2009). Preliminary studies 
assessing chondrogenesis in MSCs for therapeutic uses have focussed on culturing MSCs in 3D 
scaffolds for implantation. This provides a framework to fill the defect in-vivo, and allows 
cellular proliferation and differentiation. Natural materials such as collagen, fibrin, agarose and 
hyaluronan have been used as the scaffold (Khan et al., 2010). Likewise synthetic scaffolds 
made from polylactic acid (PLA) and polyglycolic acid (PGA), have shown promising results, but 
further long-term results are awaited (Williams and Gamradt, 2008; Khan et al., 2010).   
1.2.12  ADIPOSE TISSUE ENGINEERING 
There is a clinical need for engineered adipose tissue. Subcutaneous adipose tissue defects can 
arise from birth defects, oncologic resection and traumatic injury. Adipose tissue 
reconstruction is currently treated using methods such as autografting, fat free grafting and 
implantation of alloplastic materials (Girandon et al., 2011). These methods all suffer from 
disadvantages such as donor site morbidity and graft resorption. Multipotential mesenchymal 
stromal cells have been investigated as the cell source seeded onto suitable scaffolds to 
generate an artificial fat graft. MSCs are routinely differentiated into adipose cells in-vitro, and 
the adipogenesis of these cells is one of their characteristic features that along with 
osteogenesis and chondrogenesis, is used in the characterisation of these cells. In-vitro 
differentiation of MSCs into adipocytes is usually performed by supplementation of culture 
medium with isobutylmethylxanthine, indomethacin and hydrocortisone (Jones et al., 2002). 
Insulin has also been used to differentiate MSCs into adipose cells (Pittenger et al., 1999; 
Girandon et al., 2011) and the thiazolidinedione rosiglitasone (Fink et al., 2004; Crossno et al., 
2006). This class of compounds is used clinically as insulin-sensitising anti-diabetic agents that 
stimulate the generation of adipocytes via the activation of the nuclear hormone receptor 
PPAR-ɣ.  
The proof of concept studies using small animal models for in-vivo analysis have shown 
promising results using a variety of scaffolds in tandem with bone marrow MSCs for fat grafts. 
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PLGA hollow fibre scaffolds seeded with bone marrow MSCs encapsulated in alginate/chitin 
hydrogel capsules demonstrated sustained adipogenesis 4 weeks after implantation in nude 
mice (Bauer-Kreisel et al., 2010). Polyethylene glycol (PEG) based hydrogels have also been 
used in in-vivo models for fat grafts, again seeded with MSCs and these demonstrated 
retention of shape and dimension 4 weeks after implantation. MSCs seeded onto the scaffold 
and adipogenically differentiated before implantation resulted in the formation of adipose 
tissue in-vivo (Bauer-Kreisel et al., 2010). The majority of in-vivo studies thus far has been in 
small animal models and further in-vivo studies using longer term studies and in larger animals 
is needed. ADSCs have been also been suggested to use in soft tissue reconstruction to 
attempt to restore function and/or cosmesis. Therapies involving the use of synthetic filler 
materials are troubled with complications such as infection, cost and need for re-operative 
procedures (Wilson et al., 2011). Non-synthetic options involving fat grafting also have 
problems, with donor site morbidity/availability and graft reabsorption rates of between 20 
and 90%. The use of biomaterials has been proposed as an alternative to free ADSC transfer, 
using materials such as collagen and hyaluronic acid gel. The use of biomaterials may aid 
differentiation of the ADSCs, and provides mechanical support to the cells.   
1.2.13 AUTOLOGOUS VS ALLOGENEIC MSCS 
There are some issues that need to be addressed in the context of tissue engineering using 
MSCs. One of the main issues that needs to be addressed is the choice of donor cells; 
autologous cells, or allogeneic? If autologous cells are used the cells have to be harvested from 
the patient. Due to the low number of MSCs usually obtained in primary harvesting, there is 
inevitably a time delay as the patient’s own cells are expanded to generate sufficient numbers. 
If a scaffold is to be used, will undifferentiated MSCs be seeded directly before implantation, 
or will the cells be differentiated on the scaffold before implantation? The latter would result 
in an even greater delay before the patient receives the tissue engineered construct. If 
allogeneic cells are used MSCs could be isolated and expanded from donors, seeded onto 
scaffolds and differentiated in readiness for implantation in the patient. This approach has the 
advantage of a single invasive procedure for the recipient patient and the availability of the 
construct ‘off the shelf’. Thus the use of allogeneic MSCs is commercially extremely attractive. 
The use of allogeneic cells could potentially be restricted due to immune rejection of 
transplanted cells. MSCs are perhaps ideally suited to allogeneic transplantation, as there is a 
great deal of evidence in the literature suggesting that MSCs are immuno-privileged and are 
not subject to recognition, or elimination by the immune system (Bartholomew et al., 2002; 
Tse et al., 2003; Jones et al., 2007; Niemeyer et al., 2007; Oh et al., 2008; Suva et al., 2008). 
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1.3 IMMUNOLOGICAL RESPONSES TO ALLOGENEIC CELLS AND TISSUES 
In order to understand the concept of MSCs being immuno-priviledged, it is nessesary to 
understand how the immune system recognises alloantigens and therefore how cells are 
recognised as self, or non-self.  
1.3.1 ADAPTIVE VERSUS INNATE IMMUNITY 
The immune response in the human body is split into two levels; the innate response, and the 
adaptive (acquired) response.  
Innate Immunity is mainly comprised of reactions of a non-specific nature, such as direct 
barriers to infection (the skin), complement activation pathway, interferon secretion and 
killing of virus infected cells by natural killer (NK) cells. One of the most important cell types of 
the innate response is the phagocyte. These cells,  comprised of macrophages and neutrophils, 
are able to recognise, ingest and subsequently destroy many pathogens without the need of 
the adaptive response (Janeway et al., 2005). Phagocytes are able to recognise different 
‘patterns’ expressed by microbes (known as pathogen associated molecular patterns). Upon 
recognition of these molecules on the surface of the invading microbes, the cell engulfs the 
pathogen and internalises it in a process known as phagocytosis, culminating in the elimination 
of the engulfed pathogen. 
Adaptive immunity is characterised by two main attributes; the specificity for the ‘foreign’ 
antigen and immunological memory (the increased more rapid response towards a previously 
encountered/similar antigen). The cell types associated with adaptive immunity are antigen-
presenting cells (APCs), B-cells (bone marrow-derived lymphocytes), and T-cells (thymus-
derived lymphocytes) (Stites, 1991). Antigen presenting cells are cells whose role is to 
phago/pino-cytose foreign proteins/organisms, and process the antigen into peptide form that 
is presented on the surface of the cell via the major histocompatability complex (MHC), 
forming an immunogenic complex. The major histocompatability complex (MHC) is a large 
genomic region present in most vertebrates. The genes and hence the proteins expressed by 
the MHC are extremely polymorphic in the population. Cell surface molecules encoded by the 
MHC present antigens to T-cells allowing the T-cells to recognise ‘self’ and ‘non-self’ cells and 
take action accordingly. In humans the MHC is known as the human leukocyte antigen (HLA) 
system. T-cells, which are the effector arm of the immune response, can ordinarily only 
recognise antigens that have been processed and presented with the MHC and associated co-
stimulatory molecules present on the surface of these cells. CD4 positive T cells (also known as 
helper T cells or TH cells) require antigen to be presented with MHC class II. This subset of T-
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cells are the predominant mediators of cytokine secretion, which enhances or suppresses the 
responses of other lymphocytes (Kimball, 1990).  
MHC class I, unlike class II is expressed on all nucleated cells (Stites, 1991). Another subset of T 
cells, known as CD8 positive T-cells, or cytotoxic T-cells are able to recognise antigen presented 
on MHC class I and when appropriately activated are able to eliminate the cell.  
Monocytes, macrophages dendritic cells and B-cells are able present antigens to T-
lymphocytes via ingesting and presenting peptides from foreign proteins via MHC class I and II 
present on their cell surface and are known as antigen presenting cells. 
There are two main differences between MHC class-I and II. MHC class-I molecules present 
peptides obtained from within the cell, and MHC class-II present peptides derived from 
proteins in intracellular vesicles and therefore peptides that are derived from exogeneous 
antigens internalised by antigen presenting cells. 
1.3.2 THE ADAPTIVE RESPONSE: T-CELLS AND B-CELLS 
When T-cells develop within the thymus, they express a randomly rearranged antigen receptor 
on their cell surface called the T-cell receptor (TCR) that binds to the MHC molecule expressed 
by cells of the individual. However the majority of these T-cells, due to the randomly 
generated nature of the antigen receptor, are unable to bind to the MHC proteins that are 
expressed by the individual. About 90% of the developing T-cells in the thymus die because 
they are not able to bind to MHC proteins and do not receive a survival signal (Palmer, 2003). 
Further maturation of these putative T-cells is dependent on the ability of these cells to bind to 
antigen presenting cells (APCs) expressing MHC-self peptide complexes, and therefore that the 
T-cells express a functional TCR. The most strongly reactive T-cells are very tightly controlled, 
as although a functional TCR is desirable, self-reactive T-cells are not. It is the progenitor T-cells 
that are weakly reactive that progress further and fully mature, and engagement of a MHC 
class-I peptide complex results in the maturation of a CD8+ T-cell, whereas the recognition of 
MHC class-II – peptide results in the maturation of a CD4+ restricted T-cell (Palmer, 2003). If 
the T-cell is highly reactive and binds strongly to the MHC-self complex, this results in the 
apoptotic death of the putative T-cell, preserving self-tolerance. Mechanisms exist in the 
periphery to eliminate any auto-reactive T-cells that may have progressed through maturation 
and this is mediated through the action of CD25+CD4+ regulatory T-cells (Takahashi et al., 1998; 
Hogquist et al., 2005). Mature naive CD4+ and CD8+ T-cells reside within secondary lymphoid 
tissues and recirculate in the blood and lymph in a quiescent state until they encounter specific 
antigen. 
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B-cells are lymphocytes that are involved in the humoral immune response, and the principle 
functions of these cells are to make antibodies towards antigens, act as antigen presenting 
cells, and develop into memory B cells. B-cells are produced in the bone marrow and the 
maturation process is similar to T-cells with gene rearrangement forming the antigen binding 
region of the B-cell receptor. In the context of using allogeneic MSCs in patients, the T-cell 
response plays the central role in immune recognition, therefore will be the main subject 
focussed on.    
1.3.3 THE RECOGNITION OF ANTIGEN BY T-CELLS 
The recognition of the MHC-epitope complex by the T-cell receptor is not dependent on the 
TCR and the MHC-epitope complex alone, accessory proteins are involved. The TCR is also 
associated with CD3 forming the TCR-CD3 complex and it is the CD3 molecule that initiates the 
intracellular signalling response after interaction of the T-cell with the MHC-peptide. The 
actual recognition of the MHC-epitope is mediated by the TCR-CD3 complex, but there are also 
a number of co-stimulatory molecules that play an important accessory role in the initial 
recognition of antigen and subsequent activation of naive T-cells by strengthening the 
interaction between T-cells and the antigen-presenting cell, or playing a role in signal 
transduction (Kuby, 1997). The T-cell receptor and related co-stimulatory molecules are shown 
in Figure 1.3. Although the recognition of antigen by the CD4+ and CD8+ T-cells is the same, 
the activation of the T-cells is different, and the two types of T-cell have different 
requirements before they are activated. The CD4+ T-cell is activated when the MHC class II-
epitope is recognised and presented with co-stimulatory molecules. This activates the T-cell 
which is them able to undergo clonal expansion and mature into memory T-cells and effector 
cells. The effector cells are able to secrete cytokines that regulate and assist in the active 
immune response and it is these cells that help in the maturation of B-cells and the clonal 
expansion of cytotoxic CD8+ T-cells.  CD8+ T-cells recognise MHC class I-epitope and also need 
the presence of co-stimulatory molecules to become activated. In addition to this, these cells 
also require the help of activated CD4+ T-cells before they themselves can undergo clonal 
expansion into memory and effector cytotoxic cells. This help is in the form of secreted IL-2, 
and without this CD4+ T-cell help, CD8+ T-cells cannot respond (Janeway et al., 2005). Effector 
CD8+ T-cells are able to lyse targeted cells after recognition of the MHC class I-epitope on the 
target cell via secretion of cytotoxins such as perforin, granzymes, and granulysin. 
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Figure 1.3: T-cell receptor binding. The T-cell receptor and co-stimulatory molecules present 
on the surface of T-cells involved in the recognition of antigen by T-cells. The T-cell receptor 
(TCR) recognises antigen presented by MHC molecules, with CD4 determining specificity for 
MHC class-II, and CD8 for MHC class-I. CD3 associates with the TCR and is involved in 
downstream signalling following recognition of antigen. Lymphocyte function associated-
antigen 1 (LFA1) binds to ICAM-1 on the antigen presenting cell (APC). CD28 binds to the 
costimulatory molecules CD80 and CD86 expressed by the APC and CD40L binds to the 
costimulatory molecule CD40. 
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1.3.4 HOW T-CELLS RECOGNISE ALLOANTIGEN 
It was shown in the early 1960’s that if a mixture of lymphocytes from two different individuals 
(genetically not identical), were cultured together they were capable of stimulating each other 
and generating a large number of lymphoid blast cells in-vitro (Bain et al., 1964). It was shown 
that the strongest reaction occurred (the largest number of cells produced) in the reaction that 
had discrepancy at the major histocompatability complex. From its initial use, the mixed 
lymphocyte reaction (MLR) has been used as an important experimental method for 
investigating the cellular mechanisms involved with the rejection of allografts and more 
importantly for assessing histocompatability (Stites, 1991). 
The process by which donor cells are recognised by host T-cells is called ‘allorecognition’. 
There are 3 forms of allorecognition: direct, indirect, and semi-direct. 
The concept of direct recognition is that T-cells are able to recognize intact allogeneic MHC 
class I and II molecules on the surface of allogeneic cells (Watschinger, 1995; Hornick and 
Lechler, 1997). There are two hypotheses that are used to explain why the T-cell response to 
allogeneic MHC is so strong. The first is the multiple binary complex hypothesis; this theory 
proposes that T-cells with direct allospecificity have dual specificity for both the peptide and 
the foreign MHC molecule (Hornick and Lechler, 1997). This theory states that due to the 
extreme diversity of the bound peptides that are displayed by the MHC on the cell surface, one 
MHC molecule is able to generate several hundred different peptide:MHC complexes, that are 
each recognised by an individual clone of an alloreactive T-cell. The second theory was 
proposed later and is known as the high determinant density hypothesis. The principle of this 
theory is that the ligand of the alloreactive T-cell is the allogeneic MHC molecule itself, with 
little or no specificity for peptide bound to it (Rogers and Lechler, 2001). The name of this 
theory is derived from the fact that the determinant density available to the T-cell (number of 
matching ligands) due to any molecule of allogeneic MHC potentially acting as ligand is very 
high. The affinity of the alloreactive T-cell’s receptor could be much lower than that usually 
required for a peptide:self MHC complex, and this allows T cells with low, medium and high 
affinity into the alloreactive T cell repertoire (Hornick and Lechler, 1997; Rogers and Lechler, 
2001).  
Due to the highly polymorphic nature of the MHC molecules, responder and stimulator MHC 
molecules could be similar and share conserved sequences within the T-cell receptor 
contacting surface of the molecule. It is the regions of variation within the peptide binding 
groove that bind and present different peptides. The response observed therefore is directed 
at the multiplicity of different peptides bound by the MHC molecule (Hornick and Lechler, 
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1997). This relates to the multiple binary complex hypothesis. The alternative theory can be 
explained when the exposed surfaces of the stimulator and the responder MHC molecules are 
different. Both of these theories seem to invalidate the principle of self-MHC restriction, in 
that the TCR recognises non-self MHC molecules. In order to explain why there appears to be 
such a high proportion of alloreactive T-cells there are 2 hypotheses. The first of these is 
applicable when self and non-self MHC molecules share similar conserved regions in the 
exposed TCR contacting surface of the molecule and it is difference in the peptide binding 
region that confer specificity to the binding of different sets of peptides. The alloresponse is 
therefore generated towards the variability of the different peptides bound by the MHC 
molecule. The second theory applies when the exposed surfaces of the responder and 
stimulator MHC are significantly different. The high determinant density hypothesis then 
provided a better explanation for the strength of the alloresponse and principle of self-MHC 
restriction is explained by a small number of T-cells whose TCR is specific for self-MHC 
molecules and by chance cross react with a foreign MHC molecule (Hornick and Lechler, 1997). 
Direct antigen presentation does not explain rejection in the absence of passenger leukocytes 
and therefore in-direct recognition was proposed in the early 1980’s (Lechler and Batchelor, 
1982). This proposed that the normal pathway for antigen presentation by APCs (alloantigens 
presented by donor APC to CD4+ T-cells) was an important factor in chronic graft rejection. 
The theory behind this was that initially, the donor graft could contain enough APC’s (dendritic 
cells) that could migrate to host lymphoid tissue and perform direct alloantigen presentation. 
Over time this population of donor cells would decrease, and cases where rejection is 
prolonged (chronic) can therefore be explained by the influx of host APCs. Alloantigens that 
are shed from a graft are processed as exogenous antigens by the host APCs and are then 
presented via the host APC MHC class-II and therefore the process of indirect allorecognition is 
predominantly performed by CD4+ T-cells (Caballero et al., 2006; Afzali et al., 2007). Because 
of the nature of this response, the pathway of indirect recognition is comparatively slower 
than direct recognition. Typically in rejection, there is infiltration and proliferation of 
lymphocytes and monocytes into vascularised grafts before day 6, with full graft rejection 
occurring by 10-12 days (Kuby, 1997). Interaction and crosstalk between the direct and indirect 
pathways of recognition (indirect CD4+ T-cells are able to diminish, and amplify the direct 
pathway CD8+ T-cell responses) have previously relied on the so called 4-cell unlinked model, 
where the host CD8+ cytotoxic T-cells are stimulated via the direct pathway by the donor cells, 
while helper or regulatory CD4+ T-cells are recruited through interaction with the host APC 
presenting allogeneic MHC via the indirect pathway (Afzali et al., 2007). These two methods of 
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allorecognition do not take into account that CD4+ and CD8+ T-cells are recruited and linked 
by the same APC.  
The final method of allorecognition attempts to explain this. This method of allorecognition is 
called the semi-direct pathway. In this pathway donor MHC molecules expressing allogeneic 
antigen are transferred to the host dendritic cells, allowing the stimulation of CD8+ T-cells via 
the direct pathway and peptides of histocompatibility antigens which are then processed and 
presented allow the recruitment of CD4+ T-cells via the indirect response (Afzali et al., 2007; 
Gokmen et al., 2008). This transfer of MHC molecules can occur via cell to cell contact or 
exosomes, and links direct and indirect allorecognition pathways through a single APC. An 
overview of the three different methods of allorecognition is shown in Figure 1.4.  
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Figure 1.4: An overview of direct, indirect, and semi-direct alloantigen recognition. A) In direct 
recognition recipient T-cells are able to recognize intact allogeneic MHC molecules present on the 
surface of the donor antigen presenting cell. B) In in-direct alloantigens that are shed from graft 
cells are processed as exogenous antigens by the recipient APCs, and are then presented via the 
host APC MHC class-II to CD4+ T-cells. C) In semi-direct allorecognition donor MHC molecules 
expressing allogeneic antigen are transferred to host dendritic cells allowing the stimulation of 
CD8+ T-cells via the direct pathway, and peptides of histocompatibility antigens are processed and 
presented allow the recruitment of CD4+ T-cells via the indirect response, which aid in CD8+ T-cell 
priming. Figure taken from Gokmen et al. (2008).  
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Historically the direct pathway of recognition has been favoured as the dominant pathway in 
the role of allorecognition, in particular when acute rejection occurs when there is a rapid 
initiation of the allograft response. The current view however places a lot more emphasis on 
the role that indirect and semi-direct recognition plays in the role of allorecognition (Rogers 
and Lechler, 2001). In the role of allorecognition of MSCs, it is believed that these cells are not 
able to be recognised directly by T-cells due to their lack of co-stimulatory molecule and MHC 
class II expression. When determining if MSCs are able to elicit an immune response, it is 
important to be able to determine which part of the response are the MCSs most likely to 
encounter.  
1.4 IMMUNOGENICITY AND IMMUNOMODULATION BY MSCS 
It has been well documented that hMSCs express intermediate levels of cell-surface MHC class 
I molecules, but that MHC class II is not expressed on the cell surface. MHC class II molecules 
have been shown to be present intracellularly (Klyushnenkova et al., 2005). Le Blanc et al 
showed that when differentiated into bone, fat, and cartilage for 6-12 days, MSCs continued to 
express HLA class I, but even after the addition of interferon-γ (IFN-γ) which usually causes an 
increase in both MHC class I and II in MSCs (Klyushnenkova et al., 2005), no surface expression 
of class II was induced (Le Blanc et al., 2003a). 
If allogeneic cells are transplanted into a person with a healthy immune system without the 
administration of immunosuppressant’s, the cells will be recognised by the host’s immune 
system and killed. Human MSCs do not express co-stimulatory molecules CD40, CD80, or CD86 
even after IFN-γ administration and as such are protected from T-cell recognition by the direct 
pathway of recognition (Le Blanc and Ringden, 2007). This is not the only mechanism that 
recipient T-cells can be activated by; they can also be activated indirectly by recipient antigen 
presenting cells (APCs). The indirect activation process occurs when foreign antigens released 
from dead cells are taken up into APCs through endocytosis and are presented on the surface. 
This presentation of foreign antigen primes T-cells to target and neutralise cells expressing the 
antigen as described above. When allogeneic lymphocytes are cultured with skin fibroblasts or 
renal tubular epithelial cells, the lymphocytes have been shown proliferate (Le Blanc and 
Ringden, 2007). When differentiated MSCs (fat, bone and cartilage) and undifferentiated MSCs 
were co-cultured with allogeneic lymphocytes for up to 7 days then no proliferation was 
observed. This occured even in the presence of APCs and after the provision of co-stimulatory 
signals using both CD80 or CD86 gene transduction in the MSCs, or CD28 specific antibodies 
(Bartholomew et al., 2002; Le Blanc et al., 2003a; Beyth et al., 2005; Klyushnenkova et al., 
2005).  As well as the proliferation of lymphocytes, alloreactivity can also be measured by 
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production of IFN-γ. Studies measuring the IFN-γ production of activated lymphocytes when 
cultured with MSCs correlated with the proliferation studies; hMSCs did not elicit IFN-γ 
production in human peripheral blood mononuclear cells (PBMC), but non-immunomodulatory 
cells such as fibroblasts did (Krampera et al., 2003; Klyushnenkova et al., 2005).  
The evidence indicates that MSCs therefore do not induce lymphocyte proliferation, 
upregulate activation-associated markers, or stimulate IFN-γ production.  As well as being 
protected from the CD4+ T-cell response, MSCs have been shown to escape lysis by CD8+ 
cytotoxic T-cells (Bartholomew et al., 2002; Rasmusson et al., 2003). Rasmusson et al 
demonstrated that unseparated lymphocytes stimulated in-vitro to target PBMCs that were 
derived from a specific donor could lyse lymphocytes from the same individual, but not the 
patients MSCs (Rasmusson et al., 2003). The same group also demonstrated the ability of MSCs 
to both avoid natural killer (NK) cell specific lysis, and induce an abortive activation programme 
in fully differentiated CD8+ T-cells so that the major effector functions were not activated 
(Rasmusson et al., 2003; Le Blanc and Ringden, 2007).  
1.4.1 MSCS AND T-CELLS 
The ability of MSCs to suppress T-lymphocyte activation and proliferation was first 
demonstrated in 2002 (Di Nicola et al., 2002; Le Blanc et al., 2003a; Tse et al., 2003). T-cells 
induced by mitogens (Bartholomew et al., 2002; Di Nicola et al., 2002; Krampera et al., 2003; 
Le Blanc et al., 2003a; Tse et al., 2003), alloantigens (Le Blanc et al., 2003a; Potian et al., 2003; 
Tse et al., 2003) or antibodies to CD3 and CD28 (Bartholomew et al., 2002; Krampera et al., 
2003; Tse et al., 2003) have been shown to have their proliferation suppressed when co-
cultured with MSCs. Studies have also shown the ability of MSCs to inhibit the cytotoxic effects 
of activated cytotoxic T-cells (Potian et al., 2003), but this is thought to be due to an inhibition 
of proliferation of the T-cells rather than a direct suppression of cytolytic activity (Rasmusson 
et al., 2003) and this was further demonstrated as cytotoxicity was not affected when MSCs 
were added after the T-cells became activated.   
The suppression observed appeared to be independent of MSC source and the effects 
remained constant if either allogeneic or autologous MSCs were used (Le Blanc et al., 2003a). 
It is thought that the suppression observed was due to secreted soluble factors, as when MSCs 
were separated from PBMCs by a semi-permeable membrane no change in the effect was 
observed (Di Nicola et al., 2002; Tse et al., 2003). Interestingly, it also seemed that in order for 
the inhibitory factors to be produced, MSCs needed to be grown in the presence of 
lymphocytes. This suggested that a dynamic cross-talk between T-cells and MSCs existed 
before production of the immunosuppressive soluble factors was initiated (Nauta and Fibbe, 
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2007). Di Nicola et al have suggested that hepatocyte growth factor (HGF) and TGF-β mediated 
suppression in mixed lymphocyte cultures, a finding supported by neutralising antibodies 
towards HGF and TGF-β allowing T-cells to once again proliferate (Di Nicola et al., 2002). This 
has however been contested with other groups unable to reproduce the effects obtained (Le 
Blanc et al., 2004a). Instead different mechanisms are thought to be involved, with specific 
mechanisms depending on the stimulus.  
Another method proposed to explain how MSCs modulate the immune response is though the 
upregulation of regulatory T-cells (T-regs). These cells are naive T-cells that express CD25 and 
suppress T-cell proliferation (Blazar and Taylor, 2005). Djouad et al have shown that MSCs 
induced the formation of CD8+ regulatory T-cells that inhibited the proliferation of allogeneic 
lymphocytes (Djouad et al., 2003). When MSCs were cultured with mitogen stimulated PBMCs, 
an increase in CD4+CD25+ cells displaying regulatory phenotype (positive for FOX P3) was 
observed (Djouad et al., 2003). These cells have yet to be functionally analysed and it is 
possible that they do not have any effect on T-cell proliferation, as other studies have shown 
that CD4+CD25+ T-regs have no effect on the modulation of T-cell proliferation by MSCs 
(Krampera et al., 2003). 
Indoleamine 2, 3-dioxygenase (IDO), an enzyme catalysing tryptophan breakdown, is also 
thought to be involved in the inhibition of T-cell proliferation by MSCs (Meisel et al., 2004).  
When MSCs are exposed to IFN-γ (produced by activated T-cells) they produce IDO which 
results in the depletion of tryptophan and the production of kynurenine breakdown products. 
These products have been shown to inhibit lymphocyte proliferation (Nauta and Fibbe, 2007). 
It is still unclear what role IDO actually plays in T-cell suppression (Aggarwal and Pittenger, 
2005); one study found that the degradation of tryptophan into kynurenine products induced 
apoptosis in T-cells (Plumas et al., 2005), yet other studies have found that MSCs do not induce 
apoptosis in T-cells (Rasmusson, 2006; Le Blanc and Ringden, 2007).  
It has been shown that MSCs constitutively produce prostaglandin E2 (PGE2) and expression of 
this mediator is upregulated when MSCs are cultured with PBMCs (Tse et al., 2003). The 
suppression of PGE2 synthesis has also been reported to stop the MSC mediated inhibition of 
T-cell cytokine production and profileration (Aggarwal and Pittenger, 2005), but this effect has 
been contested by other studies (Rasmusson et al., 2003; Tse et al., 2003).   
Although there is widespread use of the term immunosuppressive effects of MSCs most of the 
evidence to date has only demonstrated the ability of MSCs to inhibit T-cell proliferation in-
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vitro, therefore primarily affecting the effector arm of the T-cell immune response (Nauta and 
Fibbe, 2007). 
1.4.2 MSCS AND APCS 
As discussed previously, APCs are able to present antigens to T-cells via MHC on the cells 
surface. T-cells can recognise this complex via their T-cell receptor resulting in the activation of 
the T-cell. MSCs have been shown to reduce the formation of dendritic cells (DCs) from 
monocyte precursors (Maccario et al., 2005). As DCs are APCs this results in reduced T-cell 
activation. When DCs were grown in the presence of MSCs their response to maturation 
signals was impaired and the ‘mature cells’ did not express CD83 or upregulate their 
expression of other co-stimulatory molecules (Zhang et al., 2004). Immature DCs grown 
together with MSCs have been shown to exhibit very poor T-cell activation efficacy (Nauta and 
Fibbe, 2007).  The cytokine secretion profile of DCs is altered when grown with MSCs, with 
decreased production of pro-inflammatory cytokines IFN-γ, IL-12 and TNF-α and an 
upregulation of the anti-inflammatory cytokine IL-10 (Aggarwal and Pittenger, 2005; Beyth et 
al., 2005; Jiang et al., 2005). From the observed effects thus far, it seems that MSC can affect 
the generation of DCs and their subsequent maturation, in order to generate a subset of DCs 
that have an immune-inhibitory phenotype. Nauta et al also demonstrated that the inhibitory 
effects of MSCs on DCs are caused in part by soluble factors (Nauta et al., 2006a). Blocking 
studies carried out on the production of IL-6 and mononuclear-phagocyte colony stimulating 
factor (M-CSF) by MSCs have shown that although these factors play a part in suppressing DC 
maturation, they are not solely responsible (Nauta and Fibbe, 2007).  PGE2 has again been 
proposed to be involved in this process, and the blocking of PGE2 synthesis restored the 
secretion of IFN-γ and TNF-α by DCs (Aggarwal and Pittenger, 2005). The increased production 
of the anti-inflammatory cytokine IL-10 by DCs when cultured with MSCs may also play a role 
in their ability to suppress T-cell proliferation, as neutralising antibodies to IL-10 increased T-
cell proliferation in culture (Beyth et al., 2005).  
As well as directly suppressing T-cell proliferation, the disruption of APC maturation and 
alteration of cytokine expression profile is thought to play a role in indirectly suppressing T-cell 
proliferation. 
1.4.3 MSCS AND B-CELLS 
There is little evidence to suggest that MSCs can suppress B-cell proliferation; it has been 
shown that MSCs can inhibit lymphocyte proliferation induced by Staphylococcus aureus 
Protein A and pokeweed mitogen (Corcione et al., 2006; Le Blanc and Ringden, 2007). As 
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protein A stimulates the proliferation of T and B-cells and lymphocyte stimulation by 
pokeweed mitogen is T-cell dependent, inhibition of B-cell proliferation cannot be shown to be 
separate from T-cells (Le Blanc and Ringden, 2007). These studies have only been carried out in 
murine models, but human MSCs have been shown to reduce the level of IgM, IgG and IgA 
produced by activated B-cells when cultured in a 1:1 ratio (Corcione et al., 2006). MSCs were 
shown to alter the expression of chemokine receptors CXCR4, CXCR5 and CCR7B through 
downregulation and also reduced the chemotaxis to CXCL12, CXCR4 ligand, CXCL13 and to the 
CXCR5 ligand, but only when large numbers of MSCs were present (Le Blanc and Ringden, 
2007). In fact, at a 10-fold lower dose of MSCs, splenic and blood derived B-cells were actually 
stimulated towards IgG production as tested by Elispot (Rasmusson et al., 2007). It is possible 
that in the presence of excess MSCs, the stimulatory path becomes overloaded, suggesting 
that the nature of the effect is influenced by the magnitude of the stimulus (Le Blanc et al., 
2003a). When separated by a semi-permeable membrane it has been shown that the soluble 
factors released result in the inhibition of proliferation of B-cells, but actual culture 
supernatant had no effect. This suggests that the inhibitory soluble factors are released only 
after paracrine stimulation of MSCs by the B-cells (Corcione et al., 2006).  
1.4.4 MSC AND NK CELLS 
Natural Killer (NK) cells express cell surface receptors that receive signals from the 
environment and other cells. Depending on this signal NK cells respond by producing effector 
molecules that can inhibit cell growth, lyse cells, and transmit signals to other cells of the 
immune system. It has been suggested that MSCs are able to suppress IL-2 and IL-15 driven 
NK-cell proliferation and IFN-γ production (Rasmusson et al., 2003; Sotiropoulou et al., 2006; 
Spaggiari et al., 2006), but are not able to inhibit lysis by freshly isolated NK cells. Again the 
proliferation and cytokine production of IL-15 stimulated NK cells was shown to be inhibited by 
soluble factors, but the cytotoxicity required cell-cell contact suggesting that different 
mechanisms exist for NK suppression by MSCs (Sotiropoulou et al., 2006). Although these 
studies suggest that MSCs are able to decrease the proliferation of NK cells, a 1:1 ratio of NK 
cells:MSCs was needed in order to get a 50% reduction in growth (Maccario et al., 2005; 
Spaggiari et al., 2006).  At ratios of 10:1 there ceased to be any inhibition of proliferation and 
at this ratio there is also no inhibition of CTL or NK cell cytotoxic function. Based on the study 
by Maccario et al, only very high concentrations of MSCs downregulated the expansion of 
CD8+ T-cells, and both Spaggari and Maccario showed that very high concentrations are 
needed for the downregulation of NK cells (Maccario et al., 2005; Spaggiari et al., 2006). It is 
not currently possible to use this many cells in in-vivo therapies, so at present these studies 
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have shown that NK-cell modulation by MSCs as a therapeutic treatment in-vivo would be 
minimal.  
A summary of the different ways in which MSCs have been reported to affect the immune 
system is shown in Figure 1.5: 
1.5 IMMUNOMODULATION BY MSCS IN-VIVO 
Although there has been a large amount of work carried out on the immunosuppressive 
effects of MSCs in-vitro there is still limited data on their in-vivo effects. Bartholomew et al 
demonstrated in baboons that a systemic infusion of allogeneic MSCs extended skin graft 
lifespan from 7 to 11 days and failed to elicit an immune response from the host lymphocytes 
(Bartholomew et al., 2002). The skin grafts were still rejected however. In a human patient 
with severe aplastic anemia, semi-allogeneic MSCs were given as an infusion after 
cyclophosphamide treatment (Fouillard et al., 2003). Severe aplastic anemia is an auto-
immune disease in which a subset of cases exhibit damage to bone marrow stroma. Analysis of 
the patient’s bone marrow after the infusion demonstrated partial recovery of stroma, and the 
presence of semi-allogeneic MSC engrafted into the bone marrow itself. LeBlanc et al had 
Figure 1.5: An overview of how the factors secreted by MSCs have been reported to affect 
the immune response. Figure taken from (Nauta and Fibbe, 2007). 
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more promising results in a study in which fully mismatched allogeneic fetal liver-derived MSCs 
were infused into a fetus diagnosed with serious osteogenesis imperfecta (Horwitz et al., 
2005). No lymphocyte proliferation against the transplanted MSCs was observed, and MSCs 
were found to have engrafted and differentiated into bone in samples analysed when the 
patient was 9 months of age. Although this study was conducted in a fetus in whom self-
tolerance mechanisms would result in the implanted MSCs being recognised as part of the 
host, this study still showed that allogeneic MSCs are able to engraft, differentiate and induce 
tolerance when transplanted into a host with an immature immune system. Koc et al 
conducted two separate studies into the use of MSCs in breast cancer patients and patients 
suffering from Hurler syndrome and metachromatic leukodystrophy (MLD) (Koc et al., 2002). 
Hurler syndrome and MLD sufferers develop significant skeletal and neurological defects that 
hinder their survival. Treatment for these diseases usually involves hematopoietic stem cell 
transplantation to partially correct some of the clinical manifestations. This is a risky process 
with the chances of the patient developing graft-versus host disease (GvHD). Following semi-
allogeneic MSC infusion, some of the MLD patients exhibited significant improvements in 
nerve conduction velocity, and bone mineral density was either maintained or improved with 
no immune rejection of MSCs noted. More recently a clinical trial was carried out in Europe, in 
which donor MSCs were infused into 14 children undergoing CD34+ HLA-disparate cell 
transplantation (Ball et al., 2007). Historic controls had shown a graft failure rate of 15% in 47 
patients, but in all patients infused with MSCs, hematopoietic engraftment was a success.  
LeBlanc et al have conducted further studies on using allogeneic MSCs as a 
treatment/preventative for GvHD. MSCs were given to a patient exhibiting severe GvHD that 
was unresponsive to all previous therapy (Le Blanc et al., 2004a); After MSC administration the 
patient made a full recovery due to the rapid immunosuppressive and healing effect on the 
gut, and one year on from the treatment the patient was still well. A larger scale study lasting 
over 60 months aimed to assess, using a large number of patients, if MSC infusion could 
alleviate GvHD occurring after haemotopoietic stem cell transplantation (HSCT). Of 55 patients 
all with steroid-resistant, acute, severe GvHD, 39 responded to MSC infusion, resulting in 
alleviated symptoms and higher survival rate (Le Blanc et al., 2008).  Over 50% of patients that 
had a complete response to treatment were alive 2 years after treatment. Although more work 
needs to be carried out on how the dose of MSC can affect the treatment of GvHD, there are 
two randomized European phase III trials that have recently started to further investigate the 
potential of allogeneic MSC as a treatment or preventative measure of acute GvHD following 
allogeneic stem cell transplantation (Nauta and Fibbe, 2007). A pilot study using 7 patients co-
administered with MSCs when undergoing HSCT again had promising results with increased 
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reconstituted haematopoiesis in patients who had previous graft failures and showing that co-
transplantation of MSCs with HSCT has positive effects (Le Blanc and Ringden, 2007). The latest 
study recruiting patients for a phase III clinical trial for steroid refractory acute GvHD and for 
newly diagnosed acute GvHD has completed enrolment and the results of this are eagerly 
anticipated (Trounson et al., 2011). The study is being conducted by a company called Osiris 
Theraputics and it is their product Prochymal (an intraveneously administered formulation of 
allogeneic MSCs) that is being evaluated for the phase III clinical trial. This product is also 
under evaluation in phase II clinical trials for repair of cardiac tissue following heart attack and 
the repair of lung tissue in patients with chronic obstructive pulmonary disease. A further 
product, Chondrogen (another injectable formula of allogeneic MSCs) is also being evaluated 
to treat arthritis in the knee.  
It is thought that transplanted MSCs migrate to a wide variety of tissues in the body to mediate 
immune suppression, and can even be found engrafted within bone tissue (Le Blanc and 
Ringden, 2007; Nauta and Fibbe, 2007). Allogeneic MSCs have also been demonstrated to 
engraft into a patient’s bone marrow (Fouillard et al., 2003). One study found that in a rat 
model after intra-venous injection of MSCs the majority of uptake of these cells was in the 
lungs up to 4 hours after infusion (Barbash et al., 2003). 
The use of MSCs in the majority of the above studies does not provide true insight into the 
immunogenicity of allogeneic MSCs in vivo, since, in these studies most of the patients had 
been subjected to immunosuppressive therapy prior to receiving the allogeneic MSCs and 
therefore were not fully immunocompetent. In instances where patients are 
immunocompetent no long term engraftment or presence of allogeneic cells has currently 
been demonstrated. 
1.6 CLINICAL USES OF MSCS 
Much of the knowledge regarding MSCs has been acquired from in-vitro experimentation, and 
more work needs to be done in clinical trials. Animal models do provide a basis on which to 
make hypotheses, but differences exist between human and animal MSCs in addition to the 
differences between the responses towards alloantigens. To help monitor progress of ongoing 
clinical trials and outcomes, a database set up within the European Group for Blood and 
Marrow Transplantation (EBMT) will hold details of patients treated, cells transplanted and 
clinical outcomes. Currently, there are over 120 clinical trials involving MSCs for human use 
(Figure 1.6). 
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The majority of these are in Phase I-II, so still in the proof of efficacy and safety studies 
(Trounson et al., 2011). The majority of these studies use autologous MSCs and the largest 
area is for the treatment of immune related and auto-immune diseases. Although it is still 
early days, there are over 400 patients treated using MSCs to reduce inflammation and halt 
disease progression and further analysis into how MSCs affect the long term stability and 
progression of diseases/conditions will occur as time progresses.  
In addition to using semi-allogeneic and allogeneic MSCs in the clinic, some studies have used 
autologous MSCs. One study performed demonstrated that autologous MSC infusion when 
performed with peripheral-blood stem cell transplantation induced rapid hematopoietic 
recovery (enhancing engraftment) (Koc et al., 2000). 
Although there is little evidence for the differentiation of MSCs into functional neuronal cells 
some clinical trials have been performed injecting autologous MSCs intrathecally into spinal 
cord cerebrospinal fluid (allowing cells access to the brain and spinal column). This was 
performed in patients suffering from multiple sclerosis and amyotrophic lateral sclerosis 
(Karussis et al., 2010). The results of this study suggested that MSCs do exhibit an 
immunomodulatory effect in-vivo, as there was an increase in regulatory T-cells and a 
Figure 1.6: Current clinical trials using MSCs in humans, with number of clinical trials on 
segments, and the clinical area in which the trials are being undertaken. Data from this 
figure are taken from clinical trials.gov. Adapted from (Trounson et al., 2011). 
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reduction in the proportion of activated dendritic cells and lymphocytes and a reduction in 
lymphocyte stimulation by PHA, observed as early as 4 hours post administration.  
There are further clinical trials currently underway, evaluating the use of MSCs in bone repair 
(the healing of non-union fractures), with 36 patients with fracture gaps of larger than 6cm 
treated with a mixture of stromal, progenitor cells, and autologous MSCs. In tandem with this 
another trial is underway  in which 24 patients with distal tibial fractures have been treated, 
again using autologous MSCs (Tseng et al., 2008). The follow up results of these studies are 
awaited. 
It has been shown that when expanded ex-vivo murine MSCs have dramatically reduced 
engraftment capacity and homing potential (Rombouts and Ploemacher, 2003). In order to 
obtain sufficient cells, current clinical trials have used expanded MSCs. With methods to 
isolate and purify MSCs resulting in ever increasing yields, it is necessary to compare the 
differences between expanded vs non-expanded MSCs in therapies; it is possible that non-
expanded MSCs would migrate and engraft more efficiently to the damaged target tissue 
resulting in greater level of targeted immunosuppression, improving the outcome of the 
treatment.  
It has been suggested in in-vivo studies that MSCs are able to avoid usual alloresponses 
supporting the possibility of using allogeneic stem cells for future therapies. As mentioned, 
these studies have usually been performed in immuno-compromised patients. There have also 
been some studies carried out in animal models that suggest that although allogeneic MSCs 
can engraft in immune-compromised hosts or at immune-privileged sites, they do in fact 
initiate an immune response in normal hosts (Nauta and Fibbe, 2007).  
The effects of differentiation on the capacity of MSCs to modulate the immune response needs 
to be determined as there is currently very little data on the immune response towards fully 
differentiated MSCs. As discussed previously many groups have demonstrated the 
immunoprivileged nature of undifferentiated MSCs, but in these studies MSCs and 
lymphocytes have only been cultured together for up to 7 days. The results of the assays 
performed do indeed indicate that, probably due to the lack of expression by MSCs of MHC 
class II and co-stimulatory molecules, and also intermediate expression of MHC class I, that 
MSCs do not stimulate the lymphocytes directly. However, in only performing the assays by 
culturing MSCs and lymphocytes together for up to 7 days, alternative methods of 
allorecognition (indirect and semi-direct) may not be given the opportunity to manifest.  
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In order to robustly test the hypothesis that MSCs are immuno-privileged, it may be necessary 
to culture MSCs with lymphocytes and APCs over prolonged time periods. 
In addition to this, if MSCs are indeed immuno-privileged, there are no ‘long term’ studies 
investigating whether once differentiated the MSCs retain their immunoprivileged status, or if 
they are effectively targeted and eliminated by the host’s immune system. The 
characterisation of MSCs requires the trilineage differentiation into bone, fat and cartilage. 
Differentiation into cartilage requires 3D culture as spheroids and bone differentiated MSCs 
are difficult to analyse due to increased expression of cell adhesion factors and calcification. 
Fat cells however are a very interesting cell type to study following differentiation of MSCs, as 
in-vivo adipose cells have been shown to secrete hormones termed ‘adipokines’, such as 
leptin, resistin, and adiponectin (Schaffler et al., 2007). These adipokines are known to exert 
potent immunomodulatory effects on immune cells (Tilg and Moschen, 2006; Bielby et al., 
2007; Schaffler et al., 2007). Adipocytes have been demonstrated to be potent producers of 
pro-inflammatory cytokines such as TNF-α and interleukin-6, as well as chemokines such as 
monocyte chemoattractant protein (MCP)-1 (Schaffler et al., 2006; Schaffler et al., 2007). 
1.7 AIMS AND OBJECTIVES 
The current belief that MSCs are immuno-privileged is based on experiments that do not fully 
appreciate the response of lymphocytes to alloantigens. The current methodology used to 
determine the immuno-privileged nature of MSCs involves culturing MSCs with peripheral 
blood mononuclear cells (PBMCs) for up to 7 days and so limits observations to the effect of 
the direct pathway of allorecognition. The assay conditions in which MSCs are cultured with 
PBMCs needs to be optimised to allow the effect of indirect and semi-direct pathways to be 
assessed. One of the defining characteristics of MSCs is their trilineage differentiation into 
bone, fat, and cartilage cell types. It was decided to use adipogenic differentiation to assess 
the effect of PBMCs on differentiated MSCs due to the close relationship of adipose tissue with 
cells of the immune system in-vivo. There are currently many methods used to quantify levels 
of adipogenesis in MSC cultures, but there is no gold standard method. The most common 
assays used to determine levels of adipogenesis are to be compared, and the most suitable 
assay used to determine which MSC donor cells exhibit the highest adipogenic potential before 
use in the aforementioned culture with PBMCs.   
It is our hypothesis that MSCs will not directly stimulate allogeneic lymphocytes in classical 
lymphocyte proliferation assays due to their lack of expression of immune-regulatory 
molecules (CD40, CD80, CD86, MHC Class-II), but will be capable of stimulating allogeneic 
40 
 
lymphocytes via the indirect pathway of antigen presentation. In order to test this hypothesis 
the following aims and objectives were set: 
 To isolate MSCs from 4 BM donors before they are expanded, and characterised. 
 To differentiate MSCs into adipose cells, before comparing methods of quantifying 
adipogenesis, with the MSC from the donor exhibiting highest levels of adipogenesis 
determined. 
 To determine the methodology used to perform the one-way lymphocyte 
transformation assay, and extend the duration of the assay beyond the typical 7 day 
period previously performed in the current literature. 
 To perform the lymphocyte transformation assay using peripheral blood mononuclear 
cells from 6 healthy volunteers cultured with the MSCs from the 4 bone marrow 
donors. 
 To differentiate the most adipogenic donor MSCs into adipose cells, and perform the 
lymphocyte transformation assay against the differentiated cells.
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Chapter 2:  GENERAL MATERIALS AND METHODS 
2.1 EQUIPMENT 
The equipment used throughout these studies is detailed in Table 2.1 
Equipment Company 
5% (v/v) CO2 in air BOC Ltd., West Sussex, UK. 
96 well microplate lid Sterilin Fisher Scientific, Loughborough, UK. 
96 well microplate Sterilin Fisher Scientific, Loughborough, UK. 
96 well U-bottom culture plates Fisher Scientific, Loughborough, UK. 
ABI Prism 7900 Applied Biosystems, Warrington, UK. 
ATPLite assay Perkin Elmer, Berkshire, UK. 
Automatic pipettes (Gilson P2-P500) Anachem, Bedfordshire, UK 
Balance-4 figure (AND GR-200) Jencons PLC, Bedforshire, UK 
Cell medium aspirator (Vacusafe 
comfort) 
Integra Biosciences, Zurich, 
Switzerland 
Centrifuge (Harrier 15/80) SANYO Biomedical Europe BV, 
Centrifuge-Micro (MSE Micro Centaur 
I) 
SANYO Biomedical Europe BV, 
Amsterdam, Holland 
Class II safety cabinet (Heraeus 85) Kendro, Hertfordshire, UK 
CO2 Incubator (MCO-20AIC) 
SANYO Biomedical Europe BV, 
Amsterdam, Holland 
Counting Chamber Improved 
Neubauer 
Scientific Laboratory Supplies Ltd 
(SLS), Nottingham, UK. 
FACScan Becton Dickinson, Oxford, UK. 
FilterMate™ cell harvester Perkin Elmer, Berkshire, UK. 
Freezer -25°C (Electrolux 3000) Jencons PLC, Bedforshire, UK 
Fume hood Whiteley, Hants, UK. 
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Glass fibre filter plates  Perkin Elmer, Berkshire, UK. 
Hot air oven (SANYO OMT225) 
SANYO Biomedical Europe BV, 
Amsterdam, Holland. 
Incubator 
Laboratory and electrical engineering, 
Nottingham, UK. 
Laminar flow cabinet (Bassaire 06HB) Jencons PLC, Bedforshire, UK 
LB940 Multilabel Reader Mithras 
Berthold Technologies, Hertfordshire, 
UK. 
Liquid nitrogen dewer (BIO65) Jencons PLC, Bedforshire, UK 
Liquid nitrogen gas BOC Ltd., West Sussex, UK 
Luminescence counter and liquid 
scintillation counter (Packard 
TopCount NX) 
Perkin Elmer, Albany street, Boston. 
Magnetic stirrer 
Bibby Sterlin Ltd, Stone, Staffordshire, 
UK. 
Microplate reader (Multiscan 
Spectrum) 
Thermo Electron Corporation, 
Waltham, USA 
Microscope-Inverted (Olympus, IX71) 
Olympus Optical Co (UK) Ltd, Southall, 
UK. 
Microscope-Upright (Olympus, BX71) 
Olympus Optical Co (UK) Ltd, Southall, 
UK. 
pH meter (3020) Jenway Ltd, Dumow, UK. 
Pipettor Tips Combitips (1ml, 2.5ml, 
5ml, 12.5ml) 
Fisher Scientific, Loughborough, UK. 
Specimen pot (60 ml, 100 ml, 250 ml) 
Scientific Laboratory Supplies Ltd 
(SLS), Nottingham, UK. 
Tissue Culture Flask (25 and 75 cm2) Fisher Scientific, Loughborough, UK. 
Tissue culture plates (6, 12, 48, 96) Fisher Scientific, Loughborough, UK. 
Topcount Glass Fibre 96 Well Plates Perkin Elmer, Albany street, Boston. 
Topseal Applicator Perkin Elmer, Albany street, Boston. 
Universal/centrifuge tube (25 ml) 
Scientific Laboratory Supplies Ltd 
(SLS), Nottingham, UK. 
Vacutainer blood collection system Becton Dickinson, Oxford, UK. 
Vortexer (Grant) Jencons PLC, Bedforshire, UK 
Water bath Fisher Scientific, Loughborough, UK. 
 
Table 2.1: Equipment used with manufacturer.  
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2.2 MATERIALS  
All laboratory consumables were obtained from Scientific Laboratory Supplies Ltd 
(Nottingham, UK) unless otherwise stated. The materials used are listed in Table 2.2. 
Materials Company 
10% (v/v) Neutral buffered formalin Sigma-Aldrich Ltd, Poole, UK. 
4',6-diamidino-2-phenylindole (DAPI) Invitrogen, Paisley, UK. 
Acid phenol pH 5  Sigma, Surrey, UK. 
Alcian Blue stain Sigma-Aldrich Ltd., Poole, UK. 
ATP-Lite-M® assay Perkin Elmer, Albany street, Boston. 
BD FACSFlow Becton Dickinson, Oxford, UK. 
Camptothecin Sigma, Surrey, UK. 
Crystal violet solution Sigma, Surrey, UK. 
Chloroform isoamylalcohol 24:1 (red)  Sigma, Surrey, UK. 
Dimethyl sulphoxide (DMSO) Invitrogen, Paisley, UK. 
DMEM Lonza, Slough, UK. 
DNase I  Ambion, Warrington, UK. 
Dulbecco’s modified Eagle’s medium 
(DMEM) 
Gibco Life Technologies Ltd., Paisley, 
Scotland 
Ethanol (100%)  Fisher Scientific, Loughborough, UK. 
Fetal calf serum Lonza, Slough, UK. 
Flat bottom culture plates Fisher Scientific, Loughborough, UK. 
FluoroNunc™ plate  
Thermofisher Scientific, 
Loughborough, UK. 
Flurescein diacetate Fisher Scientific, Loughborough, UK 
Formaldehyde (37-40%)  Gentamedical, Tockwith, UK. 
Guanidine isothionate solution Sigma, Surrey, UK. 
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Hanks balanced salt solution (HBSS) Invitrogen, Paisley, UK. 
High activity tritiated thymidine  Perkin Elmer, Berkshire, UK. 
Horse Serum Stem Cell Technologies, Sheffield, UK 
Human AB Serum Source Biosciences Life Sciences 
Hydrocortisone  Sigma, Surrey, UK. 
Hy-Q-tase® Fisher Scientific, Loughborough, UK. 
Indomethacin Sigma, Surrey, UK. 
IntraStain, Fixation and 
Permeabilization Kit for Flow 
Cytometry 
Dako, Cambridge, UK. 
Isobutylmethylxanthine Sigma, Surrey, UK. 
Isopropanol Fisher Scientific, Loughborough, UK 
Isopropanol VWR International West Chester, UK. 
L-glutamine 
Gibco Life Technologies Ltd., Paisley, 
Scotland. 
Low activity tritiated thymidine  Perkin Elmer, Berkshire, UK. 
Lymphoprep Axis-Shield, Middlesex, UK. 
Methanol (100%) Merck, Middlesex, UK. 
Methylated spirits VWR International West Chester, UK. 
Microscint-20  Perkin Elmer, Berkshire, UK. 
Mitomycin C Sigma, Surrey, UK. 
N-(2-hydroxyethyl) piperazine N;-(2-
ethansulphonic acid) [HEPES] (1M) 
Lonza, Slough, UK. 
NH Expansion Medium Miltenyi Biotech, Surrey, UK. 
Nile red Sigma, Surrey, UK. 
N-Lauryl sarcosine sodium salt  Sigma, Surrey, UK. 
Nuclease free water  
Severn Biotech Ltd, Worcestershire, 
UK. 
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Oil red-O Sigma, Surrey, UK. 
Omniscript RT Kit Qiagen, West Sussex, UK. 
PBS tablets Oxoid, Hampshire, UK. 
Penicillin-streptomycin mixture  Lonza, Slough, UK. 
Percoll Sigma-Aldrich Ltd, Poole, UK. 
Phosphate buffered saline (PBS) 
tablets 
Oxoid, Basingstoke, UK. 
Phytohaemagglutinin Sigma, Surrey, UK. 
Purelab Option distilled water still ELGA LabWater, High Wycombe, UK. 
Ribolock RNAse Inhibitor Fermentas, North Yorkshire, UK. 
RNasin Promega, Southampton, UK. 
Rosslyn Park Memorial Institute 
(RPMI) medium without L-glutamine  
Lonza, Slough, UK. 
Saponin Sigma, Surrey, UK. 
Sheath fluid (FACs instrument) Becton & Dickenson, Oxford, UK. 
Sodium acetate Fisher Scientific, Loughborough, UK 
Sodium chloride Merck, Middlesex, UK. 
Sodium citrate Sigma, Surrey, UK. 
Sodium hydroxide Sigma-Aldrich Ltd, Poole, UK. 
Sodium pyruvate 
Gibco Life Technologies Ltd., Paisley, 
Scotland 
Superscript II Invitrogen, Paisley, UK. 
Trichloroacetic acid  Fisher Scientific, Loughborough, UK 
Trigene Scientific Laboratory Supplies Ltd. 
TRIzol® RNA lysis solution Invitrogen, Paisley, UK. 
Trypan Blue (0.4%) Sigma, Surrey, UK. 
Trypsin, 0.5 % with EDTA (10x)  Invitrogen, Paisley, UK. 
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Virkon Bios Europe Ltd., Lancashire, UK 
β-mercaptoethanol  Sigma, Surrey, UK. 
 
Table 2.2: Materials used with manufacturer. 
2.2.1 GLASSWARE  
All laboratory glassware was obtained from Fisher Scientific (Loughborough, UK) unless 
otherwise stated. All glassware was cleaned by immersion in a 1 % (v/v) solution of detergent 
(Trigene®) overnight. Glassware was subsequently rinsed thoroughly in tap water followed by a 
final wash in distilled water to remove residual detergent. The glassware was then dried or 
sterilised by dry heat (Section 2.2.1.1).  
2.2.2 STERILE AND DISPOSABLE PLASTICWARE  
Tissue culture flasks (25 cm2 and 75 cm2) and Nunc branded flat bottomed 96-well plates were 
purchased from Thermo Fisher Scientific Ltd. Culture flat bottomed 24 well, 48 well and 96 
well, and  U-bottomed 96-well plates were purchased from Thermo Fisher Scientific Ltd. 
Universal containers (25 ml) and specimen containers (60 ml, 150 ml and 250 ml) were 
purchased from Scientific Laboratory Supplies Ltd. ‘Stripette’ disposable pipettes (1 ml, 2 ml, 5 
ml, 10 ml and 25 ml) were supplied by Sigma-Aldrich Ltd. Sterile, endotoxin-free filter and non-
filter pipette tips (20 μl, 200 μl and 1000 μl) were purchased from Star Labs. Disposable plastic 
syringes were purchased from Scientific Laboratories Supplies Ltd.  
2.2.3 PHOSPHATE BUFFERED SALINE (PBS)  
One PBS tablet (Oxoid) was dissolved in 100 ml of distilled water. The solution was stored at 
room temperature until required.  
2.3 METHODS  
2.3.1 DRY HEAT STERILISATION  
Items to be sterilised were placed into a hot air oven and held at a temperature of 190 °C for 4 
hours.  
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2.3.2 MOIST HEAT STERILISATION  
Objects and solutions unsuitable for dry heat sterilisation were sterilised by autoclaving at 121 
°C for 20 minutes at a pressure of 15 psi.  
2.3.3 FILTER STERILISATION  
Solutions that were unsuitable for moist heat sterilisation were sterilised by filtering through a 
filter with 0.2 μm pore size (Sartorius Ltd, UK) using a disposable syringe (Scientific Laboratory 
Supplies Ltd.). Larger filter units (Nunc brand, Fisher Scientific Ltd.) were used for larger 
volumes. All manipulations were carried out in a class II safety cabinet.  
2.3.4 MEASUREMENT OF PH  
The pH of solutions was measured using a Jenway 3020 pH meter. The pH meter was 
calibrated using solutions of pH 4, 7 and 10 made from buffer tablets (Merck Chemicals Ltd.) 
dissolved in de-ionised water. The pH of solutions was measured using temperature 
compensation. To adjust the pH of solutions, 1-6 M hydrochloric acid (HCl) or 1-6 M sodium 
hydroxide (NaOH) was added drop-wise whilst stirring.  
2.3.5 MICROSCOPY  
Bright-field microscopy was carried out using an Olympus BX51 microscope. Fluorescent 
microscopy was carried out using the same microscope in combination with a fluorescent 
vertical illuminator (BX51-RFA) using either the FITC (495/520 nm) or DAPI filters (360/460 
nm). Proliferating mammalian cells in tissue culture flasks were viewed using an inverted 
microscope (Olympus IX71) set up for phase contrast microscopy. Images were photographed 
using an attached Olympus Digital camera controlled through Cell^B software systems with 
correct Kohler illumination.  
2.3.6 RESURRECTION AND MAINTENANCE OF PRIMARY CELLS AND CELL LINES  
Cells were removed from liquid nitrogen storage and rapidly defrosted in a 37 °C water bath. 
Pre-warmed supplemented medium (10 ml) was added drop wise to the cells prior to 
centrifugation at 150 g for ten minutes. The supernatant was discarded and the pellet 
resuspended in 5 ml of supplemented medium. This was transferred to a 75 cm2 tissue culture 
flask and the cells incubated at 37 °C in 5 % (v/v) CO2 in air. The medium was changed every 
two days until the cells became confluent.  
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2.3.7 ESTIMATION OF CELL VIABILITY – TRYPAN BLUE DYE EXCLUSION METHOD  
The Trypan blue exclusion assay works on the principle that the cell membrane of viable cells is 
intact and therefore is not permeable to the dye. A cell suspension (90 μl) was mixed 
thoroughly with 10 μl Trypan blue solution. This solution was then loaded into an Improved 
Neubauer counting chamber. Cell counts were perfomed by observing both chambers under 
the inverted microscope. Non-viable cells allow the dye to permeate due to loss of membrane 
potential on cell death. This results in non-viable cells having a blue colouration and being 
excluded from the count. To allow an accurate counting method, the cell suspension was 
diluted so that between 30 and 300 cells were in the counting chamber. The total number of 
viable cells per ml was calculated as follows:  
Number of cells.ml− 1= Mean cell count × 104 × Original dilution 10/9  
2.3.8 CRYOPRESERVATION OF PRIMARY CELLS AND CELL LINES  
Cells were isolated from the tissue culture flasks and a cell count was performed as described 
above. The cell suspension was then centrifuged for 10 minutes at 150 g. The supernatant was 
carefully aspirated and the cells were resuspended in medium containing 50 % (v/v) fetal calf 
serum and 10 % (v/v) dimethyl sulphoxide (DMSO) [filter sterilised prior to use]. Cell 
suspension was then aliquoted (1 ml) into cryovials so that each vial contained 1 million cells. 
Vials were then transferred into a cryo freezing pot containing isopropanol. This was placed 
into a -80 °C freezer for 12 hours. Cryovials were then transferred into liquid nitrogen for long 
term storage.  
2.3.9 STATISTICAL ANALYSIS
All numerical data was analysed using Microsoft Excel® and GraphPad Prism®. Data is typically 
shown as mean values ± 95 % confidence limits, which were calculated using GraphPad Prism 
software. One-way analysis of variance was used to analyse data with one variable to be 
examined. Two-way analysis of variance was used to analyse experimental data with two 
variables. The non-parametric Mann Whitney-U test was used to assess whether two 
independent variables had equal values and was performed using GraphPad Prism® software. 
The Spearman rank coefficient was used to determine the statistical significance between two 
variables, values were calculated using GraphPad Prism® software. Statistical formula were 
confirmed using Sokal and Rohlf, 1981.  
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Chapter 3:  ISOLATION, CULTURE AND 
CHARACTERISATION OF MSCS 
3.1 INTRODUCTION 
Multipotent mesenchymal stromal cells (MSCs) have been referred to by various terms since 
their initial characterization by Freidstein et al. over 40 years ago. They have been called 
mesenchymal stem cells, multipotent stem cells and marrow stromal cells. Due to the diverse 
nomenclature associated with these cells, the International Society for Cellular Therapy has 
attempted to clarify the terminology associated with MSCs, and termed the cells multipotent 
mesenchymal stromal cells. The ISCT also decreed that the source should be included in the 
terminology, for example, bone marrow or dental pulp derived (Horwitz et al., 2005). As well 
as nomenclature, the ISCT also defined a set of standard minimum criteria for defining cells as 
human multipotent mesenchymal stromal cells: 
 Plastic adherent under standard culture conditions. 
 Be positive for the expression of CD73, CD90, and CD105, and negative for the 
expression of CD34, CD45, CD14 or CD11b, CD79a or CD19, and HLA-DR. 
 Be able to differentiate into adipocytes, osteocytes and chondrocytes under specific 
stimulus in vitro.   
As there is presently no single defining marker for multipotent mesenchymal stromal cells; in 
order for cells in-vitro to be classified as multipotent mesenchymal stromal cells, they have to 
fulfil all of the above criteria. For simplicity, the cells will be termed MSCs throughout this 
thesis. 
Multipotent mesenchymal stromal cells have been shown to be present in many of the tissues 
in the body, but even with increasing interest in obtaining them from adipose tissue (Uysal and 
Mizuno; Zuk et al., 2001; Zuk et al., 2002) the most well documented method of isolation of 
MSCs is from the bone marrow.  The bone marrow provides an important niche for many cell 
types in the body including  haematopoietic stem cells, mesenchymal stromal cells, and 
adipocytes (Salem and Thiemermann, 2010). In fact the population of MSCs within the 
nucleated cell portion of the bone marrow is between 0.001 % and 0.01 % (Friedenstein et al., 
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1974; Jones et al., 2002; Uccelli et al., 2006). Although there are very few MSCs present, they 
can be isolated, and expanded with relatively high efficiency (Pittenger et al., 1999). The in-
vivo markers expressed by MSCs within their native niche have proved difficult to determine, 
due to the low frequency of these cells within bone marrow aspirates. The detection of these 
cells within the bone marrow previously relied on lengthy in-vitro techniques such as the 
colony-forming unit fibroblast assay (CFU-F) (Castro-Malaspina et al., 1980). This is a 
retrospective assay that can be variable due to its reliance on factors such as cell seeding 
density and growth medium. More recently with the prevalence of more sophisticated 
equipment, techniques such as flow cytometry provide valuable tools that allow a more rapid 
method to examine the phenotype of MSCs (Jones et al., 2006). A study carried out by Jones et 
al. (2006) showed that a proportion of cells in the bone marrow strongly expressing LNGFR 
(CD271, Table 1.1) and D7-FIB provided exclusively all of the CFU-Fs, providing strong evidence 
to allow the rapid purification and isolation of MSCs directly from samples of bone marrow 
(Jones et al., 2006). D7-FIB is expressed on human fibroblasts and epithelial cells. In peripheral 
blood this cell surface markers is expressed on myeloid cells and a very small number of 
lymphocytes.  
For in-vitro culture the standard method for the isolation of MSCs relies on Percoll gradient 
centrifugation, followed by plastic adhesion of cells isolated from the density interface 
(Pittenger et al., 1999; Jones et al., 2002). Putative MSCs must then meet the ISCT standard 
criteria before classification as MSCs.    
In order to differentiate MSCs into osteocytes, cells are cultured in medium with the addition 
of dexamethasone, ascorbic acid, and β-glycerophosphate (Jaiswal et al., 1997). After culture 
with these supplements in order to determine osteogenic differentiation cells can be stained 
with alizarin red to detect calcium deposition and matrix mineralisation (Jones et al., 2002). 
Alkaline phosphatase staining is another popular method for the determination of 
osteogenesis of MSC cultures (Pittenger et al., 1999).  
Adipogenic differentiation can be induced through the addition of indomethacin, 1-methyl-3-
isobutylmethylxanthine, and hydrocortisone to the culture medium (Sekiya et al., 2004). The 
adipogenesis of MSCs in cultures was further enhanced with the addition of horse serum to 
the differentiation medium. Lipid accumulation in vesicles within cells can be visualised by light 
microscopy after 1 week, or by staining intracellular lipid content with Oil red-O (Pittenger et 
al., 1999). Other methods of adipogenic differentiation use culture medium supplemented 
with insulin or the peroxisome proliferator-activated receptor-ɣ agonist rosiglitazone.  
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Chondrogenic differentiation can be induced by culturing cells at very high densities (pellet 
cultures or micromasses) and supplementing culture medium with TGF-β3, ascorbic-2-
phosphate, insulin-transferrin-selenium (ITS), sodium pyruvate, and dexamethasone (De Bari 
et al., 2001). The differentiation into chondrocytes can be visualised through 
glycosaminoglycan deposition using alcian blue stain (Jones et al., 2002). 
3.1.1 AIMS AND OBJECTIVES 
The initial aim of this research was to obtain expanded populations of MSCs isolated from 
fresh human bone marrow aspirates, and to characterise these cells by their morphology and 
phenotype to establish if the isolated cell population were indeed MSCs. There were 4 
objectives: 
 To isolate and expand bone marrow derived MSCs in culture 
 To observe the morphology of the cells when grown on coated tissue culture plastic 
flasks. 
 To phenotype the cells using flow cytometric analysis against the cell surface markers 
CD73, CD90, CD105, CD34, CD45, CD14, CD19, and HLA-DR. 
 To assess the trilineage potential of the isolated MSCs and stain differentiated 
populations with alizarin red for calcium content, Oil red-O for intracellular lipid 
content, and alcian blue for GAG content. 
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3.2 MATERIALS AND METHODS 
3.2.1 EXTRACTION OF HUMAN BONE MARROW AND ISOLATION OF MSCS 
Reagents 
Penicillin-streptomycin mixture [5000 µg.ml-1 potassium penicillin, 5000 µg.ml-1 streptomycin 
sulphate] (Lonza). 
L-glutamine 200 mM (Gibco) 
Fetal calf serum (Lonza) 
DMEM [4.5 g.L-1 glucose without L-glutamine with sodium pyruvate (Lonza)] 
Complete DMEM: Complete DMEM medium was made by supplementing DMEM to a final 
concentration of 10% (v/v) fetal calf serum, 100 µg.ml-1 penicillin/streptomycin and 2 mM L-
glutamine.  
NH Expansion Medium (Miltenyi Biotech) 
Method 
Human bone marrow was extracted from the iliac crest. Samples were collected under full 
ethical approval (REC 07/Q1205/27) to Dr E. Jones (LIMM; University of Leeds). These samples 
were taken from theatre at St James Hosiptal, Leeds Teaching Hospital Trust. BM1 and BM2 
were obtained via this route, and MSCs isolated according to Jones et al. (2002). Briefly, 
mononuclear cells were isolated from bone marrow using a Lymphoprep™ (Axis-Shield) 
gradient before purified mononuclear cells were grown in NH medium. Plastic-adherent cells 
were cultured to passage 0 at 37°C 5 % (v/v) CO2 in air, before frozen cryovials of isolated 
MSCs were transferred from LIMM (Leeds Institute of Molecular Medicine) to the IMBE 
laboratory on dry ice, where they were stored in liquid nitrogen. Cryovials of cells were frozen 
and resuscitated as described in section 2.3.6-2.3.8. 
Bone marrow samples were also donated by patients in the trauma theatre under full ethical 
approval (REC 06/Q1206/127) to Peter Giannoudis's (St James Hospital, Leeds Teaching 
Hospital Trust), BM3 and BM4 were obtained through these ethics, and MSCs were isolated 
using the method described below. 
Human bone marrow that was obtained from volunteer patients following admission to clinic 
with bone fractures of the lower limbs was aspirated from the iliac crest. Marrow was then 
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mixed in at 1:1 ratio with complete DMEM medium, and cultured for 48 hours at 37°C 5% (v/v) 
CO2 in air in T75 tissue culture flasks (Nunc). After this 48 hour period the medium was 
removed, and the cell monolayer gently washed with PBS before 10 ml NH Expansion Medium 
was added to the flask and cells were again cultured at 37°C 5% (v/v) CO2 in air.  
3.2.2 EXPANSION OF MSCS 
Human MSCs were grown until 90% confluent in T75 tissue culture flasks in 10 ml NH 
Expansion Medium at 37°C in an atmosphere of 5% (v/v) CO2. When 90% confluency was 
reached the medium was removed from the flask and the cells were washed with 10 ml PBS 
without Ca2+ or Mg2+. PBS was removed and 2 ml Hy-Q-Tase™ (Fisher Scientific) was added to 
the flask and incubated at 37°C in an atmosphere of 5% (v/v) CO2 until cells had detached from 
the surface of the flask (approx. 10 minutes). When cells had detached the resulting cell 
suspension was added to 5 ml complete DMEM medium in a 25 ml centrifuge tube, before 
centrifugation at 150 g for 10 minutes. When centrifugation was complete the supernatant 
was discarded, and the pellet resuspended in NH Expansion medium (Miltenyi Biotech). The 
resulting cell suspension was split into double the number of T75 tissue culture flasks before 
incubation at 37°C in an atmosphere of 5% (v/v) CO2 in air.  
3.2.3 EXPANSION OF FIBROBLASTS 
Primary human dermal fibroblasts (Cascade Biologics) were grown until 90% confluent in T75 
tissue culture flasks in 10 ml complete DMEM at 37°C in an atmosphere of 5% (v/v) CO2. When 
90% confluency was reached the medium was removed from the flask and the cells were 
washed with 10 ml PBS without Ca2+ or Mg2+. Following washing the PBS was removed and 2 
ml Hy-Q-Tase™ was added to the flask, and incubated at 37°C in an atmosphere of 5% (v/v) 
CO2 until cells had detached from the surface of the flask (for approx. 10 minutes). When cells 
had detached the resulting cell suspension was added to 5 ml complete DMEM in a 25 ml 
centrifuge tube, before centrifugation at 150 g for 10 minutes. When centrifugation was 
complete the supernatant was removed, and the pellet resuspended in complete DMEM 
medium. The resulting cell suspension was split into double the number of T75 tissue culture 
flasks before incubation at 37°C in an atmosphere of 5% (v/v) CO2 in air. 
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3.2.4 FLOW CYTOMETRY 
Reagents 
2x blocking buffer: PBS/2.5mM EDTA/4% (v/v) fetal calf serum 
Method 
Cells were removed from the surface of the tissue culture plastic using 2 ml Hy-Q-Tase™ per 
T75 flask. The cell suspension was added to 5 ml complete DMEM and centrifuged at 150 g for 
10 minutes. The resulting cell pellet was then resuspended in ice cold PBS, and cells counted 
using a haemocytometer to give a final cell concentration of 1x105 cells per 100 µl as described 
in section 2.3.7. Cell suspension (100 µl) was added to clean 1.5 ml eppendorf tubes, and 100 
µl ice cold 2x blocking buffer was added before the suspension was incubated on ice for 20 
minutes. Primary conjugated antibody (1 µl undiluted as received from the manufacturer) was 
added to the cell suspension and the eppendorf gently mixed, before the mixture was 
incubated on ice for 1 hour. Ice cold PBS (300 µl) was added to the suspension and the cells 
centrifuged at 3000 g at 4°C for 5 minutes to wash. 
The supernatant was removed, and the cell pellet resuspended in 500 µl ice cold PBS. The 
resulting suspension was centrifuged at 3000 g twice more. After 3 washes, the cell pellet was 
resuspended in 200 µl ice cold PBS, before the fluorescent intensity was measured using the 
flow cytometer (Becton Dickinson FACSCalibur).  
Resulting data was analysed using CellQuest software version 3.1 (BD Biosciences) and 10,000 
events were collected per sample. The collection settings used are shown in Table 3.1: 
 The antibodies used are shown in Table 3.2.  
Table 3.1: Table of flow cytometry collection settings used for the analysis of MSCs. 
Param Detector Voltage AmpGain 
P1 FSC E-1 3.37 
P2 SSC 335 1.00 
P3 FL1 319 1.00 
P4 FL2 366 1.00 
P5 FL3 381 1.00 
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3.2.5 ADIPOGENIC DIFFERENTIATION OF HMSCS 
Reagents 
Isobutylmethylxantine (Sigma): 200 mg isobutylmethylxanthine was added to 1.8 ml dimethyl 
sulphoxide (DMSO) to make a 0.5 M stock. This solution was filtered through a 0.2 µm pore 
size filter. This stock solution was aliquoted in 100 µl volumes and frozen at -20°C; 100 µl was 
added to 100 ml adipogenic medium (i.e. 1:1000) to give a final concentration of 0.5 mM.    
Indomethacin (Sigma): A 0.6M stock solution was made by dissolving 100 mg in 467 µl of 
DMSO. This was filtered using a 0.2 µm pore size filter and frozen in 10 µl aliquots at -20°C; 10 
µl was added to 100 ml adipogenic medium (i.e. 1:1000) to give a final concentration of 0.6 
mM. 
Hydrocortisone (Sigma): 4.854 mg was added to 100 ml PBS to make a 0.1mM stock solution. 
The solution was filter sterilised using a 0.2 µm pore size filter and frozen at -20°C in 550 µl 
aliquots; 500 µl was added to 100 ml adipogenic medium immediately before use to give a 
final concentration of 0.5 µM.  
Complete Dulbecco’s modified Eagles medium (complete DMEM): Made as described in 
section 3.2.1.  
Marker Conjugate Catalogue Number Manufacturer Isotype Channel 
CD105 RPE MCA1557PET AbD Serotec IgG1 FL-2 
CD73 RPE 550257 BD Biosciences IgG1 FL-2 
CD90 RPE MCA90PET AbD Serotec IgG1 FL-2 
CD45 APC Cy-7 557833 BD Biosciences IgG1 FL-3 
CD34 RPE MCA1578PET AbD Serotec IgG1 FL-2 
CD14 RPE 555398 BD Biosciences IgG2a FL-2 
CD19 RPE MCA1940PET AbD Serotec IgG1 FL-2 
HLA-DR PE Cy-7 335830 BD Biosciences IgG2a FL-3 
HLA-ABC FITC MCA81F AbD Serotec IgG2a FL-1 
CD40 FITC MCA1590F AbD Serotec IgG1 FL-1 
CD80 FITC MCA2071F AbD Serotec IgG1 FL-1 
CD86 FITC MCA1118F AbD Serotec IgG1 FL-1 
IgG1 RPE MG4993 Caltag 
 
FL-2 
IgG2 RPE MG2A04 Caltag 
 
FL-2 
Table 3.2: Conjugated antibodies used in flow cytometry to determine MSC phenotype. 
RPE: R-phycoerythrin absorption/emission max 496/578 nm, APC CY-7: allophycocyanin 
coupled to cyanin dye CY-7 absorption/emission max 650/785, PE CY-7: phycoerythrin 
coupled to cyanin dye CY-7 absorption/emission max 596/785, FITC: fluorescein 
isothiocyanate absorption/emission max 494/520 nm.  
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Method 
Adipogenic medium was made by supplementing 100 ml complete DMEM with 10% (v/v) 
horse serum (Sigma), 100 µl isobutylmethylxanthine, 10 µl indomethacin and 500 µl 
hydrocortisone. MSCs or fibroblasts were cultured until 90 % confluent in T75 tissue culture 
flasks. Cells were removed from the surface of the tissue culture plastic using 2 ml Hy-Q-Tase™ 
per T75 flask. Cell suspensions were added to 5 ml complete DMEM and centrifuged at 150 g 
for 10 minutes. The supernatant was discarded, and the pellets resuspended in 1 ml  complete 
DMEM. Cells were counted using a haemocytometer and cells to be differentiated were 
seeded at 4x104 cells per cm2 growth area in a 24 well plate, and left to attach overnight at 
37°C in an atmosphere of 5% (v/v) CO2 in air. When attached, the culture medium was 
removed and replaced with adipogenic medium. The medium was replaced twice weekly, and 
cells were grown up to 21 days. Cultures were fixed and stained as described below on days 0, 
3, 7, 14, and 21. 
3.2.6 OIL RED-O STAINING OF ADIPOCYTES 
Reagents 
Oil red (Sigma): A 0.5% (w/v) Oil red solution was made by dissolving 50 mg in 10 ml 
isopropanol. 
Formalin (10%): 27 ml formaldehyde/formalin stock (@37%) in 73 ml dH2O. 
Method 
Medium was removed from wells and cells were washed twice with PBS. Cells were then fixed 
in 10% (v/v) formalin in dH2O for 10 minutes. Stock 0.5 % (v/v) Oil red solution was diluted to a 
working concentration of 3 parts Oil red to 2 parts water before filtering through a 0.8 µm 
pore filter and a 0.2 µm pore filter to remove particles. Formalin was removed from wells and 
the cells washed twice with PBS before addition of filtered Oil red for 10 minutes. Following 
incubation at room temperature Oil red was removed and wells were washed twice in PBS. 
The cells were allowed to dry before viewing using an Olympus IX71 inverted microscope using 
Cell^B image capture software (Olympus).  
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3.2.7 OSTEOGENIC DIFFERENTIATION OF MSCS 
Reagents 
Dexamethasone (Sigma): A 50 mM stock solution was made by dissolving 25 mg 
dexamethasone in 1280 µl 100% ethanol. This solution was dispensed into 10 µl volumes and 
frozen at -20°C. DMEM was added to the 10 µl volumes (1 ml) to give a 500 µM solution, which 
was refrozen in 20 µl aliquots, and added to osteogenic medium just before use at a 1:5000 
dilution (20 µl in 100 ml medium) to give a final concentration of 10 µM. 
Ascorbic-2-phosphate (Sigma): A 200 mM stock solution was made by dissolving 2.57 g 
ascorbic-2-phosphate in 50 ml dH2O. This stock solution was aliquoted into 50 µl volumes and 
stored at -20°C. This was added to osteogenic medium at a 1:2000 dilution (50 µl in 100 ml 
medium) to give a final concentration of 0.1 mM. 
Beta-2-glycerophosphate (Sigma): A 2 M stock solution was made by dissolving 10 g beta-2-
glycerophosphate in 23 ml dH2O. This was frozen in 500 µl aliquots and stored at -20°C. This 
was added to osteogenic medium at a 1:200 dilution (500 µl in 100 ml medium) to give a final 
concentration of 10 mM. 
Method 
Osteogenic medium was made by supplementing 100 ml complete DMEM with 20 µl 
dexamethasone, 50 µl ascorbic-2-phosphate and 500 µl beta-2-glycerophosphate. MSCs and 
fibroblasts were cultured until confluent in T75 tissue culture flasks. Cells were removed from 
the surface of the tissue culture plastic using 2 ml Hy-Q-Tase™ per T75 flask. Cell suspensions 
were added to 5 ml complete DMEM and centrifuged at 150 g for 10 minutes. The supernatant 
was discarded, and the pellets resuspended in 1 ml complete DMEM. Cells were counted using 
a haemocytometer as described in section 2.3.7 and cells to be differentiated were seeded at 
approx. 3x103 cells per cm2 growth area in a 24 well plate. The cells were left to attach 
overnight at 37°C in an atmosphere of 5% (v/v) CO2 in air. When attached, the culture medium 
was removed and replaced with osteogenic medium. The medium was replaced twice weekly, 
and cells were grown up to 21 days. Cultures were fixed and stained as below on days 0, 3, 7, 
14, and 21. 
3.2.8 ALIZARIN RED STAINING 
Reagents 
Ammonium hydroxide (10%): A 10% (v/v) ammonium hydroxide solution was made by diluting 
30 ml 28% ammonium hydroxide (Sigma) in 60 ml dH2O. 
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Alizarin red solution: A 40 mM alizarin red solution was made by dissolving 2 g alizarin red 
(Sigma) in 100 ml dH2O .The solution was made to pH 4.1 with 10% (w/v) ammonium 
hydroxide in dH2O.  
Method 
Cells were fixed with 1 ml 10% (v/v) formalin in dH2O at room temp for 15 min, before the 
formalin was removed, and the cells washed twice with 1 ml dH2O. All dH2O was removed from 
wells and cells were stained with 500 µl alizarin red solution for 20 minutes with gentle 
agitation. After 20 minutes the solution was removed, and the wells washed four times with 1 
ml dH2O. The cells were allowed to dry before viewing using an Olympus IX71 inverted 
microscope using Cell^B image capture software (Olympus). 
3.2.9 CHONDROGENIC DIFFERENTIATION OF MSCS 
Reagents 
Ascorbic-2-phosphate (Sigma): A 200 mM stock solution was made by dissolving 2.57 g 
ascorbic-2-phosphate in 50 ml dH2O. This stock solution was aliquoted into 75 µl volumes and 
stored at -20°C. This was added to chondrogenic medium at a 1:1500 dilution (75 µl in 100 ml 
medium) to give a final concentration of 1.3 mM. 
Insulin-Transferrin-Selenium x100 (Invitrogen) (100 µl in 100 ml medium) to give a final 
concentration of 1 x. 
Sodium pyruvate (Sigma): A 100 mM stock solution was made by dissolving 1.1 g sodium 
pyruvate in 100 ml dH2O. This was frozen in 0.5 ml aliquots and stored at -20°C. This was 
added to chondrogenic medium at a 1:200 dilution 0.5 ml in 100 ml medium) to give a final 
concentration of 0.5 mM. 
Method 
MSCs were cultured until 90 % confluent in a T75 tissue culture flask. Cells were removed from 
the surface of the tissue culture plastic using 2 ml Hy-Q-Tase™ per T75 flask. Cell suspension 
was added to 5 ml complete DMEM and centrifuged at 150 g for 10 minutes. The supernatant 
was discarded, and the pellet resuspended in 1 ml complete DMEM. Cells were counted using 
a haemocytometer, and resuspended at 1x107 cells per ml. Using a 20 µl pipette, a 10 µl 
volume of suspension was carefully placed in the center of a well of a 24 well plate. The cells 
were left to attach for 3 hours at 37°C 5% (v/v) CO2 in air, and after this time had elapsed the 
wells were flooded with chondrogenic culture medium and the cells were cultured at 37°C 5% 
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(v/v) CO2 in air. The medium was replaced twice weekly, and cells were grown up to 21 days. 
Cultures were fixed and stained as below on days 0, 3, 7, 14, and 21. 
3.2.10 ALCIAN BLUE STAINING 
Reagents 
Alcian blue 1 % (w/v) in acetic acid (Biostain Ready Reagents) 
Method 
Cells were fixed with 1 ml 10% (v/v) formalin at room temp for 15 min, before the formalin 
was removed, and the cells washed twice with 1 ml dH2O. All dH2O was removed from wells 
and cells were stained with 500 µl 1% (w/v) alcian blue solution for 3 minutes. This was 
removed, and the wells briefly washed with 1 ml dH2O to remove excess stain. The cells were 
allowed to dry before viewing using an Olympus IX71 inverted microscope using Cell^B image 
capture software (Olympus). 
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3.3 RESULTS 
BM 1 and 2 were isolated using the Lymphoprep method and expanded to passage 0 by Dr. E. 
Jones at the LIMM. BM 3 and 4 were isolated by the author at the IMBE laboratories at Leeds 
University. BM 1 was obtained from a donor 69 years old. BM 2 was obtained from a donor 9 
years old. BM 3 was obtained from a donor 8 years old, and BM 4 was obtained from a donor 
39 years old. 
3.3.1 ISOLATION OF CELLS FROM BONE MARROW 
A 10 ml bone marrow sample was taken from consenting donors BM 3 and 4 admitted to 
hospital following bone fracture. The bone marrow was diluted 1:1 in complete DMEM and 
plated out in a T75 flask. After 48 hours the cell monolayer was washed with 10 ml PBS, before 
remaining cells were cultured in NH Expansion Medium. Very few numbers of adherent cells 
were present initially and on average it took one-two weeks for the adherent cells to form 
colonies.  
3.3.2 MORPHOLOGY OF ADHERENT CELLS 
The plastic adherent cells exhibited a fibroblastic morphology, and after plating out bone 
marrow initially formed a sparse single cell population on the tissue culture flask. These single 
cells produced discreet colonies, and grew in a radial pattern. Colonies could be differentiated 
visually under light microscopy by the direction of the radial growth, as shown in Figure 3.1. 
This growth pattern only happened at early passages however, with the radial growth pattern 
becoming less pronounced as the passage number increased. 
Figure 3.1: Growth of low confluency early passage MSCs, and later passage at 100% 
confluency. (A) BM3 MSCs freshly isolated from bone marrow following 1 week of 
culture. (B) The radial growth pattern of BM3 MSCs at passage 2, after culture for 12 days 
from isolation. Cells were grown in NH Expansion Medium. Images are x 40 magnification. 
Scale bar in the upper left hand corner is 50µm. 
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3.3.3 PHENOTYPIC CHARACTERISATION OF MSCS USING FLOW CYTOMETRY 
BM 1-4 MSCs were expanded up to passage 6 and the phenotype of the cells was investigated 
using flow cytometry.  The events analysed were gated as shown in Figure 3.2, in order to 
discount cell debris and clumps. 
The flow cytometric analysis of BM 1-4 MSCs is shown in Figures 3.3-3.14. The analysis is 
displayed as one parameter histograms with the channel the fluorescence is recorded at on 
the x-axis, and the total count recovered on the y-axis. The gate shown in Figure 3.2 reduced 
the likelihood of cell clumps or debris being analysed. The histograms were gated with relative 
fluorescent intensities of between 100-101 excluded as being a negative reading, and values 
above 101 considered positive. 
Figure 3.2: Flow cytometric analysis dotplot. The side scatter intensity of cells 
(representing cell granularity) was plotted against the forward scatter intensity 
(representing cell size). Each of the dots represents a cell, or ‘event’ captured. A gate 
was used to exclude cell debris and clumps. 
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Figure 3.3: Flow cytometry histograms for the cell surface marker expression of the 
adherent cell population of BM 1 section 1. The text boxes indicate donor bone marrow 
followed by antigen. Data shown is representative of 10,000 events collected, and the 
resulting data was analysed in FlowJo ver. 7.6.1.The histograms were gated with staining 
above 101 being deemed positive staining. The percentage of positively staining cells is 
displayed above the gate. Cells stained negatively for CD14, CD19, CD34, and CD45, but 
positively for CD73 and CD90 fulfilling the phenotype criteria defined by the ISCT. 
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Figure 3.4: Flow cytometry histograms for the cell surface marker expression of the 
adherent cell population of BM 1 section 2. The text boxes indicate donor bone marrow 
followed by antigen. Data shown is representative of 10,000 events collected, and the 
resulting data was analysed in FlowJo ver. 7.6.1.The histograms were gated with staining 
above 101 being deemed positive staining. The percentage of positively staining cells is 
displayed above the gate. Cells stained negatively for HLA-DR, and the two isotype controls 
IgG1 and IgG2, but positively for CD105, fulfilling the phenotype criteria defined by the 
ISCT. 
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Figure 3.5: Flow cytometry histograms for the immuno-associated cell surface marker 
expression of the adherent cell population of BM 1 section 3. The text boxes indicate donor 
bone marrow followed by antigen. Data shown is representative of 10,000 events collected, 
and the resulting data was analysed in FlowJo ver. 7.6.1.The histograms were gated with 
staining above 102 being deemed positive staining. The percentage of positively staining cells 
is displayed above the gate. Cells stained negatively for CD40, CD80, and CD86, but positively 
for HLA-ABC, as has been demonstrated in previous studies. 
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Figure 3.6: Flow cytometry histograms for the cell surface marker expression of the 
adherent cell population of BM 2 section 1. The text boxes indicate donor bone marrow 
followed by antigen. Data shown is representative of 10,000 events collected, and the 
resulting data was analysed in FlowJo ver. 7.6.1.The histograms were gated with staining 
above 101 being deemed positive staining. The percentage of positively staining cells is 
displayed above the gate. Cells stained negatively for CD14, CD19, CD34, and CD45, but 
positively for CD73 and CD90 fulfilling the phenotype criteria defined by the ISCT. 
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Figure 3.7: Flow cytometry histograms for the cell surface marker expression of the 
adherent cell population of BM 2 section 2. The text boxes indicate donor bone marrow 
followed by antigen. Data shown is representative of 10,000 events collected, and the 
resulting data was analysed in FlowJo ver. 7.6.1.The histograms were gated with staining 
above 101 being deemed positive staining. The percentage of positively staining cells is 
displayed above the gate. Cells stained negatively for HLA-DR, and the two isotype controls 
IgG1 and IgG2, but positively for CD105, fulfilling the phenotype criteria defined by the 
ISCT. 
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Figure 3.8: Flow cytometry histograms for the immuno-associated cell surface marker 
expression of the adherent cell population of BM 2 section 3. The text boxes indicate donor 
bone marrow followed by antigen. Data shown is representative of 10,000 events collected, 
and the resulting data was analysed in FlowJo ver. 7.6.1.The histograms were gated with 
staining above 102 being deemed positive staining. The percentage of positively staining cells 
is displayed above the gate. Cells stained negatively for CD40, CD80, and CD86, but positively 
for HLA-ABC, as has been demonstrated in previous studies. 
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Figure 3.9: Flow cytometry histograms for the cell surface marker expression of the 
adherent cell population of BM 3 section 1. The text boxes indicate donor bone 
marrow followed by antigen. Data shown is representative of 10,000 events collected, 
and the resulting data was analysed in FlowJo ver. 7.6.1.The histograms were gated 
with staining above 101 being deemed positive staining. The percentage of positively 
staining cells is displayed above the gate. Cells stained negatively for CD14, CD19, 
CD34, and CD45, but positively for CD73 and CD90 fulfilling the phenotype criteria 
defined by the ISCT. 
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Figure 3.10: Flow cytometry histograms for the cell surface marker expression of the 
adherent cell population of BM 3 section 2. The text boxes indicate donor bone marrow 
followed by antigen. Data shown is representative of 10,000 events collected, and the 
resulting data was analysed in FlowJo ver. 7.6.1.The histograms were gated with staining 
above 101 being deemed positive staining. The percentage of positively staining cells is 
displayed above the gate. Cells stained negatively for HLA-DR, and the two isotype 
controls IgG1 and IgG2, but positively for CD105, fulfilling the phenotype criteria defined 
by the ISCT. 
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Figure 3.11: Flow cytometry histograms for the immuno-associated cell surface marker 
expression of the adherent cell population of BM 3 section 3. The text boxes indicate 
donor bone marrow followed by antigen. Data shown is representative of 10,000 events 
collected, and the resulting data was analysed in FlowJo ver. 7.6.1.The histograms were 
gated with staining above 102 being deemed positive staining. The percentage of positively 
staining cells is displayed above the gate. Cells stained negatively for CD40, CD80, and 
CD86, but positively for HLA-ABC, as has been demonstrated in previous studies. 
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Figure 3.12: Flow cytometry histograms for the cell surface marker expression of the 
adherent cell population of BM 4 section 1. The text boxes indicate donor bone 
marrow followed by antigen. Data shown is representative of 10,000 events collected, 
and the resulting data was analysed in FlowJo ver. 7.6.1.The histograms were gated 
with staining above 101 being deemed positive staining. The percentage of positively 
staining cells is displayed above the gate. Cells stained negatively for CD14, CD19, 
CD34, and CD45, but positively for CD73 and CD90 fulfilling the phenotype criteria 
defined by the ISCT. 
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Figure 3.13: Flow cytometry histograms for the cell surface marker expression of the 
adherent cell population of BM 4 section 2. The text boxes indicate donor bone marrow 
followed by antigen. Data shown is representative of 10,000 events collected, and the 
resulting data was analysed in FlowJo ver. 7.6.1.The histograms were gated with staining 
above 101 being deemed positive staining. The percentage of positively staining cells is 
displayed above the gate. Cells stained negatively for HLA-DR, and the two isotype 
controls IgG1 and IgG2, but positively for CD105, fulfilling the phenotype criteria defined 
by the ISCT. 
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Figure 3.14: Flow cytometry histograms for the immuno-associated cell surface marker 
expression of the adherent cell population of BM 4 section 3. The text boxes indicate 
donor bone marrow followed by antigen. Data shown is representative of 10,000 events 
collected, and the resulting data was analysed in FlowJo ver. 7.6.1.The histograms were 
gated with staining above 102 being deemed positive staining. The percentage of positively 
staining cells is displayed above the gate. Cells stained negatively for CD40, CD80, and 
CD86, but positively for HLA-ABC, as has been demonstrated in previous studies. 
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Flow cytometry was performed in 2 stages. Firstly for the ISCT characteristic markers CD14, 
CD19, CD34, CD45, HLA-DR, CD73, CD90 and CD105 and secondly for the immuno-associated 
markers CD40, CD80, CD86 and HLA-ABC. For the second stage when the immuno-associated 
markers were analysed the laser on the flow cytometer had been replaced. This resulted in the 
shift of the histogram peaks for the unlabelled cell controls. The histograms were re-gated at 
102 to account for this. The percentage of positive cells staining for the isotype controls or for 
the unlabelled MSCs was deducted from the percentage of cells staining positively for the 
remaining cell surface markers. The mean percentage of positive cells across all 4 BM MSC 
donors was calculated, and is presented in Table 3.3 with the separate percentage staining 
values. If a negative value was obtained, this value was reset to 0% staining.  
The markers that have been shown to stain negative had a mean number of positively staining 
cells less that 5 %. This included CD14, CD19, CD34, CD45, HLA-DR, CD40, CD80, and CD86. The 
markers that have previously been shown to be positive markers expressed on MSCs stained 
positive, and these were CD73, CD90, CD105, and HLA-ABC. 
 
BM1 BM2 BM3 BM4 Mean 
CD14 -0.45 0.11 -0.02 5.41 1.26 
CD19 0.41 -0.19 0.19 6.01 1.61 
CD34 1.56 2.15 3.09 9.41 4.05 
CD45 -5.09 -8.53 -6.74 -12.76 0.00 
HLA-DR -5.06 -6.07 -6.64 -12.83 0.00 
CD40 -7.7 -9.1 -3.4 -6.8 0.00 
CD80 -3.4 -9.8 -3.2 -4.6 0.00 
CD86 -1 -6.2 3.6 0.1 0.00 
CD73 75.87 63.55 63.69 66.91 67.51 
CD90 84.07 80.85 71.49 88.71 81.28 
CD105 88.17 77.45 76.69 88.81 82.78 
HLA-ABC 46.3 41 49.9 42.4 44.90 
 
 
 
Table 3.3: The histogram plots of fluorescent intensity were gated with cells staining greater 
than 101 deemed positive. The percentage of positively stained cells for each antibody is 
shown. The percentage values obtained have been normalized to the negative isotype controls 
(CD14, CD19, CD34, CD45, HLA-DR, CD70, CD90 and CD105) or unlabelled cells (CD40, CD80, 
CD86 and HLA-ABC). 
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3.3.4 TRI-LINEAGE DIFFERENTIATION ASSAY 
The trilineage differentiation potential of bone marrow cells and fibroblasts was investigated 
by differentiating the cells into bone, fat, and cartilage using specific differentiation medium.  
All of the adherent cell populations cultured under differentiation conditions stained positively 
for their respective differentiation markers (Figures 3.15-3.26). In osteogenic cultures, calcium 
accumulation was only observed later than Day 7, with very little orange/red staining present 
in cultures differentiated for this length of time or below. Staining appeared to be heterotypic 
between cells, with areas of localised calcium deposition appearing more intense in different 
areas of the culture well. Different donor adherent cells also exhibited different osteogenic 
potential, with cells from donors two and three staining less intensely than donor four for 
calcium. Adipogenic differentiation could be visualised by day 7 with small lipid vesicles 
appearing within cells. These vesicles grew increasingly larger in size, appearing at their largest 
by day 21. Adipogenesis also exhibited the same donor variability, with donor 3 appearing to 
have the most intracellular lipid staining by day 21. There also appeared to be heterogeneity 
within the same donor’s adherent cells, with not all cells accumulating intracellular lipid 
droplets. Levels of chondrogenesis also varied between donors; with donor three appearing to 
have the most GAG deposition by day 21.  
BM1 exhibited high levels of osteogenesis (calcium deposition) by day 21 (Figure 3.15) with the 
level of mineralisation so heavy that the cell culture has collapsed in on itself. High levels of 
adipogenesis were also observed by day 14 and especially by day 21 (Figure 3.16).However 
very low levels of chondrogenesis were observed. The levels of GAG staining appeared to be 
slightly higher than those of the fibroblast controls (Figure 3.17).  
BM2 stained for high levels of osteogenesis (calcium deposition) by day 21 but unlike BM1 
there were no areas of intense staining (black) and instead an overall increase in calcium level 
was observed (Figure 3.18). Levels of adipogenesis were also high by day 21, but less so than 
BM1 (Figure 3.19). Levels of GAG staining increased from day 0 to day 21, and staining was 
strongest in chondrogenic medium, with expansion control and fibroblast only staining weakly 
(Figure 3.20).  
BM3 had similar levels of calcium staining to BM2, with an overall increase of staining by day 
21 (Figure 3.21). Staining for intracellular lipids increased until the strongest staining was on 
day 21 (Figure 3.22). Levels of GAG staining increased from day 0 to day 21, and staining was 
highest on day 21. BM3 was the most chondrogenic and stained the strongest for GAGs by day 
21 (Figure 3.23). 
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BM4 high levels of osteogenesis (calcium deposition) by day 21, with both an increase in 
overall calcium levels, but also small regions of very intense staining appearing black (Figure 
3.24). Oil red staining showed the presence of intracellular triglycerides in adipogenic media 
only, with no staining present in expansion medium or in the fibroblast control (Figure 3.25). 
GAG staining was similar to BM2, with levels of staining higher for MSCs in chondrogenic 
media than both the expansion media and fibroblast control (Figure 3.26). 
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Figure 3.15: The osteogenic potential of donor BM1 MSCs over 21 days. Adherent cells were 
seeded into 24 well plates and grown in osteogenic induction medium (A), or expansion medium 
(B). Primary human dermal fibroblast cells were grown in osteogenic induction medium as a 
control. Calcium deposits stained red/orange, and there is a gradual accumulation of calcium 
over the timecourse (A), with the greatest staining present on day 21. Images were captured 
using Cell^B software (Olympus) at x100 magnification. Scale bars represent 500 µm. 
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Figure 3.16: The adipogenic potential of donor BM1 MSCs over 21 days. Adherent cells were 
seeded into 24 well plates and grown in adipogenic induction medium (A), or expansion medium 
(B). Primary human dermal fibroblast cells were grown in adipogenic induction medium as a 
control. Intracellular triglycerides (fat) deposits stained red, and there is a gradual accumulation 
of fat over the timecourse (A), with the greatest staining present on day 21. Images were 
captured using Cell^B software (Olympus) at x100 magnification. Scale bars represent 500 µm. 
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Figure 3.17: The chondrogenic potential of donor BM1 MSCs over 21 days. Adherent cells were 
seeded into 24 well plates and grown in chondrogenic induction medium (A), or expansion 
medium (B). Primary human dermal fibroblast cells were grown in adipogenic induction medium 
as a control. Glycosaminoglycan (GAG) deposits stained blue, and there is a gradual 
accumulation of GAGs over the timecourse (A), with the greatest staining present on day 21. 
Images were captured using Cell^B software (Olympus) at x100 magnification. Scale bars 
represent 500 µm. 
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Figure 3.18: The osteogenic potential of donor BM2 MSCs over 21 days. Adherent cells were 
seeded into 24 well plates and grown in osteogenic induction medium (A), or expansion medium 
(B). Primary human dermal fibroblast cells were grown in osteogenic induction medium as a 
control. Calcium deposits stained red/orange, and there is a gradual accumulation of calcium 
over the timecourse (A), with the greatest staining present on day 21. Images were captured 
using Cell^B software (Olympus) at x100 magnification. Scale bars represent 500 µm. 
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Figure 3.19: The adipogenic potential of donor BM2 MSCs over 21 days. Adherent cells were 
seeded into 24 well plates and grown in adipogenic induction medium (A), or expansion medium 
(B). Primary human dermal fibroblast cells were grown in adipogenic induction medium as a 
control. Intracellular triglycerides (fat) deposits stained red, and there is a gradual accumulation 
of fat over the timecourse (A), with the greatest staining present on day 21. Images were 
captured using Cell^B software (Olympus) at x100 magnification. Scale bars represent 500 µm. 
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Figure 3.20: The chondrogenic potential of donor BM2 MSCs over 21 days. Adherent cells were 
seeded into 24 well plates and grown in chondrogenic induction medium (A), or expansion 
medium (B). Primary human dermal fibroblast cells were grown in adipogenic induction medium 
as a control. Glycosaminoglycan (GAG) deposits stained blue, and there is a gradual 
accumulation of GAGs over the timecourse (A), with the greatest staining present on day 21. 
Images were captured using Cell^B software (Olympus) at x100 magnification. Scale bars 
represent 500 µm. 
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Figure 3.21: The osteogenic potential of donor BM3 MSCs over 21 days. Adherent cells were 
seeded into 24 well plates and grown in osteogenic induction medium (A), or expansion medium 
(B). Primary human dermal fibroblast cells were grown in osteogenic induction medium as a 
control. Calcium deposits stained red/orange, and there is a gradual accumulation of calcium 
over the timecourse (A), with the greatest staining present on day 21. Images were captured 
using Cell^B software (Olympus) at x100 magnification. Scale bars represent 500 µm. 
Page 84 
 
 
Figure 3.22: The adipogenic potential of donor BM3 MSCs over 21 days. Adherent cells were 
seeded into 24 well plates and grown in adipogenic induction medium (A), or expansion medium 
(B). Primary human dermal fibroblast cells were grown in adipogenic induction medium as a 
control. Intracellular triglycerides (fat) deposits stained red, and there is a gradual accumulation 
of fat over the timecourse (A), with the greatest staining present on day 21. Images were 
captured using Cell^B software (Olympus) at x100 magnification. Scale bars represent 500 µm. 
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Figure 3.23: The chondrogenic potential of donor BM3 MSCs over 21 days. Adherent cells were 
seeded into 24 well plates and grown in chondrogenic induction medium (A), or expansion 
medium (B). Primary human dermal fibroblast cells were grown in adipogenic induction medium 
as a control. Glycosaminoglycan (GAG) deposits stained blue, and there is a gradual 
accumulation of GAGs over the timecourse (A), with the greatest staining present on day 21. 
Images were captured using Cell^B software (Olympus) at x100 magnification. Scale bars 
represent 500 µm. 
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Figure 3.24: The osteogenic potential of donor BM4 MSCs over 21 days. Adherent cells were 
seeded into 24 well plates and grown in osteogenic induction medium (A), or expansion medium 
(B). Primary human dermal fibroblast cells were grown in osteogenic induction medium as a 
control. Calcium deposits stained red/orange, and there is a gradual accumulation of calcium 
over the timecourse (A), with the greatest staining present on day 21. Images were captured 
using Cell^B software (Olympus) at x100 magnification. Scale bars represent 500 µm. 
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Figure 3.25: The adipogenic potential of donor BM4 MSCs over 21 days. Adherent cells 
were seeded into 24 well plates and grown in adipogenic induction medium (A), or 
expansion medium (B). Primary human dermal fibroblast cells were grown in adipogenic 
induction medium as a control. Intracellular triglycerides (fat) deposits stained red, and 
there is a gradual accumulation of fat over the timecourse (A), with the greatest staining 
present on day 21. Images were captured using Cell^B software (Olympus) at x100 
magnification. Scale bars represent 500 µm. 
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Figure 3.26: The chondrogenic potential of donor BM4 MSCs over 21 days. Adherent cells were 
seeded into 24 well plates and grown in chondrogenic induction medium (A), or expansion 
medium (B). Primary human dermal fibroblast cells were grown in adipogenic induction medium 
as a control. Glycosaminoglycan (GAG) deposits stained blue, and there is a gradual 
accumulation of GAGs over the timecourse (A), with the greatest staining present on day 21. 
Images were captured using Cell^B software (Olympus) at x100 magnification. Scale bars 
represent 500 µm. 
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3.4 DISCUSSION 
Over 40 years ago Freidstein et al. documented a population of adherent cells present within 
the bone marrow that were fibroblast-like, and able to repair damaged bone.  Since this initial 
report, these cells have generated a large amount of interest due to their potential benefits in 
regenerative medicine, ease of isolation and expansion (Jones et al., 2002), multilineage 
potential (Pittenger et al., 1999), immune-privileged status and immune-suppressing 
capabilities (Le Blanc and Ringden, 2007; Nauta and Fibbe, 2007).   
It was the aim of this chapter to determine whether the cells obtained from donor bone 
marrow and used in this thesis were human bone marrow derived MSCs, through the 
fulfilment of the ISCT criteria.  
The radial growth pattern displayed by MSCs when freshly isolated from bone marrow 
demonstrated their ability to proliferate from single cells into colonies of daughter cells. These 
colonies of cells can be stained using crystal violet solution and a typically used method of 
enumerating MSCs in the bone marrow is by the colony-forming units-fibroblastic assay 
(Castro-Malaspina et al., 1980; Pittenger et al., 1999; Jones et al., 2002). All of the donor bone 
marrow MSCs exhibited similar morphology: fibroblastic, with long spindle-like cells growing 
very tightly together. At later passages (p10) the cells started to become senescent, spreading 
out on the tissue culture plastic and looking more granular.  
Two different methods were used to isolate potential MSCs from bone marrow. The first 
method has been well characterised, and used a Lymphoprep® density centrifugation gradient 
to separate the mononuclear cell fraction from bone marrow, before these cells were plated 
out onto tissue culture plastic, and the adherent cells attached and proliferated, while the non-
adherent cells were washed away during medium changes (Haynesworth et al., 1992; 
Pittenger et al., 1999; Jones et al., 2002). The alternate method, also called the direct plating 
method, used was to mix freshly isolated BM in a 1:1 ratio of complete DMEM growth 
medium, and plate this mixture out in T75 tissue culture flasks. After 48 hours the cell 
monolayer was washed and the medium replaced with MSC expansion medium. This method 
eliminated the need for a Lymphoprep® centrifugation step and as such resulted in a much 
more streamlined process for obtaining MSCs. When using this method it was not uncommon 
to find that within the first 48 hours of plating cells out onto tissue culture plastic that the 
bone marrow and medium mixture coagulated, resulting in a jelly-like layer forming over the 
top of the cell monolayer. If this layer was forcibly removed during medium changes or during 
the wash steps then this resulted in a very low MSC yield, with colonies taking > 2 weeks to 
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appear. However, if this layer was left on the tissue culture plastic, and allowed to gradually 
dissipate with time, the number of MSCs obtained appeared to be far greater, with colonies 
appearing in < 1 week, with rapid growth. This could have been due to the presence of 
beneficial growth factors in the coagulated layer, as this layer would contain a multitude of 
cells from within the bone marrow, and would more accurately represent the MSC niche from 
where these cells were originally isolated. It is also possible that the coagulated layer 
contained platelets that released platelet derived growth factor (PDGF), which has been shown 
to be a potent mitogen of MSCs (Caplan and Correa, 2011).  
The second criteria of the ISCT was the expression (or lack of) of a specific set of cellular 
markers by MSCs. Flow cytometry was used to allow a quantitative measure of cell marker 
expression on the adherent cells. A gate was drawn onto the histogram plots, with relative 
fluorescent intensities of between 100-101 excluded as being a negative reading, and values 
above 101 considered positive. Percentages of number of cells above 101 were given as the 
number of cells positively staining for a specific antibody. The flow cytometric analysis was 
divided into 2, with the ISCT characteristic markers CD14, CD19, CD34, CD45, HLA-DR, CD73, 
CD90 and CD105 analysed primarily and the immuno-associated markers CD40, CD80, CD86 
and HLA-ABC analysed later. For the second stage when the immuno-associated markers were 
analysed the laser on the flow cytometer had been replaced. This resulted in the shift of the 
histogram peaks for the unlabelled cell controls. The histograms were re-gated at 102 to 
account for this. 
The isotype and unstained control positive staining percentages were subtracted from 
experimental percentages, and mean positive staining percentage calculated.  
Fluctuations in donor cell variability (size and granularity) can cause small shifts in histograms, 
and as the same settings were used for collection throughout phenotyping to allow direct 
comparisons to be performed, these small shifts can manifest in variations in marker 
percentage staining.  
The histograms obtained for positively stained markers did not have a defined peak, and 
instead were spread out and had a wide footprint, possibly due to the varied heterogeneous 
nature of MSCs grown in culture; the size and granularity of MSCs can vary, creating the wide 
histograms. The differences in size appeared to be a factor of age, with cells of later passages 
having increasing numbers of larger cells present within their population. The same flow 
cytometry settings were used to collect data for each of the donor MSCs, to allow differences 
in cell marker expression to be compared. The fluorescence antibodies for CD45 and HLA-DR 
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were measured using a different channel (FL-3), and the compensation settings used meant 
that the peak fluorescence was at 100, which resulted in the very low percentage of positively 
staining cells when compared to the other negative markers. The percentage of positively 
staining cells were all greater than 65% (except for HLA-ABC), but again due to the large spread 
out nature of the histograms although the peaks were over 101 a portion of the area under the 
histogram overlapped the negative staining cut off point. All donors’ adherent cells were 
positive for CD73, CD90 and CD105 and negative for the expression of CD14, CD19, CD34, 
CD45 and HLA-DR. A fluorescently conjugated isotype antibody control was used as a negative 
control in the flow cytometry to provide a background fluorescent intensity for non-specific 
primary antibody binding, and the fluorophore for the isotype control was RPE. When 
performing flow cytometry the isotype control should have the same fluorophore as the test 
antibody. In this case, the isotype controls used were able to demonstrate that there was no 
non-specific binding for the positive markers CD73, CD90 and CD105. A limitation of the study 
was that no FITC labelled isotype control was included. However as the FITC labelled test 
antibodies used did not demonstrate positive staining, this omission not change the outcome 
of the results. 
Flow cytometry for the co-stimulatory molecules and HLA-ABC demonstrated correlation with 
previously published literature that MSCs do not express the co-stimulatory molecules CD40, 
CD80, or CD86, and also do not express HLA-DR. Multipotent mesenchymal stromal cells do 
express HLA-ABC however, and in agreement with other studies this was shown to be at a low 
level (Uccelli et al., 2006; Le Blanc and Ringden, 2007; Nauta and Fibbe, 2007; Spencer et al.,  
2010; Bassi et al., 2011).  
The final criteria that the adherent bone marrow population of cells must fulfil in order to be 
characterised as MSCs is that the cells must be able to differentiate into adipocytes, 
osteoctytes and chondrocytes using specific culture conditions. All of the trilineage 
differentiations provided varied levels of differentiation, which was believed to be due to the 
heterogenic nature of MSCs, and the differences in ages of donor (D'Ippolito et al., 1999; 
Kretlow et al., 2008).  
Adipogenic differentiation was heterogenic across the adherent cell population for each BM 
donor with a small subset of the cells accumulating no lipid vesicles, even at day 21. The 
accumulation of lipid vesicles within the cells also appeared to be dependent on the area of 
the tissue culture well that the cells were grown in; the outer perimeter and the centre of the 
well displayed highest levels of differentiation. Also, it was noted that adipogenesis occurred in 
‘patches’, with areas of the well appearing very dense for mature fat cells (cells containing 
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large lipid vesicles) , and other areas having little differentiation. It is possible that where a 
cluster of adherent cells differentiated into adipocytes, cell signalling molecules or cytokines 
were released to promote cells in the vicinity to also differentiate. Alternatively, the presence 
of discreet areas of adipogenesis (or areas where adipogenesis appeared to be noticeably 
increased when compared to the surroundings) could have been due to cell clumping when 
the adherent cells were initially plated. Early on during the differentiation time course, as early 
as day 7 it could be seen that there were a large number cells starting to accumulate lipid 
vesicles around the circumference of the wells, as well as a dense area of cells in the center of 
the wells. The differentiation of the adherent cells into adipocytes demonstrated the 
heterogeneity of the cell population, and the variability of adipogenesis between donors. 
Osteogenic differentiation showed a gradual increase in calcium deposition/accumulation as 
the 21 day timecourse progressed, with the formation of ‘bony nodules’ or areas of intense 
staining (almost black rather than red/orange). There was a faint orange tint to the negative 
control cultures, but this was thought to be due to staining being performed on very dense cell 
monolayers (MSCs in osteogenic differentiation medium appeared to continue proliferation 
and differentiation). In some cases the monolayer had started to lift off from the tissue culture 
plastic or curl around onto itself due to the mineralisation of the culture becoming so heavy. 
This was most prolific when MSCs were seeded at high densities, such as for osteogenesis. 
When adipogenic differentiation was performed this was not as large an issue, as MSCs were 
seeded at lower densities, and began differentiating earlier with little discernable growth 
phase. 
When undergoing osteogenesis the cell population grew until confluent before accumulating 
calcium, as initially cultures appeared far less dense. When cells were grown in wells already at 
confluency and differentiation attempted, most of the cell monolayer was lost due to curling 
or from lifting off the bottom of the well. This was in comparison to adipogenesis, where the 
population of cells seeded into wells began differentiation instead of initially proliferating.   
Chondrogenesis was performed using micromass culture. A large number of cells within a 
small volume (10µl) were deposited in a tissue culture plate, and this high number of cells 
attached to the surface of the well, forming a dense micromass of cells. GAG accumulation was 
used as a marker of chondrogenesis, and levels of staining when the adherent cells were 
grown in chondrogenic differentiation medium did not appear to be significantly different than 
cells grown in expansion medium. There was a small amount of residual staining in the cells 
grown in expansion medium, which could have been due to the regions of very dense cell 
growth. The chondorogenesis demonstrated by BM MSCs 1-4 was generally low, with weak 
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increases in staining observed for differentiated MSCs combined with high background staining 
in the fibroblast control, and also to some extent in the undifferentiated controls. This was 
perhaps due to the limitations of micromass culture (it is still essentially a two dimensional 
culture system), and higher levels of chondrogenesis would have possible been observed if 
pellet culture was used, and MSCs were grown in three dimensional culture. Although levels of 
chondrogenesis were minimal, it was still possible to observe visible differences between day 0 
and day 21 of culture.  
In conclusion, the adherent cell population from four bone marrow donors was purified and 
expanded, before morphological, phenotypic and trilineage differentiation was performed in 
order to determine if these cells were MSCs. These cells were plastic adherent under standard 
culture conditions. Flow cytometry demonstrated that these cells were positive for the 
expression of CD73, CD90 and CD105 and negative for the expression of CD34, CD45, CD14, 
CD19 and HLA-DR. The adherent cells were also able to differentiate into adipocytes, 
osteoctyte and chondrocytes.  
All adherent cell populations fulfilled the criteria as defined by the ISCT for the definition of 
mesenchymal stromal cells. 
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Chapter 4:  A COMPARISON OF METHODS USED TO 
EVALUATE THE ADIPOGENESIS OF MSCS 
4.1 INTRODUCTION 
Adipose tissue can be divided into two main types, brown adipose tissue and white adipose 
tissue (Fantuzzi, 2005; Tilg and Moschen, 2006). The major role of brown adipose tissue is 
nonshivering thermogenesis, whereas the main role of white adipose tissue is energy storage, 
and this forms the majority of adipose tissue in humans. White adipose tissue is composed of 
many cell types, including macrophages and fibroblasts, but the major cellular constituents are 
adipose cells (Fantuzzi, 2005).  
MSCs were first shown to differentiate into adipose cells in the early 1980’s, when it was 
demonstrated that the incubation of the fibroblastic cells from bone marrow with 
hydrocortisone could induce the formation of lipid droplets within the adherent cells (Kaneko 
et al., 1982). Adipose cells present in white adipose tissue are known to be linked with 
inflammation and immunity, and have been shown to be able to secrete various pro-
inflammatory and anti-inflammatory factors (Tilg and Moschen, 2006) and this is unsurprising 
given the presence of macrophages within adipose tissue and the often close physical 
proximity between white adipose tissue and lymphoid tissue (Pond, 2003). The link between 
immunity/inflammation is not only due to the physical proximity of the cells of the immune 
system with adipose tissue, but also due to the paracrine factors secreted by adipose cells. In 
particular, adipose cells have been demonstrated to secrete a specific family of proteins called 
‘adipokines’. The differentiation of MSCs into adipocytes presents an interesting system for the 
study of the immunological properties of MSC following differentiation. Mature adipose cells 
have been shown to secrete adipokines, such as leptin, resistin, and adiponectin (Schaffler et 
al., 2007). These adipokines are known to exert potent immunomodulatory effects on cells of 
the immune system (Tilg and Moschen, 2006; Bielby et al., 2007; Schaffler et al., 2007). At the 
same time adipocytes have been demonstrated to be potent producers of pro-inflammatory 
cytokines such as TNF-α and interleukin-6, as well as chemokines such as monocyte 
chemoattractant protein (MCP)-1 (Schaffler et al., 2006; Schaffler et al., 2007).  
In order to study the immunological properties of MSC during the process of differentiation 
into adipocytes, a robust method to quantify and determine the level of adipogenesis in-vitro 
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was required. Various methods have been employed to evaluate adipogenesis, such as oil red-
O staining (English et al., 2007; Platt and El-Sohemy, 2009), qrt-PCR of adipogenic markers 
(Janderova et al., 2003; Fink et al., 2004; Neubauer et al., 2004; Sekiya et al., 2004; Blum and 
Benvenisty, 2008), flow cytometry of adipogenic markers (Greenspan et al., 1985; Smyth and 
Wharton, 1992; Dennis et al., 1999; Fink et al., 2004), and Nile red staining (Greenspan et al., 
1985).  
qrt-PCR is a method that can be used to monitor the progression of a PCR reaction in real time 
(RT), and quantify (q) the PCR product as it is produced. The process of PCR allows the 
detection and amplification of specific DNA sequences from a mixture of DNA species. When 
using rt-PCR however the aim is to look at the levels of mRNA expression in cells, and therefore 
a reverse transcriptase step to convert mRNA into cDNA is required. This step can be carried 
out using different methods, from random primers, oligo-dT primers, or even specific 
sequence primers, and a reverse transcriptase enzyme that creates the cDNA from free 
oligonucleotides also added to the reaction (Bustin et al., 2005). Theoretically, the more mRNA 
transcripts for a specific gene there are in a sample, then the higher the number of 
corresponding cDNA sequences will be present in the final sample to perform PCR. Specific 
primers used during PCR amplify specific genes/regions of interest, and there are 2 main 
methods used to quantify the amount of transcript generated from the PCR process; a 
fluorescent DNA dye, or a specific Taqman® probe. The Taqman® probe is an oligonucleotide 
specific for the gene/region of interest with a fluorescent molecule attached to the 5’ end, and 
a quencher molecule attached to the 3’ end (Heid et al., 1996). The close proximity of the 
quencher to the probe results in no fluorescence. When the primer anneals to the specific 
sequence, the Taq polymerase extends the primer along the length of the transcript, and when 
it reaches the bound Taqman® probe the 5’ exonuclease activity of the polymerase cleaves the 
bound probe, and releases the fluorescent molecule and quencher, allowing the fluorescent 
molecule to freely fluoresce, and this can then be quantified by the detector. An overview of 
this method is shown in Figure 4.1. 
The second widely used method is less specific, and uses a dye (SYBR green) that binds to 
double stranded DNA and fluoresces, such that as the levels of amplified template increase, 
the fluorescence increases proportionally. An overview of this method is shown in Figure 4.2. 
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Figure 4.1: An overview of the Taqman® probe. A) A fluorescent reported dye (R) and 
a quencher (Q) are attached to the 5’ and 3’ ends of a Taqman® probe, which is 
sequence specific for the gene of interest. B) When the probe binds to the cDNA the 
close proximity of the quencher molecule prevents the fluorescence of the dye. C) 
During the extension cycle the DNA polymerase cleaves the reporter dye from the 
Taqman® probe as it travels along the cDNA. D) When the dye is free from the close 
proximity of the quencher, it fluoresces, and this fluorescence is measured. The more 
cDNA transcripts present the larger the number of Taqman® probes will bind and 
therefore the higher the fluorescence will be as the reporter dyes are freed.  
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Figure 4.2: An overview of the SYBR green method of measuring qRT-PCR. A) SYBR green 
(S) binds to double stranded DNA, so in the initial reaction before the denaturisation step 
the dye is able to bind to the double stranded cDNA and fluoresce. B) The denaturisation 
step causes the cDNA to become single stranded, the the SYBR green is released, and stops 
fluorescing. C) PCR causes the amplification of the specific sequence of interest. D) When 
polymerisation has been completed, there is amplification of cDNA sequence of interest. 
When the cDNA strands re-anneal and form double stranded DNA, the SYBR green dye 
binds again to the DNA and fluoresces. Due to the amplification of the sequence of interest 
there is a larger amount of double stranded cDNA present and this results in the increase of 
fluorescence that is then measured. 
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In this study SYBR green was used to measure gene expression, due to the experience of using 
this technique within the laboratory. Two genes were selected to measure an early 
transcription factor peroxisome proliferator activated receptor (PPAR-ɣ) and a late marker of 
adipogenesis, fatty acid binding protein 4 (FABP4) due to their previous reported expression 
during adipogenesis (Nolte et al., 1998; Janderova et al., 2003; Fink et al., 2004; Neubauer et 
al., 2004; Sekiya et al., 2004; Blum and Benvenisty, 2008). Both of these transcripts have been 
shown to increase in adipogenesis. PPAR-ɣ is a nuclear receptor that upon stimulation with 
ligand binds to retinoid-X receptor and this complex can bind to the DNA and initiate 
transcription (Nolte et al., 1998). An overview of the response of PPAR-ɣ to ligand is shown in 
Figure 4.3  
Figure 4.3: An overview of the response of PPAR-ɣ to ligand. Upon stimulation PPAR-ɣ binds 
to retinoid-X-receptor (RXR), and this complex binds to DNA in the presence of co-activators, 
to stimulate the expression of adipogenic target genes aP2 (also known as FABP4), adipose 
differentiation related protein (ADRP), CCAAT-enhancer binding proteins (c/EBP) and low 
density lipoprotein (LDL) and to block the expression of pro-inflammatory genes COX2, IL-1 
and TNF. Image was created by Dr. J. Heuvel for the PPAR resource page in association with 
the Penn State University; (http://ppar.cas.psu.edu/pathways.html). 
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The exact factors involved in the differentiation into mature adipocytes are not currently fully 
understood, but many different genes have been reported to be involved, with knockout 
studies demonstrating decreased adipogenesis when these genes are not transcribed or qRT-
PCR demonstrating increased levels of gene expression during adipogenesis; CAAT/enhancer 
binding protein-α (C/EBPα), FABP4, insulin-like growth factor binding protein 2 (IGFBP2) 
resistin, adiponectin, and lipoprotein lipase, which simulates fatty acid binding and 
sequestering in mature adipocytes (Hartig et al.; Wu et al., 1999; Rival et al., 2004; Sekiya et 
al., 2004). FABP4 is also known as fatty acid binding protein (aP2) in other mammals and is a 
protein involved in the metabolism and intracellular transport of fatty acids in adipose cells; 
FABP4 is able to bind the fatty acids with a high affinity and re-localise them to other parts of 
Figure 4.4: Overview of the general functions of FABP4. FABP4 (coloured molecular structure 
displayed in center of image) interacts with hormone-sensitive lipase (HSL) to affect its catalytic 
activity, and also integrates into several signalling networks that control inflammatory 
responses [potentially through the JNK/IKK (inhibitor of kappa kinase)] and insulin action in the 
adipocyte. FABP4 is able to regulate fatty acid influx, and is thought to be important in 
controlling lipid hormone production to regulate distant targets. Image taken from Furuhashi 
et al (2008).  
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the cell (Gorbenko et al., 2006). An overview of the general functions of FABP4 is shown in 
Figure 4.4. 
In addition to these roles, FABP4 performs the general role of fatty acid binding protein aiding 
in the transport of lipids to specific compartments in the cell; to lipid droplets for storage, the 
endoplasmic reticulum for signalling, trafficking and membrane synthesis, to the mitochondria 
or peroxisome for oxidation, to cytosolic or other enzymes to regulate their activity, to the 
nucleus for the control of lipid mediated transcriptional programs via nuclear hormone 
receptors, or other transcription factors that respond to lipids (Furuhashi and Hotamisligil, 
2008).  
Flow cytometry has been used to measure adipogenesis previously, using Nile red dye 
(Greenspan et al., 1985; Neubauer et al., 2004). Nile red is a selective fluorescent stain for 
intracellular lipid droplets at 528-570 nm, and has been coupled with flow cytometry to detect 
adipocytes through the accumulation of intracellular lipids within the cells (Greenspan et al., 
1985; Smyth and Wharton, 1992; Dennis et al., 1999; Fink et al., 2004). Nile red is fluorescent 
in all organic solvents, but the hydrophobicity of the solvent can change the emission and 
excitation maxima by up to 60nm (Greenspan et al., 1985).  Within intracellular lipid vesicles 
therefore, the excitation of Nile red occurs at 450-500 nm, and the emission at 528-570 nm.  
Oil red-O dye is frequently used for demonstrating adipogenesis, and is widely used as a 
lysochrome to visualise intracellular lipid droplets (Pittenger et al., 1999; Jones et al., 2002; 
English et al., 2007; Platt and El-Sohemy, 2009). In addition to its use as a visual representation 
of adipogenesis, attempts have been made to increase the accuracy and use the amount of Oil 
red-O staining as a quantifiable indicator of fat. This has been done by visually grading and 
counting adipogenically differentiated MSCs (English et al., 2007), and also through the 
spectrophotometric analysis after Oil red-O is removed from the stained cells by isopropanol, 
and the absorbance measured at 415 nm (Platt and El-Sohemy, 2009). 
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4.1.1 AIMS AND OBJECTIVES 
The aim of this chapter was to differentiate MSCs into adipose cells, and verify that the cell 
population obtained was adipose cells. In addition to this, a suitable method for quantifying 
the level of adipogenesis of the MSC population was sought. The objectives were therefore: 
 To differentiate MSCs from four donors into adipose cells. 
 To verify that the differentiated cell population were adipose cells. 
 To assess the suitability of the following methods for measuring adipogenesis: 
1. Oil red-O staining and semi-quantitative scoring. 
2. Real time PCR for PPAR-ɣ and FABP4. 
3. Flow cytometry using intracellular antibody to FABP4 and Nile red. 
4. Fluorescent microplate assay using Nile red and DAPI.  
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4.2 MATERIALS AND METHODS 
4.2.1 ISOLATION AND EXPANSION OF MSCS AND CONTROL SKIN FIBROBLASTS 
Human bone marrow MSCs were isolated as described in Chapter 3 section 3.2.1.  
Human skin fibroblasts were obtained from the American Type Culture Collection (ATCC) 
(Teddington, UK) and were expanded as described in Chapter 3 section 3.2.3. 
4.2.2 ADIPOGENIC DIFFERENTIATION OF MSCS AND FIBROBLASTS 
Adipogenic medium was made as described in Chapter 3 section 3.2.5.  Adipogenic 
differentiation assays were performed in 6-, 24- and 48-well plates, using a constant cell 
seeding density of 4x104 cells per cm2. Adipogenic medium was changed twice weekly (½ 
media changes) during a 21 day time course, and samples were taken for analysis at different 
time-points on days 0, 3, 7, 14, and 21.  
4.2.3 OIL RED-O STAINING FOR SEMI-QUANTITATIVE SCORING OF ADIPOGENESIS 
Oil red-O staining was performed as described in Chapter 3 section 3.2.6. 
The amount of fat in individual cells was scored semi-quantitatively using a grading scheme 
developed by English et al. (English et al., 2007). The level of adipogenesis was described by 
ranking 500 cells in a middle area of the well on their fat content. Ranks were allocated based 
on the percentage of cytoplasm occupied by fat globules: Grade 1; 0-24%, Grade 2; 25-49%, 
Grade 3; 50-74%, Grade 4; 75-100%.  Semi-quantitative scoring was performed on BM 1, BM 2, 
and BM 3 donor MSCs, and fibroblasts, with final ranks representing mean values of triplicate 
wells. 
4.2.4 QUANTITATIVE REAL-TIME PCR FOR PPAR-Ɣ AND FABP4 GENE EXPRESSION 
Reagents 
Sodium acetate solution (5M): 68.04 g sodium acetate (Fisher Scientific) dissolved in 80 ml 
dH2O, adjusted to pH 5.2 using glacial acetic acid (Fisher Scientific). Volume made up to 100 ml 
using dH2O. 
Sodium citrate (1M): 29.4 g sodium citrate tribasic dihydrate (Sigma) dissolved in 100 ml dH2O. 
Guanidine isothionate solution (Sigma) 
N-Lauryl sarcosine solution (5 %): 5 g N-Lauryl sarcosine sodium salt (Sigma) was added to 100 
ml dH2O. 
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β-mercaptoethanol (Sigma) 
RNA lysis buffer was made by combining guanidine isothionate (1 ml) with N-Lauryl sarcosine 
solution (10 µl), sodium citrate solution (4 µl) and β-mercaptoethanol (5 µl). This solution was 
stored for up to 2 weeks at 4°C. 
Acid phenol pH 5 (Sigma)  
Chloroform isoamylalcohol 24:1 (red) (Sigma) 
Ethanol 100 % (v/v) (ThermoFisher Scientific) 
Ethanol 80 % (v/v) in dH2O 
Nuclease free water (Severn Biotech Ltd) 
 
Method 
Adipogenic medium was removed from wells of a 6 well plate, and total RNA was isolated from 
cells using 500µl RNA lysis buffer per well. The lysates were stored in a 1.5 ml eppendorf at -
80°C until chloroform-phenol extraction. 
Sodium acetate (50 µl), acid phenol (500 µl) and chloroform isoamylalcohol 24:1 (100 µl) was 
added to the cells in RNA lysis buffer, and the eppendorf tubes were vortexed for 2-3 minutes 
before an incubation on ice for 10 minutes. This mixing and incubation step was repeated. The 
solution was centrifuged at 13,000 g in a microfuge for 20 minutes at 4°C. The top aqueous 
layer (~500 µl) was removed and added to a new 1.5 ml eppendorf tube, before the addition of 
an equal volume of propan-2-ol. The tube was then inverted several times to mix, before an 
overnight incubation at -20°C to allow the RNA to precipitate. The sample was then 
centrifuged at 13,000 g for 30 minutes at 4°C and the supernatant discarded. Ethanol (70 %, 
500 µl) was added to each tube to wash the pellet, before centrifugation at 6500 g for 5 
minutes at 4°C. The supernatant was removed, and the pellets air dried at room temperature 
for between 30-60 minutes before the RNA pellet was resuspended in 50 µl nuclease free 
water. The RNA was treated with 10U DNase I (Pharmacia Biotech AB) and 33U RNasin 
(Promega UK Ltd) at 37°C for 30 minutes, and at 65°C for 10 minutes to denature the nuclease.  
The following procedure was used for creating cDNA; a 1 µg sample of RNA was incubated with 
1 µl Oligo(dT) primers (Qiagen) and 12*µl nuclease free water (*volume adjusted so total 
reaction volume 20µl) before the sample was incubated at 75°C for 10 minutes. After 10 
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minutes, the reaction was placed on ice. A 1 µl volume of a 100 mM dNTPs set (Qiagen) and 4 
µl reaction buffer (Qiagen) were added, and the mixture incubated at 42°C for 5 minutes, 
before 1 µl Superscript II (Invitrogen) was added and the reaction mixture incubated at 42°C 
for 2 hours. A final 15 minute incubation at 75°C inactivated the enzyme, and cDNA samples 
were stored at -20°C. 
Real-time PCR was performed using an ABI Prism 7900 sequence detection system (Applied 
Biosystems) in the presence of SYBR-green. The cycle used was as follows: 
 
Primers were designed by Dr. S. Churchman using Primer Express 2 (Applied Biosystems) and 
supplied by MWG Biotech. Expression was normalized using a house-keeping gene GAPDH. 
Primer concentrations were optimized by Dr. S. Churchman and the sequences used are listed 
later on in this chapter in Table 4.1. MSCs from three different donor MSCs were used, and 
each for each time point the mean cycle threshold (Ct) of each gene of three technical 
replicates was used to calculate the relative gene expression. The Ct is defined as the number 
of cycles needed for the fluorescence levels to reach a specific threshold of detection. The Ct is 
inversely correlated with the amount of template cDNA present in the reaction.  
To calculate the relative gene expression the Ct difference between the gene of interest and 
the housekeeping gene is first calculated. As qRT-PCR is an exponential process this Ct 
difference is then inverse logged to calculate the relative levels of gene expression when 
compared to the housekeeping gene (2- Ct).   
4.2.5 FLOW CYTOMETRY FOR FABP4 AND NILE RED STAINING  
On days 0, 3, 7, 14, and 21 adipogenic medium was removed from wells of the 6 well plate and 
cells were washed twice with PBS. 
For Nile red staining cells were harvested by treatment with 1 ml trypsin, 0.5 % (10x) with 
EDTA  (Invitrogen), diluted to 1x in PBS for 5 minutes until cells had detached from the tissue 
culture plastic. The detached cells were added to 15 ml PBS in a universal, and centrifuged for 
10 minutes at 150 g. The supernatant was then discarded and the pellet washed in 10 ml PBS. 
The cells were centrifuged at 150 g, and the above step repeated, before the pellet was 
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suspended in 200 µl PBS. The cell solution was transferred to a 96 well U-bottomed plate for 
staining. 
Stock Nile red (Sigma) solution (0.1 mg.ml-1, prepared in methanol) was added to cells at a final 
concentration of 0.05 µg.ml-1 (1:2000 dilution in PBS) (Greenspan et al., 1985) and incubated at 
4°C for 20 minutes in the dark. The plate was centrifuged at 13,000 g before the supernatant 
was removed. Cells were washed in 200 µl BD FACSflow™ again before centrifugation at 
13,000 g. The supernatant was discarded, and the pellets resuspended in 200 µl BD FACSflow™ 
before the fluorescent intensity was measured using the flow cytometer (Becton Dickinson 
FACScan). Nile red fluorescence emission in adipogenically-differentiated MSCs was detected 
on the FL2 channel. 
FABP4 protein was detected using a purified goat anti-human FABP4 antibody (R & D Systems) 
at 1:20 dilution in PBS. For intracellular staining with FABP4, trypsinised cells were initially 
fixed in 100 µl of Intrastain reagent A (Dako). FABP4 antibody was added simultaneously with 
100 µl of permeablising reagent/Intrastain reagent B (Dako) for 15 minutes at RT in the dark. 
After two washes with 200 µl PBS and 13,000 g, cells were incubated with 200 µl biotinilated 
rabbit anti-goat secondary antibody (1:400 dilution in PBS, Dako) for 15 minutes at RT in the 
dark. Following 2 further washes in PBS the binding was visualised using streptavidin-FITC (1:50 
dilution, BD Sciences). After 2 final washes, the fluorescence were analysed on the FL1 channel 
with 10,000 events being collected for each sample.  
4.2.6 MEASURE OF ADIPOGENIC DIFFERENTIATION USING NILE RED/DAPI STAINING ON A 48 
WELL PLATE        
Reagents 
Nile red (1:2000 dilution): 1 µl stock into 100 µl PBS, 4 µl of this solution was diluted into 80 µl 
PBS. 
Paraformaldehyde (10 % v/v): 2 ml 40% (v/v) formaldehyde (Gentamedical) and 8ml PBS. 
Saponin (0.2 % w/v): 0.2 g saponin powder (Sigma) in 100 ml PBS. 
Method 
MSCs and fibroblasts (4x104/well) were seeded in a 48 well plate (Nunc) and cultured for 21 
days in adipogenic or control NH medium. On days 0, 3, 7, 14, and 21 the level of adipogenesis 
was determined utilising a luminescent plate reader (LB940 Multilabel Reader Mithras; 
Berthold Technologies) with each treatment and each day timepoint having six replicate wells.  
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Culture medium was removed from wells and cells washed twice with PBS. Paraformaldehyde 
(200 µl) was added to the wells for 30 minutes, before the cell layer was washed with 200 µl 
PBS. The PBS was removed, and 200 µl PBS was added to each well. A 200 µl volume of crystal 
violet solution (Sigma) was added to the gaps in between the wells of the plate to minimise 
light reflection. The background fluorescence was read using 4',6-diamidino-2-phenylindole, 
DAPI (355/460) and Nile red (485/540) filter sets as per the manufacturer’s instructions. These 
filter sets were used as they provided the closest match to DAPI, excitation at 358 nm, and 
emission at 461 nm, and Nile red, excitation at 450-500 nm, and emission at >528 nm. Wells 
were spot read in a 10x10 pattern per well. The PBS was removed from the wells, and 200 µl 
saponin (0.2% w/v in PBS) was added along with DAPI (Invitrogen) at a final concentration of 1 
µg.ml-1, and Nile red at a final concentration of 1 µg.ml-1. The plate was then wrapped in foil 
and incubated at RT for 15 minutes. Following three washes with PBS, 200 µl PBS was added, 
and plates were again read as above. 
Plates were wrapped in foil and stored at 4°C for up to 48 hours if fluorescent microscopy was 
required. A ratio of adipogenesis was calculated by taking the mean fluorescence reading of 
the repeats for both Nile red and DAPI stained cells and creating a ratio of Nile red:DAPI 
fluorescence. 
4.2.7 STATISTICAL CORRELATIONS 
In order to determine whether the methods used for measuring adipogenic progression were 
comparable, R values were calculated using Spearmans Rank correlation and a two tailed p-
value in Graphpad Prism 5™.  
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4.3 RESULTS 
4.3.1 SEMI-QUANTITATIVE SCORING OF ADIPOGENESIS IN MSCS USING OIL RED-O STAINING 
Initially the most common method for staining for adipogenically-differentiated MSCs was 
used (Oil Red staining) and differentiation quantified using a grading system developed by 
English et al, (2007). In this method 500 cells in a central area of the dish were identified using 
an Oil red-O stain, and the level of adipogenic progression was ranked (1-4) based on the 
percentage of cytoplasm occupied by fat (Figure 4.5).  
 
Figure 4.5: Oil red grading scheme: The Oil red grading scheme rates cells based on their fat 
content; Grade 1 (0-24%), Grade 2 (25-49%), Grade 3 (50-74%), and Grade 4 (75-100%). 
Images labelled A-D represent each of the Grades; A=Grade 1, B=Grade 2, C=Grade 3, and 
D=Grade 4.  500 cells in a central area of the dish were identified using an Oil red-O stain, and 
the level of adipogenic progression was ranked. This process was performed 3 times per well.  
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In these experiments MSCs from 3 donors and negative control fibroblasts were grown in 
adipogenic medium for 21 days and scoring was performed on days 0, 3, 7 14 and 21 post-
induction. BM1 MSCs differentiated over 21 days into fat and stained with Oil red (A=Day 3 
BM1, B=Day 7 BM1, C=Day 14 BM1, and D=Day 21 BM1) are shown in Figure 4.6 (left panel), 
and right panels show fibroblasts also grown in adipogenic differentiation medium over the 
same timecourse. 
Fibroblasts gradually accumulated cells with Grade 1 fat content (Figure 4.7A); however they 
were unable to progress to higher grades and to increase fat accumulation (Figure 4.7B). In all 
MSCs differentiation had similarly begun as a gradual accumulation of Grade 1 cells (by day 7) 
(Figure 4.7A). In contrast to fibroblasts however, MSCs continued to accumulate fat in their 
cytoplasm and by days 14-21 contained cells with very high fat content (Grades 3-4) (Figure 
4.7B).  
Figure 4.6: Adipogenesis of MSCs and fibroblasts stained with Oil red. Cultures of BM1 
MSCs (left panels) differentiated over 21 days into fat and stained with Oil red (A=Day 3 
BM1, B=Day 7 BM1, C=Day 14 BM1, and D=Day 21 BM1). Right panels fibroblasts also 
grown in adipogenic differentiation medium over the same timecourse (E=Day 3 
fibroblasts, F=Day 7 fibroblasts, G=Day 14 fibroblasts, and H=Day 21 fibroblasts). 
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Altogether these experiments confirmed that although fibroblasts had some very low capacity 
for adipogenesis, they were clearly inferior to MSCs. Secondly, adipogenic progression in MSCs 
from the same donor was heterogenous, with some cells progressing to Grades 3-4 and others 
remaining to be Grade 1. Finally, donor-to-donor differences were observed in the rates and 
the amounts of adipogenesis in MSCs, with Donor BM1 exhibiting less adipogenesis compared 
to the other two donors (the latter easily progressed to grades 3-4). 
 
A 
B 
Figure 4.7: Percentage of cells graded based on lipid vacuole 
accumulation within the cytoplasm. Figure A the percentage of Grade 1 
cells within the population. Figure B the number of Grade 2+3+4 (more 
mature fat cells). 
110 
 
4.3.2 QUANTITATIVE CHANGES IN PPAR-Ɣ AND FABP4 EXPRESSION IN MSCS UNDERGOING 
ADIPOGENESIS 
Adipogenesis-specific peroxisome proliferator activated receptor (PPAR-γ) and the late marker 
of adipogenesis, fatty acid binding-protein 4 (FABP4) have been previously shown to closely 
reflect adipogenic progression of MSCs (Janderova et al., 2003; Neubauer et al., 2004; Sekiya 
et al., 2004; Blum and Benvenisty, 2008). The next aim was to determine whether PPAR-γ and 
FABP4 mRNA were upregulated in adipogenically-differentiated MSCs and whether these 
changes paralleled to morphological fat accumulation within the cells. Quantitative real-time 
PCR was performed on RNA extracted on days 0, 3, 7, 14 and 21 post-induction. An example 
amplification plot of relative fluorescent intensity against Ct is shown in Figure 4.8 of day 7 
GAPDH, PPAR-ɣ and FABP4 gene expression. The changes in relative expression levels of the 
genes were normalised to GAPDH (Figure 4.9). The primer sequences used are displayed in 
Table 4.4.   
Primer Sequence Concentration 
PPARγ F: cac aag aac aga tcc agt ggt tg 500nM 
PPARγ R: gag gct tat tga gag ctg agt ctt ct 500nM 
FABP4 F: cca taa aga gaa aac gag agg atg at 1000nM 
FABP4 R: tgg aag tga cgc ctt tca tga 1000nM 
GAPDH F: aac agc gac acc cac tcc tc 500nM 
GAPDH R: cat acc agg aaa tga gct tga caa 500nM 
Table 4.4: Primer sequences and concentrations used for qRT-PCR. 
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Figure 4.8: The amplification plot of relative fluorescent intensity against 
Ct for day 7 displaying GAPDH, PPAR-ɣ and FABP4 respectively (n=3).  
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A 
B 
Figure 4.9: Quantitative real-time polymerase chain reaction (qRT-PCR) as a method to 
measure adipogenesis. Human MSCs and fibroblasts were cultured in adipogenic 
medium for 21 days. Peroxisome proliferator activated receptor-gamma (PPAR-ɣ) and 
fatty acid binding protein-4 (FABP4) expression was determined by qRT-PCR performed 
on RNA taken from cells on days 0, 3, 7, 14 and 21. Levels of gene expression are 
normalised to housekeeping gene GAPDH and displayed as fold increase over day 0.  
113 
 
The fold increase of PPAR-γ gene expression compared to Day 0 was slightly down-regulated in 
fibroblasts on day 3, before increasing to approximately 5 fold higher on day 7, 20 fold higher 
by day 14, and 30 fold on day 21. BM1 PPAR-γ gene expression increased 5 fold by day 3, 
decreased to 3 fold by day 7 before increasing to 10 fold by day 14, and 20 fold by day 21. BM2 
followed a similar trend with expression increasing 5 fold by day 3 before decreasing slightly by 
day 7, before increasing to 8 fold on days 14 and 21. BM3 PPAR-γ gene expression was up-
regulated 30 fold by day 3, increasing to 100 fold by day 7. This decreased to 10 fold by day 14, 
and 20 fold by day 21.  
The fold increase of FABP4 gene expression in fibroblasts compared to Day 0 was slightly 
down-regulated on day 3, before increasing to approximately 5 fold higher on day 7, and 50 
fold higher by day 14 and 21. BM1 FABP4 gene expression increased 8 fold by day 3, 700 fold 
by day 7 before increasing to 4000 fold by day 14, and 8000 fold by day 21. BM2 followed a 
similar trend with expression increasing 4 fold by day 3 before increasing to 50 fold by day 7, 
90 fold on days 14, and 200 fold by day 21. BM3 FABP4 gene expression was up-regulated 50 
fold by day 3, increasing to 70 fold by day 7. This remained the same on day 14, increasing to 
200 fold by day 21.  
These data showed that PPAR-γ expression generally increased during adipogenesis, however 
the changes were relatively small and did not reflect adipogenic transformation in MSCs, 
clearly visible using Oil red staining. In contrast, FABP4 expression rose gradually up to day 21 
and generally paralleled microscopic fat accumulation. Nevertheless, the results did not 
exactly match, as donor BM1 displayed the highest up-regulation in FABP4 mRNA (800-fold) 
whilst its fat content was the lowest (mainly Grade 1).  
4.3.3 MONITORING FABP4 PROTEIN ACCUMULATION AND NILE RED STAINING FOLLOWING 
MSC ADIPOGENIC PROGRESSION BY FLOW CYTOMETRY 
Since FABP4 appeared to be a suitable adipogenesis marker by qPCR, the next aim was to 
monitor FABP4 protein accumulation in MSCs using flow cytometry. This was performed by 
intracellular labelling with FABP4 antibody on days 0, 3, 7, 14 and 21 post-induction (Figure 
4.10A, right histograms). The side scatter (SSC) represents the granular intensity of the sample. 
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Figure 4.10: Flow cytometry of MSCs cultured in adipogenic medium. (A): BM1, BM2, and 
BM3 MSCs were cultured in adipogenic medium for 21 days. On days 0, 3, 7, 14 and 21 cells 
were stained with either FABP4 (right histograms), or with Nile red (centre histograms). The 
representative dot plots (far left) show the scatter characteristics of the cells. It shows that 
a population of more granular cells with high side scatter (SSC) increased in number until 
day 14. The dashed lines shown on the dot plots represent gating used, with events above 
this line gated into the high side scatter (SSC) category, and below into the low SSC 
category. The numbers in the top right of the histograms are the geometric means of the 
relative fluorescent intensities of the cells. This number is an average calculated from the 
means of BM1-3 in Nile red staining, and is donor BM1 in FABP4 staining. Data shown is 
representative of 10,000 events per experiment. 
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Figure 4.11: Line graphs of side scatter variation following timecourse 
progression. A) Line graph of SSC shows the increasing granularity of the total 
MSC population as number of lipid vacuoles in cytoplasm increases as the 
timecourse progresses. B) Split axis line graph compares the granularity of 
both populations of gated cells, low and high SSC, demonstrating increasing 
granularity throughout the timecourse. Days 0 and 3 omitted due to the high 
error encountered when reading fluorescent intensity on the flow cytometer 
(when gated <10 events were collected for high SSC). 
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Previous studies have identified marked changes in cell size/granularity profiles upon their 
adipogenic induction with larger cells being postulated to be more differentiated (Lee et al., 
2004). Fatty acid binding protein-4 accumulation was therefore investigated in differentiating 
MSCs in larger cells (dotted line on dot plots represents gating) and the majority of smaller 
cells. Indeed, a gradual accumulation of larger cells as the time-course progressed was 
observed, however they peaked on day 14, not on day 21, (Figure 4.10, far right panels). 
The shift to the right was observed on the histograms for both the low SSC and high SSC cells, 
however it was obvious that larger cells contained up to 20-fold more FABP4 at every time-
point (Figure 4.10, far right panels). Interestingly, smaller cells were not resistant to 
adipogenesis and also accumulated FABP4 during the whole duration of adipogenesis, albeit at 
a reduced amount (Figure 4.10, right panels). These data clearly confirmed the existence of 
cellular heterogeneity within the same adipogenesis-driven MSC cultures, first observed by 
morphological analysis with Oil red. Importantly, flow cytometry for FABP4 and semi-
quantitative scoring with Oil red displayed excellent correlation with each other (Spearman R 
value of r = 0.978, p = <0.0001, Figure 4.14). 
Similar trends were observed if Nile Red staining for lipids was used for flow cytometry instead 
of FABP4 (Figure 4.10, centre histograms). This shift in Nile red fluorescence was increased as 
the time course progressed, with high SSC cells having similarly higher amounts of Nile red 
fluorescence compared to low SSC cells.  
SSC increased throughout the timecourse, indicating an increase in the granularity of the cells, 
produced by the accumulation of lipid droplets within the cells (Figure 4.11A). Relative 
fluorescent intensity (geometric mean) of high and low SSC populations stained with Nile red 
were compared, and accumulation of lipid occurs in parallel within both populations, albeit at 
a much higher level in high SSC cells (Figure 4.11B).  
The geo-metric mean for days 0 and 3 are omitted, as too few cells were counted to give an 
accurate representation of fluorescence in the high SSC gate.  
Nile red dye and intracellular FABP4 antibody labelling by flow cytometry demonstrated 
excellent correlation with each other r = 0.918, p=<0.0001, Figure 4.14. Additionally, Nile-red 
based flow cytometry showed good correlation with morphological semi-quantitative scoring r 
= 0.907, p = <0.0001, Figure 4.14. 
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4.3.4 QUANTIFICATION OF MSC ADIPOGENIC PROGRESSION USING MICROPLATE ASSAY WITH 
NILE RED   
Semi-quantitive scoring provided a visual method of quantification of adipogenesis, but it was 
subjective and very time consuming. qRT-PCR was similarly time-consuming, and measured 
mRNA levels instead of protein/lipid. Flow cytometry correlated well with morphological lipid 
accumulation in MSCs, however there was a danger of losing mature floating fat cells during 
cell trypsinization/centrifugation steps. The utility of a Nile red-based fluorescence microplate 
assay to measure adipogenesis, using DAPI staining for cell nuclei for normalization was 
therefore explored (Figure 4.12).  
MSCs or fibroblasts were cultured in adipogenic and normal expansion medium in wells of a 48 
well plate. On days 0, 3, 7, 14, and 21 levels of adipogenesis in cells were measured as a ratio 
of cell number compared to fat content using DAPI or Nile red dye staining, respectively, and 
normalised to day 0. In order to see if adipogenesis could be measured using DAPI or Nile red 
only, levels of fluorescence for DAPI only and Nile red only were calculated and normalised to 
day 0. Non-adipogenic controls were fibroblasts grown in adipogenic medium (Figure 4.13).  
Levels of DAPI staining remained fairly constant in fibroblasts, and also fluctuated in MSCs 
after day 3. Nile red staining in fibroblasts remained very low and showed a greater increase in 
BM 1 - 3 MSCs. Levels of DAPI staining were varied and did not appear to correlate with levels 
of Nile red staining observed, for example BM demonstrated increasing staining for Nile red 
but relatively low staining for DAPI, whereas BM 4 stained relatively strongly for DAPI but not 
Nile red. Levels of adipogenesis were normalised to cell number using the florescent intensity 
of DAPI staining, and a ratio of Nile red/DAPI was used to measure adipogenesis. Nile red to 
Figure 4.12: Nile red and DAPI staining of MSCs. MSCs and fibroblasts were grown for 0, 3, 7, 
14, and 21 days in adipogenic medium, and stained using Nile red dye, and DAPI. 
Representative images of MSCs (A) and fibroblasts (B) on day 21 are shown. Intracellular lipid 
droplets in cells stain yellow/gold, and the nucleus of cells is stained blue. Images were taken 
using an Olympus IX71 inverted microscope using Cell^B image capture software (Olympus) 
and are x200 magnification. 
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DAPI ratios demonstrated minimal adipogenesis in fibroblasts grown in adipo-inductive 
medium but an increase in adipogenesis to day 21 in BM 1-4 (Figure 4.13).  
Both Nile red microplate assays and morphological scoring with Oil Red significantly correlated 
with each other; r = 0.866, p = <0.0001, Figure 4.14. 
The adipogenesis of all 4 BM donors and fibroblasts was measured using the fluorescent 
microplate assay. BM1, 2, and 3 demonstrated adipogenic ratios of increasing to ~10, but BM4 
exhibited the highest adipogenesis with ratios to 20 and above (Figure 4.13). It was therefore 
decided that BM4 would be used in later assays where high levels of adipogenesis were 
required (Chapter 7).  
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Figure 4.13: Microplate reader as a method of quantifying adipogenesis. Levels of 
fluorescence for DAPI and Nile red were calculated and normalised to day 0 (n=3) for BM 
MSCs 1-4 and fibroblasts cultured in adipogenic medium.  There was minimal adipogenesis in 
fibroblasts cultured in adipo-inductive medium, whereas Nile red to DAPI ratios generally 
demonstrated an increase in adipogenesis to day 21 in MSCs. X-axis values are day 
timepoints, and the mean values of fluorescence were calculated using Microsoft Excel™ 
before these were processed into ratios. Error bars shown are ± 95% confidence limits  
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Figure 4.14: Correlation graphs for methods to evaluate adipogenesis in MSCs.  Correlation 
graphs and linear regression analysis were plotted and performed using Graphpad Prism™ 
FABP4 and Nile red flow cytometry (top left; r2=0.978), semi-quantitative scoring and FABP4 
flow cytometry (top right; r2=0.918), semi-quantitative scoring and Nile red flow cytometry 
(bottom left; r2=0.907) and semi-quantative scoring and Nile red microplate ratios (bottom 
right; r2=0.866).  
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4.4 DISCUSSION 
In this chapter several of the previously used methods to measure the adipogenesis of MSCs 
were compared: semi-quantitative staining with Oil red-O dye, quantitative real-time PCR of 
fat markers, flow cytometry, and Nile red staining.  This was to verify that the population of 
MSCs was differentiating into adipose cells, and in order to develop a suitable method for 
quantifying this level of adipogenesis.  
The most commonly used staining method for adipogenically-differentiated MSCs (Oil red-O 
staining was initially used) and differentiation quantified using a grading system developed by 
English et al, (2007). Alternative methods for quantifying the amount of Oil red-O dye present 
in stained samples are available (such as the absorbance measurement of Oil red-O dye 
staining the lipid vesicles within cells), but only give an overall level based on total dye content 
in a sample (Platt and El-Sohemy, 2009). The Oil red-O dye binds to neutral triglycerides and 
lipids present in cells and the greater the amount of lipids, the greater the volume of staining. 
Interestingly, semi-quantitative scoring of fibroblasts grown in adipogenic medium suggested 
that the fibroblasts exhibited a low level of adipogenic differentiation capacity. However, they 
did not progress into the larger fat cells, with very few Grade 2-4 fat cells present. For MSCs, 
Oil red-O staining demonstrated an increase in both the percentage of fat-laden cells and the 
amount of fat per cell during the 21-day time course. Although this method provided a visual 
method of quantification, it was subjective and very time consuming and as such it was not 
suitable as a higher throughput method for the quantification of adipogenesis. Morphological 
analysis using Oil red-O staining showed heterogeneity in the same adipogenesis-driven MSC 
cultures, with not all cells within the assay differentiating into adipocytes at the same rate, and 
a subset of the cells failing to differentiate into fat cells. 
For quantitative real-time PCR, two genes associated with adipogenesis were selected; 
peroxisome proliferator activated receptor (PPAR-γ) and the late marker of adipogenesis, fatty 
acid binding-protein 4 (FABP4). Both of these genes have been shown to increase in expression 
as MSCs undergo adipogenesis (Janderova et al., 2003; Fink et al., 2004; Neubauer et al., 2004; 
Sekiya et al., 2004; Blum and Benvenisty, 2008). In contrast to previously published data 
(Janderova et al., 2003; Sekiya et al., 2004), although PPAR-γ expression generally increased 
during adipogenesis the changes were relatively small and did not reflect visible adipogenic 
differentiation in the MSCs. In agreement with previous studies (Sekiya et al., 2004; Boucher et 
al., 2009) FABP4 expression rose gradually up to day 21. It was noted however that increased 
expression of FABP4 did not always translate into higher level of visual fat content.  
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Altogether, FABP4 PCR was highly quantitative and able to track adipogenesis on a 
transcriptional level, it was time consuming and therefore not considered suitable for a reliable 
high-throughput measurement of adipogenesis.  
To further evaluate the use of FABP4 as a suitable marker for adipogenesis, FABP4 protein 
accumulation in MSCs was monitored using flow cytometry. Flow cytometry provides 
information on intensity of staining, size of cells, and cell number. Fatty acid binding protein-4 
accumulation in differentiating MSCs was investigated and a gradual accumulation of more 
granular cells (high SSC) was observed as the time-course progressed, correlating with 
increasing FABP4 levels in these cells.  
Nile red dye has previously been used in flow cytometry to stain adipocytes (Greenspan et al., 
1985; Smyth and Wharton, 1992; Dennis et al., 1999; Fink et al., 2004). It is a selective 
fluorescent stain for intracellular lipid droplets at 528-570nm. When Nile red staining for lipids 
was assessed by flow cytometry, a shift in intracellular Nile red fluorescence increased as the 
time course progressed, with higher SSC cells having similarly higher amounts of Nile red 
fluorescence compared to lower SSC cells.  
Staining with both antibodies to FABP4 and Nile red showed similar trends. Both of these 
methods resulted in the higher mean fluorescence intensity of the higher SSC, more positively 
staining population of cells peaking on day 14. This population of cells decreased in size from 
day 14 to day 21. This was in contrast to a previous study which showed an increase in staining 
as the timecourse progressed, including on the final day 28 (Smyth and Wharton, 1992). This 
trend was not observed visually when the cells were viewed microscopically, and it is 
hypothesized that the observed reduction in the larger, more mature fat cells was due to the 
loss of these cells during the wash steps required during preparation for flow cytometry, due 
to the increased buoyancy of the cells. Data for high SSC cells for days 0 and 3 was omitted as 
there were too few cells gated (as there was very little to no lipid accumulation within the 
cells).   
Overall, semi-quantitive scoring provided a visual method of quantifiying adipogenesis, but it 
was subjective and very time consuming. qRT-PCR was similarly time-consuming, and 
measured mRNA levels instead of protein or lipid directly. Flow cytometry correlated well with 
morphological lipid accumulation in MSCs, however there was a danger of losing mature 
floating fat cells during the preparation steps.  Since these methods did not provide robust and 
time efficient assays for quantifying adipogenic differentiation we explored the utility of a Nile 
red-based fluorescence microplate assay to measure adipogenesis (Jaiswal et al., 2000). This 
assay used intracellular Nile red fluorescence for lipid accumulation and DAPI staining for cell 
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nuclei for normalization. The average fluorescent intensity for DAPI and Nile red for each well 
was measured, and a ratio of adipogenesis determined based on the number of cells present 
(DAPI) to amount of intracellular Nile red staining. MSCs stained only with DAPI have increased 
fluorescence over the timecourse, demonstrating that proliferation continues, even when 
differentiating. Nile red can be used to measure adipogenesis as a single dye, but due to the 
proliferation of cells a ratio using Nile red and DAPI together is preferred.  
The fluorescent microplate assay provided both highly quantitative measurements and 
fluorescent images of fat droplet distribution per cell, allowing a numbered measurement to 
be assigned to differentiated cultures based on their level of adipogenesis, with visual 
verification of adipocyte content. The results obtained demonstrated the need to normalise 
the staining of intracellular lipids to cell number to obtain a measured value that takes into 
account not only levels of adipogenesis, but how this relates to the total cell number present 
(to distinguish between low cell numbers that are very adipogenic, or a high cell number that 
are weakly adipogenic).  
Previous studies have demonstrated the differentiation heterogeneity of MSCs from different 
donors undergoing osteogenesis (Phinney et al., 1999; Siddappa et al., 2007). During the 
timecourse and throughout the various methods employed it was also observed that this 
variation between donors existed for adipogenesis.  
There was strong correlation between all the methods used in this study (Spearmans R-values 
were between R=0.866-0.978). As Nile red is a chemical dye it is a more cost effective 
alternative to antibodies and the microplate assay was also found to be the most efficient and 
simple to perform on a larger volume of samples. Using this method allowed MSCs with 
greater adipogenesis to be selected for further experiments, where a higher grade of 
differentiation would be beneficial.  It was decided that BM4 would be used in later assays in 
Chapter 7 where a high degree of adipogenesis was required. 
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Chapter 5:  THE OPTIMISATION OF THE LYMPHOCYTE 
TRANSFORMATION ASSAY 
5.1 INTRODUCTION 
An early goal of cellular immunologists was to develop in-vitro assays as alternatives to the 
then only in-vivo methods such as skin testing and allograft rejection in small animals. The 
solution that was developed was the lymphocyte transformation or proliferation assay. For 
example, if a lymphoid cell population isolated from a donor capable of transferring a delayed 
type hypersensitivity (DTH) reaction to tuberculin is cultured together with the antigen, the 
antigen specific lymphocytes will be stimulated to divide (Kimball, 1990). Radioactive 
thymidine (tritiated 3H) added to the culture medium will be incorporated into the DNA of the 
cells undergoing mitosis and the levels of radioactivity incorporated into DNA will be indicative 
of the degree of response. This method, the lymphocyte transformation assay, was the original 
method developed to study cell mediated immunity in-vitro. 
It was also shown in the early 1960’s that if periphal blood mononuclear cells (PBMCs) from 
two different individuals (genetically not identical) were cultured together, the cells would 
stimulate each other and generate a large number of lymphoid blast cells in-vitro (Bain et al., 
1964). It was discovered that the strongest reaction occurred (the largest number of cells 
produced) using mixtures of lymphocytes that had high discrepancy at the major 
histocompatability complex. From its initial use, the mixed lymphocyte reaction (MLR) has 
been used as an important experimental method for investigating the cellular mechanisms 
involved with the rejection of allografts, and more importantly for assessing histocompatability 
(Stites, 1991). The most common form of this reaction is a ‘one way’ mixed lymphocyte 
reaction. In this assay the cells from the donors are split into either responder or stimulator 
cells. The stimulator cells are treated to prevent mitosis either by irradiation, or treatment 
with mitomycin C (an antibiotic that crosslinks DNA at CpG motifs) (Kimball, 1990; Stites, 1991; 
Oh et al., 2008; Nasef et al., 2009; Wada et al., 2009; Kuci et al., 2010; Prasanna et al., 2010). 
This treatment prevents the stimulator cells from dividing and therefore incorporating 3H, but 
otherwise the cells remain metabolically active. Tritiated thymidine is incorporated into the 
DNA of the dividing cells, and when these cells are processed and radioactive counts 
determined, the counts are proportional to the level of response. 
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The reaction is used to measure the responder lymphocytes reaction to the histocompatibility 
antigens that are present on the stimulator cells. In order to convert the counts per minute 
into a practical comparable result, the results from the assay are usually expressed as the 
stimulation index (SI): 
SI =   Average counts per minute in test cultures    
         Average counts per minute in control cultures (without stimulator cells) 
 
The responding cells of the MLR have been shown to be predominantly T-cells, with B-cells 
also thought to play a small part, as an increase in immunoglobin synthesis  has been detected 
in such assays (Stites, 1991). Although a very useful tool as an in-vitro correlate of the 
transplantation reaction, there are certain flaws to the methodology when used to assess the 
immunogenicity of non-lymphoid cells. 
The one way MLR is an in-vitro correlation of the transplantation reaction. This measures the 
direct pathway of recognition, in which stimulator antigen presenting cells expressing 
CD80/86, CD40, and foreign MHC class II + epitope can be recognised by responder T-cells, and 
proliferate. Over recent years, the assay has been adopted to study the immunogenicity of 
MSCs and studies have shown that MSCs have little capacity to stimulate allogeneic 
lymphocytes. Strictly speaking, when the one-way mixed ‘lymphocyte’ reaction is used to test 
the immunogenicity of MSCs, it is better described as a lymphocyte transformation assay or 
reaction, since the stimulator cells (MSCs) are not of the lymphoid lineage. Since MSCs do not 
normally express co-stimulatory molecules or MHC class II it is perhaps unsurprising that they 
fail to stimulate allogeneic lymphocytes in the classical one-way mixed ‘lymphocyte’ reaction. 
The MLR and LTA are very useful methods as in-vitro assays to measure the direct pathway of 
immune recognition, but there are limitations. A review of the prevailing literature in which 
the immunogenicity of allogeneic MSCs has been evaluated in-vitro revealed that the assay 
conditions varied considerably in terms of numbers of stimulator MSCs: to responder cells, 
mitotic inhibition of stimulator cells, method of measurement of lymphocyte proliferation, use 
of PBMCs or purified T-cells, and types of plate (U, flat, V, coated or uncoated not usually 
specified) [Table 5.1]. In this study uncoated U-bottomed plates were used, due to previous 
lab experience (Ingham et al., 1993; Ketheesan et al., 1994; Ketheesan et al., 1996b; Ketheesan 
et al., 1996a). 
Moreover, in none of the studies was the incubation period extended for over 7 days. 
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It was theorised that the assay conditions required optimisation (this chapter) and that the 
assay should be carried out over an increased time period (Chapter 6) with MSCs as the 
stimulator cells in order to allow indirect antigen recognition to take place. 
5.1.1 AIMS AND OBJECTIVES 
The aim of the work in this chapter was to develop the methodology for performing the 
lymphocyte transformation assay using MSCs as the stimulator cells. There were 5 specific 
objectives: 
 To determine the concentration of PHA (mitogen) for use as the positive control for 
lymphocyte activation. 
 To determine the method for spiking the cells (using tritiated thymidine). 
 To determine the concentration of mitomycin C for the mitotic inhibition of stimulator 
cells. 
 To determine the cell number and ratio of responder and stimulator cells in the one 
way MLR. 
 To determine the concentration and source of serum for cell culture medium 
supplementation. 
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Table 5.1: A comparison of the methods used to assess the immunogenicity of MSCs 
Type of 
plate 
Method of 
mitotic 
inhibition 
Responder 
to stimulator 
cell ratios 
Length of 
MLR 
Measure of 
cellular 
proliferation 
Were Cells Immunogenic? Reference 
96 well V-
bottom 
plates 
Gamma 
Irradiated 
10:0.1 
10:1 
1:1 
5 Days 1µCi/well, 13 
hours 
MSCs failed to elicit a proliferative response from 
allogeneic lymphocytes. MSCs added into a mixed 
lymphocyte reaction, either on day 0 or on day 3, or to 
mitogen-stimulated lymphocytes, led to a greater than 
50% reduction in proliferative activity. 
Bartholomew et 
al., (2002) 
96 well plate Gamma 
Irradiated 
10:1 7 Days 2.5 µCi/well, 
24 hrs 
In co-culture with allogenic PBMCs, adipo-derived stem 
cells and MSCs failed to lead to any significant stimulation, 
including when osteogenically differentiated. 
Niemeyer et al., 
(2007) 
96 well plate 10 µg/ml 
Mitomycin C 
1000:1 
100:1 
10:1 
6 Days BrdU for 18 hrs MSCs did not provoke allogeneic PBMC proliferation, even 
when their HLA molecule expression was up-regulated by 
IFN-ɣ pretreatment. 
MSCs actively suppressed the allogeneic proliferation of 
the responder lymphocytes in MLR. 
Oh et al., (2008) 
24 well plate Not Fixed 1:1 5 Days CFSE and flow 
cytometry 
MSC did not deliver a mitogenic signal to purified, 
unstimulated T cells. 
Suva et al., 
(2008) 
96 well plate Gamma 
Irradiated 
1:0.15 7 Days 1.6 µCi/well, 
18hrs 
MSC failed to elicit a proliferative response when 
cocultured with allogeneic PBMC. 
Tse et al., (2003) 
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5.2 MATERIALS AND METHODS 
5.2.1 ISOLATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS 
Reagents: 
Transport Medium 
Rosslyn Park Memorial Institute (RPMI) medium without L-glutamine (Lonza) 
Penicillin-streptomycin mixture [5000 µg.ml-1 potassium penicillin, 5000 µg.ml-1 streptomycin 
sulphate] (Lonza). 
L-glutamine 200 mM (Gibco) 
HEPES 1 M (Lonza) 
RPMI transport medium was made by combining  RPMI-1640 with 50 µg.ml-1 penicillin and 50 
µg.ml-1 streptomycin, 2 mM L-glutamine and 0.05 M HEPES. 
Complete Medium 
Human AB Serum (Source Biosciences Life Sciences) – Heat inactivated by heating to 56°C in a 
water bath for 1 hour, before being frozen at -20°C in 10 ml aliquots. 
Fetal calf serum (Lonza) 
RPMI complete medium was made by combining transport medium with 10% human or fetal 
calf serum (v/v). 
Method  
Human venous blood from healthy volunteers (age range 22-57 years, n=4 female donors, n=2 
male) was obtained by venupuncture (30 ml; ethics reference R1508) using the Vacutainer 
blood collection system (Becton Dickinson) and diluted 1:1 in 30 ml RPMI-1640 transport 
medium. Diluted blood (7 ml) was layered onto Lymphoprep™ (3 ml) in plastic test tubes. 
Following centrifugation (800g) for 30 minutes the peripheral blood mononuclear cells 
(PBMCs) were removed from the interface using endotoxin free sterile glass pipettes, washed 
three times in RPMI-1640 transport medium (450 g for 30 minutes, 150 g for 30 minutes twice) 
and resuspended in 10 ml RPMI-1640 complete medium. Cells were counted using the trypan 
blue dye exclusion assay as described in section 2.3.7. 
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5.2.2 TITRATION OF PHA AND DETERMINATION OF LYMPHOCYTE TRANSFORMATION USING LOW 
AND HIGH ACTIVITY 
3H THYMIDINE 
Phytohaemagglutinin was used as a positive control in all lymphocyte transformation (LTA) 
assays to show that the PBMCs were capable of mitotic activation 
Reagents 
High activity tritiated thymidine (specific activity >10Ci.mmol-1) was purchased from 
Amersham, and diluted 1:10 into RPMI-1640 (0.25 µCi.ml-1) and stored at 4°C until depleted.  
Low activity tritiated thymidine (specific activity 5-6 Ci.mmol-1) was purchased from Perkin 
Elmer, and diluted 1:20 into RPMI-1640 (0.25 µCi.ml-1) and stored at 4°C until depleted.  
Complete RPMI-1640 medium 
Phytohaemagglutinin (PHA) (Sigma). A stock solution of 1 mg.ml-1 phytohaemagglutinin in 
dH2O was made. Aliquots (100µl) were frozen at -20°C in 0.5ml eppendorfs. PHA (64 µl) was 
diluted in 1 ml complete RPMI-1640 medium, and a dilution series created transferring 500 µl 
PHA in medium, to 500 µl medium to generate concentrations of 64, 32, 16, 8, 4, and 2 µg.ml-1 
PHA. These dilutions were then added to wells at a 1:1 ratio of PHA to PBMCs in medium to 
achieve the final concentrations of 32, 16, 8, 4, 2 and 1 µg.ml-1.  
Method 
Peripheral blood mononuclear cells were isolated from a healthy volunteer and 10,000 cells 
were cultured in 200 µl of complete RPMI-1640 medium in uncoated U-bottom 96 well plates 
(VWR) for 0, 3, 5, 7, and 14 days with or without the addition of 1-32 µg.ml-1 PHA. Each 
concentration of PHA was tested in replicates of 5 and cells without PHA, plus PHA without 
cells were used as controls. The set up of the 96 well plates is shown in Figure 5.1. The 
experiment was carried out twice. Once using low activity and once using high activity 3H 
thymidine, to determine the extent of lymphocyte transformation. 
The 96 well plates were cultured at 37°C in an atmosphere of 5% (v/v) CO2 in air. Sixteen hours 
before each timepoint, each well of the plate was spiked with 10 µl of low activity tritiated 
thymidine to give a final concentration of 0.0125 µCi.ml-1 in complete culture medium and the 
cells cultured at 37°C in an atmosphere of 5% (v/v) CO2 in air. Sixteen hours post spiking the 
cells were harvested onto glass fibre filter plates for determination of the response at each 
timepoint using a FilterMate™ (Perkin Elmer) cell harvester. In tandem with this on the day of 
each time point each well of a replicate plate was spiked with 10 µl of high activity tritiated 
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thymidine to give a final concentration of 0.0125 µCi.ml-1 in complete culture medium and 
cultured at 37°C in an atmosphere of 5% (v/v) CO2 in air for 4 hours. Following this incubation 
(4 hours post spiking) the cells were harvested onto glass fibre filter plates using a FilterMate™ 
(Perkin Elmer) cell harvester. 
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Figure 5.1: Diagram of the 96 well plate experimental wells used to determine the optimal concentration of PHA to stimulate peripheral blood 
mononuclear cells. Figures indicate concentration of PHA added to 104 PBMCs per well, cells in medium only; no PHA, and PHA and medium; no 
cells. 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A                         
B   0µgml-1  1 µgml-1  2 µgml-1  4 µgml-1  8 µgml-1  16 µgml-1  32 µgml-1          
C   0µgml
-1  1 µgml-1  2 µgml-1  4 µgml-1  8 µgml-1  16 µgml-1  32 µgml-1          
D   0µgml-1  1 µgml-1  2 µgml-1  4 µgml-1  8 µgml-1  16 µgml-1  32 µgml-1          
E   0µgml-1  1 µgml-1  2 µgml-1  4 µgml-1  8 µgml-1  16 µgml-1  32 µgml-1          
F   0µgml-1  1 µgml-1  2 µgml-1  4 µgml-1  8 µgml-1  16 µgml-1  32 µgml-1          
G   
Cells in 
medium 
only 
Cells in 
medium 
only 
Cells in 
medium 
only         
32 µgml-1 
and 
Medium 
32 µgml-1 
and 
Medium 
32 µgml-1 
and 
Medium   
H                         
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5.2.3 HARVESTING CELLS USING THE FILTERMATE CELL HARVESTER 
Reagents 
Saline solution (0.85 % w/v) (NaCl, Merck) in H2O. 
Trichloroacetic acid (10 % w/v) (TCA, Fisher Scientific) in H2O. 
Methanol (100%) (Merck) 
Method 
A FilterMate™ cell harvester (Perkin Elmer) was used to harvest cells from the U-bottomed 96-
well microtitre plates onto 96 well Unifilter GFC plates (Perkin Elmer).  The UniFilter 96 plate 
was pre-wet with 100 ml H2O. The spiked cells and medium were then aspirated from the 
plate, and the filter retained the cells. A 0.85 % saline solution (150 ml) was used to wash the 
cells on the filter membrane. A 10% (w/v) TCA solution (100 ml) was aspirated through the 
plate, and this lysed the cells, and precipitated the DNA onto the filter membrane. The final 
wash of methanol (100 ml) aided in the precipitation of any remaining DNA, and also in the 
drying of the plate. Microscint-20 (Perkin Elmer) was added to each ‘well’ (35 µl) before 
radioactive counts were measured on the TopCount™ plate reader. The radioactive counts 
were measured as counts per minute.   
5.2.4 DETERMINATION OF THE OPTIMAL CONCENTRATION OF MITOMYCIN C TO ARREST CELL 
DIVISION USING THE ATPLITE™ ASSAY TO DETERMINE CELL VIABILITY 
Reagents 
Mitomycin C stock: Mitomycin C (10 mg; Sigma) was added to 10 ml H2O to create a 1 mg.ml
-1 
stock solution. This was frozen at -20°C in 100 µl aliquots in 0.5 ml eppendorfs.  
Camptothecin stock: Camptothecin (100mg; Sigma) was added to 100 ml HBSS (Gibco) to 
create a 1 mg.ml-1 stock solution.  
ATPlite assay (Perkin Elmer) 
Methods 
L929 Fibroblasts 
An immortalised mouse lung fibroblast cell line was obtained from the European Collection of 
Animal Cell Cultures. L929 cells were cultured in DMEM complete medium (DMEM with 2 mM 
L-glutamine, 100 µg.ml-1 penicillin and 100 μg.ml-1 streptomycin and 10% (v/v) FCS), at 37°C in 
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a humidified atmosphere containing 5% (v/v) CO2 in air. Every 3 days, medium was removed 
and replaced with fresh. Cells were passaged as previously described in section 3.2.3.  
The ATPLite™ Assay 
The ATPLite assay allows the concentration of adenosine triphosphate (ATP) to be measured 
by the reaction of ATP with D-luciferin using the enzyme luciferase to produce adenosine 
monophosphate (AMP), inorganic pyrophosphate (PPi) and light. The reaction is outlined 
below.  
ATP + D-Luciferin + O2 Oxyluciferin + AMP + PPi + CO2 + Light 
The light produced is proportional to the ATP concentration. Since the concentration of ATP in 
cells is reduced when cells undergo apoptosis, higher levels of ATP present within wells 
correlates with viable cell number. Endogenous ATPases are inactivated by raising the pH to 11 
through the addition of cell lysis solution. The subsequent addition of the substrate reduces 
the pH to 7.6, hence allowing the reaction with D-luciferin and luciferase to occur. 
In order to determine the optimum concentration of mitomycin C to arrest the mitotic division 
of L929 cells, the ATPlite assay was performed after culturing cells following exposure to 
mitomycin C (MMC). 
L929 cells (10,000) were added to wells of a flat bottomed 96 well tissue culture plate (Nunc) 
in 100 µl DMEM complete medium, and left to attach for 4 hours. A concentration series of 
MMC was prepared by diluting the stock solution of MMC into complete culture medium to 
concentrations of 12.5 – 400 µg.ml-1. One hundred microlitres was added to wells containing 
100 µl culture medium and cells to final concentrations of 6.25 – 200 µg.ml-1 of MMC in 
replicates of six. Controls were untreated cells in medium only or treated with 4 µg.ml-1 
camptothecin. To treat cells with camptothecin, 4 µl stock solution was added to 996 µl culture 
medium to create a 4 µg.ml-1 solution. Culture medium already in wells was removed and 
replaced with the camptothecin medium. Cells were incubated at 37°C in a humidified 
atmosphere containing 5% (v/v) CO2 in air for 1 hour. Following incubation for 1 hour, the 
MMC medium was removed, and cells were washed twice with PBS, before 200 µl DMEM 
complete medium was added to wells (cells only and MMC treated). Camptothecin was added 
to wells at a final concentration of 0.1 µg.ml-1 as a positive control for cell death, and the plates 
were incubated at 37°C in an atmosphere of 5% (v/v) CO2 in air.  A 96 well plate template for 
the experimental setup is shown in Figure 5.2 and six plates were set up. 
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The ATPlite assay was performed on the cells at days 0, 2, 4, 6, 8, and 10 following exposure to 
mitomycin C.  
ATPLite assay reagents and solutions were allowed to reach room temperature. The 
luciferase/luciferin substrate (77 mg) was reconstituted with substrate buffer solution (5 ml). 
The subsequent procedure was carried out under dim light conditions. One hundred 
microlitres (from 200 μl) of culture medium was removed from a well of the culture plate 
containing cells, cell lysis solution (50 μl) was added to the well (containing 100 μl of medium) 
and the plate was placed on an orbital plate shaker (700 rpm) for 5 minutes. Substrate solution 
(50 μl) was added to the well and the plate was placed on an orbital plate shaker (700 rpm) for 
5 minutes. An adherent seal was placed on the plate to prevent contamination of the 
luminometer detectors and the plate was placed in the TopCount (NXT) luminometer, which 
was programmed to dark-adapt the plate for 10 minutes and read the luminescence of each 
well for 5 seconds. The reading output of each well was presented as counts per second (CPS).  
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Figure 5.2: Diagram of the 96 well plate experimental wells used to determine the optimal concentration of mitomycin C to arrest cell 
division of L929 cells. Figures indicate concentration of mitomycin C added to 104 L929 cells per well, cells and medium, and cells and 0.1 
µg.ml-1 campththecin as a negative control for proliferation. 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A                         
B   
Cells 
Only  
Campto. 
Treated  200 µgml-1  100 µgml-1  75 µgml-1  50 µgml-1  25 µgml-1  12.5 µgml-1  6.25 µgml-1      
C   
Cells 
Only  
Campto. 
Treated  200 µgml-1  100 µgml-1  75 µgml-1  50 µgml-1  25 µgml-1  12.5 µgml-1  6.25 µgml-1      
D   
Cells 
Only  
Campto. 
Treated  200 µgml-1  100 µgml-1  75 µgml-1  50 µgml-1  25 µgml-1  12.5 µgml-1  6.25 µgml-1      
E   
Cells 
Only  
Campto. 
Treated  200 µgml-1  100 µgml-1  75 µgml-1  50 µgml-1  25 µgml-1  12.5 µgml-1  6.25 µgml-1      
F   
Cells 
Only  
Campto. 
Treated  200 µgml-1  100 µgml-1  75 µgml-1  50 µgml-1  25 µgml-1  12.5 µgml-1  6.25 µgml-1      
G   
Cells 
Only  
Campto. 
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5.2.5 DETERMINATION OF THE CONCENTRATION OF MITOMYCIN C TO ARREST CELL DIVISION 
USING FLUORESCEIN DIACETATE TO DETERMINE CELL VIABILITY 
Reagents 
Fluorescein diacetate (FDA) stock: FDA (20 mg; Fisher Scientific) was dissolved in 20 ml DMSO 
to create a 1 mg.ml-1 stock solution. This was stored at room temperature in the dark.  
Fluorescein sodium stock: Fluorescein sodium (20 mg; Fisher Scientific) was dissolved in 20 ml 
H2O to create a 1 mg.ml
-1 stock solution. This was stored at room temperature in the dark. 
Method 
Primary human dermal fibroblasts (PHDFs) were cultured in complete DMEM (DMEM with 2 
mM L-glutamine, 50 µg.ml-1 penicillin and 50 μg.ml-1 streptomycin and 10% (v/v) FCS), at 37°C 
in a humidified atmosphere containing 5% (v/v) CO2 in air. Every 3 days, medium was removed 
and replaced with fresh. Cells were passaged as previously described in section 3.2.3.  
Mesenchymal stromal cells from donor BM1 were cultured in NH Expansion medium at 37°C in 
a humidified atmosphere containing 5% (v/v) CO2 in air. Every 3 days, medium was removed 
and replaced with fresh. Cells were passaged as previously described in section 3.2.2. 
Fluorescein diacetate is a fluorochrome that has been used to differentiate between live and 
dead cells in monolayer culture (Krause et al., 1984). This dye is permeable to cell membranes, 
and in live cells, cell esterases can convert FDA into the fluorescent compound fluorescein. This 
compound is impermeable and therefore is a useful marker of viable cells in culture (only live 
cells will fluoresce).  
Primary human dermal fibroblasts (10,000) were added to wells of a flat bottomed black 96 
well FluoroNunc™ plate (Nunc) in 100 µl culture medium, and left to attach for 4 hours. 
Following this incubation MMC was added to the wells at 12.5 – 50 µg.ml-1 in replicates of six. 
Controls were untreated or treated with 4 µg.ml-1 camptothecin. Cells were incubated at 37°C 
in a humidified atmosphere containing 5% (v/v) CO2 in air for 1 hour. 
Following incubation, the MMC medium was removed, and cells were washed twice with PBS, 
before 200 µl complete DMEM culture medium was added to wells (cells only and MMC 
treated). Camptothecin was added to wells at a final concentration of 0.1 µg.ml-1 as a positive 
control for cell death, and the plates were incubated at 37°C in an atmosphere of 5% (v/v) CO2 
in air.  FDA staining was carried out on days 0, 2, 4, 8, and 12. FDA (1 µl) was added to wells 
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and left for 2 minutes at room temperature. Cells were then washed with 200 µl PBS 3 times, 
before finally adding 200 µl PBS to wells and 200 µl 10 µg.ml-1 fluorescein sodium to one 
empty well. Fluorescent intensity was measured on a Fluostar Optima plate reader using the 
fluorescein sodium as a constant gain adjustment. Settings were set to read at 485 nm 
excitation, and 520 nm emission for 1 cycle, 1 second cycle time, and 10 flashes per well per 
cycle.  
Mesenchymal stromal cells (10,000) were allowed to attach to wells of a black 96 well 
FluoroNunc™ plate (Nunc). After 4 hours the attached cells were treated with MMC at the final 
concentrations shown in Figure 5.3 for 1 hour. Following incubation for 1 hour, the mitomycin 
C medium was removed, and cells were washed twice with PBS, before 200 µl NH expansion 
medium was added to wells (cells only and MMC treated). Camptothecin was added to wells at 
a final concentration of 0.1 µg.ml-1 as a positive control for cell death, and the plates were 
incubated at 37°C in an atmosphere of 5% (v/v) CO2 in air.  FDA staining was carried out on 
days 0, 2, 4, 8, and 12. FDA (1 µl) was added to wells and left for 2 minutes at room 
temperature. Wells were then washed with 200 µl PBS 3 times, before finally adding 200 µl 
PBS to wells and 200 µl 10 µg.ml-1 fluorescein sodium to one empty well. Fluorescent intensity 
was measured on a Fluostar Optima plate reader using the fluorescein sodium as a constant 
gain adjustment. Settings were set to read at 485 nm excitation, and 520 nm emission for 1 
cycle, 1 second cycle time, and 10 flashes per well per cycle.  
A 96 well plate template for the experimental setup is shown in Figure 5.3. 
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Figure 5.3: Diagram of the 96 well plate experimental wells used to determine the optimal concentration of mitomycin C to arrest cell division 
of 104 PHDF and MSCs. Cells grown in medium only were used as a negative control for cell death. Cells grown in 0.1 µg.ml-1 camptothecin were 
used as a positive control for cell death. Figures represent concentrations of mitomycin C used to treat PHDFs and MSCs to inhibit mitosis. FDA 
was used as a positive stain for cell viability. Fluorescein sodium was used as a constant gain adjustment to allow comparisons between plates. 
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5.2.6 ONE-WAY MLR TO DETERMINE CELL NUMBERS AND RATIOS OF PBMCS 
PBMC were isolated from 2 healthy volunteer’s human peripheral blood, and one population 
was treated with 12.5 µg.ml-1 MMC for 1 hour at room temperature (the stimulator cells). The 
cells were centrifuged at 150 g for 30 minutes, and MMC medium was removed and cells were 
washed in 10 ml PBS twice before they were finally resuspended in 10 ml fresh RPMI-1640 
complete medium. Cells were counted using trypan blue dye exclusion (as described in section 
2.3.7) and dispensed into a 96 well uncoated U-bottomed plate; untreated PBMCs  and MMC 
treated PBMCs were added to create ratios of 1:1, 1:10, and 1:100 responder to stimulator 
cells as shown in Figure 5.4. The total numbers of cells per well were 10,000, 50,000, and 
100,000. The negative control for proliferation was responder PBMCs grown in complete 
medium only, and positive control was responder PBMCs stimulated with 32 µg.ml-1 PHA. 
Plates were harvested on days 3, 5, 7, and 12. 
Plates were cultured at 37°C in an atmosphere of 5% (v/v) CO2 in air. Sixteen hours before the 
desired timepoint each well of the plate was spiked with 10 µl of low activity tritiated 
thymidine (0.0125 µCi.ml-1) and cultured at 37°C in an atmosphere of 5% (v/v) CO2 in air 
overnight. Sixteen hours post spiking the cells were harvested onto glass fibre filter plates 
using a FilterMate™ (Perkin Elmer) cell harvester, before MicroScint-20™ was added and 
radioactive counts were measured on a TopCount scintillation counter as described in section   
5.2.3 
A 96 well plate template for the experimental setup is shown in Figure 5.4. 
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Figure 5.4: Diagram of the 96 well plate experimental wells used to determine the optimal ratio of responder:stimulator PBMCs, and the 
optimal total cell number per well. Numbers in bold represent responder cells and italics represent stimulator cells. Ratios of 1:1, 1:10, and 
1:100 responder to stimulator cells were used and total numbers of cells per well were 10000, 50000, and 100000. The negative control for 
proliferation was responder PBMCs grown in complete medium only, and positive control was responder PBMCs stimulated with 32 µg.ml-1 
PHA. Plates were harvested on days 3, 5, 7, and 12. 
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5.2.7 COMPARISON OF THE RESPONSE OF PBMCS IN FETAL CALF SERUM AND HUMAN SERUM 
Isolation of autologous human serum: Freshly isolated blood was dispensed into a sterile test 
tube, and allowed to clot for 2 hours at 37 °C. The test tube was then centrifuged at 2000 g for 
10 minutes, and the serum (straw coloured fluid) was removed aseptically and dispensed into 
a sterile universal. 
Method 
PBMCs were isolated from healthy volunteer’s human peripheral blood, and counted using 
trypan blue dye exclusion. The PBMCs (25,000, 50,000 and 100,000) were dispensed into 
uncoated U-bottomed 96 well plates, and either cultured in complete medium, or complete 
medium with 32 µg.ml-1 PHA. Two separate timecourses were performed using complete 
medium supplemented with 10 % (v/v) fetal calf serum, or 10 % (v/v) autologous human 
serum.  
Plates were cultured at 37°C in an atmosphere of 5% (v/v) CO2 in air for 5, 7, and 12 days. 
Sixteen hours prior the day of the timecourse each well of the plate was spiked with 10 µl of 
low activity tritiated thymidine (0.0125 µCi.ml-1) and cultured at 37°C in an atmosphere of 5% 
(v/v) CO2 in air overnight. Sixteen hours post spiking the cells were harvested onto glass fibre 
filter plates using a FilterMate™ (Perkin Elmer) cell harvester, before MicroScint-20™ was 
added and radioactive counts were measured on a TopCount scintillation counter as described 
in section 5.2.3.  
A 96 well plate template for the experimental setup is shown in Figure 5.5. 
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Figure 5.5: Diagram of the 96 well plate experimental wells used to determine effects of culturing PBMCs in human or fetal calf serum. 
PBMCs (25,000, 50,000 and 100,000) were isolated from peripheral human blood and cultured for 5, 7, and 12 days using complete medium 
supplemented with either 10 % (v/v) fetal calf serum, or 10 % (v/v) human autologous serum. Cells grown in medium only were used as a 
negative control for lymphocyte stimulation. Cells grown in PHA (32 µg.ml-1) were used as a positive control for lymphocyte stimulation. 
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5.2.8 DETERMINATION OF HUMAN SERUM CONCENTRATION FOR USE IN THE LTA 
PBMC were isolated from 2 healthy volunteer’s human peripheral blood, and counted using 
trypan blue dye exclusion. The PBMCs (50,000) were dispensed into uncoated U-bottomed 96 
well plates. Complete medium was made supplemented with 2, 5, and 10% (v/v) human AB 
serum.  PBMCs were either cultured in complete medium, or complete medium with 32 µg.ml-
1 PHA at 37°C in an atmosphere of 5% (v/v) CO2 in air.  
Plates were cultured for 3, 5, and 7 days. At sixteen hours before the desired timepoint each 
well of the plate was spiked with 10 µl of low activity tritiated thymidine stock and cultured at 
37°C in an atmosphere of 5% (v/v) CO2 in air overnight. Sixteen hours post spiking the cells 
were harvested onto glass fibre filter plates using a FilterMate™ (Perkin Elmer) cell harvester, 
before MicroScint-20™ was added and radioactive counts were measured on a TopCount 
scintillation counter as described in section 5.2.3. 
A 96 well plate template for the experimental setup is shown in Figure 5.6. 
5.2.9 DATA ANALYSIS 
Data generated in one-way MLR’s and LTA’s were Log10 transformed to satisfy the normality 
assumption required in order to perform an ANOVA. A post-hoc Tukey test for unequal sample 
sizes was performed, as recommended by Sokal and Rholf, 1981, which is hithero referred to 
as the T-method. The Log10 transformed data at each time point was analysed by one-way 
analysis of variance and the minimum significant difference (MSD; p<0.05) between each 
group mean determined using the T-method (Sokal and Rohlf, 1981). 
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Figure 5.6: Diagram of the 96 well plate experimental wells used to determine the optimal concentration of human AB serum. PBMCs 
(50,000) from two donors were cultured using 2, 5, or 10% human AB serum, either in complete medium or in complete medium 
supplemented with 32 µg.ml-1 PHA. PBMCs gown in medium only were a negative control for stimulation, and PBMCs grown in PHA were a 
positive control for stimulation. In positive control wells ‘-1’ and ‘-2’ are representative of cells from donor 1 and donor 2 respectively. Plates 
were cultured for 3, 5, and 7 days. 
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5.3 RESULTS 
5.3.1 TITRATION OF PHA AND DETERMINATION OF LYMPHOCYTE TRANSFORMATION USING LOW 
AND HIGH ACTIVITY 
3H THYMIDINE 
Phytohaemagglutinin (PHA) is a lectin found in plants, especially in legumes. It has common 
uses as a mitogen, a potent stimulator of cell division. In the one-way MLR it is used as a 
positive control for responder PBMC stimulation. In order to determine the concentration of 
PHA to be used to stimulate the PBMCs a titration assay was performed using a gradient of 
increasing concentration of PHA with a fixed number of PBMCs. The stimulation of the PBMCs 
was measured using tritiated thymidine incorporation into the DNA of the cells, both low 
activity, and high activity. The stimulation index was calculated as: 
SI = Mean cpm in cultures with PHA 
        Mean cpm in control cultures 
 
The control cultures were PBMCs cultured with no stimulation in medium alone.  
Tritiated thymidine incorporation occurs when cells enter mitosis and use the thymidine in the 
synthesis of new DNA. The radiation is lethal to the cells however and because of this shorter 
incubation times are required using high activity tritiated thymidine rather than using low 
activity.
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Figure 5.8: The effect of PHA concentration on the stimulation of PBMCs over time as 
measured by incorporation of high activity tritiated thymidine into DNA (cpm). PBMCs were 
treated with 0, 1, 2, 4, 8, 16, and 32 µg.ml-1 PHA. On the day of harvesting the cells were 
spiked with high activity tritiated thymidine for 4 hours, and counts per minute were 
determined. Negative control for stimulation was PBMCs cultured in complete medium only 
in the absence of mitogen. Cells were cultured for 3, 5, 7, and 14 days. Results are displayed 
as the mean Log10 counts per minute (n=5) over time with 95% confidence intervals. * 
indicates significant differences (p<0.05) compared to 0 µg.ml-1 PHA used to stimulate 
cultured cells as determined by the T-method.    
Figure 5.7: The effect of PHA concentration on the stimulation of PBMCs over time as 
measured by incorporation of high activity tritiated thymidine into DNA (SI). PBMCs were 
treated with 0, 1, 2, 4, 8, 16, and 32 µg.ml-1 PHA. On the day of harvesting the cells were 
spiked with high activity tritiated thymidine for 4 hours, and counts per minute were 
determined. Negative control for stimulation was PBMCs cultured in complete medium only 
in the absence of mitogen. Cells were cultured for 3, 5, 7, and 14 days. Results are displayed 
as the stimulation index over time. 
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Figure 5.10: The effect of PHA concentration on the stimulation of PBMCs over time as 
measured by incorporation of low activity tritiated thymidine into DNA (cpm). PBMCs were 
treated with 0, 1, 2, 4, 8, 16, and 32 µg.ml-1 PHA. Sixteen hours before the day of harvesting 
the cells were spiked with low activity tritiated thymidine. After 16 hour incubation, counts 
per minute were determined. Negative control for stimulation was PBMCs cultured in 
complete medium only in the absence of mitogen. Cells were cultured for 3, 5, 7, and 14 
days. Results are displayed as the mean Log10 counts per minute (n=5) over time with 95% 
confidence intervals. * indicates significant differences (p<0.05) compared to 0 µg.ml-1 PHA 
used to stimulate cultured cells as determined by the T-method.    
 
Figure 5.9: The effect of PHA concentration on the stimulation of PBMCs over time as 
measured by incorporation of low activity tritiated thymidine into DNA (SI). PBMCs were 
treated with 0, 1, 2, 4, 8, 16, and 32 µg.ml-1 PHA. Sixteen hours before the day of harvesting 
the cells were spiked with low activity tritiated thymidine. After 16 hour incubation, counts 
per minute were determined using a Topcount ™ scintillation counter. Negative control for 
stimulation was PBMCs cultured in complete medium only in the absence of mitogen. Cells 
were cultured for 3, 5, 7, and 14 days. Results are displayed as the stimulation index over 
time. 
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The results for PBMCs spiked with high activity and low activity thymidine are presented in 
Figures 5.7-5.8 and 5.9-5.10 respectively. When PBMCs were stimulated with PHA at 1, 2, or 4 
µg.ml-1 and spiked with low activity thymidine the stimulation index was less than 30. With 8, 
16, or 32 µg.ml-1 PHA stimulation, SI’s of 200 or greater were recorded at day 5. The SI’s at 
days 3, 7, and 14 were lower, indicating a peak response at day 5. This pattern of response was 
also observed when high activity tritiated thymidine was used. Although when the results are 
displayed as stimulation indices, cells stimulated with 32 µg.ml-1 PHA did not appear to peak at 
day 5 (Figure 5.7), when the counts per minute were analysed the counts were the highest on 
this day (Figure 5.8).  
The stimulation indices were highest when low activity tritiated thymidine was used to spike 
the cells, and 32 µg.ml-1 PHA was used to stimulate the cells. These parameters were therefore 
selected to use in subsequent experiments. 
5.3.2 DETERMINATION OF THE CONCENTRATION OF MITOMYCIN C TO ARREST CELL DIVISION 
USING THE ATPLITE™ ASSAY TO MEASURE CELL NUMBER/VIABILITY 
To arrest mitotic division of cells, mitomycin C (MMC) was used. A range of concentrations of 
MMC were used (200, 100, 75, 50, 25, 12.5, and 6.25 µg.ml-1) to assay its effectiveness to 
arrest the division of an L929 cell line. L929 cells were used in initial experiments to gain an 
understanding of the concentrations of MMC required to mitotically arrest mesenchymal cells. 
After treating the cells with MMC, the concentration of ATP present was measured as counts 
per minute on days 0-10. In the absence of MMC treatment, the L929 cells showed increased 
ATP levels up to day four of culture, after which the cellular ATP levels remained stationary 
until day 8, and then declined at day 10 (Figure 5.11).  
On day 0 directly after treatment with MMC the concentration of ATP (represented by the 
counts per second) varied between the cultures treated with different concentrations of MMC 
applied to the cells.  
When L929 cells were treated with camptothecin (positive control for cell death) the ATP 
levels declined from day 0 to day 2, and continued to decline throughout the 10 day culture 
period. When treated with MMC there was a dose dependent inhibition of ATP levels observed 
in L929 cells in comparison to the untreated control cells. The cells however, continued to 
proliferate following treatment with MMC at concentrations of up to 100 µg.ml-1 MMC. Data is 
also presented as a percentage relative to L929 cells grown in medium without MMC (Figure 
5.12). Treatment of L929 cells with mitomycin C at all concentrations caused ATP levels within 
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cells to fluctuate (demonstrated by deviations from cells in medium only on day 0 after 
treatment). Due to these fluctuations an alternative method to assess cell viability/growth 
after mitomycin C treatment was used. 
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Figure 5.12: The effect of varying concentrations of mitomycin C treatment on the growth of L929 
cells over 10 days. L929 cells were treated with MMC (200, 100, 75, 50, 25, 12.5, 6.25 µg.ml-1) for 1 
hour, washed and cultured for 10 days. Cell proliferation was determined using an ATPLite assay. 
Data is expressed as a percentage relative to L929 cells grown in medium alone. 
 
Figure 5.11: The effect of varying concentrations of mitomycin C treatment on the growth 
of L929 cells over 10 days. L929 cells were treated with MMC (200, 100, 75, 50, 25, 12.5, 
6.25 µg.ml-1) for 1 hour, washed and cultured for 10 days. Cell proliferation was determined 
using an ATPLite assay. Data is expressed as Log10 mean (n=6) counts per second ± 95% 
confidence limits. 
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5.3.3 DETERMINATION OF THE OPTIMAL CONCENTRATION OF MITOMYCIN C TO ARREST CELL 
DIVISION USING FLUORESCEIN DIACETATE 
From the experiment with L929 cells described above, it was concluded that this cell line had 
resistance to mitomycin C treatment and therefore a cell type more closely matching MSCs 
was chosen for further experiments. Primary dermal human fibroblasts provided a primary cell 
source to investigate the effect of mitomycin C. In addition, treating cells with mitomycin C 
was shown to affect the ATP levels of the cells (Figure 5.12) so an alternative assay for cell 
viability was used. In the literature the concentration of MMC used to inhibit mitosis in MSCs is 
commonly 25 µg.ml-1. Concentrations of MMC at 50, 25, and 12.5 µg.ml-1 were therefore 
selected for further testing. Fluoroscein diacetate was used to stain cells after treatment with 
MMC as the alternative to the ATPLite assay. Initially PHDFs were used as a primary cell type to 
assess the effect of MMC treatment on cell proliferation using FDA (Figure 5.13). BM1 MSCs 
were then also treated with MMC (50, 25, and 12.5 µg.ml-1) and cells stained with FDA on days 
0, 2, 4, 8, and 10 (Figure 5.14). 
PHDFs grown in culture medium without MMC failed to exhibit normal growth, and showed an 
extended lag period (Figure 5.13). Primary dermal human fibroblasts treated with 
camptothecin showed reduced cell viability from day 0 to day 2, then a sharp decrease in 
viability to day 4. All three concentrations of mitomycin C used to treat the PHDFs inhibited cell 
proliferation, but also reduced cell viability at time 0 (Figure 5.13). 
Mesenchymal stromal cells exhibited a more typical growth curve, with cells grown in medium 
only proliferating up to day 4, before the number of viable cells dropped on day 8, and 
remained at this level on day 12. Mesenchymal stromal cells treated with camptothecin 
remained viable until day 4, but by day 8 there was a marked decrease in cell viability, further 
decreasing by day 12. As with PHDFs, treatment of MSCs with 50, 25, and 12.5 µg.ml-1 
mitomycin C inhibited cell proliferation but with reduced cell viability at time 0 (Figure 5.14).  
All 3 concentrations of MMC arrested the mitotic division of both PHDFs and MSCs (no 
definitive increase in fluorescence) therefore a final concentration of 12.5 µg.ml-1 was selected 
to use in further assays to provide the minimum concentration of MMC that would inhibit cell 
division but maintain cell viability over time in culture. 
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Figure 5.13: Relative fluorescence intensity of PHDFs treated with various doses of 
mitomycin C. Human dermal fibroblasts were treated with MMC with at 50, 25, and 
12.5 µg.ml-1 for one hour and then cultured for 0, 2, 4, 8, and 12 days, and the 
fluorescence intensity after FDA staining was used to assess cell proliferation. The green 
line is the positive control; cells grown in medium, and the red line is cells grown in 0.1 
µg.ml-1 camptothecin as an inducer of cell death.  Data is displayed as mean relative 
fluorescent intensity (n=6) ± 95% confidence limits 
Figure 5.14: Relative fluorescence intensity of MSCs treated with various doses of 
mitomycin C. Human MSCs were treated with MMC with at 50, 25, and 12.5 µg.ml-1 
for one hour and then cultured for 0, 4, 8, and 12 days, and the fluorescence 
intensity after FDA staining was used to assess cell proliferation. The green line is the 
positive control; cells grown in medium, and the red line is cells grown in 0.1 µg.ml-1 
camptothecin as an indicer of cell death.  Data is displayed as mean relative 
fluorescent intensity (n=6) ± 95% confidence limits. 
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5.3.4 ONE-WAY MLR TO DETERMINE CELL NUMBERS AND RATIOS OF PBMCS TO USE TO 
GENERATE OPTIMUM COUNTS PER MINUTE   
In order to determine suitable cell numbers and ratios of responder PBMCs to stimulator cells 
treated with MMC, experiments were performed at PBMCs to stimulator PBMC ratios of 1:1, 
1:10, and 1:100. In addition the number of responder PBMCs was varied between 5000, 25,000 
and 50,000 to give total cell numbers (responders plus stimulators) of 10,000, 50,000 and 
100,000. 
Peripheral blood mononuclear cells treated with PHA as the positive control for stimulation 
(Figure 5.15) gave maximal counts on day 5, before a decline to day 12. 
Responder PBMCs (10,000) cultured alone in complete medium without stimulation (Figure 
5.15) did not appear to proliferate over the 12 day culture period, whereas responder PBMCs 
(50,000 and 100,000) demonstrated some degree of proliferation from day 3, throughout the 
culture period to day 12.  
When cultured in a 1:1 ratio of responder cells:stimulator cells using 10,000 total cells per well, 
counts per minute remained stable from day 3 to day 12. However, when cultured at a 1:1 
ratio and with 50,000 and 100,000 total cells counts per minute increased from day 3, to peak 
stimulation at day 7, before counts reduced by day 12 (Figure 5.15). 
When a 1:10 ratio of responder cells:stimulator cells were cultured together a similar trend to 
PBMCs cultured at a 1:1 ratio was observed, with 10,000 total cell number demonstrating no 
increase in counts of the 12 day culture period, but both 50,000 and 100,000 total cell 
numbers resulted in increased counts from day 3, peaking on day 7, before again reducing by 
day 12. Counts per minute were slightly less than when a 1:1 ratio was used, but the trend 
observed was the same (Figure 5.15). 
When a 1:100 ratio of responder cells:stimulator cells were cultured together no stimulation 
was observed when 10,000 and 50,000 total cell number were used. When 100,000 total cell 
number was used, the counts continued increasing to day 12, (Figure 5.15).  
The data was analysed by one way ANOVA and the MSD (p=0.05) between group means 
determined at each time point. The results of the analysis are presented in Figure 5.16. This 
revealed that at day 3 for the 1:1 ratio counts per minute for 100,000 total cells were 
significantly greater than for 50,000 and 10,000 cells. Moreover the counts per minute for the 
1:1 ratio with both the 50,000 and 100,000 cells was significantly higher than the counts per 
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minute for the 1:10 and 1:100 ratios for the same number of total cells. At day 5 and day 7, for 
cells at 1:1 ratio there was no significant difference between the counts per minute for 50,000 
and 100,000 cells, however the counts per minute for both was significantly higher than the 
counts per minute for 10,000 cells. Again the cells cultured at 1:1 ratio gave significantly higher 
counts compared to the cells cultured at 1:10 and 1:100 for the same total cell number.  
At day 12 the counts were highly variable across all cell cultures. There was no significant 
difference observed between the cells only negative control and 1:1, 1:10, and 1:100 ratios of 
stimulator to responder cells, when 10,000, 50,000 and 100,000 total cells were used; except 
for 50,000 cells at 1:100 ratio, this ratio and cell number had a significantly lower counts per 
minute. 
The highest counts per minute were observed when a 1:1 ratio of responder:stimulator PBMCs 
was used, and both 50,000 and 100,000 total cell number demonstrated high stimulation. 
Using 50,000 cells in downstream applications it was possible to conserve the number of cells 
required to perform the assays, allowing a greater ‘n’number to be utilised within the 
requirements of using cells before passage 6 (using 100,000 cells would double the number of 
cells needed per assay). It was therefore decided to use a 1:1 ratio, and a 50,000 total cell 
number in further experiments.   
The increase in counts of the PBMCs in medium only (Figure 5.12) indicated potential 
stimulation from the fetal calf serum, therefore it was decided to perform the LTA using 
human serum, and compare counts to an LTA using fetal calf serum.   
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Figure 5.15:  A one-way MLR to determine the ratio of responder:stimulator PBMCs, and the 
total cell number per well that generated the optimum counts per minute (stimulation). 
Untreated PBMCs (10,000, 5000, 1000, and 100) and mitomycin C treated PBMCs (5000, 9000, 
9900, and 10,000) were cultured in ratios of 1:1, 1:10, and 1:100 responder to stimulator cells. The 
total numbers of cells per well were 10,000, 50,000, and 100,000. The positive control for 
stimulation was responder PBMCs stimulated with 32 µg.ml-1 PHA. The negative control for 
stimulation was responder PBMCs cultured in complete culture medium (Cells only). Data is 
expressed as mean Log10 counts per minute (n=4) ± 95% confidence limits. 
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Figure 5.16: Grouped bar chart of Log10 counts per minute for a one-way MLR to determine the ratio of responder:stimulator PBMCs and the total 
cell number per well that generated the optimum counts per minute (stimulation). Untreated PBMCs and mitomycin C treated PBMCs were 
cultured in ratios of 1:1, 1:10, and 1:100 responder to stimulator cells. The total numbers of cells per well were 10000, 50000, and 100000. The 
positive control for stimulation was responder PBMCs stimulated with 32 µg.ml-1 PHA (Cells and PHA). The negative control for stimulation was 
responder PBMCs cultured in complete culture medium (Cells only). Data is expressed as mean Log10 counts per minute (n=4). Data (log10 cpm) at 
each time point was analysed by one-way ANOVA and the MSD (P<0.05) calculated using the t-method. Error bars are plotted as ± ½ MSD (p<0.05). If 
error bars from different group means do not overlap, then there is significant difference at p<0.05. 
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5.3.5 A LYMPHOCYTE TRANSFORMATION ASSAY TO DETERMINE IF USING HUMAN AB SERUM   AS 
AN ALTERNATIVE TO FETAL CALF SERUM IN COMPLETE MEDIUM CHANGES THE RESPONSE OF 
PBMCS WHEN STIMULATED WITH PHA 
Day 5 was selected as the starting day for analysis, as typically when PHA was used to 
stimulate PBMCs, peak stimulation occurred on this day. 
Peripheral blood mononuclear cells were cultured with and without PHA stimulation at 25,000, 
50,000, and 100,000 cells per well for 5, 7, and 12 days in medium supplemented with FBS or 
human AB serum. In PBMC cultures without PHA no significant stimulation was observed and 
the counts per minute obtained remained low (Figure 5.17). In the presence of PHA, when 
25,000 cells were used, the highest stimulation observed was on day 5, with counts per minute 
decreasing on day 7, and further by day 12. Peripheral blood mononuclear cells cultured at 
25,000, 50,000 and 100,000 cells per well showed resulted in the same growth characteristics, 
with highest stimulation on day 5, and lowest by day 12.   
As there was no overall difference in Log10 counts per minute between 25,000, 50,000 or 
100,000 PBMCs when stimulated with PHA, this further supported the use of 25,000 responder 
PBMCs in future assays as this agrees with previous data of maximal counts observed when 
25,000:25,000 PBMCs were used in the MLR. 
In addition to this, counts in the presence of AB serum were significantly higher than when 
fetal calf serum was used in complete medium, for 25,000, 50,000 and 100,000 PBMCs. It was 
decided to use human AB serum as a supplement in complete medium for PBMCs due to the 
generation of higher positive control counts when this serum is used. 
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Figure 5.17: Counts per minute of PBMCs cultured without stimulation, and in the presence of 
PHA using both fetal calf serum, and human AB serum supplemented complete medium. PBMCs 
(25,000, 50,000, and 100,000) were cultured for 5, 7, and 12 days and the counts per minute of 
both stimulated and unstimulated PBMCs was compared. Data is expressed as mean Log10 counts 
per minute (n=4) ± 95% confidence limits. Data (log10 cpm) for cells cultured in FCS and human AB 
serum supplemented medium were compared at each time point for stimulated and unstimulated 
cells by one-way ANOVA. Significant differences between fetal calf serum and autologous human 
serum are indicated by * = p<0.05.   
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5.3.6 THE EFFECT OF HUMAN AB SERUM CONCENTRATION IN COMPLETE MEDIUM ON 
STIMULATED (PHA TREATED) AND UNSTIMULATED PERIPHERAL BLOOD MONONUCLEAR 
CELLS 
Both stimulated and unstimulated PBMCs from both donor 1 and donor 2 failed to display any 
significant proliferation when cultured in complete medium containing 2, 5, or 10% human AB 
serum, as measured by Log10 counts per minute and one way analysis of variance as 
determined by the T-method (Figure 5.18). 
When PBMCs were stimulated with PHA and cultured in complete medium supplemented with 
human AB serum, all three concentrations of serum for both donors displayed similar trends. 
The counts per minute increased from day 3 to peak on day 5, before counts dropped by day 7.  
The concentration of serum used to supplement medium in lymphocyte transformation assays 
in the literature is typically 10%. It was therefore decided to keep the concentration of serum 
used as 10% due to the lack of any significant difference between 2, 5, or 10% serum 
supplementation. 
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Figure 5.18: Counts per minute of PBMCs cultured in complete medium supplemented 
with 2, 5, and 10% human AB serum, and either stimulated with PHA, or unstimulated 
(medium alone). PBMCs (25,000) were cultured for 5, 7, and 12 days. Data (counts per 
minute) was Log10 transformed. Log10 data for each donor at each time point, stimulated 
and unstimulated was compared by one-way ANOVA (p<0.05) using the T-method.  
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5.4 DISCUSSION 
There were 5 main objectives for this part of the study. These were the determination of the 
concentration of PHA (mitogen) for use as the positive control for lymphocyte activation and 
of the method for spiking the cells (using tritiated thymidine), the determination of the 
concentration of mitomycin C for the mitotic inhibition of stimulator cells while maintaining 
their viability and cell number and ratio of responder and stimulator cells in the one way MLR, 
and finally the determination of the concentration and source of serum for cell culture 
medium supplementation. 
Primarily PBMC were isolated using a Lymphoprep® density centrifugation gradient. This 
commercially available preparation has been widely used for the isolation of mononuclear cells 
from peripheral blood, based on the lower buoyant density of mononuclear cells compared to 
the poly-morphonuclear granulocytes or the erythrocytes. The mononuclear cell population 
has a buoyant density below 1.077 g.ml-1, therefore centrifugation using a medium of this 
density causes the granulocytes and erythrocytes to pass through the solution, but 
mononuclear cells remain at the interface. These cells were then aspirated using glass Pasteur 
pipettes, and the mononuclear cells were then washed to remove traces of Lymphoprep®. 
A positive control for stimulation of cultured PBMCs was required to ensure the functional 
capacity of the isolated cells. A range of concentrations of PHA, a plant lectin that induces 
mitosis, was used to stimulate cultured PBMCs to proliferate. Proliferation was measured using 
tritiated thymidine (3H) incorporation, both high activity and low activity. Tritiated thymidine is 
a low energy beta (β) emitter; low activity 3H has a lower specific activity, and high activity 3H 
has a higher specific activity. The higher the specific activity is, the higher the number of 
decays per second, per amount of 3H.  
The high activity 3H required a shorter incubation time with the cells (4 hours) in comparison 
with the low activity 3H (16 hours). The low activity 3H provided significantly higher counts per 
minute over the high activity, and therefore was selected for future experiments. A PHA 
concentration of 32 µg.ml-1 gave the highest counts, and this was selected to use as a positive 
control for lymphocyte stimulation in further assays. The use of proper controls is vital when 
calculating the stimulation index in lymphocyte proliferation assays, as in negative control 
counts a variation between 100-200 (which in actual counts per minute terms is a very small 
difference) can cause the stimulation index to as much as halve in value.  
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In assays to determine the immunogenicity of MSCs, the MSCs act as the stimulator cells. The 
mitotic ability of these cells needed to be inhibited, so that the incorporation of 3H measured 
was only due to the proliferation of the responder lymphocytes. In order to do this, the 
chemical compound mitomycin-C (MMC) was selected; this compound has been used to 
inhibit proliferation of stimulator cells in MLRs (Oh et al., 2008; Nasef et al., 2009; Prasanna et 
al., 2010). Initially concentrations of MMC between 6.25 and 200 µg.ml-1 were used to treat 
the L929 cell line, and the effect of MMC on the proliferation of these cells over 10 days was 
measured using the ATPLite® assay. The basis of this assay is that ATP levels are measured, and 
increasing concentrations of ATP are used signify increasing cell numbers. Initial treatment 
with MMC caused the concentration of ATP (represented by the counts per second) to vary 
between the different concentrations of MMC applied to the cells. ATP levels were higher in 
MMC treated cells on day 0. This is in agreement with previous studies that found MMC also 
was able to affect mitochondrial DNA and ATP levels within cells treated with MMC can vary 
extensively due to this (Maehara et al., 1987; Pritsos and Briggs, 1996). Hence, an alternative 
method of assessing cell proliferation was used. Fluorescein diacetate is a membrane 
permeable compound, that upon entering viable cells is converted using cell esterase’s into 
the fluorescent fluorescein (Krause et al., 1984). This compound is unable to pass across the 
cell membrane, and the end result is that viable cells fluoresce. The rationale in using this 
compound to assess cell proliferation was that if cells are able to divide, the fluorescence will 
increase, but if cells are unable to proliferate, no increase in fluorescence will occur. In order 
to determine the concentration of MMC that would arrest cell division in PHDFs 3 
concentrations of MMC (50, 25, and 12.5 µg.ml-1) were selected based on the literature. All 
three concentrations appeared to inhibit the proliferation of the PHDFs, while maintaining 
viability. The same assay was repeated on MSCs, and displayed similar results (all three 
concentrations inhibited cell proliferation and maintained cell viability). The concentration of 
MMC selected to use in downstream assays was 12.5 µg.ml-1 as this was the lowest 
concentration (so least cytotoxic) that inhibited proliferation of both PHDFs and MSCs. 
Whereas MSCs exhibited a typical growth curve, the PHDFs exhibited a delay in growth due to 
the low seeding density used, and did not start proliferating until after day 4, causing the 
atypical growth curve in Figure 5.13. 
The optimum cell number and ratio of PBMCs that generated the highest counts was 
determined using a one way MLR. Ratios of 1:1, 1:10, and 1:100 of responder: stimulator cells 
were selected for testing since in a traditional tissue engineering application, in which MSCs 
are expanded from an allogeneic donor and seeded onto a scaffold prior to implantation, it is 
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likely that the APCs of the host will encounter the MSCs at a high cell density. This scenario 
was recreated in-vitro using ratios of MSCs, in excess of donor PBMCs. 
It was shown that the highest counts were obtained when a ratio of 1:1 responder cells to 
stimulator cells was used. Optimum counts per minute were also obtained when 100,000 total 
cell number per well was used, however, 50,000 total number of cells also showed high counts 
per minute comparable to 100,000 cells. 
The final factor used in the LTA that required determination was the type, and concentration 
of serum used in the complete culture medium. When developing the assay, PBMC cultured in 
medium plus fetal calf serum showed some proliferation. It was hypothesised that the foreign 
proteins (immunogens) in the fetal calf serum might stimulate the PBMCs to proliferate. 
Human AB serum was used as an alternative. The serum from donors of blood group AB 
contains no antibodies to either A or B antigens, and provided a commercial alternative to 
using autologous serum. The serum was heat treated to inactivate the serum complement 
proteins before it was used in the LTA or MLR assays. A comparison between fetal calf serum, 
and human AB serum supplemented medium revealed no significant difference in lymphocyte 
proliferation in unstimulated cultures. However, the positive control counts were significantly 
higher when human serum was used; therefore human AB serum was selected to be used in 
further assays. The effect of serum concentration also was assessed on the proliferation of 
PBMCs. Previously 10% FCS has been used in LTA (Nasef et al., 2009; Wada et al., 2009; 
Prasanna et al., 2010), or 5-10% human serum (Bocelli-Tyndall et al., 2007; Niemeyer et al., 
2007) so LTAs were performed using 2, 5, and 10% (v/v) human serum in complete RPMI 
culture medium.  There was no significant difference between the concentrations of serum 
used, so 10% was chosen for future assays. 
In conclusion the developed LTA used 32 mg.ml-1  PHA as positive control for stimulation, a 
ratio of 1:1 25,000 PBMCs to MSCs, 12.5 mg.ml-1 mitomycin C to mitotically inactivate the 
responder cells, and 10% (v/v) human AB serum in RPMI-1640 complete culture medium. Low 
activity trititiated thymidine was used to determine the incorporation of thymidine into the 
DNA of responder cells. 
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Chapter 6:  ASSESSMENT OF THE IMMUNOGENICITY OF 
MULTIPOTENT MESENCHYMAL STROMAL CELLS USING 
LYMPHOCYTE TRANSFORMATION ASSAYS OVER 21 DAYS 
6.1 INTRODUCTION 
The lymphocyte transformation assay is routinely used to assess the proliferative response of 
peripheral blood mononuclear cells (PBMCs) to antigenic stimulation. In this study the ultimate 
aim was to assess the response of PBMCs to mesenchymal stromal cells (MSCs).  
The immunogenicity of MSCs is controversial. These cells have been reported to be immuno-
privileged and have immunosuppressive properties (Bartholomew et al., 2002; Le Blanc et al., 
2003b; Tse et al., 2003). Given the ability of these cells to differentiate into bone, fat, and 
cartilage cell types (Prockop, 1997; Pittenger et al., 1999; Barry and Murphy, 2004; McGonagle 
and Jones, 2008) and potential applications in tissue engineering, the question regarding the 
immunogenicity of MSCs is important to fully explore in both in-vitro and in-vivo systems. 
The potential application of MSCs for use in tissue engineering has generated a large amount 
of interest, as cells with trilineage potential that would remain immunologically inert after 
allogeneic transplantation would be prime candidates for regenerative medicine applications. 
This would enable donor banks of MSCs to be established and used to populate scaffolds 
before implantation, or used to repopulate scaffolds which are then cultured under 
differentiation conditions to direct cells down the desired lineage, before implantation.  The 
question arises regarding whether tissue engineered constructs based on allogeneic MSCs 
would be accepted by the recipient’s immune system.  
As discussed previously, MSCs have been shown not to stimulate a proliferative response 
when co-cultured with allogeneic lymphocytes. Upon review of the literature, the 
methodology used to investigate the immunogenicity of MSCs has limitations. The assay used 
to demonstrate the immune-privileged nature of MSCs has primarily been the classical 
lymphocyte transformation assay, in which MSCs have been co-cultured with allogeneic 
lymphocytes for up to 7 days (Bartholomew et al., 2002; Tse et al., 2003; Niemeyer et al., 2007; 
Oh et al., 2008; Suva et al., 2008). MSCs do not express co-stimulatory molecules CD40, CD80, 
or CD86, and lack expression of cell surface MHC class-II (Le Blanc and Ringden, 2007). Hence 
the lack of stimulation when MSCs are co-cultured with lymphocytes for up to 7 days is 
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unsurprising, as in all likelihood MSCs will not be recognised via the direct pathway of 
allorecognition. In theory however, MSCs should have the capacity to be recognised by the 
indirect and semi-direct pathways of allorecognition in which alloantigens are taken up or 
transferred to recipient antigen presenting cells and presented to recipient CD4+ T-cells. The 
CD4+ T-cells would then be able to recognise the presented antigen as ‘foreign’, and 
proliferate in response to this. This proliferation would be measurable via the incorporation of 
tritiated thymidine into the T-cell DNA.  
It was hypothesized that, by extending the culture time of the LTA it would be possible to 
measure indirect and/or semi-direct antigen presentation, and that this would give a clearer 
indication of the immunogenicity of MSCs. Primary dermal human fibroblasts were used as a 
control cell type due to their mesenchymal lineage and availability. 
In the previous chapter methods for carrying out the LTA were developed and the following 
parameters established. 
 32 mg.ml-1  PHA as a positive control for cell stimulation 
 PBMCs (25,000) and MSCs (25,000) cultured in a 1:1 ratio of responder: stimulator 
cells. 
 Mitomycin C treatment (12.5 mg.ml-1) for one hour to arrest mitosis of MSCs.  
 Human AB serum (10% (v/v)) in complete culture medium. 
 U-shaped, uncoated 96 well tissue culture plates. 
In addition to this methodology developed in the previous chapter, it was decided to culture 
the MSCs/PHDFs with PBMCs for 3, 5, 7, 12, 16, and 21 days before spiking with low activity 
tritiated thymidine for 16 hours prior to harvesting. 
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6.1.1 AIMS AND OBJECTIVES 
The aims of this chapter were to assess the capacity of human bone marrow derived MSCs for 
stimulation of allogeneic lymphocytes in the LTA over an extended culture period of 21 days. 
There are two main objectives: 
 To determine the lymphocyte transformation response of PBMCs from six donors 
stimulated by MSCs from 4 unrelated donors in LTA assays for up to 21 days. 
 To compare the lymphocyte transformation response of PBMCs from six donors when 
stimulated with MSCs and PHDFs.
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6.2 MATERIALS AND METHODS 
6.2.1 THE LYMPHOCYTE TRANSFORMATION ASSAY 
Reagents 
Phytohaemagglutinin (1 mg.ml-1 in dH2O) 
Phosphate buffered saline 
Hy-Q-Tase™ cell detachment solution  
NH expansion medium (Section 5.2.1) 
Transport medium (Section 5.2.1) 
Complete medium (Section 5.2.1) 
Mitomycin C (1 mg.ml-1 in dH2O) 
Method 
Bone marrow 1-4 MSCs were cultured in NH Expansion medium up to passage 6, at 37°C in a 
humidified atmosphere containing 5% (v/v) CO2 in air. Every 3 days, medium was removed and 
replaced with fresh. Cells were passaged as previously described in section 3.2.2. 
Multipotent mesenchymal stromal cells were cultured in NH expansion medium until confluent 
in 4 T75 tissue culture flasks. When confluency was reached the medium was removed from 
the flask and the cells were washed with 10 ml PBS without Ca2+ or Mg2+. PBS was removed 
and 2 ml Hy-Q-Tase™ was added to the flask, before incubation at 37°C in an atmosphere of 
5% (v/v) CO2 until cells had detached from the surface of the flask (approx. 10 minutes). When 
cells had detached the resulting cell suspension was resuspended in 5 ml complete medium, 
and 62.5µl MMC stock was added to give a final concentration of 12.5 µg.ml-1. Following 1 
hour incubation the cells were centrifuged at 150 g for 10 minutes, the mitomycin C medium 
removed, and cells were washed twice with 10ml complete medium. Finally MSCs were 
resuspended in 5ml complete medium before counting using trypan dye exclusion as described 
in section 2.3.7. The MSCs from BM 1-4 (25,000) were dispensed into wells of 6 uncoated U-
bottom shaped 96 well tissue culture plates as shown in Figure 6.1 (24 plates in total). 
Primary human dermal fibroblasts were cultured in M-DMEM at 37°C in a humidified 
atmosphere containing 5% (v/v) CO2 in air. Every 3 days, medium was removed and replaced 
with fresh. Cells were passaged as previously described in section 3.2.3, and 25,000 were 
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dispensed into the well of 6 uncoated U-bottom shaped 96 well tissue culture plates as shown 
in Figure 6.2, using the same method as the MSCs. 
Peripheral blood mononuclear cells were isolated from 6 healthy volunteer’s human peripheral 
blood as described in section 5.2.1. Following isolation PBMCs were counted using trypan dye 
exclusion as described in section 2.3.7. These cells (25,000) were dispensed into the wells of 24 
uncoated U-bottom shaped 96 well tissue culture plates as shown in Figure 6.1. 
The negative control for proliferation was responder PBMCs grown in complete medium only, 
and positive control was responder PBMCs stimulated with 32 µg.ml-1 PHA. 
Phytohaemagglutinin stock (64 µl) was diluted in 1 ml complete RPMI-1640 medium, and 
added to wells at a 1:1 ratio of PHA to PBMCs in medium to achieve a final concentration of 32 
µg.ml-1 in the wells shown in Figure 6.1. 
Plates were cultured at 37°C in an atmosphere of 5% (v/v) CO2 in air. Sixteen hours before the 
desired timepoint each well of the plate was spiked with 10 µl of low activity tritiated 
thymidine stock and cultured at 37°C in an atmosphere of 5% (v/v) CO2 in air overnight. Sixteen 
hours post spiking the cells were harvested onto glass fibre filter plates using a FilterMate™ 
(Perkin Elmer) cell harvester, before 35 µl MicroScint™ was added and radioactive counts were 
measured on a TopCount scintillation counter as described in section 5.2.3. Plates were 
harvested on days 3, 5, 7, 12, 16 and 21. On day 12, 100 µl of the complete medium in the 
wells was removed from the remaining plates, and replaced with 100 µl of fresh complete 
medium.  
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Figure 6.1:  Diagram of the 96 well plate experimental wells used to determine the stimulation of peripheral blood mononuclear cells when cultured in 
complete medium only (negative control for stimulation), in the presence of PHA (positive control for stimulation), and co-cultured with mitomycin C 
treated MSCs. MSCs in complete medium only are also used as a negative control for proliferation. Donor 1, 2, and 3 represent the donor PBMCs. Plates 
were also prepared using the same format with PBMCs from donors 4, 5, and 6. 
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Figure 6.2: Diagram of the 96 well plate experimental wells used to determine the stimulation of peripheral blood mononuclear cells when cultured in 
complete medium only (negative control for stimulation), in the presence of PHA (positive control for stimulation), and co-cultured with mitomycin C 
treated PHDFs, and MSCs. Donor 1, 2, and 3 represent the donor PBMCs. Plates were also prepared using the same format with PBMCs from donors 4, 5, and 
6. 
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6.2.2 THE LYMPHOCYTE TRANSFORMATION ASSAY CO-CULTURING PERIPHERAL BLOOD 
MONONUCLEAR CELLS AND MSCS IN V-BOTTOM UNCOATED 96 WELL TISSUE CULTURE 
PLATES 
In addition to performing the LTA in uncoated U-bottom 96 well tissue culture plates, the same 
methodology as described in section 6.2.1 was used, but uncoated V-bottom plates were used 
as an alternative. 
6.2.3 ANALYSIS OF DATA 
Data (counts per minute) from the lymphocyte transformation assays was log10 transformed 
and is presented as log10 counts per minute ± 95% confidence limits. The log10 counts per 
minute at each timepoint (day 3, 5, 7, 12, 16, and 21) were compared by one-way analysis of 
variance and the MSD calculated using the T-method (p<0.05). Data was also used to calculate 
the stimulation indices from the following equation: 
SI =   Average counts per minute PBMCs + MSCs (or PHDFs)    
         Average counts per minute of PBMCs cultured alone 
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6.3 RESULTS 
6.3.1 THE CO-CULTURE OF MSCS AND PHDFS WITH PBMCS IN THE LYMPHOCYTE 
TRANSFORMATION ASSAY 
Peripheral blood mononuclear cells were isolated from the blood of 6 healthy volunteers. 
These cells were co-cultured with MSCs isolated from 4 donor bone marrows. The counts per 
minute were log10 transformed to conform to the requirements of analysis of variance 
(variances shown to be homogeneous after log10 transformation). The counts obtained for the 
positive control cultures with PHA were omitted from analyses since these were included to 
ensure that the assays were valid (PBMCs were functioning by responding to the mitogen) and 
it was not part of the experimental design to compare the level of response of the MSCs or 
PHDFs to the level of response to the mitogen.  
The results are presented in Figures 6.3-6.50. The results have been presented as both the 
log10 counts per minute for PBMCs at each time point and the stimulation indices at each time 
point for each donor PBMC vs each bone marrow derived MSC and PHDF. This allowed 
comparison of the data presented in each form. 
6.3.1.1 BM1 
When PBMCs from donor 1 were cultured with PHA, maximal counts were observed on days 3-
5 after which the response declined over the remaining 21 day culture period. This response 
observed when PBMCs were stimulated with PHA was observed for all PBMC donors in all BM 
1-4 cultures. When PBMCs from donor 1 were cultured with BM1 MSCs, significantly higher 
counts were recorded on days 3, 5, 16, and 21 compared to the unstimulated PBMCs (p<0.05 
ANOVA). When PBMCs from donor 1 were cultured with PHDFs significantly higher counts 
were recorded only on day 3 compared to unstimulated PBMCs (Figure 6.3; p<0.05, ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.4. This showed 
stimulation indices above 3 for PHA stimulated PBMCs from day 3, demonstrating the ability of 
the PBMCs to proliferate. The proliferation of PBMCs was repeated for all 3 PBMC donors upon 
stimulation with PHA. Stimulation indices above 3 were observed for PBMCs from donor 1 in 
response to BM1 MSCs at days 3 (SI of 3.18), 5 (SI of 3.83), 7 (SI of 4.38), 12 (SI of 12.31), 16 (SI 
of 12.95), and 21 (SI of 3.88). For PBMC from donor 1 in response to PHDFs, a stimulation index 
of above 3 was recorded at days 3 (SI of 3.27) and 12 (SI of 10.66). 
When PBMCs from donor 2 were cultured with BM1 MSCs, significantly higher counts were 
recorded on days 3, 5, 12, 16, and 21 compared to the unstimulated PBMCs (p<0.05 ANOVA). 
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When PBMCs from donor 2 were cultured with PHDFs significantly higher counts were 
recorded on days 3, 5, and 7 compared to unstimulated PBMCs (Figure 6.5; p<0.05, ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.6. This showed 
stimulation indices above 3 for PBMCs from donor 2 in response to BM1 MSCs at days 5 (SI of 
5.12), 7 (SI of 3.30), 12 (SI of 30.80), 16 (SI of 19.05), and 21 (SI of 7.42). For PBMC from donor 
2 in response to PHDFs, a stimulation index of above 3 was recorded at days 5 (SI of 4.07), 7 (SI 
of 10.45), 12 (SI of 14.87), 16 (SI of 5.93), and 21 (SI of 10.03). 
When PBMCs from donor 3 were cultured with BM1 MSCs, significantly higher counts were 
recorded on days 3, 5, 12, 16, and 21 compared to the unstimulated PBMCs (p<0.05 ANOVA). 
When PBMCs from donor 3 were cultured with PHDFs significantly higher counts were also 
recorded on days 3, 5, 12, 16, and 21 compared to unstimulated PBMCs (Figure 6.7; p<0.05, 
ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.8. This showed 
stimulation indices above 3 for PBMCs from donor 3 in response to BM1 MSCs at days 5 (SI of 
6.43), 7 (SI of 20.60), 12 (SI of 23.07), 16 (SI of 5.88), and 21 (SI of 11.15). For PBMC from donor 
3 in response to PHDFs, a stimulation index of above 3 was recorded at days 3 (SI of 3.66), 5 (SI 
of 3.63), 7 (SI of 15.61), 12 (SI of 12.99), 16 (SI of 6.28), and 21 (SI of 7.57). 
When PBMCs from donor 4 were cultured with BM1 MSCs, significantly higher counts were 
recorded on days 3, 5, and 13 compared to the unstimulated PBMCs (p<0.05 ANOVA). When 
PBMCs from donor 4 were cultured with PHDFs significantly higher counts were also recorded 
on days 3, 5, and 13 compared to unstimulated PBMCs (Figure 6.9; p<0.05, ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.10. This showed 
stimulation indices above 3 for PBMCs from donor 4 in response to BM1 MSCs at days 13 (SI of 
33.40), and 18 (SI of 7.00). For PBMC from donor 4 in response to PHDFs, a stimulation index of 
above 3 was recorded at day 13 (SI of 16.28). 
When PBMCs from donor 5 were cultured with with BM1 MSCs, significantly higher counts 
were recorded on days 3, 5, and 18 compared to the unstimulated PBMCs (p<0.05 ANOVA). 
When PBMCs from donor 5 were cultured with PHDFs significantly higher counts were also 
recorded on days 3, 5, and 18 compared to unstimulated PBMCs (Figure 6.11; p<0.05, ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.12. This showed no 
stimulation indices above 3 for PBMCs from donor 5 in response to BM1. For PBMC from 
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donor 5 in response to PHDFs, a stimulation index of above 3 was recorded at days 3 (SI of 
3.27), 13 (SI of 4.30), and 18 (SI of 3.12). 
When PBMCs from donor 6 were cultured with BM1 MSCs, significantly higher counts were 
recorded on days 3 and 5 compared to the unstimulated PBMCs (p<0.05 ANOVA). When 
PBMCs from donor 6 were cultured with PHDFs significantly higher counts were also recorded 
on days 3 and 5 compared to unstimulated PBMCs (Figure 6.13; p<0.05, ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.14. This showed 
stimulation indices above 3 for PBMCs from donor 6 in response to BM1 MSCs at days 3 (SI of 
3.31), 5 (SI of 3.64), and 13 (SI of 6.28). For PBMC from donor 6 in response to PHDFs, a 
stimulation index of above 3 was recorded at days 3 (SI of 4.70) and 5 (SI of 6.40).  
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Figure 6.3: Counts per minute of donor 1 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), or with 
donor BM1 MSCs or PHDFs for 21 days. Data is expressed as the mean log10 counts per 
minute (n=3-4) ± 95% confidence limits. Data was analysed by one-way analysis of 
variance at each time point. * indicates significant differences (p<0.05) compared to the 
PBMCs cultured in medium alone as determined by the T-method. 
Figure 6.4: The stimulation index (SI) of donor 1 PBMCs cultured with PHA (positive control 
for stimulation), or with donor BM1 MSCs or PHDFs, for 21 days. The red line intersects the 
y-axis at 3, and values above this height (SI>3) are considered positive stimulation indices. 
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Figure 6.6: The stimulation index (SI) of donor 2 PBMCs cultured with PHA (positive control 
for stimulation), or with donor BM1 MSCs or PHDFs, for 21 days. The red line intersects the 
y-axis at 3, and values above this height (SI>3) are considered positive stimulation indices. 
Figure 6.5: Counts per minute of donor 2 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), or with 
donor BM1 MSCs or PHDFs for 21 days. Data is expressed as the mean log10 counts per 
minute (n=3-4) ± 95% confidence limits. Data was analysed by one-way analysis of variance 
at each time point. * indicates significant differences (p<0.05) compared to the PBMCs 
cultured in medium alone as determined by the T-method. 
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Figure 6.8: The stimulation index (SI) of donor 3 PBMCs cultured with PHA (positive 
control for stimulation), or with donor BM1 MSCs or PHDFs, for 21 days. The red line 
intersects the y-axis at 3, and values above this height (SI>3) are considered positive 
stimulation indices. 
Figure 6.7: Counts per minute of donor 3 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), or with 
donor BM1 MSCs or PHDFs for 21 days. Data is expressed as the mean log10 counts per 
minute (n=3-4) ± 95% confidence limits. Data was analysed by one-way analysis of 
variance at each time point. * indicates significant differences (p<0.05) compared to the 
PBMCs cultured in medium alone as determined by the T-method. 
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Figure 6.10: The stimulation index (SI) of donor 4 PBMCs cultured with PHA (positive 
control for stimulation), or with donor BM1 MSCs or PHDFs, for 21 days. The red line 
intersects the y-axis at 3, and values above this height (SI>3) are considered positive 
stimulation indices. 
Figure 6.9: Counts per minute of donor 4 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), or with 
donor BM1 MSCs or PHDFs for 21 days. Data is expressed as the mean log10 counts per 
minute (n=3-4) ± 95% confidence limits. Data was analysed by one-way analysis of variance at 
each time point. * indicates significant differences (p<0.05) compared to the PBMCs cultured 
in medium alone as determined by the T-method. 
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Figure 6.12: The stimulation index (SI) of donor 5 PBMCs cultured with PHA (positive 
control for stimulation), or with donor BM1 MSCs or PHDFs, for 21 days. The red line 
intersects the y-axis at 3, and values above this height (SI>3) are considered positive 
stimulation indices. 
Figure 6.11: Counts per minute of donor 5 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), or with 
donor BM1 MSCs or PHDFs for 21 days. Data is expressed as the mean log10 counts per 
minute (n=3-4) ± 95% confidence limits. Data was analysed by one-way analysis of variance at 
each time point. * indicates significant differences (p<0.05) compared to the PBMCs cultured 
in medium alone as determined by the T-method. 
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Figure 6.14: The stimulation index (SI) of donor 6 PBMCs cultured with PHA (positive 
control for stimulation), or with donor BM1 MSCs or PHDFs, for 21 days. The red line 
intersects the y-axis at 3, and values above this height (SI>3) are considered positive 
stimulation indices. 
Figure 6.13: Counts per minute of donor 6 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), or with 
donor BM1 MSCs or PHDFs for 21 days. Data is expressed as the mean log10 counts per 
minute (n=3-4) ± 95% confidence limits. Data was analysed by one-way analysis of variance 
at each time point. * indicates significant differences (p<0.05) compared to the PBMCs 
cultured in medium alone as determined by the T-method. 
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6.3.1.2 BM2 
When PBMCs from donor 1 were cultured with BM2 MSCs, significantly higher counts were 
recorded on days 3, 5, 12, and 21 compared to the unstimulated PBMCs (p<0.05 ANOVA). 
When MSCs from BM2 were cultured in complete medium alone there was no difference in 
counts compared to unstimulated PBMCs (Figure 6.15; p<0.05, ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.16. This showed 
stimulation indices above 3 for PBMCs from donor 1 in response to BM2 MSCs at days 5 (SI of 
3.45), 7 (SI of 11.92), 12 (SI of 4.69), 16 (SI of 14.96), and 21 (SI of 4.00). For BM2 MSCs 
cultured in medium alone no stimulation indices of above 3 were recorded. 
When PBMCs from donor 2 were cultured with BM2 MSCs, significantly higher counts were 
recorded on days 5, 12, and 16 compared to the unstimulated PBMCs (p<0.05 ANOVA). When 
MSCs from BM2 were cultured in complete medium alone there was no difference in counts 
compared to unstimulated PBMCs (Figure 6.17; p<0.05, ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.18. This showed 
stimulation indices above 3 for PBMCs from donor 2 in response to BM2 MSCs at days 12 (SI of 
5.87) and 16 (SI of 6.02). For BM2 MSCs cultured in medium alone no stimulation indices of 
above 3 were recorded. 
When PBMCs from donor 3 were cultured with BM2 MSCs, significantly higher counts were 
recorded on days 3 and 7 compared to the unstimulated PBMCs (p<0.05 ANOVA). When MSCs 
from BM2 were cultured in complete medium alone there was no difference in counts 
compared to unstimulated PBMCs (Figure 6.19; p<0.05, ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.20. This showed 
stimulation indices above 3 for PBMCs from donor 3 in response to BM2 MSCs at days 5 (SI of 
3.64), 12 (SI of 4.04), 16 (SI of 3.30) and 21 (SI of 7.91). For BM2 MSCs cultured in medium 
alone no stimulation indices of above 3 were recorded. 
When PBMCs from donor 4 were cultured with BM2 MSCs, significantly higher counts were 
recorded on days 3, 5 and 7 compared to the unstimulated PBMCs (p<0.05 ANOVA). When 
MSCs from BM2 were cultured in complete medium alone significantly higher counts were 
recorded on days 3 and 5 compared to the unstimulated PBMCs (Figure 6.21; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.22. This showed 
stimulation indices above 3 for PBMCs from donor 4 in response to BM2 MSCs at days 7 (SI of 
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13.04), 12 (SI of 5.48), 16 (SI of 36.00)  and 21 (SI of 7.42). For BM2 MSCs cultured in medium 
alone a stimulation index above 3 was recorded on day 5 (SI of 3.29). 
When PBMCs from donor 5 were cultured with BM2 MSCs, significantly higher counts were 
recorded on days 3, 5, 7 and 21 compared to the unstimulated PBMCs (p<0.05 ANOVA). When 
MSCs from BM2 were cultured in complete medium alone significantly higher counts were 
recorded on days 3 and 5 compared to the unstimulated PBMCs (Figure 6.23; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.24. This showed 
stimulation indices above 3 for PBMCs from donor 5 in response to BM2 MSCs at days 3 (SI of 
3.87), 5 (SI of 5.34), 7 (SI of 9.33), 12 (SI of 8.57), 16 (SI of 6.62) and 21 (SI of 6.95). For BM2 
MSCs cultured in medium alone stimulation indices above 3 were recorded on day 3 (SI of 
3.23) and 5 (SI of 5.87). 
When PBMCs from donor 6 were cultured with BM2 MSCs, significantly higher counts were 
recorded on days 3 and 5 compared to the unstimulated PBMCs (p<0.05 ANOVA). When MSCs 
from BM2 were cultured in complete medium alone significantly higher counts were recorded 
on days 3 and 5 compared to the unstimulated PBMCs (Figure 6.25; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.26. This showed 
stimulation indices above 3 for PBMCs from donor 6 in response to BM2 MSCs at days 3 (SI of 
3.10) and 5 (SI of 4.72). For BM2 MSCs cultured in medium alone a stimulation index above 3 
was recorded on day 5 (SI of 8.43). 
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Figure 6.16: The stimulation index (SI) of donor 1 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM2 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height (SI>3) 
are considered positive stimulation indices. 
Figure 6.15: Counts per minute of donor 1 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with donor 
BM2 MSCs or MSCs cultured in complete medium alone for 21 days. Data is expressed as the 
mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was analysed by one-way 
analysis of variance at each time point. * indicates significant differences (p<0.05) compared 
to the PBMCs cultured in medium alone as determined by the T-method. 
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Figure 6.17: Counts per minute of donor 2 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with donor 
BM2 MSCs or MSCs cultured in complete medium alone for 21 days. Data is expressed as the 
mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was analysed by one-way 
analysis of variance at each time point. * indicates significant differences (p<0.05) compared 
to the PBMCs cultured in medium alone as determined by the T-method. 
Figure 6.18: The stimulation index (SI) of donor 2 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM2 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height (SI>3) 
are considered positive stimulation indices. 
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Figure 6.19: Counts per minute of donor 3 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM2 MSCs or MSCs cultured in complete medium alone for 21 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was 
analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined by 
the T-method. 
Figure 6.20: The stimulation index (SI) of donor 3 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM2 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
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Figure 6.21: Counts per minute of donor 4 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM2 MSCs or MSCs cultured in complete medium alone for 21 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was 
analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined by 
the T-method. 
Figure 6.22: The stimulation index (SI) of donor 4 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM2 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
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Figure 6.23: Counts per minute of donor 5 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM2 MSCs or MSCs cultured in complete medium alone for 21 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was 
analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined by 
the T-method. 
Figure 6.24: The stimulation index (SI) of donor 5 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM2 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
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Figure 6.26: The stimulation index (SI) of donor 6 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM2 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height (SI>3) 
are considered positive stimulation indices. 
Figure 6.25: Counts per minute of donor 6 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with donor 
BM2 MSCs or MSCs cultured in complete medium alone for 21 days. Data is expressed as the 
mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was analysed by one-way 
analysis of variance at each time point. * indicates significant differences (p<0.05) compared 
to the PBMCs cultured in medium alone as determined by the T-method. 
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6.3.1.3 BM3 
When PBMCs from donor 1 were cultured with BM3 MSCs, significantly higher counts were 
recorded on days 3, 5 and 21 compared to the unstimulated PBMCs (p<0.05 ANOVA). When 
MSCs from BM3 were cultured in complete medium alone significantly higher counts were 
recorded on day 21 compared to the unstimulated PBMCs (Figure 6.27; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.28. This showed 
stimulation indices above 3 for PBMCs from donor 1 in response to BM3 MSCs at days 5 (SI of 
3.26), 16 (SI of 11.94) and 21 (SI of 3.15). For BM3 MSCs cultured in medium alone stimulation 
indices above 3 were recorded on days 16 (SI of 4.71) and 21 (SI of 3.27). 
When PBMCs from donor 2 were cultured with BM3 MSCs, significantly higher counts were 
recorded on days 3, 5 and 21 compared to the unstimulated PBMCs (p<0.05 ANOVA). When 
MSCs from BM3 were cultured in complete medium alone there was no difference in counts 
compared to the unstimulated PBMCs (Figure 6.29; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.30. This showed no 
stimulation indices above 3 for PBMCs from donor 2 in response to BM3 MSCs. For BM3 MSCs 
cultured in medium alone no stimulation indices above 3 were recorded. 
When PBMCs from donor 3 were cultured with BM3 MSCs, significantly higher counts were 
recorded on days 3, 5, 7 and 21 compared to the unstimulated PBMCs (p<0.05 ANOVA). When 
MSCs from BM3 were cultured in complete medium alone significantly higher counts were 
recorded on day 12 compared to the unstimulated PBMCs (Figure 6.31; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.32. This showed 
stimulation indices above 3 for PBMCs from donor 3 in response to BM3 MSCs at days 3 (SI of 
3.02), 5 (SI of 3.43) and 21 (SI of 3.77). For BM3 MSCs cultured in medium alone stimulation 
indices above 3 were recorded on day 16 (SI of 4.56). 
When PBMCs from donor 4 were cultured with BM3 MSCs, significantly higher counts were 
recorded on days 3 and 5 compared to the unstimulated PBMCs (p<0.05 ANOVA). When MSCs 
from BM3 were cultured in complete medium alone significantly higher counts were recorded 
on day 3 compared to the unstimulated PBMCs (Figure 6.33; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.34. This showed 
stimulation indices above 3 for PBMCs from donor 4 in response to BM3 MSCs at days 3 (SI of 
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3.79), 7 (SI of 6.24), 12 (SI of 4.71) and 16 (SI of 4.78). For BM3 MSCs cultured in medium alone 
no stimulation indices above 3 were recorded. 
When PBMCs from donor 5 were cultured with BM3 MSCs, significantly higher counts were 
recorded on days 3 and 5 compared to the unstimulated PBMCs (p<0.05 ANOVA). When MSCs 
from BM3 were cultured in complete medium alone significantly higher counts were recorded 
on days 3 and 5 compared to the unstimulated PBMCs (Figure 6.35; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.36. This showed 
stimulation indices above 3 for PBMCs from donor 5 in response to BM3 MSCs at days 5 (SI of 
3.41), 16 (SI of 19.15) and 21 (SI of 9.87). For BM3 MSCs cultured in medium alone no 
stimulation indices above 3 were recorded. 
When PBMCs from donor 6 were cultured with BM3 MSCs, significantly higher counts were 
recorded on days 3, 5 and 21 compared to the unstimulated PBMCs (p<0.05 ANOVA). When 
MSCs from BM3 were cultured in complete medium alone significantly higher counts were 
recorded on days 3 and 5 compared to the unstimulated PBMCs (Figure 6.37; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.38. This showed 
stimulation indices above 3 for PBMCs from donor 6 in response to BM3 MSCs at days 5 (SI of 
3.18) and 16 (SI of 4.77). For BM3 MSCs cultured in medium alone no stimulation indices above 
3 were recorded. 
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Figure 6.27: Counts per minute of donor 1 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM3 MSCs or MSCs cultured in complete medium alone for 21 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data 
was analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined 
by the T-method. 
Figure 6.28: The stimulation index (SI) of donor 1 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM3 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
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Figure 6.29: Counts per minute of donor 2 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM3 MSCs or MSCs cultured in complete medium alone for 21 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data 
was analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined 
by the T-method. 
Figure 6.30: The stimulation index (SI) of donor 2 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM3 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
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Figure 6.31: Counts per minute of donor 3 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM3 MSCs or MSCs cultured in complete medium alone for 21 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data 
was analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined 
by the T-method. 
Figure 6.32: The stimulation index (SI) of donor 3 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM3 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
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Figure 6.34: The stimulation index (SI) of donor 4 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM3 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
Figure 6.33: Counts per minute of donor 4 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM3 MSCs or MSCs cultured in complete medium alone for 21 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data 
was analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined 
by the T-method. 
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Figure 6.35: Counts per minute of donor 5 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM3 MSCs or MSCs cultured in complete medium alone for 21 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was 
analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined by 
the T-method. 
Figure 6.36: The stimulation index (SI) of donor 5 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM3 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
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Figure 6.37: Counts per minute of donor 6 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM3 MSCs or MSCs cultured in complete medium alone for 21 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data 
was analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined 
by the T-method. 
Figure 6.38: The stimulation index (SI) of donor 6 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM3 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
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6.3.1.4 BM4 
When PBMCs from donor 1 were cultured with BM4 MSCs, significantly higher counts were 
recorded on days 3, 5, 7, 12, 16 and 21 compared to the unstimulated PBMCs (p<0.05 ANOVA). 
When MSCs from BM4 were cultured in complete medium alone there was no difference in 
counts compared to the unstimulated PBMCs (Figure 6.39; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.40. This showed 
stimulation indices above 3 for PBMCs from donor 1 in response to BM4 MSCs at days 5 (SI of 
6.89), 7 (SI of 7.53), 12 (SI of 11.69), 16 (SI of 4.20) and 21 (SI of 6.36). For BM4 MSCs cultured 
in medium alone no stimulation indices above 3 were recorded. 
When PBMCs from donor 2 were cultured with BM4 MSCs, significantly higher counts were 
recorded on days 3, 5 and 21 compared to the unstimulated PBMCs (p<0.05 ANOVA). When 
MSCs from BM4 were cultured in complete medium alone there was no difference in counts 
compared to the unstimulated PBMCs (Figure 6.41; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.42. This showed 
stimulation indices above 3 for PBMCs from donor 2 in response to BM4 MSCs at day 16 (SI of 
3.11). For BM4 MSCs cultured in medium alone no stimulation indices above 3 were recorded. 
When PBMCs from donor 3 were cultured with BM4 MSCs, significantly higher counts were 
recorded on days 3, 5 and 12 compared to the unstimulated PBMCs (p<0.05 ANOVA). When 
MSCs from BM4 were cultured in complete medium alone significantly higher counts were 
recorded on day 3 compared to the unstimulated PBMCs (Figure 6.43; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.44. This showed 
stimulation indices above 3 for PBMCs from donor 3 in response to BM4 MSCs at days 3 (SI of 
3.25), 5 (SI of 3.14), 7 (SI of 8.66), 12 (SI of 13.50) and 16 (SI of 14.40). For BM4 MSCs cultured 
in medium alone no stimulation indices above 3 were recorded. 
When PBMCs from donor 4 were cultured with BM4 MSCs, significantly higher counts were 
recorded on days 3, 5 and 7 compared to the unstimulated PBMCs (p<0.05 ANOVA). When 
MSCs from BM4 were cultured in complete medium alone significantly higher counts were 
recorded on days 3 and 5 compared to the unstimulated PBMCs (Figure 6.45; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.46. This showed 
stimulation indices above 3 for PBMCs from donor 4 in response to BM4 MSCs at days 3 (SI of 
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3.44), 5 (SI of 5.83), 7 (SI of 6.88), 12 (SI of 6.17), 16 (SI of 15.08) and 21 (SI of 5.77). For BM4 
MSCs cultured in medium alone a stimulation index above 3 was recorded on day 3 (SI of 3.32). 
When PBMCs from donor 5 were cultured with BM4 MSCs, significantly higher counts were 
recorded on days 3, 5, 7 and 21 compared to the unstimulated PBMCs (p<0.05 ANOVA). When 
MSCs from BM4 were cultured in complete medium alone significantly higher counts were 
recorded on days 3 and 5 compared to the unstimulated PBMCs (Figure 6.47; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.48. This showed 
stimulation indices above 3 for PBMCs from donor 5 in response to BM4 MSCs at days 3 (SI of 
3.40), 5 (SI of 4.31), 7 (SI of 9.39), 16 (SI of 14.85) and 21 (SI of 9.11). For BM4 MSCs cultured in 
medium alone no stimulation indices above 3 were recorded. 
When PBMCs from donor 6 were cultured with BM4 MSCs, significantly higher counts were 
recorded on days 3 and 5 compared to the unstimulated PBMCs (p<0.05 ANOVA). When MSCs 
from BM4 were cultured in complete medium alone significantly higher counts were also 
recorded on days 3 and 5 compared to the unstimulated PBMCs (Figure 6.49; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.50. This showed 
stimulation indices above 3 for PBMCs from donor 6 in response to BM4 MSCs at days 3 (SI of 
3.06), 5 (SI of 3.18) and 7 (SI of 4.16). For BM4 MSCs cultured in medium alone no stimulation 
indices above 3 were recorded. 
A summary table of the maximal stimulation indices observed when MSCs from BM1-4 were 
cultured with PBMCs from donor 1-6 is shown in Table 6.1. When SI’s are grouped together 
and displayed in tabular format, it appears that donor 6 responses to MSCs and to PHDFs are 
relatively low when compared to responses from the other PBMC donors (SI <6.5). Other 
PBMC donors demonstrate SI’s of greater than 14. BM 1-4 responses appear to be variable 
throughout the PBMC donors, with strong stimulation observed with certain donors, while 
relatively low SI’s are observed with others.  
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Figure 6.39: Counts per minute of donor 1 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM4 MSCs or MSCs cultured in complete medium alone for 21 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was 
analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined by 
the T-method. 
Figure 6.40: The stimulation index (SI) of donor 1 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM4 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
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Figure 6.41: Counts per minute of donor 2 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM4 MSCs or MSCs cultured in complete medium alone for 21 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data 
was analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined 
by the T-method. 
Figure 6.42: The stimulation index (SI) of donor 2 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM4 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
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Figure 6.43: Counts per minute of donor 3 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM4 MSCs or MSCs cultured in complete medium alone for 21 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data 
was analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined 
by the T-method. 
Figure 6.44: The stimulation index (SI) of donor 3 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM4 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
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Figure 6.45: Counts per minute of donor 4 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM4 MSCs or MSCs cultured in complete medium alone for 21 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was 
analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined by 
the T-method. 
Figure 6.46: The stimulation index (SI) of donor 4 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM4 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
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Figure 6.47: Counts per minute of donor 5 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM4 MSCs or MSCs cultured in complete medium alone for 21 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data 
was analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined 
by the T-method. 
Figure 6.48: The stimulation index (SI) of donor 5 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM4 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
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Figure 6.49: Counts per minute of donor 6 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM4 MSCs or MSCs cultured in complete medium alone for 21 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data 
was analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined 
by the T-method. 
Figure 6.50: The stimulation index (SI) of donor 6 PBMCs cultured with PHA (positive 
control for stimulation), with donor BM4 MSCs, or MSCs cultured in complete medium 
alone, for 21 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
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Table 6.2: Summary table of the PHDFs and MSCs (BM1-4) stimulating PBMCs (donors 1-6) with a positive stimulation index (>3), showing 
the maximum SI, and day of maximal stimulation. Green cell colour represents positive SI value, and red represents no significant 
stimulation recorded on days 3-21 of culture. 
  Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 
PHDFs 10.66 
Day 12 
14.87 
Day 12 
15.61 
Day 7 
16.28 
Day 13 
4.30 
Day 13 
6.40 
Day 5 
BM1 12.95 
Day 16 
30.80 
Day 12 
23.07 
Day 12 
33.40 
Day 13 
- 6.28 
Day 13 
BM2 14.96 
Day 16 
6.02 
Day 16 
7.91 
Day 21 
36.00 
Day 16 
9.33 
Day 7 
4.72 
Day 5 
BM3 11.69 
Day 16 
- 3.77 
Day 21 
7.48 
Day 16 
19.15 
Day 16 
4.77 
Day 16 
BM4 11.69 
Day 12 
3.10 
Day 16 
14.40 
Day 16 
15.08 
Day 16 
14.85 
Day 16 
4.16 
Day 7 
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6.3.2 THE CO-CULTURE OF MSCS WITH PBMCS IN THE LYMPHOCYTE TRANSFORMATION ASSAY 
PERFORMED IN 96 WELL UNCOATED V-BOTTOM TISSUE CULTURE PLATES 
The data presented in the previous sections indicated that overall, the MSCs were capable of 
stimulating PBMCs in the extended duration lymphocyte transformation assay. However, at 
time periods greater than 7 days the counts showed a high degree of variability as indicated by 
the large error bars (in Figures 6.45, 6.47 and 6.49 for example). It was though that this might 
be due to the culture conditions not being ideal and that culture in V-bottomed plates might 
provide more favourable conditions. Hence the experiments with PBMCs from the previous 
healthy donors (1-3) and MSCs from bone marrow donors BM1, 2, and 4 were repeated using 
V-bottomed 96 well tissue culture plates.  
6.3.2.1 BM1 
When PBMCs from donor 1 were cultured with PHA, maximal counts were observed on days 3-
5 after which the response declined over the remaining 16 day culture period. This trend of 
PHA stimulation was observed throughout all the PBMC donors and in all BM MSC cultures. 
When PBMCs from donor 1 were cultured with BM1 MSCs, significantly higher counts were 
recorded on day 3 compared to the unstimulated PBMCs (p<0.05 ANOVA). When MSCs from 
BM1 were cultured in complete medium alone significantly higher counts were not recorded 
compared to the unstimulated PBMCs (Figure 6.51; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.52. This showed 
stimulation indices above 3 for PHA stimulated PBMCs from day 3, demonstrating the ability of 
the PBMCs to proliferate. The proliferation of PBMCs was repeated for all 3 PBMC donors upon 
stimulation with PHA. Stimulation indices above 3 were observed for PBMCs from donor 1 in 
response to BM1 MSCs at day 3 (SI of 3.92). For BM1 MSCs cultured in medium alone 
stimulation indices above 3 were not recorded. 
When PBMCs from donor 2 were cultured with BM1 MSCs, significantly higher counts were 
recorded on days 3 and 12 compared to the unstimulated PBMCs (p<0.05 ANOVA). When 
MSCs from BM1 were cultured in complete medium alone there was no difference in counts 
compared to the unstimulated PBMCs (Figure 6.53).  
The stimulation indices were calculated and are presented in Figure 6.54. This showed 
stimulation indices above 3 for PBMCs from donor 2 in response to BM1 MSCs at day 3 (SI of 
3.02). For BM1 MSCs cultured in medium alone stimulation indices above 3 were not recorded. 
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When PBMCs from donor 3 were cultured with BM1 MSCs, significantly higher counts were 
recorded on day 3 compared to the unstimulated PBMCs (p<0.05 ANOVA). When MSCs from 
BM1 were cultured in complete medium alone significantly higher counts were not recorded 
compared to the unstimulated PBMCs (Figure 6.55; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.56. This showed 
stimulation indices above 3 for PBMCs from donor 3 in response to BM1 were not recorded. 
For BM1 MSCs cultured in medium alone stimulation indices above 3 were not recorded. 
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Figure 6.52: The stimulation index (SI) of donor 1 PBMCs cultured in V-bottom plates with 
PHA (positive control for stimulation), with donor BM1 MSCs, or MSCs cultured in complete 
medium alone, for 21 days. The red line intersects the y-axis at 3, and values above this 
height (SI>3) are considered positive stimulation indices. 
Figure 6.51: Counts per minute of donor 1 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with donor 
BM1 MSCs or MSCs cultured in complete medium alone for 16 days. Data is expressed as the 
mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was analysed by one-way 
analysis of variance at each time point. * indicates significant differences (p<0.05) compared 
to the PBMCs cultured in medium alone as determined by the T-method. 
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Figure 6.54: The stimulation index (SI) of donor 2 PBMCs cultured in V-bottom plates with 
PHA (positive control for stimulation), with donor BM1 MSCs, or MSCs cultured in 
complete medium alone, for 21 days. The red line intersects the y-axis at 3, and values 
above this height (SI>3) are considered positive stimulation indices. 
Figure 6.53: Counts per minute of donor 2 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM1 MSCs or MSCs cultured in complete medium alone for 16 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was 
analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined by 
the T-method. 
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Figure 6.56: The stimulation index (SI) of donor 3 PBMCs cultured in V-bottom plates with 
PHA (positive control for stimulation), with donor BM1 MSCs, or MSCs cultured in complete 
medium alone, for 21 days. The red line intersects the y-axis at 3, and values above this 
height (SI>3) are considered positive stimulation indices. 
Figure 6.55: Counts per minute of donor 3 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM1 MSCs or MSCs cultured in complete medium alone for 16 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was 
analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined by 
the T-method. 
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6.3.2.2 BM2 
When PBMCs from donor 1 were cultured with BM2 MSCs, significantly higher counts were 
recorded on day 3 compared to the unstimulated PBMCs (p<0.05 ANOVA). When MSCs from 
BM2 were cultured in complete medium alone there was no difference in counts compared to 
the unstimulated PBMCs (Figure 6.57; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.58. This showed 
stimulation indices above 3 for PBMCs from donor 1 in response to BM2 MSCs at day 3 (SI of 
3.12). For BM2 MSCs cultured in medium alone stimulation indices above 3 were not recorded. 
When PBMCs from donor 2 were cultured with BM2 MSCs, significantly higher counts were 
recorded on day 3 compared to the unstimulated PBMCs (p<0.05 ANOVA). When MSCs from 
BM2 were cultured in complete medium alone there was no difference in counts compared to 
the unstimulated PBMCs (Figure 6.59; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.60. This showed 
stimulation indices above 3 for PBMCs from donor 2 in response to BM2 MSCs were not 
recorded. For BM2 MSCs cultured in medium alone stimulation indices above 3 were not 
recorded. 
When PBMCs from donor 3 were cultured with BM2 MSCs, significantly higher counts were 
recorded on day 3 compared to the unstimulated PBMCs (p<0.05 ANOVA). When MSCs from 
BM2 were cultured in complete medium alone there was no difference in counts compared to 
the unstimulated PBMCs (Figure 6.61; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.62. This showed 
stimulation indices above 3 for PBMCs from donor 3 in response to BM2 MSCs at day 3 (SI of 
4.25). For BM2 MSCs cultured in medium alone stimulation indices above 3 were not recorded. 
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Figure 6.57: Counts per minute of donor 1 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM2 MSCs or MSCs cultured in complete medium alone for 16 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was 
analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined by 
the T-method. 
Figure 6.58: The stimulation index (SI) of donor 1 PBMCs cultured in V-bottom plates 
with PHA (positive control for stimulation), with donor BM2 MSCs, or MSCs cultured in 
complete medium alone, for 21 days. The red line intersects the y-axis at 3, and values 
above this height (SI>3) are considered positive stimulation indices. 
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Figure 6.59: Counts per minute of donor 2 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM2 MSCs or MSCs cultured in complete medium alone for 16 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data 
was analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined 
by the T-method. 
Figure 6.60: The stimulation index (SI) of donor 2 PBMCs cultured in V-bottom plates 
with PHA (positive control for stimulation), with donor BM2 MSCs, or MSCs cultured 
in complete medium alone, for 21 days. The red line intersects the y-axis at 3, and 
values above this height (SI>3) are considered positive stimulation indices. 
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Figure 6.61: Counts per minute of donor 3 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM2 MSCs or MSCs cultured in complete medium alone for 16 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was 
analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined by 
the T-method. 
Figure 6.62: The stimulation index (SI) of donor 3 PBMCs cultured in V-bottom plates with 
PHA (positive control for stimulation), with donor BM2 MSCs, or MSCs cultured in 
complete medium alone, for 21 days. The red line intersects the y-axis at 3, and values 
above this height (SI>3) are considered positive stimulation indices. 
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6.3.2.3 BM4 
When PBMCs from donor 1 were cultured with BM4 MSCs, significantly higher counts were not 
recorded compared to the unstimulated PBMCs (p<0.05 ANOVA). When MSCs from BM4 were 
cultured in complete medium alone there was no difference in counts compared to the 
unstimulated PBMCs (Figure 6.63; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.64. This showed 
stimulation indices above 3 for PBMCs from donor 1 in response to BM4 MSCs. For BM4 MSCs 
cultured in medium alone stimulation indices above 3 were not recorded. 
When PBMCs from donor 2 were cultured with BM4 MSCs, significantly higher counts were 
recorded on days 3 and 5 compared to the unstimulated PBMCs (p<0.05 ANOVA). When MSCs 
from BM4 were cultured in complete medium alone there was no difference in counts 
compared to the unstimulated PBMCs (Figure 6.65; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.66. This showed 
stimulation indices above 3 for PBMCs from donor 2 on days 3 (SI of 3.38), 12 (SI of 10.96) and 
16 (SI of 3.12) in response to BM4 MSCs. For BM4 MSCs cultured in medium alone stimulation 
indices above 3 were not recorded. 
When PBMCs from donor 3 were cultured with BM4 MSCs, significantly higher counts were 
recorded on day 3 compared to the unstimulated PBMCs (p<0.05 ANOVA). When MSCs from 
BM4 were cultured in complete medium alone there was no difference in counts compared to 
the unstimulated PBMCs (Figure 6.67; p<0.05 ANOVA).  
The stimulation indices were calculated and are presented in Figure 6.68. This showed 
stimulation indices above 3 for PBMCs from donor 3 in response to BM4 MSCs. For BM4 MSCs 
cultured in medium alone stimulation indices above 3 were not recorded. 
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Figure 6.63: Counts per minute of donor 1 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM4 MSCs or MSCs cultured in complete medium alone for 16 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was 
analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined by 
the T-method. 
Figure 6.64: The stimulation index (SI) of donor 3 PBMCs cultured in V-bottom plates with 
PHA (positive control for stimulation), with donor BM2 MSCs, or MSCs cultured in 
complete medium alone, for 21 days. The red line intersects the y-axis at 3, and values 
above this height (SI>3) are considered positive stimulation indices. 
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Figure 6.66: The stimulation index (SI) of donor 3 PBMCs cultured in V-bottom plates 
with PHA (positive control for stimulation), with donor BM2 MSCs, or MSCs cultured in 
complete medium alone, for 21 days. The red line intersects the y-axis at 3, and values 
above this height (SI>3) are considered positive stimulation indices. 
Figure 6.65: Counts per minute of donor 2 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with donor 
BM4 MSCs or MSCs cultured in complete medium alone for 16 days. Data is expressed as 
the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data was analysed by 
one-way analysis of variance at each time point. * indicates significant differences (p<0.05) 
compared to the PBMCs cultured in medium alone as determined by the T-method. 
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Figure 6.67: Counts per minute of donor 3 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with 
donor BM4 MSCs or MSCs cultured in complete medium alone for 16 days. Data is 
expressed as the mean log10 counts per minute (n=3-4) ± 95% confidence limits. Data 
was analysed by one-way analysis of variance at each time point. * indicates significant 
differences (p<0.05) compared to the PBMCs cultured in medium alone as determined 
by the T-method. 
Figure 6.68: The stimulation index (SI) of donor 3 PBMCs cultured in V-bottom plates 
with PHA (positive control for stimulation), with donor BM4 MSCs, or MSCs cultured in 
complete medium alone, for 21 days. The red line intersects the y-axis at 3, and values 
above this height (SI>3) are considered positive stimulation indices. 
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6.4 DISCUSSION 
The aim of the work in this chapter was to perform LTAs by culturing MSCs from 4 donors with 
peripheral blood mononuclear cells isolated from 6 donors over a culture period up to 21 days. 
In addition to this, LTAs using human dermal fibroblasts as stimulator cells were also 
performed.  
There have been conflicting reports in the literature about the immunological effects of MSCs. 
In addition to the reported ability of these cells to down regulate an active immune response 
in-vitro (Bartholomew et al., 2002; Le Blanc et al., 2003b; Bocelli-Tyndall et al., 2007; Nasef et 
al., 2009; Wada et al., 2009; Kuci et al., 2010; Prasanna et al., 2010), MSCs have also been 
reported to be immune-privileged. When allogeneic MSCs have been cultured with PBMCs in-
vitro no proliferation has been observed (Bartholomew et al., 2002; Tse et al., 2003; Jones et 
al., 2007; Niemeyer et al., 2007; Oh et al., 2008; Suva et al., 2008). As discussed in Chapter 5, 
there is very little homogeneity between the methods used by different research groups to 
measure the immunogenicity of MSCs, and the methods that have been used so far to assess 
the immunogenicity of MSCs have limitations. The majority of these studies have involved 
culturing MSCs with the PBMCs for less than 7 days and therefore may have only measured the 
direct pathway of alloantigen recognition. Here, the duration of the assay in which MSCs were 
co-cultured with PBMCs was extended up to 21 days, in an attempt to incorporate 
measurement of indirect allorecognition.  
To maximise HLA incompatability, bone marrow MSCs were used from 4 donors and cultured 
with allogeneic PBMCs from 6 healthy volunteers. Stimulation of PBMCs was assessed through 
the incorporation of radioactive thymidine into the DNA of proliferating cells. The data from 
these assays was expressed both as log10 counts per minute and as the stimulation index. The 
counts per minute were log10 transformed to normalise the data, so that statistical analysis 
(one-way ANOVA) could be performed and significant differences in counts of radioactive 
thymidine when cells were cultured with and without stimulation by MSCs could be 
determined. The stimulation index is a method of measuring stimulation of cells that utilises 
PBMCs cultured in medium only as the negative control for stimulation, and the counts per 
minute obtained for the PBMCs following stimulation are divided by these counts. A 
stimulation index above 3 is considered to be a positive response (Ivanyi and Lehner, 1970; 
Hirose et al., 1989; Kimball, 1990; Gupta et al., 1996; Satoskar et al., 1998).  
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In order to assess the stimulation of PBMCs in culture, both negative and positive controls for 
stimulation were needed, these being PBMCs cultured in complete medium alone and PBMCs 
cultured with PHA to stimulate proliferation.  
In the assays reported here, all six donor PBMCs responded to PHA. For the majority of PBMCs 
stimulated with PHA, maximal stimulation occurred on days 3-5 as observed in Chapter 5.  
Statistical analysis using one-way ANOVA of log10 counts per minute provided a method of 
determining which counts were significantly greater when PBMCs were cultured with MSCs or 
PHDFs compared to those of PBMCs cultured in medium alone. Due to the variability of counts 
obtained within replicate wells data was often not significant at longer culture durations.  
There was a general trend that the data from the counts per minute which were significantly 
different by ANOVA also gave SI>3. The converse however was not always the case. In some 
cases the stimulation indices were greater than 10, resulting in positive SI, but when the log10 
counts per minute were analysed, no statistical significance was observed (BM2, donor 4, day 
16, Figures 6.21-6.22). Although variability between replicates was a factor that affected the 
analysis, the calculation of stimulation indices was dependent on good negative controls. As 
negative control counts values were generally low, small variations in negative control values 
had a very large effect on the SI. For example, negative control counts per minute of between 
50 and 100 were normal and both very low. However, the effect a fluctuation of between 50 
and 100 had on the stimulation index was to halve the SI. 
It was important therefore to display the data as both counts per minute, and stimulation 
indices in order to assess the capacity of the MSCs to stimulate the PBMCs. 
In some instances (Figure 6.3; day 12) mean log10 counts per minute were higher when PBMCs 
were cultured with MSCs compared to unstimulated controls, but due to the variability in 
counts the difference between the means were not statistically significant. 
However, relying on purely statistical analysis did not give a good representation of 
stimulation; in many of the assays in which undifferentiated MSCs were cultured with PBMCs 
statistical difference between means was recorded early on days 3 and 5, and yet the SI’s were 
less than 3. Hence this was not considered to be positive stimulation. 
In a few cases the MSCs cultured alone incorporated low levels of tritiated thymidine. When 
this was observed it was usually early in the culture duration at days 3-5. This indicated that 
the MSCs may have been capable of incorporation of some thymidine into DNA despite the 
mitomycin C treatment. The counts however were extremely low compared to the counts 
obtained in test wells with PBMCs and did not affect the overall interpretation of the data.  
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When both significant increases in log10 counts per minute and the SI were used to assess 
proliferation, stimulation of PBMCs by MSCs was observed with the strongest stimulation 
usually between days 12-16. Levels of stimulation when measured by the SI were greater than 
30 in some instances, and there were only two instances out of the twenty four MSC/PBMC 
combinations when stimulation was not observed. Extending the duration of the LTA has not 
been attempted before, and in doing this it was clearly shown that MSCs are capable of 
stimulating allogeneic lymphocytes to proliferate in-vitro. This provided evidence to dispute 
the prevailing hypothesis that MSCs are immuno-privileged. Lower stimulation also occurred 
for some MSC/PBMC combinations on days 7 and 21. The data was also in agreement with 
previous studies in that little stimulation was observed up to day 7 (Bartholomew et al., 2002; 
Le Blanc et al., 2003b; Tse et al., 2003). These findings highlight the need to extend the 
duration of LTA’s in order to assess the immunogenicity of allogeneic cells which have no 
capacity for direct antigen presentation. 
The age of the MSC donor did not appear to affect the stimulatory capacity of the cells 
observed, with the oldest donor’s cells (BM1, age 69 years old) stimulating 3 PBMC donors 
with SI’s between 20-30, but then stimulating another PBMC donor’s cells with an SI of 6.28, 
and failing completely to stimulate the cells of one of the other PBMC donors. Equally, one of 
the young donor’s cells (BM2, age 9 years old) had the highest SI (36) observed when cultured 
with PBMC. PBMCs from donor 6 did demonstrate consistently lower stimulation when 
cultured with all 4 BM MSCs, with the SI failing to rise above 6.4. The stimulation of these cells 
by PHA however produced SI’s as high and higher (in some cases) than the other PBMCs 
donors.  The remaining PBMC donors did not exhibit any difference in stimulation however.  
Primary human dermal fibroblasts were used to represent a mature differentiated 
mesenchymal cell type to use in the LTAs for comparative purposes. When PHDFs were 
cultured with PBMCs, there was a general trend of the stimulation of PBMCs in co-cultures, but 
not to the same extent that MSCs stimulated the PBMCs. Primary human dermal fibroblasts 
were originally cultured as a cell type predicted to stimulate a response in allogeneic PBMCs.  
In the recent literature skin fibroblasts have been shown to be able to differentiate into bone, 
fat and cartilage in-vitro and express similar phenotypic markers to those expressed by MSCs 
(Haniffa et al., 2007; Cappellesso-Fleury et al., 2010; Blasi et al., 2011), and also have similar 
effects of inhibiting the proliferation of stimulated PBMCs in-vitro. In the LTAs using extended 
culture durations surprisingly it was discovered that allogeneic MSCs stimulated PBMCs to a 
greater extent than the PHDFs. 
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There was a high degree of variability between wells of the same experimental plate, and it 
was hypothesized that this may have been due to the culture conditions, and that if MSCs and 
PBMCs were cultured such a way to encourage the cells to be in even more intimate contact, 
they would have increased cell-cell interactions, and more consistent reactions.  In an attempt 
to encourage closer proximity between the cells in co-culture, uncoated V-bottom 96 well 
tissue culture plates were used, and the same LTA’s using MSCs and PBMCs were performed.  
This however resulted in almost no significant stimulation of the PBMCs when cultured with 
MSCs, and the stimulation indices obtained for PBMCs treated with PHA were much lower 
than those observed when uncoated U-bottom 96 well tissue culture plates were used. It was 
hypothesized that the reason for lower counts when V-bottom wells were used was due to the 
lack of optimisation in these plates. As shown in the previous Chapter, to gain optimum counts 
the assay conditions had to be modified from those commonly reported in the literature. With 
more time, further optimization of the V-bottom plates may have yielded a solution to the 
variability between wells, but unfortunately time was a limiting factor and it was decided to 
continue using the U-bottom tissue culture plates. 
In conclusion, it was demonstrated in this chapter, in agreement with published literature that 
PBMCs cultured with allogeneic MSCs for up to 7 days exhibit little to no proliferation. 
However, when the duration of the assay is extended beyond the 7 days it was shown that 
allogeneic MSCs stimulated proliferation of PBMCs in 22 out of 24 cases. The stimulation 
observed was generally higher when MSCs were cultured with PBMCs compared to PHDF’s. It 
was also important to confirm positive SI values with statistical analysis of the counts per 
minute (tritiated thymidine), as the SI is very dependent on negative control values. Finally, 
changing the plates from U-bottomed to V-bottomed encouraging the cells to be in intimate 
contact did not solve the issue of variability observed between replicates.
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Chapter 7:  ASSESSMENT OF THE IMMUNOGENICITY OF 
ADIPOGENICALLY DIFFERENTIATED MULTIPOTENT 
MESENCHYMAL STROMAL CELLS USING LYMPHOCYTE 
TRANSFORMATION ASSAYS OVER 16 DAYS 
7.1 INTRODUCTION 
Before the discovery of leptin in 1995, adipose tissue was regarded as a passive and silent 
organ, whose role in the body was to store excess energy as triglycerides, and to release this 
energy as fatty acids (Schaffler et al., 2006; Schaffler et al., 2007). Since then adipose tissue has 
become increasingly recognised as an endocrine organ that secretes a wide variety of 
cytokines, hormones, chemokines and growth factors, that have an effect on many aspects of 
the bodies physiology, including appetite, fertility, metabolism, vascular function and, 
specifically of interest to this study, immunity and inflammation (Schaffler et al., 2006).  
There is a need for engineered adipose tissue in the clinic. Subcutaneous adipose tissue 
defects can arise from congenital abnormalities, oncologic resection and traumatic injury. Soft 
tissue reconstruction is currently carried using methods such as autografting, fat free grafting, 
and implantation of alloplastic materials (Girandon et al., 2011). These methods all suffer from 
disadvantages such as donor site morbidity and graft resorption. A preferred strategy is one 
that promotes the regeneration of adipose tissue, rather than the replacement of the 
damaged tissue. In tissue engineering research, this strategy is usually performed through the 
use of a biocompatible scaffold, seeded with cells of an appropriate phenotype. There are a 
variety of scaffolds both natural and synthetically created, with an increasing number being 
developed, but the cells seeded onto the scaffold are usually adipogenic precursor cells 
(Girandon et al., 2011). These cells can either be purified from adipose tissue, or more 
commonly adipose derived stem cells or multipotent mesenchymal stromal cells have been 
used (Zuk et al., 2001; Zuk et al., 2002; De Ugarte et al., 2003; Girandon et al., 2011). The 
adipogenic potential of MSCs is well documented, and is in fact one of the differentiation 
characteristics that defines a mesenchymal stromal cell in trilineage  differentiation assays 
(Horwitz et al., 2005).  
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There are some issues that need to be addressed regarding the future clinical use of tissue 
engineered adipose tissue utilising MSCs. Firstly, will it be necessary to utilise autologous MSCs 
to seed the scaffolds? This would involve patients undergoing two procedures to a) harvest the 
MSCs, expand the cells, and differentiate the cells or seed the scaffold, and b) implantation. 
Secondly, can allogeneic cells be used that allow the process to be reduced to a one stage 
process with the potential for commercialisation? Due to the conflicting evidence regarding 
the immuno-privileged nature of MSCs, one might suspect that allogeneic cells could be used. 
As shown in the previous chapter however, MSCs even when undifferentiated are able to 
stimulate the proliferation of allogeneic peripheral blood mononuclear cells.  
Adipose tissue has been shown to function as an immunological organ, and in-vivo up to 10% 
of the stromovascular fraction of adipose tissue has been reported to be CD14+CD31+ 
macrophages (Fantuzzi, 2005). Adipose tissue has also been shown to secrete various pro-
inflammatory cytokines (IL-6 and TNF-α), chemokines (monocyte chemoattractant protein-1) 
and adipose tissue specific ‘adipokines’ that may have direct immunological effects. Three of 
the main adipokines secreted by adipocytes are leptin, adiponectin, and resistin (Fantuzzi, 
2005; Tilg and Moschen, 2006). Leptin is pro-inflammatory, and has been shown to increase 
both T-cell proliferation and the TH1 response (increased secretion of IL-2 and interferon-ɣ) 
(Fantuzzi, 2005; Tilg and Moschen, 2006). Adiponectin is anti-inflammatory, and has been 
shown to reduce secretion of cytokines IL-6 and interferon-ɣ and expression of the 
transcription factor NF-kB, while promoting secretion of the anti-inflammatory cytokine IL-10 
in human macrophages, monocytes and dendritic cells (Tilg and Moschen, 2006). Resistin is 
another pro-inflammatory adipokine, increasing expression of IL-6, IL-12 and NF-kB by 
macrophages, but its effect on the adaptive immune response are not yet fully determined. In 
addition, in humans the expression of resistin is predominantly by macrophages as opposed to 
adipose cells (Fantuzzi, 2005; Tilg and Moschen, 2006). Two cytokines released by adipose 
tissue that have received most interest are IL-6 and TNF-α, both are pro-inflammatory;  
IL-6 is involved in the promotion of B-cells ability to secrete immunoglobins, and TNF-α is 
involved in the activation of NF-kB and MAPK pathways. 
Interleukin-6 has been shown to be a multi-functional cytokine able to influence various 
inflammatory reactions. It has been shown to be involved in promoting growth and survival of 
various cell types, inducing differentiation of monocytes to macrophages, and the recruitment 
of peripheral blood monocytes to areas of inflammation (Hallbeck et al., 2001). Interleukin-6 
exhibits a large number of pleotrophic effects, and one of the main effects in-vivo is the 
promotion of acute-phase proteins by the liver. Several of these proteins mimic the action of 
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antibodies, but have a broad specificity for pathogen-associated molecular patterns (PAMPs); 
specific proteins associated with various pathogens (Janeway et al., 2005). In the context of 
the in-vitro LTA the effects of IL-6 observed are the effects this cytokine has on T and B-cells. 
Interleukin-6 has been shown to increase T-cell activation, and increase the ability of B-cells to 
secrete immunoglobulins (promote the differentiation of B-cells to plasma cells), as well as act 
as a growth factor for the fully differentiated plasma cells (Kimball, 1990). With regards to T-
cells, IL-6 has been shown to be an activating factor that is able to provide the second (antigen-
nonspecific) signal that is required in addition to the immunogen for T-cell activation (Stites, 
1991).  
Tumor necrosis factor-α binds to two receptors present on many cell surfaces, TNFRI and 
TNFRII. TNFRI is ubiquitously expressed on mammalian cells and is involved with regulation of 
apoptosis, inflammation, differentiation and cell proliferation (Szlosarek and Balkwill, 2003). 
TNFRII is mainly involved with endothelial and haematopoietic cell signalling. The binding of 
TNF-α to TNFRI ultimately leads to the activation of two main transcription factors, NFkB and c-
Jun (Chen and Goeddel, 2002).The transcription factor NFkB is able to protect cells from 
apoptosis (Livolsi et al., 2001), and promote the survival and maturation of B and T-cells, and 
myeloid dendritic cells (Hayden and Ghosh, 2011). The transcription factor c-Jun products form 
one half of the translational promoter complex, and when bound to products of the opposing 
half c-fos forms the complex activator protein-1 (AP-1). Both of these transcription factors are 
stimulated by the presence of TNF-α (Angel and Karin, 1991). Activator protein-1 has been 
shown to increase expression of transforming growth factor α and β, and IL-2, and translation 
stimulated by AP-1 trends towards proliferation and differentiation of cells (Angel and Karin, 
1991).  
There are many factors that may affect the immunology of adipogenically differentiated in 
comparison to undifferentiated MSCs (stem cell vs mature cell, secretion of pro-inflammatory 
adipokines and cytokines, expression of different cell surface markers) and it was hypothesized 
that the capacity of MSCs to stimulate a proliferative response in allogeneic PBMCs would 
increase when MSCs were differentiated into adipose cells. During the process of 
differentiating MSCs into adipose cells, it was noted that the mature culture of differentiated 
cells was a heterogeneous population of mature adipocytes, and undifferentiated MSCs. These 
undifferentiated cells could have an effect on the stimulation of PBMCs when differentiated 
MSCs are used in co-culture with PBMCs. A method to separate the mixed cell population was 
initially sought, in order that assays using populations of fully mature fat cells could be 
performed, as opposed to assays with a mixed population of cells. 
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7.1.1 AIMS AND OBJECTIVES 
The aim of the work described in this Chapter was to test the hypothesis that the 
immunogenicity of MSCs would increase following their differentiation into adipose cells. 
Objectives: 
 To develop a method for the isolation of mature differentiated adipose cells from 21 
day differentiated MSC cultures. 
 To determine the capacity of BM4 donor MSCs to stimulate the proliferation of 
allogeneic PBMCs from 3 donors before and after differentiation into adipose cells in 
culture using the LTA. 
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7.2 MATERIALS AND METHODS 
7.2.1 PURIFICATION OF MATURE ADIPOCYTES FROM CULTURED MSCS USING DENSITY 
CENTRIFUGATION 
Previous experiments performed in Chapter 2 demonstrated the buoyancy of adipose cells, 
and the more mature fat cells were lost during the wash steps involved in the staining process 
for flow cytometry. To separate the mature adipose cells, it was hypothesized that 
centrifugation for a reduced time would enable the separation of the cell population, with the 
MSCs containing very little to no intracellular lipids drawn to the bottom of the centrifuge tube 
by the centripetal forces, whereas the mature fat cells containing a large volume of 
intracellular lipids would resist the centripetal forces due to their reduced density, and instead 
float to the surface. 
Reagents 
Phosphate buffered saline 
Hy-Q-Tase™ cell detachment solution  
NH expansion medium (section 3.2.2.) 
Adipogenic medium(section 3.2.5.) 
Complete DMEM medium(section 3.2.1.) 
Method 
BM2 donor MSCs were isolated and cultured in NH Expansion medium at 37°C in a humidified 
atmosphere containing 5% (v/v) CO2 in air. Every 3 days, medium was removed and replaced 
with fresh. Cells were passaged as previously described in section 3.2.2. MSCs were expanded 
until 80% confluent in 4 T75 tissue culture flasks. When MSCs were 80% confluent the NH 
expansion medium was replaced with 10 ml adipogenic differentiation medium. Adipogenic 
medium was changed twice weekly (½ media changes) over a 21 day period. 
After differentiating the MSCs for 21 days, the adipogenic medium was removed from the 
cultured cells and the cells were washed with 10 ml PBS without Ca2+ or Mg2+.  The PBS was 
removed and discarded, and 2 ml Hy-Q-tase™ cell detachment solution was added before 
incubation at 37°C for 5 minutes (until all cells were in suspension).  The cells were added to 10 
ml complete DMEM culture medium in a polythene test tube and centrifuged at 150 g for 5 
minutes. The medium was decanted and the cell pellet resuspended in 5 ml PBS.  The resulting 
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cell suspension was centrifuged at 150 g for 1 minute, and samples (100 µl) of supernatant 
removed using a 1 ml syringe. Samples were taken from the top of the meniscus, 1 cm below 
the meniscus, and 2 cm below the meniscus. Each sample was placed onto a SuperFrost Plus® 
glass slide and covered with a glass coverslip, before examination using microscopy to locate 
mature adipogenically differentiated MSCs. 
7.2.2 CEILING CULTURE SEPARATION OF ADIPOGENICALLY DIFFERENTIATED MSCS 
Reagents 
As in section 6.1.1. 
Method 
As above (section 6.1.1), BM4 donor MSCs were isolated and cultured in NH Expansion 
medium at 37°C in a humidified atmosphere containing 5% (v/v) CO2 in air. Every 3 days, 
medium was removed and replaced with fresh. Cells were passaged as previously described in 
section 3.2.2. MSCs were expanded until 80% confluent in 4 T75 tissue culture flasks. When 
MSCs were 80% confluent the NH expansion medium was replaced with 10 ml adipogenic 
differentiation medium. Adipogenic medium was changed twice weekly (½ media changes) 
over a period of 21 days. 
After differentiating the MSCs for 21 days, the adipogenic medium was removed from the 
cultured cells and the cells were washed with 10 ml PBS without Ca2+ or Mg2+.  The PBS was 
removed and discarded, and 2 ml Hy-Q-tase™ cell detachment solution was added before 
incubation at 37°C for 5 minutes (until all cells were in suspension).  The flask was then filled 
completely with complete DMEM culture medium, and a solid screw top was used instead of 
the usual filter cap to seal the flask. The flask was then incubated at 37°C in a humidified 
atmosphere containing 5% (v/v) CO2 in air for 4 hours to allow the more buoyant fat cells to 
attach to the roof of the flask, and the less buoyant stromal cells to remain attached to the 
bottom of the flask. After 4 hours, the flask was drained of medium, and turned upside down. 
Hy-Q-tase™ cell detachment solution (1 ml) was added to the flask before incubation at 37°C 
for 5 minutes (until all cells were in suspension). The 1 ml cell suspension was then added to 1 
ml NH expansion medium, and 100 µl of this was dispensed into wells of a U-shaped coated 96 
well tissue culture plate. This plate was inverted, and fat cells were left to attach overnight at 
37°C in a humidified atmosphere containing 5% (v/v) CO2 in air. Following overnight 
incubation, the medium was replaced with fresh NH expansion medium, and plates were 
viewed using microscopy to examine the purity of separated differentiated MSC population. 
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7.2.3 THE ADIPOGENESIS OF BM2 MSCS CULTURED IN ADIPOGENIC MEDIUM IN UNCOATED AND 
COATED U-BOTTOM 96 WELL TISSUE CULTURE PLATES 
Reagents 
Complete DMEM medium 
Adipogenic medium 
Phytohaemagglutinin (1 mg.ml-1 in dH2O) 
Phosphate buffered saline 
Hy-Q-Tase™ cell detachment solution  
NH expansion medium 
Transport medium 
Complete medium 
Nile red (1:2000 dilution): 1 µl stock into 100 µl PBS, and diluting 4 µl of this solution into 80 µl 
PBS. 
Paraformaldehyde (10% v/v in PBS) 
Saponin (0.2% w/v in PBS) 
Method 
Multipotent mesenchymal stromal cells from donor BM4 were cultured in NH expansion 
medium until 100% confluent in 2 T75 tissue culture flasks. When 100% confluency was 
reached the medium was removed from the flask and the cells were washed with 10 ml PBS 
without Ca2+ or Mg2+. PBS was removed and 2 ml Hy-Q-Tase™ was added to the flask, before 
incubation at 37°C in an atmosphere of 5% (v/v) CO2 until cells had detached from the surface 
of the flask (approx. 10 minutes). When cells had detached the resulting cell suspension was 
resuspended in 5 ml adipogenic medium (supplementing  complete DMEM with 10% v/v horse 
serum, 0.5 mM isobutylmethylxanthine, 0.6mM indomethacin and 50 pM hydrocortisone), 
before counting using trypan dye exclusion as described in section 2.3.7. The MSCs (25,000) 
were dispensed into wells and left to attach for 4 hours in U-bottom coated 96 well tissue 
culture plates (Nunc), and uncoated U-bottom 96 well tissue culture plates (Fisher Scientific) 
and differentiated for 21 days at 37°C in a humidified atmosphere containing 5% (v/v) CO2 in 
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air. Six repeats of n=6 were prepared and adipogenic medium was changed twice weekly (½ 
media changes) over a 21 day period.  
On day 21 the culture medium was removed from wells and cells washed twice with PBS. 
Paraformaldehyde (200 µl) was added to the wells for 30 minutes, before the cell layer was 
washed with 200 µl PBS. The PBS was removed and 200 µl fresh PBS was added to each well. A 
100µl volume of crystal violet solution was added to the gaps in between the wells of the plate 
to minimise light reflection. The background fluorescence was read using 4',6-diamidino-2-
phenylindole, DAPI (355/460) and Nile red (485/540) filter sets as per the manufacturer’s 
instructions. These filter sets were used as they provided the closest match to DAPI, excitation 
at 358 nm, and emission at 461nm, and Nile red, excitation at 450-500 nm, and emission at 
>528 nm. The overall average fluorescent intensity for each well was read. The PBS was 
removed from the wells, and 200µl saponin (0.2% w/v in PBS) was added along with DAPI at a 
final concentration of 1 µg.ml-1 and Nile red at a final concentration of 1 µg.ml-1. The plate was 
then wrapped in foil and incubated at room temperature for 15 minutes. Following three 
washes with PBS, 200µl PBS was added, and the fluorescence of the wells were again read as 
above. A ratio of adipogenesis was calculated by taking the mean fluorescence reading of the 
repeats for both Nile red and DAPI stained cells and creating a ratio of Nile red:DAPI 
fluorescence (using the methodology developed in Chapter 4 section 4.3.4).  
7.2.4 THE LYMPHOCYTE TRANSFORMATION ASSAY CO-CULTURING PERIPHERAL BLOOD 
MONONUCLEAR CELLS AND MSCS AND THE SEPARATION OF ADIPOCYTES FROM PBMCS 
WHEN CULTURED TOGETHER IN THE LTA USING FLUORESCENCE ACTIVATED CELL SORTING 
(FACS). 
For these experiments eight 96 well plates were prepared as shown in Figure 7.1 (4 plates for 
day 3, 7, 12, and 16 (x2)), with 4 plates set up to use with tritiated thymidine incorporation to 
assess PBMC proliferation, and the replicate 4 plates set up to sort the mixed MSC and PBMC 
population via FACS, before RNA isolation for qRT-PCR analysis.  
Reagents 
Complete DMEM medium 
Adipogenic medium 
Phytohaemagglutinin (1 mg.ml-1 in dH2O) 
Phosphate buffered saline 
231 
 
Hy-Q-Tase™ cell detachment solution  
NH expansion medium 
Transport medium 
Complete medium 
Mitomycin C 
2x blocking buffer: PBS/2.5mM EDTA/4% (v/v) human AB serum 
TRIzol® RNA lysis solution 
Anti-human CD45 APC Cy-7 conjugated antibody (BD Biosciences) 
Method 
MSCs from BM4 were cultured in NH Expansion medium at 37°C in a humidified atmosphere 
containing 5% (v/v) CO2 in air. Every 3 days, medium was removed and replaced with fresh. 
Cells were passaged as previously described in section 3.2.2. 
MSCs from donor BM4 were cultured in NH expansion medium until 100% confluent in 4 T75 
tissue culture flasks. When 100% confluency at passage 6 was reached the medium was 
removed from each flask and the cells were washed with 10 ml PBS without Ca2+ or Mg2+. PBS 
was removed and 2 ml Hy-Q-Tase™ was added to each flask, before incubation at 37°C in an 
atmosphere of 5% (v/v) CO2 until cells had detached from the surface of the flask (approx. 10 
minutes). When cells had detached the resulting cell suspension from all flasks was combined 
and resuspended in 5 ml complete medium before counting using trypan dye exclusion as 
described in section 2.3.7. The MSCs (25,000) were dispensed into wells of 8 U-bottom coated 
96 well tissue culture plates as shown in Figure 7.1, seeding only in columns 6-8, and the 
remaining cells were cryopreserved for 18 days until they were resuscitated and grown in 2 
T75 tissue culture flasks as described in section 2.3.6-2.3.8. The MSCs in the eight 96 well 
tissue culture plates were differentiated for 21 days in adipogenic medium at 37°C in a 
humidified atmosphere containing 5% (v/v) CO2 in air. The medium was changed twice weekly 
(½ media changes). 
Mitomycin C stock (250 µl) was added to 20 ml complete medium to form a solution with a 
concentration of 12.5 µg.ml-1. This MMC medium was added to wells (200 µl) and the cells 
incubated for 1 hour at 37°C in a humidified atmosphere containing 5% (v/v) CO2 in air. 
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Following the 1 hour incubation, medium was removed, and the cell monolayer was gently 
washed twice with 200 µl complete medium. 
Resuscitated MSCs grown in the two T75 tissue culture flasks were cultured until 100% 
confluency was reached, then medium was removed from the flask and the cells were washed 
with 10 ml PBS without Ca2+ or Mg2+. PBS was removed and 2 ml Hy-Q-Tase™ was added to the 
flask, before incubation at 37°C in an atmosphere of 5% (v/v) CO2 until cells had detached from 
the surface of the flask (approx. 10 minutes). When cells had detached the resulting cell 
suspension was pooled and resuspended in 5 ml complete medium, and 62.5µl MMC stock 
was added to form the final concentration of 12.5 µg.ml-1. Following 1 hour incubation the 
cells were centrifuged at 150 g for 10 minutes, the mitomycin C medium removed, and cells 
were washed twice with 10ml complete medium. Finally cells were resuspended in 10 ml 
complete medium before counting using trypan dye exclusion as described in section 2.3.7. 
Mitomycin C treated MSCs (25,000) were then dispensed into wells of the eight U-bottom 
coated 96 well tissue culture plates as shown in Figure 7.1, seeding in columns 9-11. 
Peripheral blood mononuclear cells were isolated from 3 healthy volunteer’s human peripheral 
blood as described in section 5.2.1. Following isolation PBMCs were counted using trypan dye 
exclusion as described in section 2.3.7. These cells (25,000) were dispensed into the wells of 
the U-bottom coated 96 well tissue culture plates. Phytohaemagglutinin stock (64 µl) was 
diluted in 1 ml complete RPMI-1640 medium, then added to wells at a 1:1 ratio of PHA to 
PBMCs in medium to achieve the final concentration of 32 µg.ml-1 in the wells shown in Figure 
7.1.  
The negative control for proliferation was responder PBMCs grown in complete medium only, 
and positive control was responder PBMCs stimulated with 32 µg.ml-1 PHA. Plates were 
cultured at 37°C in an atmosphere of 5% (v/v) CO2 in air.  
7.2.4.1 THE LTA 
For the assessment of PBMC proliferation in four of the eight plates, sixteen hours before the 
desired timepoint each well of the plate was spiked with 10 µl of low activity tritiated 
thymidine stock at a final concentration of 0.0125 µCi.ml-1 and cultured at 37°C in an 
atmosphere of 5% (v/v) CO2 in air overnight. Sixteen hours post spiking the cells were 
harvested onto glass fibre filter plates using a FilterMate™ (Perkin Elmer) cell harvester, before 
35µl MicroScint™ was added and radioactive counts were measured on a TopCount 
scintillation counter as described in section 5.2.3. Plates were harvested on days 3, 7, 12, and 
16. On day 12, 100 µl medium was removed from all wells of the 96 well tissue culture plates, 
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and frozen in polypropylene 96 well plates at -80°C for later analysis, before 100 µl fresh 
complete medium was added.  
7.2.4.2 CELL SEPARATION  
The remaining 4 tissue culture plates were utilised for the separation of adipocytes from 
PBMCs for RNA expression analysis. The addition of PBMCs and undifferentiated MSCs to the 
96 well tissue culture plates was day 0. On days 3, 7, 12, and 16, 150 µl medium was removed 
from the wells, and was stored in a 96 well polypropylene plate at -80°C. On day 12, 100 µl of 
the medium in all wells was removed, and 100 µl fresh complete medium added. Medium 
removed was stored in a 96 well polypropylene plate at -80°C. 
To wells containing single cell populations (PBMCs alone and with PHA) 100 µl TRIzol® RNA 
lysis solution was added. This was incubated for 5 minutes at room temperature, before 
removing and freezing at -80°C.  
Blocking buffer solution (2x) was made (4ml). To this 15 µl primary antibody against CD45 was 
added. This solution (100 µl) was added to wells containing mixed populations of cells (the 
adipogenically differentiated MSCs, and undifferentiated MSCs) and incubated on ice for 1 
hour. Following incubation, 100 µl ice cold PBS was added to the wells, and the plate was 
centrifuged at 3000 g for 1 minute. The supernatant was removed from the wells, and 200 µl 
ice cold PBS added, before the plate was centrifuged again at 3000 g for 1 minute. The PBS was 
removed from the wells, and 100 µl Hy-Q-tase™ cell detachment solution was added. The plate 
was then incubated in the dark on ice for at least 30 minutes before cell separation was 
performed.  
Lymphocytes and MSCs were separated by fluorescence activated cell sorting on a BD 
FACSAria II flow cytometer. Scatter parameters were established using either pure lymphocyte 
or MSC preparations prior to sorting the mixed samples. Lymphocytes were identified by a low 
forward (size) and side scatter (granularity) signal and positive staining for APC-Cy7 conjugated 
CD45. MSCs were identified by their high scatter properties. Detector voltages for the scatter 
parameters were set so that both lymphocyte and MSC populations were visible on the same 
scatter plot (forward scatter-area (FSC-A) voltage = 75, log scale, side scatter-are (SSC-A) = 346, 
log scale). APC-Cy7 fluorescence was excited with the 633nm laser and collected through a 
780/60nm band pass filter. Detector voltage for the APC-Cy7 signal was established using 
unstained cells (voltage = 808, log scale). Cell sorting was performed with a 100 µm nozzle and 
sheath pressure of 20 psi. Cells were identified from a bivariant dot plot of side scatter vs APC-
Cy7 fluorescence. Lymphocytes were identified as having a low side scatter and high 
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fluorescence signal in the APC-Cy7 plots, while MSCs were identified as having a high side 
scatter and low fluorescence signal in these plots and gated appropriately on the plots. Cells 
were sorted at a rate of 3000-5000 events per second and a flow rate below 5 (the flow rate is 
an arbitrary value. On this specific FACSAria II the actual flow rate was approximately 1 
µl.second-1).  
A sort mask was applied to ensure maximal cell purity ('purity' mask). Lymphocytes and MSCs 
were collected into separate wells of a 96 well plate containing 50 µl TRIzol® lysis solution and 
plate positioning was controlled by an automated cell deposition unit (ACDU) robotic arm 
within the flow cytometer. Plates containing TRIzol® and cell populations were stored at -80°C 
for future gene expression analysis using qRT-PCR. 
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Figure 7.1: Diagram of the 96 well plate experimental wells used to determine the stimulation of peripheral blood mononuclear cells when 
cultured in complete medium only (negative control for stimulation), in the presence of PHA (positive control for stimulation), and co-
cultured with adipogenically differentiated BM4 MSCs (Adipo), and undifferentiated BM4 MSCs (MSCs). Donor (1), (2), and (3) represent the 
donor PBMC. 
236 
 
7.2.5 ANALYSIS OF DATA  
Data (counts per minute) from the lymphocyte transformation assays was log10 transformed 
and is presented as log10 counts per minute ± 95 % confidence limits. The log10 counts per 
minute at each time point (3, 7, 12, and 16) were compared by one-way analysis of variance 
and the MSD calculated using the T-method (p<0.05). Data was also used to calculate the 
stimulation indices from the following equation: 
cpm PBMCs + MSCs (or adipo) 
cpm PBMCs alone 
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7.3 RESULTS 
7.3.1 PURIFICATION OF MATURE ADIPOCYTES FROM CULTURED MSCS USING DENSITY 
CENTRIFUGATION 
When planning to perform the LTA using adipogenically differentiated MSCs, a pure population 
of mature fat cells to co-culture with PBMCs was desired. However, when MSCs were 
differentiated into fat, the final population of differentiated cells was heterogeneous, with 
some MSCs remaining fibroblastic rather than developing intracellular lipid globules within the 
cytoplasm and differentiating into mature fat cells. A method to separate the mature fat cells 
from the fibroblastic MSCs was sought, and due to the observations in Chapter 4 about the 
increased buoyancy of mature adipogenically differentiated MSCs the separation of this cell 
population using centrifugation was initially used. 
Centrifugation of adipogenically differentiated MSCs was performed at 150 g for 1 minute, and 
samples of supernatant taken from various areas surrounding the meniscus. However, no 
mature fat cells were observed in any of the samples of supernatant observed at 20x 
magnification using an Olympus microscope. 
7.3.2 CEILING CULTURE SEPARATION OF ADIPOGENICALLY DIFFERENTIATED MSCS 
The next method used to attempt separate mature adipose cells from undifferentiated MSCs 
again utilised the observed buoyancy of the adipose cells. Adipogenically differentiated MSCs 
were cultured in a T75 tissue culture flask before separation into coated U-bottom 96 well 
tissue culture plates. When the mixed population of cells was detached from the tissue culture 
plastic and the flask filled with medium, undifferentiated MSCs adhered to the bottom of the 
flask (Figure 7.2), and the more buoyant adipose cells floated and attached to the roof of the 
flask (Figure 7.3). Further treatment of the adipose cells with cell detachment solution allowed 
the cells to be dispensed into coated U-bottom 96 well tissue culture plates (Figure 7.4).  
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Figure 7.2: Undifferentiated MSCs grown in adipogenic medium for 21 days attached 
to the bottom of the tissue culture flask following detachment using Hy-Q-tase™ cell 
detachment solution, and filling the flask with culture medium. 
Figure 7.3: Adipogenically differentiated MSCs grown in adipogenic medium for 21 
days attached to the roof of the tissue culture flask following detachment using Hy-Q-
tase™ cell detachment solution, and filling the flask with culture medium. 
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Although it was possible to separate adipogenically differentiated MSCs from undifferentiated 
MSCs using ceiling culture (Figure 7.3), and then dispense them into U-bottom plates (Figure 
7.4), the total number of mature adipose differentiated MSCs was very low. Therefore, 
although it was possible to obtain a pure population of mature adipose cells using this method, 
due to the small number of cells and the difficulty in assessing cell number it was not 
practicable to use this approach to isolate the number of cells required for the LTAs. The 
decision was therefore made to perform the LTAs using MSCs from donor BM4 differentiated 
into adipocytes over 21 days and not separated. Donor BM4 was the most adipogenic MSC 
donor observed in Chapter 4. It was theorised that any effect the undifferentiated MSCs would 
have in the LTA would be minimal when this donor was used, especially when combined with 
the evidence in Chapter 5 with regards to the effect of undifferentiated MSCs on PBMCs. 
 
 
 
Figure 7.4: Adipogenically differentiated MSCs following detachment using Hy-Q-
tase™ cell detachment solution and ceiling culture attachment to U-bottom 96 well 
tissue culture plates. 
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7.3.3 THE ADIPOGENESIS OF BM2 MSCS CULTURED IN ADIPOGENIC MEDIUM IN UNCOATED AND 
COATED U-BOTTOM 96 WELL TISSUE CULTURE PLATES 
To assess the difference in adipogenesis between BM2 MSCs cultured in coated and uncoated 
U-bottom 96 well tissue culture plates a direct comparison was made using 25,000 BM4 MSCs 
differentiated for 21 days in adipogenic medium. The levels of adipogenesis were measured on 
day 21 using the fluorescent microplate reader assay developed in Chapter 4. The ratio 
obtained when uncoated wells were used was 1.17, compared to 6.11 when coated wells were 
used (Figure 7.5). 
When adipogenic differentiation was performed in uncoated U-bottomed 96 well tissue 
culture plates, the initial population of MSCs dispensed into the wells formed a pellet of cells 
at the bottom of the well. This pellet of cells did exhibit good levels of differentiation (when 
viewed under bright field microscopy and when stained with Nile red), but medium changes 
were difficult to perform, as the pellets did not attach to the surface of the wells, and the act 
of withdrawing and replacing medium from these wells disturbed the pellet, with the pellet 
becoming more fragile and easier to disrupt as differentiation progressed. 
Figure 7.5: Differences of adipogenesis when BM4 MSCs are cultured in adipogenic medium 
on day 21 in uncoated, and coated U-bottomed 96 well tissue culture plates. Data is 
expressed as mean (n=6) ± 95% confidence limits. A significant difference was observed 
(p=0.0022) between uncoated compared to coated wells as determined using an unpaired 
Mann-Whitney U test. 
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Due to the higher levels of adipogenesis, and easier culture method (for medium changes and 
higher retention of mature adipocytes) the coated plates were chosen to perform the LTA 
following the differentiation of MSCs into adipocytes. 
7.3.4 THE LYMPHOCYTE TRANSFORMATION ASSAY CO-CULTURING PERIPHERAL BLOOD 
MONONUCLEAR CELLS AND MSCS 
Peripheral blood mononuclear cells were isolated from the blood of 3 healthy volunteers. 
These cells were co-cultured with BM2 donor MSCs, both undifferentiated and differentiated 
into adipose cells for 3, 7, 12, and 16 days. As previously, the counts per minute obtained were 
log10 transformed to conform to the requirements of analysis of variance (variances shown to 
be homogeneous after log10 transformation). The counts obtained for the positive control 
cultures with PHA were omitted from analyses since these were included to ensure that the 
assays were valid (PBMCs were functioning by responding to the mitogen) and it was not part 
of the experimental design to compare the level of response to the MSCs to the level of 
response to the mitogen. 
When PBMCs from donor 1 were cultured with PHA, maximal counts were observed on day 3, 
after which the response declined over the remaining 16 day culture period. This response to 
PHA stimulation was repeated for all 3 PBMC donors. When PBMCs from donor 1 were 
cultured with BM2 MSCs differentiated into adipose cells, significantly higher counts were 
recorded on days 3 and 16 compared to the unstimulated PBMCs (P<0.05 ANOVA). When 
PBMCs from donor 1 were cultured with undifferentiated BM2 MSCs significantly higher 
counts were recorded on days 3 and 7 compared to unstimulated PBMCs (Figure 7.6; p<0.05, 
ANOVA).  
The stimulation indices were calculated and are presented in Figure 7.7. This showed 
stimulation indices above 3 for PHA stimulated PBMCs from day 3, for all 3 PBMC donors.  
Stimulation indices above 3 were recorded for PBMCs from donor 1 in response to BM2 MSCs 
differentiated into adipose cells at days 3 (SI of 6.4), 12 (SI of 4.4) and 16 (SI of 12.3). For PBMC 
from donor 1 in response to undifferentiated BM2 MSCs, a stimulation index above 3 was 
recorded at days 3 (SI of 4.4) and 16 (SI of 10.7).  
When PBMCs from donor 2 were cultured with BM2 MSCs differentiated into adipose cells, 
significantly higher counts were recorded on days 3, 12, and 16 compared to the unstimulated 
PBMCs (P<0.05 ANOVA) . When PBMCs from donor 2 were cultured with undifferentiated BM2 
MSCs significantly higher counts were recorded on days 3 and 12 compared to unstimulated 
PBMCs (Figure 7.8; p<0.05, ANOVA).  
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The stimulation indices were calculated and are presented in Figure 7.9. This showed 
stimulation indices above 3 for PBMCs from donor 2 in response to BM2 MSCs differentiated 
into adipose cells at days 3 (SI of 5.0), 12 (SI of 3.3) and 16 (SI of 30.8). For PBMC from donor 2 
in response to undifferentiated BM2 MSCs, a stimulation index above 3 was also recorded at 
days 3 (SI of 3.6), 12 (SI of 10.4) and 16 (SI of 14.9). 
When PBMCs from donor 3 were cultured with BM2 MSCs differentiated into adipose cells, 
significantly higher counts were recorded on all days 3, 7, 12, and 16 compared to the 
unstimulated PBMCs (P<0.05 ANOVA). When PBMCs from donor 3 were cultured with 
undifferentiated BM2 MSCs significantly higher counts were also recorded on all days 3, 7, 12, 
and 16, compared to unstimulated PBMCs (Figure 7.10; p<0.05, ANOVA).  
The stimulation indices were calculated and are presented in Figure 7.11. This showed 
stimulation indices above 3 for PBMCs from donor 3 in response to differentiated BM2 MSCs 
at days 3 (SI of 9.0), 7 (SI of 3.2), 12 (SI of 20.6) and 16 (SI of 23.1). For PBMC from donor 3 in 
response to undifferentiated BM2 MSCs, a stimulation index above 3 was recorded at days 3 
(SI of 3.8), 12 (SI of 15.6) and 16 (SI of 13.0). 
A summary table for the stimulation indices of adipogenically and undifferentiated MSCs from 
donor BM2 when cultured with donor 1-3 PBMCs is shown in Figure 7.12. There was initial low 
trend stimulation on day 3 in adipogenically differentiated cultures, before stimulation 
dropped to 3.2 or below on day 7 for all cultures. The stimulation of PBMCs increased to 
greater than 3 by day 12, and again by day 16. The stimulation observed for adipogenically 
differentiated MSCs in the majority of cultures was higher than in the undifferentiated 
cultures.
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Figure 7.6: Log10 counts per minute of donor 1 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with BM2 
MSCs differentiated into adipose cells, or with undifferentiated BM2 MSCs. Data is 
expressed as mean (n=6) ± 95% confidence limits. Data was analysed by one-way analysis of 
variance at each time point. * indicates significant difference (p<0.05) compared to the 
PBMCs cultured in medium alone as determined by the T-method. 
Figure 7.7: The stimulation index (SI) of donor 1 PBMCs cultured with PHA (positive 
control for stimulation), with BM2 MSCs differentiated into adipose cells, or with 
undifferentiated BM2 MSCs for 16 days. The red line intersects the y-axis at 3, and values 
above this height (SI>3) are considered positive stimulation indices. 
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Figure 7.9: The stimulation index (SI) of donor 2 PBMCs cultured with PHA (positive control 
for stimulation), with BM2 MSCs differentiated into adipose cells, or with undifferentiated 
BM2 MSCs for 16 days. The red line intersects the y-axis at 3, and values above this height 
(SI>3) are considered positive stimulation indices. 
Figure 7.8: Log10 counts per minute of donor 2 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with BM2 
MSCs differentiated into adipose cells, or with undifferentiated BM2 MSCs. Data is 
expressed as mean (n=6) ± 95% confidence limits. Data was analysed by one-way analysis of 
variance at each time point. * indicates significant difference (p<0.05) compared to the PBMCs 
cultured in medium alone as determined by the T-method. 
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Figure 7.11: The stimulation index (SI) of donor 3 PBMCs cultured with PHA (positive 
control for stimulation), with BM2 MSCs differentiated into adipose cells, or with 
undifferentiated BM2 MSCs for 16 days. The red line intersects the y-axis at 3, and values 
above this height (SI>3) are considered positive stimulation indices. 
Figure 7.10: Log10 counts per minute of donor 3 PBMCs cultured in complete medium only 
(negative control for proliferation), with PHA (positive control for stimulation), with BM2 
MSCs differentiated into adipose cells, or with undifferentiated BM2 MSCs. Data is 
expressed as mean (n=6) ± 95% confidence limits. Data was analysed by one-way analysis of 
variance at each time point. * indicates significant difference (p<0.05) compared to the PBMCs 
cultured in medium alone as determined by the T-method 
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 Day 3 Day 7 Day 12 Day 16 
Adipo. Undiff. Adipo. Undiff. Adipo. Undiff. Adipo. Undiff. 
Donor 1 6.4 4.4 <3 <3 4.4 <3 16.0 12.7 
Donor 2 5.0 3.6 <3 <3 3.3 10.4 30.8 14.9 
Donor 3 9.0 3.8 3.2 <3 20.6 15.6 16.0 13.0 
Figure 7.12: Summary table of the adipogenically differentiated (Adipo.) and 
undifferentiated MSCs (Undiff.) from donor BM2 stimulating PBMCs (donors 1-3) with a 
positive stimulation index (>3), detailing the SI, and day of stimulation. Green cell colour 
represents positive SI value, and red is no significant stimulation. 
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7.3.5 THE SEPARATION OF ADIPOCYTES FROM PBMCS WHEN CULTURED TOGETHER IN THE LTA 
USING FLUORESCENCE ACTIVATED CELL SORTING (FACS). 
In addition to measuring the stimulation of PBMCs using tritiated thymidine incorporation, co-
cultures of MSCs and PBMCs were also fluorescently labelled using an anti-CD45 antibody and 
separated using a FACSAria II FACS cell sorter. Separated populations were resuspended in 
TRIzol® RNA lysis solution, and stored at -80°C. All culture medium removed from the wells on 
the tissue culture plate was stored in a polypropylene 96 well plate at -80°C. Cells stored in 
TRIzol® would be able to be subjected to qRT-PCR for expression of genes associated with the 
immunology of adipose tissue, and the immune response of T-cells. The culture medium was 
stored to enable the future assessment of the content of the medium for secreted soluble 
factors that could be present and affecting the response of the PBMCs towards both the 
differentiated and undifferentiated MSCs.  
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7.4 DISCUSSION 
There were two aims of this chapter, to develop a method for the isolation of mature 
differentiated adipose cells from 21 day differentiated MSC cultures and to determine the 
capacity of BM4 donor MSCs to stimulate the proliferation of allogeneic PBMCs from 3 donors 
before and after differentiation into adipose cells in culture using the LTA.  
When this study commenced it had been reported in the literature that MSCs were immuno-
privileged (Bartholomew et al., 2002; Tse et al., 2003; Jones et al., 2007; Niemeyer et al., 2007; 
Oh et al., 2008; Suva et al., 2008). If undifferentiated MSCs were immune-privileged then it 
was hypothosized that when these cells were differentiated they would lose this immune-
privileged phenotype, as the cells would be effectively changing from a multipotent stem cell 
into a mature terminally differentiated adipose cell (any characteristics of the undifferentiated 
MSC that allowed it to escape recognition by the immune system would change on its 
differentiation into the mature cell type in theory, since otherwise if the source of this tissue 
in-vivo  derives from the MSCs, then the tissues themselves would retain their immune-
privileged capabilities).   
When planning to perform the LTA using adipogenically differentiated MSCs it was desirable to 
utilise a pure population of mature fat cells. However, when MSCs were differentiated into fat, 
the final population of differentiated cells was heterogeneous, with some MSCs remaining 
fibroblastic rather than developing intracellular lipid globules within the cytoplasm and 
differentiating into mature fat cells.  
Previous experiments performed in Chapter 2 had demonstrated the buoyancy of adipose 
cells, with the more adipogenically differentiated MSCs exhibiting more buoyancy than 
undifferentiated MSCs. Mature fat cells were lost during the wash steps involved in the 
staining process for flow cytometry. In order to separate the mature adipose cells, it was 
hypothesized that centrifugation for a reduced time would allow the separation of the cell 
populations, with the MSCs containing very little to no intracellular lipids drawn to the bottom 
of the centrifuge tube by the centripetal forces, whereas the mature fat cells containing a large 
volume of intracellular lipids would resist the centripetal forces due to their reduced density, 
and instead float to the surface of the PBS they were suspended in. When this method was 
performed no adipose cells were found at the surface of the meniscus of the PBS, or up to 2 
cm below it. This was thought to be due to the speed of centrifugation, and the density of the 
PBS used to suspend the MSCs. Instead of remaining buoyant in the solution, the centripetal 
force used was still great enough over the shorter time used to cause the mature adipose cells 
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to collect at the bottom of the centrifuge tube, with the more fibroblastic less differentiated 
MSCs. 
The next method that was used to separate the differentiated from undifferentiated MSCs was 
a modified version of the ceiling culture protocol originally developed in 1986 (Sugihara et al., 
1986). The mixed population of differentiated MSCs was detached from the surface of the 
tissue culture plastic and the flask filled with medium. When the detached cells separated out, 
the mature adipogenically differentiated MSCs floated to the top of the flask and attached, 
while the less differentiated MSCs sank and attached to the floor of the flask. This was a 
successful method of isolating the mature fat cells, as when the roof and floor of the flask 
were viewed using bright field microscopy the roof had only differentiated cells containing a 
large volume of multilocular fat, whereas the floor of the flask did not have any mature 
adipose cells attached. Although a population of mature differentiated adipose cells could be 
isolated in a tissue culture flask, the problem remained of how to transfer these cells into a U-
bottomed 96 well tissue culture plate, in which the LTA was to be performed. The buoyancy of 
the fat cells was a hindrance, since if these cells were detached from the flask and transferred 
directly to the plate, the cells would not attach as they would float on the surface of the 
medium. It was theorised that if the mature fat cells cultured on the ceiling of the flask were 
detached, and a small volume of medium containing the fat cells dispensed into the culture 
plate then the surface tension of the liquid would keep the medium from running out of the 
wells. This would allow the fat cells to float upwards and attach to the plate. This method was 
successful in that when the wells of the tissue culture plates were viewed using brightfield 
microscopy mature fat cells could be seen attached to the wells. However, this method was 
not a viable way to separate the differentiated MSCs for use in the LTA, as for this assay a 
precise number of cells was required. Centrifugation steps followed by cell counting would 
introduce the problems seen in the flow cytometry wash steps, with increased loss of cells and 
difficulty in counting due to the fragile and buoyant nature of the fat cells. 
Due to the difficulty in obtaining a large enough population of pure adipose cells, and also 
following the stimulation of PBMCs observed when co-cultured with undifferentiated MSCs (if 
undifferentiated MSCs stimulate PBMCs then the presence of them in the LTA using mature 
differentiated MSCs was less of an issue) it was decided to perform the LTA using one of the 
more adipogenic BM MSCs. BM4 was selected for this as MSCs from this donor demonstrated 
consistently high levels of adipogenesis as measured using semi-quantitative scoring using oil 
red-O, and the fluorescent plate reader assay.  
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As discussed in Chapter 5, when performing the LTA, the optimum 96 well tissue culture plates 
were uncoated U-bottomed plates. Culturing cells in these plates is difficult when medium 
changes are needed, as the cells are not well adhered to the tissue culture plastic, therefore 
any removal of medium from the wells poses a very high risk of removing cells. Differentiating 
MSCs into adipose cells in these wells requires regular medium changes twice weekly, and the 
increasing buoyancy of the cells coupled with the poor adhesion to the plastic made medium 
changes without losing cells extremely difficult. This was further demonstrated by the 
reduction in the ratio of adipogenesis when BM4 MSCs were cultured for 21 days in both 
coated and uncoated U-bottomed 96 well tissue culture plates. Adipogenesis in coated wells 
was higher (6.11) than uncoated (1.17). Although the optimum plate to perform the LTA was 
the uncoated (Ingham et al., 1993; Ketheesan et al., 1994; Ketheesan et al., 1996b; Ketheesan 
et al., 1996a) for this assay higher levels of adipogenesis were desired, and therefore the 
coated plates were chosen to perform the differentiation of MSCs into adipose cells before the 
LTA was performed. 
As in the previous chapter both the counts per minute and the stimulation indices were 
considered in order to determine the extent of the response of the PBMCs in the LTA’s. The 
PBMCs from all three donors tested gave significantly higher counts on days 3 and 16 when 
stimulated with MSCs differentiated into adipocytes compared to cells cultured without 
stimulation (ANOVA). The PBMCs from donor 2 also gave significantly higher counts on day 12, 
and PBMCs from donor 3 on all days. When PBMCs from donor 1 were cultured with 
undifferentiated MSCs significantly higher counts compared to cells cultured without 
stimulation on days 3 and 7 were recorded. The PBMCs from donor 2 also gave significantly 
higher counts on days 3 and 12, and PBMCs from donor 3 on day 3, 12 and 16. 
Stimulation observed with undifferentiated MSCs on day 3 may have been due to low level 
non-specific stimulation (stimulation index was <4), whereas significant stimulation on day 3 
observed in adipogenically differentiated MSCs (between 4-9), could have been due to the 
production of adipokines and pro-inflammatory cytokines by the fat cells following MMC 
treatment.   
When the SI were calculated for the LTA’s with differentiated MSCs, PBMCs from all donors 
were stimulated on days 3, 12, and 16, with donors 2 and 3 exhibiting significant stimulation 
on all days. For undifferentiated MSCs stimulation was observed on days 3 and 12 for all 
donors, with donors 2 and 3 also exhibiting stimulation on day 16. 
Although significant, the counts per minute recorded in the LTA’s were lower than those 
recorded in Chapter 6. This was most probably due to the use of coated plates, as opposed to 
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uncoated. The positive control counts were noticeably higher when uncoated plates were 
used. In order to allow comparison between undifferentiated and adipose differentiated MSCs, 
and due to the use of different tissue culture plates than those used in Chapter 6, both adipose 
differentiated and undifferentiated MSCs were used in the LTA using the coated plates. The 
highest SI observed was with the differentiated MSCs and donor 2 PBMCs on day 16 (SI=30.8). 
The highest SI obtained for co-cultures of donor 1-3 PBMCs with undifferentiated BM2 MSCs 
was 15.6 (donor 3 day 12), and again this provided strong evidence for the stimulation of 
PBMCs by allogeneic undifferentiated MSCs.  
When the SI was compared between the differentiated and undifferentiated MSCs, 
adipogenically differentiated MSCs exhibited a trend towards having higher SI than their 
undifferentiated counterparts. This supported the hypothesis that following differentiation 
into adipocytes, the immunogenicity of the MSCs increased and could be explained by the 
relationship that adipose tissue has been reported to have with the immune system and the 
secretion of various pro-inflammatory factors (Fantuzzi, 2005; Tilg and Moschen, 2006). This 
increase in stimulation also supported the theory of the loss of any immuno-privileged nature 
of the MSCs as they change from immature stem cells, to mature terminally differentiated 
adipose cells. 
Unfortunately, time was a limiting factor in these experiments and the additional experimental 
work that was planned to aid understanding potential mechanisms could not be completed, 
specifically involving two types of analysis, gene expression and the production of cytokines. 
During these LTA’s on each day that cells were harvested the medium from replicate cultures 
was removed, and stored at -80°C in polypropylene 96 well plates. This was stored so that 
ELISA’s to detect cytokines secreted by MSCs that may have an effect of the stimulation of 
PBMCs could be performed. As discussed chapter 1, the soluble factors secreted by MSCs are 
thought to be heavily involved in how they down regulate the immune response. Indoleamine 
2,3-dioxygenase (Meisel et al., 2004) and prostaglandin E2 (Tse et al., 2003; Aggarwal and 
Pittenger, 2005; Yanez et al., 2010) have both been strongly suggested to play a large role in 
how MSCs inhibit activated T cell proliferation and pro-inflammatory cytokine production. The 
presence of both of these secreted factors in the co-culture medium could be determined to 
assess how quantities changed as the length of time the MSCs were in co-culture increased.  
In addition to storing culture medium for performing ELISA’s for cytokines, co-cultures of 
differentiated and undifferentiated MSCs with PBMCs were separated and stored in RNA lysis 
buffer. The aim of this was to enable the expression of adipose-specific adipokines leptin and 
adiponectin, and also the expression of two pro-inflammatory cytokines IL-6 and TNF-α, the 
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co-stimulatory molecules CD40, CD80, and CD86, and MHC class-I and II to be assessed by qRT-
PCR (qRT-PCR was chosen to determine levels of expression as opposed to ELISA as FACS 
enabled a pure population of the differentiated and undifferentiated MSCs to be separated 
from the PBMCs, so expression in the two cell populations could be determined, rather than 
the combined expression as an ELISA using the culture medium would determine). 
In conclusion, a suitable method to allow the separation of adipogenically differentiated MSCs 
that allowed the accurate enumeration and dispensing into wells of a 96 well plate was not 
determined. It was possible to separate the mature differentiated MSCs using modified ceiling 
culture separation, but the handling of the separated cells for further assays in which a specific 
number was required was difficult. The LTA was therefore performed on a heterogeneous 
differentiated MSC population, in coated U-bottom tissue culture plates, again to aid in the 
generation of a suitable number of mature adipose cells to be co-cultured with PBMCs. It was 
found that when the adipogenically differentiated MSCs were co-cultured with PBMCs, the 
PBMCs did exhibit significant stimulation. Levels of stimulation were also more frequent, and 
to a higher level in adipogenically differentiated cultures than the undifferentiated 
counterparts. As has been shown in the previous chapter (Chapter 6) maximal stimulation was 
observed at 12-16 days. Extending the LTA to assay for the immunogenicity of MSCs has not 
been performed before, and it is through doing this that it has been possible to demonstrate 
that MSCs may not be immuno-privileged as indicated in the prevailing literature, and MSCs 
when differentiated exhibit greater immunogenicity than when in their naive undifferentiated 
state. 
In order to maximize the available data generated from the LTA, the culture medium was 
retained for future analysis of cytokine content (such as IDO and PGE2) by ELISA. In addition, 
the sorting of the PBMCs from the MSCs allows the future analysis of gene expression by qRT-
PCR for such genes as the co-stimulatory molecules, MHC class-I and II, pro-inflammatory 
cytokines IL-6 and TNF-α, and the proinflammatory adipokines leptin and adiponectin. 
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Chapter 8:  FINAL DISCUSSION 
All stem cells exhibit three important characteristics that define them as a stem cell. They are 
unspecialised cells, that are capable of self renewal, and they can differentiate into other 
specialised mature cell types. There are three main categories of stem cells, these being 
totipotent stem cells such as those from the fertilised zygote (can differentiate into all tissues, 
including extra-embryonic), pluripotent stem cells such as those found in the blastocyst inner 
cell mass (embryonic stem cells, have the potential to differentiate into any cell within the 
body), and finally multipotent stem cells such as the bone marrow derived stem cells used in 
this study (these cells can only differentiate into a limited subset of defined tissue types). 
There is also a further subset of ‘stem cells’ which are known as induced pluripotent stem cells 
(iPS). These cells have the characteristics displayed by embryonic stem cells, but their 
pluripotency is induced by the forced expression of genes, such as the transcription factors 
Oct3/4, Sox2, Klf4, and c-Myc (Takahashi et al., 2007).  
With regard to their use in the clinic as regenerative cell therapies or in tissue engineering 
applications, ESCs will always be allogeneic due to the means by which they are derived. 
Undifferentiated and differentiated ESCs express MHC class-I (Drukker and Benvenisty, 2004) 
and their immunogenicity has yet to be fully explored in-vitro and in-vivo. One of the drivers 
for the development of methods to generate patient derived iPS cells has been that these cells 
have the potential to provide an unlimited supply of autologous  pluripotent cells for 
regenerative medicine applications. However, there are issues regarding the safety of iPS cells 
such as their potential for tumorgenicity which remain to be resolved.       
Adult multipotential mesenchymal stem cells (MSC) can be derived from the patient requiring 
therapy, expanded in-vitro or used with minimal manipulation to treat the patient from whom 
they are derived (autologous). On the other hand, they may be isolated from donors, 
expanded in-vitro and used to treat allogeneic recipients.  There are minimal issues regarding 
the safety of using autologous adult MSC in clinical applications. Moreover, the accumulating 
evidence that allogeneic MSC have immunosuppressive and immune-evasive properties has 
led to their use in some clinical applications.  
It is not surprising then that the majority of clinical trials that have been undertaken or are 
currently recruiting utilise MSCs.  On clinicaltrials.gov, there are 13 trials registered for iPS 
cells, the majority of which are still active or recruiting and 17 trials for ESCs, again with the 
majority active or recruiting. However there are 188 studies involving MSC with a mixture of 
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completed, active and recruiting trials (source clinicaltrials.gov, accessed September 2011). 
The majority of trials involving ESCs and iPSCs focus on the potential of these cells for non-
mesodermal applications (such as nerve cell or retina regrowth) which MSC would not be 
suitable for. Currently MSCs represent an easier to obtain and safer alternative for 
mesenchymal applications. 
In the early 1960’s, a population of adherent cells present within the bone marrow was 
documented (Friedenstein et al., 1968). These cells were fibroblastic, were able to repair 
damaged bone and were called osteogenic progenitors. In the early 1990’s Arnold Caplan then 
coined the term mesenchymal stem cell and applied this to these cells cultured ex-vivo 
(Caplan, 1991). The in-vitro trilineage assays demonstrating MSCs multipotency and the 
expression of CD73 and CD105 were published by Mark Pittenger in 1999 (Pittenger et al., 
1999), before the lack of standardised nomenclature and characterisation prompted the 
declaration by the ISCT of the criteria that currently defines the description for cells to be 
recognised as MSCs (Dominici et al., 2006). These cells have been widely studied and have 
been acclaimed for their potential uses within the field of regenerative medicine for their 
advantages such as ease of isolation and expansion (Jones et al., 2002) and immune-privileged 
status and immune-suppressing capabilities (Le Blanc and Ringden, 2007; Nauta and Fibbe, 
2007). The majority of studies on the immuno-regulatory properties of MSCs have investigated 
the ability of MSCs to reduce an active ongoing immune response. This capability has been 
demonstrated frequently in-vitro (Bartholomew et al., 2002; Di Nicola et al., 2002; Djouad et 
al., 2003; Krampera et al., 2003; Le Blanc et al., 2004a; Bocelli-Tyndall et al., 2007; Nasef et al., 
2009; Kuci et al., 2010), and also in-vivo (Le Blanc et al., 2004b; Le Blanc et al., 2008). 
The main area of successful use of MSCs in the clinic is for the treatment of autoimmune 
conditions, in particular for GvHD and Crohns disease. With regard to GvHD, MSCs were first 
used to treat a patient with treatment-resistant grade IV GvHD resulting in a significant clinical 
improvement (Le Blanc et al., 2004b). Following on from this study a phase II trial in 55 
patients used MSCs again to treat severe GvHD, and reported significant improvements in the 
majority of patients treated (Le Blanc et al., 2008). The therapeutic effects of MSC in the 
treatment of GvHD appeared to be independent of donor-HLA match. There are currently 23 
clinical trials using MSCs to treat GvHD, the majority of which utilise allogeneic MSCs 
(clinicaltrials.gov accessed September 2011). On the other hand,  a recent study demonstrated 
that although there was an increase in initial survival, there was no change in the long term (>2 
years) survival in severe GvHD patients after allogeneic MSC administration (Remberger et al., 
2011). This is in contention with another recent study that used a commercial product based 
on expanded allogeneic MSCs (Prochymal™; Osiris Theraputics) in the treatment of severe 
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GvHD in paediatric patients which demonstrated favourable results with 5/12 patients still 
alive 611 days post-treatment (Prasad et al., 2011).  
Currently, there are 8 clinical trials underway that are utilising MSCs to treat patients with 
Crohns disease (clinicaltrials.gov accessed September 2011), with 50% of these using 
Prochymal™. This product is also undergoing phase III clinical trials for treatment of GvHD and 
Crohns disease, and is also being developed for the repair of cardiac tissue following heart 
attack.  
Although allogeneic MSCs appear to have significant promise based on the current clinical 
results, it is necessary to determine the repeatability and safety of using allogeneic MSCs in 
additional clinical applications, such as their use in tissue engineering of bone, cartilage and 
fat, in order to progress potential solutions from research level to clinical application. Very 
little work has currently been performed investigating the inherent immunogenicity of 
allogeneic MSC at different stages of their differentiation. The work undertaken in this study 
was to increase knowledge of the immunogenicty of allogeneic MSC and thus gain a better 
understanding of their potential clinical applications through refining and developing 
methodologies for the in-vitro assessment of the adipogenesis of human bone marrow MSCs, 
and to refine the methodology currently used to assess the immunogenicity of human bone 
marrow MSCs in-vitro. Tissue engineered products using allogeneic MSCs do exist on the 
market (Osteocel™ from Nuvasive for example, an allograft cellular matrix containing MSCs) 
however it is quite difficult to find clinical data on long term post-operative results. As 
allogeneic MSCs are starting to make their way into the clinic, it becomes important to assess 
what happens to these cells when they proliferate and differentiate after implantation. 
The first stage in the investigation was to obtain expanded populations of MSCs isolated from 
fresh human bone marrow isolates, and to characterise these cells by their morphology and 
phenotype to establish if the isolated cell populations were indeed MSCs. In order to do this, 
fresh bone marrow isolates were processed to isolate the adherent cell population and these 
cells were expanded in culture. The morphology of the cells when grown on coated tissue 
culture plastic flasks was observed and the cells were phenotyped using flow cytometric 
analysis against cell surface markers. The trilineage potential of the isolated MSCs was 
observed, and populations were stained with alizarin red for calcium content, Oil red-O for 
intracellular lipid content, and alcian blue for GAG content. 
Putative MSCs isolated from bone marrow were plastic adherent, exhibited fibroblastic 
morphology and formed distinct colonies when expanded. Using flow cytometry for analysis of 
cell surface marker expression these cells were positive for CD73, CD90, CD105, and HLA-ABC 
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and negative for the expression of CD14, CD19, CD34, CD40, CD45, CD80, CD86, and HLA-DR. 
The pattern of expression of these cell surface markers is replicated throughout the literature 
(Barry and Murphy, 2004; Dominici et al., 2006; Uccelli et al., 2006; Chamberlain et al., 2007; 
Nauta and Fibbe, 2007). 
The MSCs exhibited trilineage potential, and were able to differentiate into adipocytes, 
osteoctytes and chondrocytes using specific culture conditions. In the trilineage differentiation 
assays the MSCs showed varied levels of differentiation, which was believed to be due to the 
heterogenic nature of MSCs, and the differences in the ages of the donors (D'Ippolito et al., 
1999; Kretlow et al., 2008). The chondrogenic differentiation observed using the micromass 
technique was minimal. Increased staining was observed for all bone marrows from day 0, but 
at variable levels between the bone marrow donors. BM1 demonstrated the least 
chondrogenesis and this could have been due to the age of the donor (69). Levels of 
chondrogenesis may have been imporoved the the cells had been grown in true three 
dimensional pellet culture. 
All of the donor adherent cells isolated fulfilled the criteria as defined by the ISCT for the 
definition of a mesenchymal stromal cell; MSCs were plastic adherent under standard culture 
conditions, expressed CD73, CD90, and CD105, and did not express CD14, CD19, CD34, CD45, 
and HLA-DR, and were able to differentiate into adipocytes, osteoblasts and chondroblasts 
(Dominici et al., 2006).  
This fulfilled the aims of the first part of the study, and after determining that the cells used 
were MSCs, the next step was to perform further analysis of the adipogenesis of the MSCs.  
Adipogenically differentiated MSCs were chosen as a mature differentiated cell type to use to 
study the immunology of differentiated allogeneic MSCs as native adipose tissue has been 
shown to function as an immunological organ and as a tissue is able to secrete various pro-
inflammatory cytokines (IL-6 and TNF-α), chemokines (monocyte chemoattractant protein-1) 
and adipose tissue specific ‘adipokines’ that have direct immunological effects (such as leptin, 
adiponectin, and resistin). Although the production of TNF-α is mainly due to the macrophages 
present in adipose tissue, adipocytes have been reported to contribute up to one third of the 
circulating IL-6 in obese patients (Tilg and Moschen, 2006).  
Donor MSCs were differentiated into adipose cells using adipogenic differentiation medium 
and several published methods for measuring adipogenesis were assayed for suitability; Oil 
red-O staining of cells and semi-quantitative scoring, real-time PCR using the markers of 
adipogenesis PPAR-ɣ and FABP4, flow cytometry using an intracellular antibody towards FABP4 
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and the chemical dye Nile red, and finally a fluorescent microplate reader assay using Nile red 
and DAPI. A quantitative method of assessing adipogenesis was required, as in the final stages 
of this study the aim was to assess the proliferative response of PBMCs when cultured with the 
differentiated MSCs. Since, in-vivo, adipose cells are believed to contribute to the secretion of 
pro-inflammatory cytokines, the MSCs with the greatest adipogenic potential were sought. 
Initially Oil red-O staining was used to stain the intracellular lipid droplets and the 
differentiation quantified using a grading system (English et al., 2007). Alternative methods for 
quantifying the amount of Oil red-O dye present in stained samples were available (the most 
common being the absorbance measurement of Oil red-O dye staining the lipid vesicles within 
cells using spectrometry), but this method only gave an overall level based on total dye 
content in a sample (Platt and El-Sohemy, 2009). The Oil red-O dye binds to neutral 
triglycerides and lipids present in cells and the greater the amount of lipids, the greater the 
intensity of staining. It was found that fibroblasts appeared to exhibit low levels of 
differentiation potential, with fibroblasts cultured in adipogenic medium developing small 
quantities of intracellular lipids. This remained at a low level though and using the grading 
scheme very few Grade 2-4 fat cells were present. In MSCs, Oil red-O staining demonstrated an 
increase in both the percentage of fat-laden cells and the amount of fat per cell. Although this 
method provided a visual method of quantification, it was subjective and very time consuming 
and as such it was not suitable as a higher throughput method for the quantification of 
adipogenesis.  
For quantitative real-time PCR, two genes associated with adipogenesis were selected; 
peroxisome proliferator activated receptor (PPAR-γ) and the late marker of adipogenesis, fatty 
acid binding-protein 4 (FABP4). Both of these genes have been shown to increase in expression 
as MSCs undergo adipogenesis (Janderova et al., 2003; Fink et al., 2004; Neubauer et al., 2004; 
Sekiya et al., 2004; Blum and Benvenisty, 2008). In contrast to previously published data 
(Janderova et al., 2003; Sekiya et al., 2004) although PPAR-γ expression generally increased 
during adipogenesis the changes were relatively small and did not reflect visible adipogenic 
differentiation in the MSCs. However in agreement with previous studies FABP4 expression 
rose gradually up to day 21 (Sekiya et al., 2004; Boucher et al., 2009). It was noted however 
that increased expression of FABP4 did not always translate into a higher level of visual fat 
content.  
It was concluded that qRT-PCR was highly quantitative and able to track adipogenesis on a 
transcriptional level, but it was time consuming and labour intensive and therefore not 
considered suitable for a reliable high-throughput measurement of adipogenesis.  
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To further evaluate the use of FABP4 as a suitable marker for adipogenesis, FABP4 protein 
accumulation in MSCs was monitored using flow cytometry in differentiating MSCs using an 
intracellular antibody. A gradual accumulation of more granular cells was observed as the 
time-course progressed, correlating with increasing FABP4 levels in these cells. In addition to 
this Nile red dye was also used to stain for lipids using flow cytometry and Nile red 
fluorescence increased as the time course progressed, with the more granular cells having 
higher amounts of Nile red fluorescence compared to the less granular cells. Both of these 
methods resulted in the higher mean fluorescence intensity of the more granular positively 
staining population of cells peaking on day 14 and decreasing on day 21. This was in contrast 
to a previous study which showed an increase in staining as the timecourse progressed, 
including on the final day 28 (Smyth and Wharton, 1992). The reduction in the positively 
staining population was not observed when the cells were viewed microscopically and it was 
hypothesized that the reduction in the more granular, more mature fat cells was perhaps 
because of the loss of these cells during the wash steps required in preparation for flow 
cytometry, due to the increased buoyancy of the cells.  
After comparing the various methods that were routinely used to assess adipogenesis in 
differentiated MSCs it was concluded that semi-quantitive scoring provided a visual method of 
quantifiying adipogenesis, but it was subjective and very time consuming. qRT-PCR was 
similarly time-consuming, and measured mRNA levels instead of protein or lipid directly. Flow 
cytometry correlated well with morphological lipid accumulation in MSCs, however there was 
a danger of losing mature floating fat cells during the preparation steps.  
Since these methods did not provide a robust and efficient assay for quantifying adipogenic 
differentiation, the utility of a Nile red-based fluorescence microplate assay to measure 
adipogenesis was explored. This assay used intracellular Nile red fluorescence to quantify lipid 
accumulation, and DAPI staining for cell nuclei for normalization. The average fluorescent 
intensity for DAPI and Nile red for each well was measured and a ratio of adipogenesis 
determined based on the number of cells present (represented by DAPI fluorescence) to 
amount of intracellular Nile red staining. MSCs stained only with DAPI were found to have 
increased fluorescence over the timecourse, demonstrating that proliferation of MSCs 
continued even when differentiating. It was also found that Nile red could be used to measure 
adipogenesis as a single dye, but due to the aforementioned proliferation of cells, the ratio 
using Nile red and DAPI together was preferred.  
The fluorescent microplate assay provided both highly quantitative measurements and 
fluorescent images of fat droplet distribution per cell and allowed a numbered measurement 
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to be assigned to differentiated cultures based on their level of adipogenesis, with visual 
verification of adipocyte content. This method had the additional advantage of being high 
throughput and cost effective. 
Previous studies have demonstrated the differentiation heterogeneity of MSCs from different 
donors undergoing osteogenesis (Phinney et al., 1999; Siddappa et al., 2007). During the 
timecourse and throughout the various methods employed it was also observed that this 
variation between donors existed for adipogenesis. MSCs from different donors varied in their 
adipogeneic differentiation potential and morphological analysis of the mature adipose cells 
using Oil red-O staining showed heterogeneity in the same adipogenesis-driven MSC cultures, 
with not all cells within the assay differentiating into adipocytes at the same rate and a subset 
of the cells failing to differentiate into fat cells. From this it appears that there a certain subset 
of the MSCs that possess the ability to differentiate into adipocytes, while the remaining cells 
are unable to progress into mature fat cells. This may be due to preconditioning of the bone 
marrow MSCs that even at this stage of development in the stem cell population there exists a 
number of cells whose fate has already been predetermined to such a degree that 
differentiation into adipocytes cannot be achieved in 21 days. It is possible that given longer 
these remaining cells would differentiate into mature adipose cells, or it is also possible that 
the method of culture would need to be adapted to promote the adipogenesis of these cells. 
Adipogenesis in-vivo does not occur in a two dimensional monolayer and our method of 
culture may preclude MSCs that are not predisposed for adipogenesis from turning into fully 
mature adipose cells. 
The microplate assay was also found to be the most efficient and simple to perform on a larger 
volume of samples, and as Nile red is a chemical dye it was a more cost effective alternative to 
using antibodies. Using this method allowed MSCs with a greater adipogenesis to be selected 
for further experiments, in which a higher grade of differentiation would be beneficial.It was 
found that BM 4 exhibited the highest levels of adipogenesis as measured using the microplate 
assay.  
As mentioned previously, the immunogenicity of MSCs is controversial. These cells have been 
reported to be immuno-privileged and have immunosuppressive properties (Bartholomew et 
al., 2002; Le Blanc et al., 2003b; Tse et al., 2003). Given the ability of these cells to differentiate 
into bone, fat, and cartilage cell types (Prockop, 1997; Pittenger et al., 1999; Barry and 
Murphy, 2004; McGonagle and Jones, 2008) and potential applications in tissue engineering, 
the question regarding the immunogenicity of MSCs is important to fully explore in both in-
vitro and in-vivo systems. There are various methods used in the literature to study the 
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immunogenicity of MSCs; by tracking T-lymphocyte responder cell divisions using CFSE and 
flow cytometry or BrdU incorporation, or looking at the effect of MSCs on other immune cells 
such as NK-cells or B-cells (Sotiropoulou et al., 2006; Oh et al., 2008; Suva et al., 2008; Asari et 
al., 2009). The most commonly used method and the one most viable for the determination of 
rejection by the adaptive response is the lymphocyte transformation assay. The methods used 
in the literature, however, have been highly variable, with different numbers of stimulator 
MSCs to responder cells, different methods for mitotic inhibition of responder cells, the 
method of measurement of lymphocyte proliferation, the use of PBMCs or purified T-cells, and 
the types of plate (Bartholomew et al., 2002; Tse et al., 2003; Niemeyer et al., 2007; Oh et al., 
2008; Suva et al., 2008). Most importantly though, the incubation time used has not been 
extended beyond 7 days in any of the studies, and so may not give enough time for the 
indirect immune response to occur. 
The next stage therefore was to develop the methodology to assess the proliferation of PBMCs 
when cultured in lymphocyte transformation assays with MSCs. The LTA can be used for the in-
vitro assessment of the immune response of peripheral blood mononuclear cells (PBMCs) 
towards an antigen, and was originally developed as an in-vitro alternative to the then 
previously only in-vivo assays to measure cell mediated immunity. In addition to using MSCs in 
the LTA, human dermal fibroblasts were also used as a differentiated control cell type, to 
compare levels of stimulation. 
There were 5 main objectives that were required for the development of the LTA, the 
determination of the concentration of PHA (mitogen) for use as the positive control for 
lymphocyte activation, which method to use to for spiking the cells (using tritiated thymidine), 
the determination of the concentration of mitomycin C for the mitotic inhibition of stimulator 
cells while retaining  cell viability, the determination of the cell number and ratio of responder 
and stimulator cells in the LTA and finally the determination of the concentration and source of 
serum for cell culture medium supplementation. 
Peripheral blood mononuclear cells were isolated using a Lymphoprep® density centrifugation 
gradient and PHA was selected to treat PBMCs as a positive control for stimulation. The 
proliferation of cells when stimulated was measured using tritiated thymidine (3H) 
incorporation (high and low activity). The low activity 3H provided significantly higher counts 
per minute over the high activity, and therefore was selected to use in experiments. A PHA 
concentration of 32 µg.ml-1 also gave the highest counts from the concentrations used and was 
selected to use as a positive control for lymphocyte stimulation.  
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In the LTA, the cell population acting as the stimulator cells is the MSCs. The mitotic ability of 
these cells required inhibition, in order that the incorporation of 3H measured was only due to 
the proliferation of the responder (lymphocyte) cells. Previously cell division has been 
mitotically inhibited using gamma irradiation (Bartholomew et al., 2002; Tse et al., 2003; 
Niemeyer et al., 2007). Other studies have used the chemical compound MMC, in 
concentrations between 10 and 25 µg.ml-1 (Oh et al., 2008; Nasef et al., 2009; Prasanna et al., 
2010). These studies did not report upon whether the treated MSCs were unable to 
proliferate, or were indeed viable, after treatment with MMC. It was decided to evaluate 
concentrations of MMC in the 10-25 µg.ml-1 range and determine if the MSCs treated were still 
viable but unable to divide in culture. In order to do this MSCs and fibroblasts were treated 
with 3 concentrations of MMC (50, 25, and 12.5 µg.ml-1) and the proliferation measured using 
fluorescein diacetate. It was found that all 3 concentrations of MMC inhibited the proliferation 
of cells, so 12.5 µg.ml-1 was selected for subsequent use since this was the lowest (and 
therefore least cytotoxic) that inhibited the proliferation of both cell types whilst the cells 
remained viable. 
The optimum cell number and ratio of PBMCs that generated the highest counts was 
determined using a one way MLR, and it was shown that the highest counts were obtained 
when a ratio of 1:1 responder cells to stimulator cells was used. In contrast with previous 
studies optimum counts per minute were also obtained when 100,000 total cell number per 
well was used (as opposed to Tse et al. who used 100,000 PBMCs and 15,000 MSCs (Tse et al., 
2003), LeBlanc et al. who used 100,000 PBMCs and between 10-40,000 MSCs (Le Blanc et al., 
2003b) and Bartholomew et al. who used 100,000 PBMCs and 100,000 MSCs (Bartholomew et 
al., 2002). The majority of the previous literature therefore used 100,000 PBMCs before the 
addition of MSCs to the culture, however in this study it was found that 50,000 total number of 
cells also demonstrated high counts per minute comparable to 100,000 cells with no significant 
difference between the two cell densities.  
Finally the type and concentration of serum used in the complete culture medium was 
determined. A comparison assay of fetal calf serum and human AB serum showed no 
significant difference in counts per minute in the negative controls, however, the positive 
control counts were significantly higher when human serum was used; therefore human AB 
serum was selected to be used in subsequent LTAs. Previously 10% FCS has been used in LTAs 
(Nasef et al., 2009; Wada et al., 2009; Prasanna et al., 2010), or 5-10% human serum (Bocelli-
Tyndall et al., 2007; Niemeyer et al., 2007) so LTAs were performed using 2, 5, and 10% (v/v) 
human serum in complete RPMI culture medium. No significant difference was observed 
between the concentrations of serum used, so 10% was chosen. It was also important to avoid 
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the use of FCS, since this is of xenogeneic origin and might be capable of stimulating PBMCs in 
negative controls without PHA or stimulator cells.   
The developed LTA used 32 mg.ml-1 PHA as positive control for stimulation. The ratio of PBMCs 
to MSCs was 1:1 and 25,000 cells were used for each (giving a total cell number of 50,000 per 
well). In order to mitotically inhibit the responder MSCs the cells were incubated with 12.5 
mg.ml-1 mitomycin C for one hour. The culture medium used was RPMI-1640 supplemented 
with 10% (v/v) human AB serum. In order to determine levels of stimulation, test cultures were 
spiked with low activity tritiated thymidine before the stimulation index was calculated by 
dividing the negative control counts per minute into test counts per minute. For further 
analysis of the data,  Log10 counts per minute in control and test wells were compared using 
one-way ANOVA, and the minimum significant difference (p<0.05) between group means 
determined (Sokal and Rohlf, 1981). 
Once the conditions for the assay had been determined, lymphocyte transformation assays 
were performed using 4 donor MSCs with PBMCs isolated from 6 donors. In addition to this, 
LTAs using human dermal fibroblasts were also performed. The MSCs/PHDFs were cultured 
with PBMCs for 3, 5, 7, 12, 16 and 21 days before spiking with low activity tritiated thymidine 
and the stimulation determined. 
Previous studies of the immunogenicity of MSCs using similar LTAs have only reported the data 
from tritiated thymidine incorporation as the stimulation index (Le Blanc et al., 2003b). A 
stimulation index greater than 3 is considered significant (Ivanyi and Lehner, 1970; Hirose et 
al., 1989; Kimball, 1990; Gupta et al., 1996; Satoskar et al., 1998). It has been reported that the 
SI is a problematic indicator of lymphocyte proliferation because, being a ratio, it weighs 
unstimulated values so heavily (Herbert et al., 1994). The main problem found with the 
unstimulated values in LTA’s is that they vary a great deal. In order to combat this, 
unstimulated controls were performed on a minimum of four replicates and mean counts were 
used. When the LTA was being optimised discrepancies did occur between the repeat values, 
but the substitution of fetal calf serum for human AB serum minimised the variances observed. 
In addition, the log10 counts per minute obtained in the LTA’s were statistically analysed 
(ANOVA) to determine significanct differences between unstimulated and stimulated cultures. 
Significant stimulation observed using the SI generally correlated with the significant 
differences in the counts. Using the SI as a method to determine stimulation allowed 
comparisons to be made to previous studies of MSC and PBMC LTA’s.  
As discussed previously, the calculation of the SI is dependent on good negative controls. The 
negative control for stimulation was PBMCs cultured in medium alone, and these cultures 
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were performed in replicates of four, and the mean used to calculate the SI. It was found that 
PHDFs and MSC from all BM donors (1-4) stimulated all of the PBMC donors, with 2 
exceptions; BM1 with donor 5 PBMCs, and BM3 with donor 2 PBMCs. This is in strong 
contention, with the majority of the literature in which MSCs failed to stimulate allogeneic 
PBMCs in LTAs (Bartholomew et al., 2002; Le Blanc et al., 2003b; Tse et al., 2003). Even in the 
more recent literature, it is still the commonly held belief that allogeneic MSCs are immuno-
privileged (Bassi et al., 2011; English and Mahon, 2011). That this is the widely held opinion is 
not surprising, given that in the majority of the studies in which LTAs have been performed 
using allogeneic MSCs, the incubation period of co-culture is usually less than seven days. The 
highest levels of stimulation observed in this study were usually observed after day 7, with the 
greatest stimulation observed at days 12-16. Given the low/lack of MHC class-II and co-
stimulatory molecule expression this, as mentioned previously, is not especially surprising. 
Previous studies have focused on the ability of MSCs to stimulate the direct response through 
limiting the culture of PBMCs with MSCs for less than 7 days. As discussed in the Introduction, 
the indirect and semi-direct pathways of allorecognition rely on the alloantigens that are shed 
from the graft cells, which are then processed as exogenous antigens by recipient APCs before 
presentation to naive T-cells. This process was theorised to take longer than direct recognition 
and by extending the duration of the LTA up to 21 days it has clearly been demonstrated that 
MSC have the capacity to stimulate the proliferation of allogeneic PBMC in-vitro. It is 
hypothesised that the stimulation observed was due to indirect and semi-direct pathways of 
recognition of the allogeneic MSCs. 
In addition to production of various anti-inflammatory cytokines, MSCs have also been shown 
to produce growth and proinflammatory factors, such as bFGF, IL-6, and TNFα, which may also 
explain some of the stimulatory effect of MSCs on PBMCs in-vitro (Crop et al., 2010). Il-6 and 
TNF-α mainly augment the specific immune response indirectly through the stimulation of the 
maturation of dendritic cells or B-cells (Janeway et al., 2005), appropriate recognition of 
antigen by lymphocytes would still be necessary for a proliferative response.   
Very few studies have investigated the effect of how the differentiation of MSCs affects the 
stimulation of PBMCs. In one study bone marrow MSCs were differentiated into osteocytes for 
14 days, before performing the LTA for 7 days. They found no significant stimulation with 
either allogeneic undifferentiated or differentiated MSCs (Niemeyer et al., 2007). An earlier 
study used undifferentiated MSCs and MSCs differentiated into bone, fat, and cartilage 
following differentiation for 6 to 12 days, before performing the LTA for 6 days. This study 
found that there was no proliferative response observed when undifferentiated MSCs were 
used, and also no response when adipogenic, osteogenic, or chondrogenic differentiated MSCs 
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were co-cultured with PBMCs (Le Blanc et al., 2003a). When the LTA was performed in this 
study using differentiated MSCs it was found that adipogenically differentiated MSCs 
significantly stimulated PBMCs, and they did this at a higher level than undifferentiated MSCs. 
The stimulation observed however was not as strong as might have been hypothesized, but 
this could have been due to the use of tissue culture plates that were not optimal for LTAs (U-
bottomed coated 96 well tissue culture plates had to be used due to the nature of the 
differentiated mature fat cells).  
In light of these findings, it is relevant to discuss why the therapeutic use of allogeneic MSCs in 
the clinic has proved successful. As a cellular therapy MSC have been shown to be able to aid 
in the alleviation of symptoms in conditions such as GvHD and Crohns disease. In the 
treatment of patients with these conditions, allogeneic MSCs are generally administered 
intravenously, a route that would not instigate danger signals and is known to be tolerogenic. 
Moreover, the patients treated are often immunocompromised or immunosuppressed.  There 
is very little evidence to suggest that allogeneic MSCs survive in the longer term in 
immunocompetent patients. The potential use of MSCs in tissue engineering applications 
poses very different issues. In tissue engineering applications such as the replacement of bone, 
cartilage or fat, a high density of allogeneic MSCs would be delivered with a scaffold into a 
surgical wound, instigating danger signals. It is therefore contended that in this context, the 
allogeneic MSC would be recognised and eliminated by the recipient immune system.   
More recently there have been a small number of studies that have shown that MSCs do in 
fact stimulate PBMCs in murine (Nauta et al., 2006b) and rat models (Huang et al., 2010) and 
using human MSCs (albeit adipose tissue derived) significant stimulation of PBMCs in co-
culture was also observed (Crop et al., 2010). Nauta at al. demonstrated the existence of 
memory T-cells towards allogeneic MSCs 4 weeks after MSC administration. Huang et al. 
demonstrated increased MHC class I and II expression after differentiation of allogeneic MSCs 
into myogenic, endothelial or smooth muscle type lineages resulting in increased cytotoxicity 
when cultured with allogeneic leukocytes. In the in-vivo experiments allogeneic MSCs were 
implanted into infarcted rat myocardium and these cells were eliminated within 5 weeks after 
implantation. Any functional benefits obtained from the treatment were lost within 5 months. 
They concluded that the long term ability of allogeneic MSCs to preserve function on the 
infarcted heart is limited due to the differentiation of the MSCs, from an immuno-privileged 
phenotype into an immunogenic state (Huang et al., 2010). Crop et al. demonstrated that 
allogeneic MSCs did stimulate proliferation of PBMCs after 7 days of co-culture (4 fold 
increase) but also showed that autologous MSCs stimulated a 3 fold increase in PBMC 
proliferation. Interestingly, in these experiments, MSC were removed after 7 days of culture 
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and the PBMC cultures that were maintained demonstrated an increase in proliferation (up to 
25 fold) that was not observed if MSCs remained in the cultures with PBMCs for 14 days. 
PBMCs were cultured with MSCs at a 5:1 ratio (50,000:10,000) (Crop et al., 2010). Although 
this study is one of the first in extending the duration of the LTA past 7 days (up to 14) some 
stimulation of PBMCs was observed from day 0. However the lack of negative control data and 
the fact that the data was presented as the median results of four experiments make this 
study difficult to evaluate. As shown in Chapter 6, the specific responses of PBMCs to MSCs can 
vary between donor to donor, so a greater number of experiments should be performed to 
clarify the results obtained (Crop et al., 2010).  
Interestingly, when PHDFs were co-cultured with PBMCs they produced significant stimulation, 
and the stimulation was comparable to that observed with MSCs. For some of the BM donor 
MSC the stimulation indices were higher than for fibroblasts when tested against the same 
PBMC donor. This may actually not be all that surprising as there have been reports of 
fibroblasts exhibiting similar characteristics to MSCs. Skin fibroblasts have been shown to be 
able to differentiate into bone, fat, and cartilage in-vitro and express similar phenotypic 
markers and also have similar effects on inhibiting the proliferation of stimulated PBMC 
(Haniffa et al., 2007; Cappellesso-Fleury et al., 2010; Blasi et al., 2011). It is starting to emerge 
that fibroblasts are more similar to MSCs than previously believed, and share many of the 
characteristics that were thought to be distinguishing features of MSCs (such as the trilineage 
potential, and immuno-regulatory properties) . The similarity between fibroblasts and MSCs 
may be dependent on the specific fibroblasts obtained; in this study fibroblasts did not 
demonstrate trilineage differentiation, but were overall less immunogenic than MSCs (albeit 
still stimulating PBMCs). It is difficult to distinguish between two cell types (fibroblasts and 
MSCs) as both cell types appear to demonstrate the same morphology and express the same 
cell surface markers. It is possible that there is a resident population of multipotent cells 
residing in the mesenchymal tissues with mature fibroblast cells, and that the methods used 
for the isolation and culture of “fibroblasts” favours selection of cells with the characteristics 
of MSC.  
8.1 FUTURE WORK 
Following on from the conclusions that undifferentiated MSCs stimulate PBMC and 
adipogenically differentiated MSCs also stimulate the proliferation of PBMCs, a number of 
unanswered questions regarding the immunogenicity of MSCs remain to be addressed. Future 
studies should address the mechanisms of interaction between MSC and PBMCs in short and 
long term cultures of undifferentiated and differentiated MSC. This could be carried out by 
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investigating cytokine secretion and gene expression by both the stimulatory cells and 
responder cells in the LTAs over a culture period of up to 21 days. Any changes in expression 
by undifferentiated MSCs of the co-stimulatory molecules, MHC class-I and II, or the secreted 
factors such as PGE2 or IDO when undifferentiated MSCs are co-cultured in LTAs would aid in 
the determination if this plays any role in the stimulation of PBMCs observed.  
It would also be of interest to determine the phenotype and function of the lymphocytes that 
respond to allogeneic MSC in LTAs. It will be important to determine whether the responding 
cells are CD4+, IFN-ɣ producing, CD 8+ cytotoxic cells or indeed CD4+CD25+Foxp3+ regulatory T-
cells.  
Whether allogeneic MSCs are able to survive long term in-vivo needs to be addressed. Since it 
may not be possible to perform such studies in man, such studies should be carried out in a 
range of animal models. Currently there is little evidence to suggest that allogeneic MSC 
survive in the longer term. There are already clinical products that use allogeneic MSCs such as 
Prochymal™ and Osteocel™ but clinical data on these treatments is hard to find. Long term 
survival studies tracking MSCs in-vivo would offer more conclusive evidence of whether MSCs 
are immuno-privileged or eliminated by the immune system.   
It will also be important to determine whether the repeated treatment of patients with 
allogeneic MSC leads to a diminuation of therapeutic effect. If allogeneic MSC are 
immunogenic in-vivo, then repeated exposure of a given patient to a range of alloantigens 
expressed by therapeutic MSC would theoretically lead the induction of alloantigen specific 
memory T-cells. Hence, the therapeutic effects of allogeneic MSC could be ablated.  
8.2 FINAL WORDS 
MSCs do stimulate allogeneic PBMCs and are not therefore immune to the attentions of cells 
of the immune system. They are not strongly immunogenic however and therefore when 
placed into non-inflammatory environments they may be able to ‘remain hidden’ and avoid 
immediate detection and elimination by the immune system. Low (not negative) expression of 
co-stimulatory molecules and HLA-DR with positive expression of HLA-ABC could account for 
the lack of initial immune response and explain why it is currently believed that allogeneic 
MSCs are immuno-privileged. MSCs are able to produce anti-inflammatory cytokines and 
factors that decrease the inflammatory response (IDO, PGE2). In addition to this, the MSCs are 
able to affect the maturation of immune cells such as DCs and T-cells and stimulate the 
production of a regulatory phenotype of T-cells. The use therefore of allogeneic MSCs in the 
traditional engineering setting may be limited and a very cautious approach should be taken 
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before allogeneic MSCs are used to aid in the regeneration or creation of tissue replacements. 
Where allogeneic MSCs do appear to currently excel is as a transient anti-inflammatory 
treatment (such as in the treatment of GvHD or Crohns disease), or to aid in the reduction of 
inflammation (such as to aid engraftment of HSCs after transplantation).   
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